[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\n1. Acrokeratosis paraneoplastic syndrome\n2. APN (Acrokeratosis paraneoplastica nodularis)\n3. Paraneoplastic acrokeratosis\n4. Paraneoplastic acrokeratotic syndrome\n5. PAS (Paraneoplastic acrokeratosis syndrome)\nNote: These synonyms are used interchangeably to refer to the same condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome.\n2. APN is an abbreviation for Acrokeratosis paraneoplastica nodularis.\n3. Paraneoplastic acrokeratosis is a synonym for Acrokeratosis paraneoplastica.\n4. Acrokeratosis paraneoplastica can be referred to as Paraneoplastic acrokeratotic syndrome.\n5. PAS stands for Paraneoplastic acrokeratosis syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome.",
      "APN is an abbreviation for Acrokeratosis paraneoplastica nodularis.",
      "Paraneoplastic acrokeratosis is a synonym for Acrokeratosis paraneoplastica.",
      "Acrokeratosis paraneoplastica can be referred to as Paraneoplastic acrokeratotic syndrome.",
      "PAS stands for Paraneoplastic acrokeratosis syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: APN is often used as an abbreviation for Acrokeratosis Paraneoplastica, not specifically \"Acrokeratosis Paraneoplastica Nodularis.\"\n3. TRUE\n4. TRUE\n5. UNKNOWN [clarification]: PAS can stand for Paraneoplastic Acrokeratosis Syndrome, but PAS is a nonspecific abbreviation and could represent other syndromes or terms in different contexts. Without further context, it is unclear whether PAS is commonly used to refer to Paraneoplastic Acrokeratosis Syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that affect brain development and can cause developmental delays, intellectual disability, and other physical abnormalities. However, they are distinct disorders with different genetic causes and clinical features.\nWeaver syndrome is caused by mutations in the PTEN gene, which encodes a protein that regulates the PI3K/AKT signaling pathway. This pathway is important for cell growth and survival, and mutations in the PTEN gene can lead to uncontrolled cell growth and division, resulting in the characteristic features of Weaver syndrome.\nSotos syndrome, on the other hand, is caused by mutations in the NSD1 gene, which encodes a protein that plays a role in the regulation of chromatin structure and gene expression. Sotos syndrome is characterized by growth delays, intellectual disability, and a distinctive facial appearance, as well as an increased risk of certain medical conditions such as heart defects and immune system problems.\nWhile both disorders can cause developmental delays and intellectual disability, the clinical features of Weaver syndrome are generally milder than those of Sotos syndrome. Weaver syndrome typically causes mild to moderate developmental delays, while Sotos syndrome can result in more significant delays and intellectual disability. Additionally, the facial features of Weaver syndrome are less distinct than those of Sotos syndrome, and the risk of certain medical conditions may be lower in Weaver syndrome.\nIn summary, while both Weaver syndrome and Sotos syndrome are genetic disorders that affect brain development, they have distinct genetic causes and clinical features, and Weaver syndrome is generally milder than Sotos syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is a genetic disorder caused by mutations in the PTEN gene.\n2. Sotos syndrome is a genetic disorder caused by mutations in the NSD1 gene.\n3. PTEN gene mutations affect the PI3K/AKT signaling pathway, leading to uncontrolled cell growth and division.\n4. Sotos syndrome is characterized by a distinctive facial appearance, growth delays, and an increased risk of heart defects and immune system problems.\n5. Clinical features of Weaver syndrome are generally milder than Sotos syndrome, with mild to moderate developmental delays in comparison to the more significant delays and intellectual disability found in Sotos syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is a genetic disorder caused by mutations in the PTEN gene.",
      "Sotos syndrome is a genetic disorder caused by mutations in the NSD1 gene.",
      "PTEN gene mutations affect the PI3K/AKT signaling pathway, leading to uncontrolled cell growth and division.",
      "Sotos syndrome is characterized by a distinctive facial appearance, growth delays, and an increased risk of heart defects and immune system problems.",
      "Clinical features of Weaver syndrome are generally milder than Sotos syndrome, with mild to moderate developmental delays in comparison to the more significant delays and intellectual disability found in Sotos syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weaver syndrome is a genetic disorder caused by mutations in the EZH2 gene, not the PTEN gene.\n2. TRUE\n3. TRUE\n4. TRUE, but the statement does not mention an important characteristic of Sotos syndrome, which includes overgrowth and learning disabilities. The risk of heart defects and immune system problems is not the primary concern with Sotos syndrome. It's more associated with a distinctive facial appearance, overgrowth in childhood, and intellectual disability.\n5. UNKNOWN: The clinical features of Weaver syndrome can vary, and while they can include growth acceleration and intellectual disability, the comparison of severity with Sotos syndrome can be complex and isn't uniformly characterized as milder. The severity of symptoms in genetic syndromes like Weaver and Sotos can be highly variable from individual to individual.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Junkunc et al., 2003) is a database of transcription factor binding site (TFBS) matrices for various organisms. Here are the releases of the JASPAR database:\n1. JASPAR Release 1 (2003): The first release of the JASPAR database, containing TFBS matrices for 12 organisms, including humans, mice, and yeast.\n2. JASPAR Release 2 (2006): An updated version of the database, with new matrices for additional organisms and improved methods for predicting TFBSs.\n3. JASPAR Release 3 (2009): A major update of the database, with new matrices for 24 organisms, including improved matrices for human and mouse.\n4. JASPAR Release 4 (2012): A significant update of the database, with new matrices for 30 organisms, including improved matrices for human and mouse, and new matrices for zebrafish and D. melanogaster.\n5. JASPAR Release 5 (2016): The latest version of the database, with new matrices for 37 organisms, including improved matrices for human and mouse, and new matrices for several non-model organisms.\n6. JASPAR-M (2017): A companion database to JASPAR, containing matrices for predicting the binding of transcription factors to enhancers and other long-range regulatory elements.\n7. JASPAR-T (2018): A database of transcription factor binding sites (TFBSs) and their target genes, with a focus on the regulation of gene expression.\n8. JASPAR-C (2019): A database of chromatin state profiles for various cell types and tissues, with information on the epigenetic marks and their distribution.\nThese releases have improved the accuracy and coverage of the TFBS matrices, as well as the methods for predicting TFBSs and their target genes. The JASPAR database has been widely used in the scientific community for studying transcriptional regulation and its role in various biological processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1 was launched in 2003 with TFBS matrices for 12 organisms including humans, mice, and yeast.\n2. JASPAR Release 2 came out in 2006 with additional matrices and improved prediction methods for TFBSs.\n3. JASPAR Release 3 was released in 2009 and included new matrices for 24 organisms.\n4. JASPAR Release 4 in 2012 featured new matrices for 30 organisms, including zebrafish and D. melanogaster.\n5. JASPAR Release 5, the latest mentioned version, was released in 2016 and included matrices for 37 organisms.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1 was launched in 2003 with TFBS matrices for 12 organisms including humans, mice, and yeast.",
      "JASPAR Release 2 came out in 2006 with additional matrices and improved prediction methods for TFBSs.",
      "JASPAR Release 3 was released in 2009 and included new matrices for 24 organisms.",
      "JASPAR Release 4 in 2012 featured new matrices for 30 organisms, including zebrafish and D. melanogaster.",
      "JASPAR Release 5, the latest mentioned version, was released in 2016 and included matrices for 37 organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about each JASPAR release and their contents, it is difficult to accurately determine the veracity of statements 3, 4, and 5 regarding the exact details and features of those releases.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a protein encoded by the KP4 gene in certain viruses, including the herpes simplex virus (HSV) and the human cytomegalovirus (HCMV). The KP4 protein has several functions, including:\n1. Regulation of gene expression: The KP4 protein can bind to specific DNA sequences and regulate the transcription of nearby genes.\n2. Cell-to-cell spread: The KP4 protein can facilitate the spread of virus particles from infected cells to nearby uninfected cells.\n3. Inhibition of immune response: The KP4 protein can inhibit the activity of immune cells, such as T cells and macrophages, which can help the virus to evade the host immune system.\n4. Modulation of the actin cytoskeleton: The KP4 protein can interact with the actin cytoskeleton and modulate its dynamics, which can help the virus to move and spread within the host cell.\nOverall, the KP4 protein plays a multifaceted role in the replication and pathogenesis of HSV and HCMV, and is a promising target for the development of antiviral therapies.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KP4 gene in certain viruses, including herpes simplex virus (HSV) and human cytomegalovirus (HCMV).\n2. The KP4 protein can regulate gene expression by binding to specific DNA sequences.\n3. The KP4 protein facilitates the spread of virus particles from infected cells to nearby uninfected cells.\n4. The KP4 protein can inhibit the activity of immune cells such as T cells and macrophages.\n5. The KP4 protein interacts with the actin cytoskeleton and modulates its dynamics.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KP4 gene in certain viruses, including herpes simplex virus (HSV) and human cytomegalovirus (HCMV).",
      "The KP4 protein can regulate gene expression by binding to specific DNA sequences.",
      "The KP4 protein facilitates the spread of virus particles from infected cells to nearby uninfected cells.",
      "The KP4 protein can inhibit the activity of immune cells such as T cells and macrophages.",
      "The KP4 protein interacts with the actin cytoskeleton and modulates its dynamics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: KP4 is a fungal toxin protein encoded by the Ustilago maydis virus (UMV) KP4 gene; it is not encoded by either herpes simplex virus (HSV) or human cytomegalovirus (HCMV).\n2. TRUE: KP4-like proteins can regulate gene expression by binding to specific DNA sequences (generally speaking about DNA-binding proteins, although KP4 is not directly involved in regulating gene expression through DNA binding but rather acts as a toxin).\n3. FALSE [correction]: KP4 does not facilitate the spread of virus particles; instead, as a fungal toxin, it is known to protect the fungus by inducing resistance to certain plant defenses.\n4. UNKNOWN: Information about KP4's direct interaction with immune cells like T cells and macrophages is not commonly documented in the context of the well-known functions of the KP4 protein from Ustilago maydis.\n5. UNKNOWN: There is no widespread evidence supporting the KP4 protein's specific interaction with the actin cytoskeleton to modulate its dynamics. It is known, however, that some viral proteins are capable of this in a general sense, but whether KP4 has this function is not clear.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (3,3'-dithiobis(propionitrophenol) or di-tert-butyl hydroxyquinoline) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is a synthetic compound that mimics the action of thyroid hormones in the body, and it has been used to study the mechanisms of thyroid hormone action and to treat various thyroid-related disorders.\nIn experimental studies, DITPA has been used to investigate the role of thyroid hormones in various physiological processes, such as cell growth, differentiation, and metabolism. DITPA has been shown to mimic the effects of thyroid hormones in these processes, allowing researchers to study the specific mechanisms of action of thyroid hormones.\nIn clinical studies, DITPA has been used to treat hypothyroidism, a condition in which the thyroid gland does not produce enough thyroid hormones. DITPA has been shown to be effective in replacing the missing thyroid hormones and restoring normal thyroid function in patients with hypothyroidism. DITPA has also been used to treat other thyroid-related disorders, such as thyroid cancer and thyroiditis.\nIt is important to note that while DITPA can mimic the effects of thyroid hormones, it is not a natural thyroid hormone and can have different effects on the body compared to natural thyroid hormones. As such, DITPA should only be used under the close supervision of a healthcare professional.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA (3,3'-dithiobis(propionitrophenol) or di-tert-butyl hydroxyquinoline) is a thyroid hormone analog.\n2. DITPA has been utilized in both experimental and clinical studies.\n3. In experimental studies, DITPA is used to investigate the role of thyroid hormones in physiological processes such as cell growth, differentiation, and metabolism.\n4. DITPA has been used in clinical studies to treat hypothyroidism and restore normal thyroid function in patients.\n5. DITPA has been used to treat various thyroid-related disorders, including thyroid cancer and thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA (3,3'-dithiobis(propionitrophenol) or di-tert-butyl hydroxyquinoline) is a thyroid hormone analog.",
      "DITPA has been utilized in both experimental and clinical studies.",
      "In experimental studies, DITPA is used to investigate the role of thyroid hormones in physiological processes such as cell growth, differentiation, and metabolism.",
      "DITPA has been used in clinical studies to treat hypothyroidism and restore normal thyroid function in patients.",
      "DITPA has been used to treat various thyroid-related disorders, including thyroid cancer and thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: DITPA has not been used in clinical studies to treat hypothyroidism and restore normal thyroid function in patients. It has been studied for its potential in treating conditions such as heart failure and obesity, where its effects mimic some actions of thyroid hormones.\n5. FALSE [correction]: DITPA has been evaluated for its potential therapeutic effects in various conditions, primarily focusing on cardiovascular benefits, not specifically for treating thyroid cancer and thyroiditis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (COmprehensive UniQue Genome Rearrangement tool) is a computational tool used to identify and characterize genomic rearrangements, such as translocations, deletions, and amplifications, in cancer genomes. It can be used to analyze a wide range of cancer types, including solid tumors and hematological malignancies.\nCOUGER works by aligning the genomic sequences of cancer cells to a reference genome, and then identifying regions of the genome that are rearranged compared to the reference. These regions are then characterized using a variety of computational methods, including k-mer analysis, sequence alignment, and functional annotation.\nCOUGER can be used to identify potential driver mutations in cancer, as well as to identify genomic rearrangements that may be targeted by cancer therapies. It can also be used to compare the genomic profiles of different cancer types, and to identify potential biomarkers for cancer diagnosis and prognosis.\nOverall, COUGER is a powerful tool for analyzing and understanding the complex genomic alterations that occur in cancer, and it has the potential to be used in the development of new cancer therapies.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for COmprehensive UniQue Genome Rearrangement tool.\n2. COUGER is used to identify and characterize genomic rearrangements in cancer genomes.\n3. The tool is applicable for analysis across various cancer types, including both solid tumors and hematological malignancies.\n4. COUGER aligns cancer cell genomic sequences to a reference genome to identify rearranged regions.\n5. The tool can assist in identifying potential driver mutations and genomic rearrangements that might be targeted by cancer therapies.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for COmprehensive UniQue Genome Rearrangement tool.",
      "COUGER is used to identify and characterize genomic rearrangements in cancer genomes.",
      "The tool is applicable for analysis across various cancer types, including both solid tumors and hematological malignancies.",
      "COUGER aligns cancer cell genomic sequences to a reference genome to identify rearranged regions.",
      "The tool can assist in identifying potential driver mutations and genomic rearrangements that might be targeted by cancer therapies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: COUGER stands for COmprehensive Unbiased Genome Evaluation of Rearrangements. \n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of tick-borne encephalitis (TBE). The most commonly used drugs for TBE are:\n1. Antiviral medications: Ribavirin, a nucleoside analogue, is the most commonly used antiviral drug for the treatment of TBE. It has been shown to reduce the severity of symptoms and the duration of illness in patients with TBE.\n2. Corticosteroids: Corticosteroids, such as prednisone, are sometimes used to reduce inflammation in the brain and spinal cord.\n3. Immunoglobulins: Immunoglobulins, such as intravenous immunoglobulin (IVIG), may be used in severe cases of TBE to reduce the severity of symptoms and prevent complications.\n4. Supportive care: Patients with TBE may require supportive care, such as oxygen therapy, hydration, and pain management, to manage symptoms and prevent complications.\nIt is important to note that the effectiveness of these drugs can vary depending on the severity and duration of the illness, as well as the patient's overall health. In some cases, a combination of drugs may be used to treat TBE.\nIt is also important to note that these drugs are not a substitute for prevention, and the best way to prevent TBE is to avoid tick bites by using insect repellents, wearing protective clothing, and conducting regular tick checks when spending time outdoors in areas where TBE is common.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is used as an antiviral medication for the treatment of tick-borne encephalitis (TBE).\n2. Corticosteroids like prednisone may be used to treat inflammation in patients with TBE.\n3. Intravenous immunoglobulin (IVIG) can be used in severe cases of TBE.\n4. Supportive care for TBE may include oxygen therapy, hydration, and pain management.\n5. Preventive measures against TBE include avoiding tick bites, using insect repellents, wearing protective clothing, and conducting tick checks.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is used as an antiviral medication for the treatment of tick-borne encephalitis (TBE).",
      "Corticosteroids like prednisone may be used to treat inflammation in patients with TBE.",
      "Intravenous immunoglobulin (IVIG) can be used in severe cases of TBE.",
      "Supportive care for TBE may include oxygen therapy, hydration, and pain management.",
      "Preventive measures against TBE include avoiding tick bites, using insect repellents, wearing protective clothing, and conducting tick checks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ribavirin has not shown to be effective for the treatment of tick-borne encephalitis (TBE).\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers and databases available for DNA shape annotations. Some of the popular ones include:\n1. ChromHMM: ChromHMM is a genome-scale model of chromatin structure and epigenetic marks that provides DNA shape annotations for various organisms, including humans.\n2. HiC-Pro: HiC-Pro is a database of chromosome conformation capture (Hi-C) data that provides a comprehensive view of chromosome structure and interactions. It includes DNA shape annotations for various organisms.\n3. 4C-DB: 4C-DB is a database of 4C (chromosome conformation capture) data that provides information on the three-dimensional organization of chromosomes and their interactions. It includes DNA shape annotations for various organisms.\n4. DNase-seq: DNase-seq is a database of DNase I footprinting data that provides information on the accessibility of the DNA molecule and can be used to infer DNA shape annotations.\n5. FAIRE: FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements) is a database of chromatin accessibility data that provides information on the open chromatin structure and can be used to infer DNA shape annotations.\n6. H3K27ac: H3K27ac is a database of histone H3 lysine 27 acetylation data that provides information on the active chromatin structure and can be used to infer DNA shape annotations.\n7. H3K4me3: H3K4me3 is a database of histone H3 lysine 4 trimethylation data that provides information on the constitutive heterochromatin structure and can be used to infer DNA shape annotations.\n8. H3K9ac: H3K9ac is a database of histone H3 lysine 9 acetylation data that provides information on the active chromatin structure and can be used to infer DNA shape annotations.\n9. H3K27me3: H3K27me3 is a database of histone H3 lysine 27 trimethylation data that provides information on the repressive chromatin structure and can be used to infer DNA shape annotations.\n10. Topologically Associating Domain (TAD): TAD",
    "llama-2-7b-chat-hf_fact_raw": "1. ChromHMM provides DNA shape annotations for various organisms, including humans.\n2. HiC-Pro is a database that includes DNA shape annotations and offers a comprehensive view of chromosome structure and interactions.\n3. 4C-DB is a database that provides information on the three-dimensional organization of chromosomes, including DNA shape annotations.\n4. DNase-seq is a database of DNase I footprinting data that can be used to infer DNA shape annotations.\n5. FAIRE is a database that provides information on open chromatin structure, which can be used to infer DNA shape annotations.",
    "llama-2-7b-chat-hf_fact": [
      "ChromHMM provides DNA shape annotations for various organisms, including humans.",
      "HiC-Pro is a database that includes DNA shape annotations and offers a comprehensive view of chromosome structure and interactions.",
      "4C-DB is a database that provides information on the three-dimensional organization of chromosomes, including DNA shape annotations.",
      "DNase-seq is a database of DNase I footprinting data that can be used to infer DNA shape annotations.",
      "FAIRE is a database that provides information on open chromatin structure, which can be used to infer DNA shape annotations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ChromHMM is a software tool that uses chromatin state data to predict chromatin states across the genome, such as enhancers and promoters, rather than specifically providing DNA shape annotations.\n2. FALSE [correction]: HiC-Pro is not a database; it is a software pipeline that processes Hi-C data to study chromosome conformation and interactions, without directly providing DNA shape annotations.\n3. TRUE [clarification]: While 4C-DB is a database that contains data on chromosomal interactions (captured by the 4C technology, Chromosome Conformation Capture-on-Chip), if it includes data that can infer DNA shapes, then this statement could be considered true. However, 4C-DB's primary focus is on interactions rather than DNA shape.\n4. FALSE [correction]: DNase-seq is not a database but a laboratory technique that identifies regions of accessible DNA across the genome. While the data produced by DNase-seq can be used to infer aspects of chromatin structure and potentially DNA shape indirectly, it is not explicitly a provider of DNA shape annotations.\n5. FALSE [correction]: FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) is not a database but a technique used to identify regions of open chromatin. Similar to DNase-seq, the data from FAIRE-seq experiments can be used to inform about chromatin structure which can have implications for understanding DNA shape, but it is not a database that solely provides DNA shape annotations.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes the enzyme enzyme histone methyltransferase 2A (EZH2), which plays a crucial role in regulating gene expression by modifying histone proteins. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Rubinstein-Taybi syndrome (RTS): A rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and various other physical abnormalities.\n2. Noonan syndrome: A rare genetic disorder characterized by short stature, congenital heart defects, facial dysmorphism, and various other physical abnormalities.\n3. Costello syndrome: A rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and various other physical abnormalities.\n4. PTEN hamartoma tumor syndrome (PHTS): A rare genetic disorder characterized by the development of benign and malignant tumors, primarily in the skin and brain.\n5. Cowden syndrome: A rare genetic disorder characterized by multiple hamartomas, including those in the skin, thyroid, and gastrointestinal tract, as well as an increased risk of developing cancer.\nThese syndromes are caused by mutations in the EZH2 gene, which disrupt its normal function of regulating gene expression and lead to the development of various symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are associated with Rubinstein-Taybi syndrome.\n2. Mutations in the EZH2 gene are associated with Noonan syndrome.\n3. Mutations in the EZH2 gene are associated with Costello syndrome.\n4. Mutations in the EZH2 gene are associated with PTEN hamartoma tumor syndrome.\n5. Mutations in the EZH2 gene are associated with Cowden syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are associated with Rubinstein-Taybi syndrome.",
      "Mutations in the EZH2 gene are associated with Noonan syndrome.",
      "Mutations in the EZH2 gene are associated with Costello syndrome.",
      "Mutations in the EZH2 gene are associated with PTEN hamartoma tumor syndrome.",
      "Mutations in the EZH2 gene are associated with Cowden syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in genes like PTPN11, SOS1, RAF1, RIT1, and others are associated with Noonan syndrome.\n3. FALSE [correction]: Costello syndrome is typically associated with mutations in the HRAS gene.\n4. FALSE [correction]: PTEN hamartoma tumor syndrome is associated with mutations in the PTEN gene.\n5. FALSE [correction]: Cowden syndrome is also associated with mutations in the PTEN gene.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that undergo a dimer-to-tetramer transition, which is a common structural conversion in proteins. Here are some examples:\n1. P53 tumor suppressor protein: The P53 protein is a transcription factor that regulates cell cycle and apoptosis. It exists as a tetramer in its active form, but can dimerize in response to DNA damage or other signals.\n2. Cyclin-dependent kinase 4 (CDK4): CDK4 is a key regulator of the cell cycle and is involved in the transition from the G1 phase to the S phase. It exists as a dimer in its inactive form and forms a tetramer upon phosphorylation.\n3. Cyclin-dependent kinase 6 (CDK6): Similar to CDK4, CDK6 is also a key regulator of the cell cycle and exists as a dimer in its inactive form, which becomes a tetramer upon phosphorylation.\n4. Retinoblastoma protein (Rb): Rb is a tumor suppressor protein that regulates the G1/S checkpoint. It exists as a monomer in its inactive form and forms a tetramer upon phosphorylation.\n5. E2F transcription factor: E2F is a transcription factor that regulates the expression of genes involved in DNA replication and cell cycle progression. It exists as a dimer in its inactive form and forms a tetramer upon binding to DNA.\n6. Myc proto-oncogene (MYC): MYC is a transcription factor that regulates cell proliferation and apoptosis. It exists as a dimer in its inactive form and forms a tetramer upon phosphorylation.\n7. Max transcription factor (MAX): MAX is a transcription factor that regulates the expression of genes involved in cell growth and differentiation. It exists as a dimer in its inactive form and forms a tetramer upon binding to its partner protein, Myb.\n8. Myb transcription factor (MYB): MYB is a transcription factor that regulates the expression of genes involved in cell growth and differentiation. It exists as a dimer in its inactive form and forms a tet",
    "llama-2-7b-chat-hf_fact_raw": "1. The P53 protein is a transcription factor that exists as a tetramer in its active form and can dimerize in response to DNA damage or other signals.\n2. Cyclin-dependent kinase 4 (CDK4) exists as a dimer in its inactive form and forms a tetramer upon phosphorylation.\n3. Cyclin-dependent kinase 6 (CDK6) is a dimer in its inactive form and becomes a tetramer upon phosphorylation.\n4. Retinoblastoma protein (Rb) exists as a monomer in its inactive form and forms a tetramer upon phosphorylation.\n5. E2F transcription factor exists as a dimer in its inactive form and forms a tetramer upon binding to DNA.",
    "llama-2-7b-chat-hf_fact": [
      "The P53 protein is a transcription factor that exists as a tetramer in its active form and can dimerize in response to DNA damage or other signals.",
      "Cyclin-dependent kinase 4 (CDK4) exists as a dimer in its inactive form and forms a tetramer upon phosphorylation.",
      "Cyclin-dependent kinase 6 (CDK6) is a dimer in its inactive form and becomes a tetramer upon phosphorylation.",
      "Retinoblastoma protein (Rb) exists as a monomer in its inactive form and forms a tetramer upon phosphorylation.",
      "E2F transcription factor exists as a dimer in its inactive form and forms a tetramer upon binding to DNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Cyclin-dependent kinase 4 (CDK4) forms a complex with cyclin D, not a dimer in its inactive form, and does not form a tetramer upon phosphorylation; rather, it becomes activated when forming a complex with cyclin D and then phosphorylated.\n3. FALSE [correction]: Cyclin-dependent kinase 6 (CDK6) is similar to CDK4 and does not become a tetramer upon phosphorylation. It forms a complex with cyclin D to be activated and then phosphorylates its target proteins.\n4. FALSE [correction]: Retinoblastoma protein (Rb) exists as a monomer in both its active and inactive forms. Phosphorylation by CDK-cyclin complexes leads to its inactivation, but it does not form a tetramer upon phosphorylation.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Phospholamban (PLN) is an anti-apoptotic protein that has been found to interact with the protein BCL-2 (B-cell lymphoma 2). BCL-2 is an anti-apoptotic protein that inhibits the induction of apoptosis by preventing the activation of pro-apoptotic proteins such as BAX and BAK. PLN and BCL-2 have been shown to interact and cooperate in protecting cells from apoptosis, suggesting that they may play a role in the development of certain diseases, including cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Phospholamban (PLN) is an anti-apoptotic protein.\n2. PLN has been found to interact with the protein BCL-2 (B-cell lymphoma 2).\n3. BCL-2 is an anti-apoptotic protein that prevents the activation of pro-apoptotic proteins, including BAX and BAK.\n4. PLN and BCL-2 interaction can protect cells from apoptosis.",
    "llama-2-7b-chat-hf_fact": [
      "Phospholamban (PLN) is an anti-apoptotic protein.",
      "PLN has been found to interact with the protein BCL-2 (B-cell lymphoma 2).",
      "BCL-2 is an anti-apoptotic protein that prevents the activation of pro-apoptotic proteins, including BAX and BAK.",
      "PLN and BCL-2 interaction can protect cells from apoptosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Phospholamban (PLN) is not typically described as an anti-apoptotic protein. It is a regulatory protein that in its phosphorylated form relieves inhibition of SERCA (sarcoplasmic reticulum Ca²⁺-ATPase), thereby affecting muscle contraction.\n2. UNKNOWN: The interaction between PLN and BCL-2 is not widely recognized or documented in mainstream scientific literature as of my last knowledge update. Specific interactions would have to be verified with current research data.\n3. TRUE: BCL-2 is indeed an anti-apoptotic protein that prevents the activation of pro-apoptotic proteins such as BAX and BAK, thereby inhibiting apoptosis.\n4. UNKNOWN: Without validated scientific studies to support this statement, the interaction between PLN and BCL-2 protecting cells from apoptosis remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2013 meta-analysis published in the Journal of the American Geriatrics Society pooled data from 17 randomized controlled trials involving over 11,000 older adults. The analysis found that vitamin D supplementation was associated with a significant reduction in the risk of falls (RR=0.77, 95% CI=0.65-0.90).\n2. A 2010 randomized controlled trial published in the Journal of Gerontology found that vitamin D and calcium supplementation reduced the incidence of falls in older adults with low baseline vitamin D levels (n=110).\n3. A 2014 randomized controlled trial published in the Journal of the American Medical Directors Association found that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment (n=106).\n4. A 2017 systematic review and meta-analysis published in the journal Nutrients pooled data from 15 randomized controlled trials involving over 6,000 older adults. The analysis found that vitamin D supplementation was associated with a significant reduction in the risk of falls (RR=0.79, 95% CI=0.67-0.93).\nIt's important to note that while these studies suggest a potential benefit of vitamin D supplementation in reducing falls in older adults, the evidence is not yet conclusive, and more research is needed to confirm these findings and establish the optimal dosage and duration of supplementation. Additionally, it's important to consult with a healthcare professional before starting any supplement regimen.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2013 meta-analysis published in the Journal of the American Geriatrics Society indicated that vitamin D supplementation is associated with a significant reduction in the risk of falls among older adults.\n2. The meta-analysis from 2013 analyzed data from 17 randomized controlled trials involving over 11,000 older adults.\n3. A 2010 randomized controlled trial published in the Journal of Gerontology reported that vitamin D and calcium supplementation reduced the incidence of falls in older adults with low baseline vitamin D levels.\n4. A 2014 study published in the Journal of the American Medical Directors Association found that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment.\n5. A 2017 systematic review and meta-analysis published in the journal Nutrients which included data from 15 randomized controlled trials suggested that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults.",
    "llama-2-7b-chat-hf_fact": [
      "A 2013 meta-analysis published in the Journal of the American Geriatrics Society indicated that vitamin D supplementation is associated with a significant reduction in the risk of falls among older adults.",
      "The meta-analysis from 2013 analyzed data from 17 randomized controlled trials involving over 11,000 older adults.",
      "A 2010 randomized controlled trial published in the Journal of Gerontology reported that vitamin D and calcium supplementation reduced the incidence of falls in older adults with low baseline vitamin D levels.",
      "A 2014 study published in the Journal of the American Medical Directors Association found that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment.",
      "A 2017 systematic review and meta-analysis published in the journal Nutrients which included data from 15 randomized controlled trials suggested that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that Jarid2 (Jumonji H3-domain containing 2) is involved in the regulation of miR-155 (microRNA-155) expression in Th17 cells.\nTh17 cells are a subset of T cells that play a key role in the immune response and are involved in the development of autoimmune diseases such as multiple sclerosis and psoriasis. MiR-155 is a microRNA that is known to play a critical role in the regulation of Th17 cell differentiation and function.\nStudies have shown that Jarid2 is a negative regulator of miR-155 expression in Th17 cells. Specifically, Jarid2 has been shown to bind to the 3'UTR (untranslated region) of the miR-155 mRNA and prevent its degradation, leading to increased levels of miR-155 in Th17 cells. This results in the activation of target genes that promote Th17 cell differentiation and inflammation.\nIn contrast, other studies have suggested that Jarid2 may also play a role in the regulation of miR-155 expression in other cell types, such as cancer cells.\nOverall, the association between Jarid2 and miR-155 in Th17 cells suggests that Jarid2 may be a potential therapeutic target for the treatment of autoimmune diseases characterized by Th17 cell-mediated inflammation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is involved in the regulation of miR-155 expression in Th17 cells.\n2. Th17 cells play a key role in the immune response and are involved in the development of autoimmune diseases.\n3. MiR-155 is critical in the regulation of Th17 cell differentiation and function.\n4. Jarid2 acts as a negative regulator of miR-155 expression by interacting with the 3'UTR of its mRNA in Th17 cells.\n5. Elevated levels of miR-155 in Th17 cells can lead to increased Th17 cell differentiation and inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is involved in the regulation of miR-155 expression in Th17 cells.",
      "Th17 cells play a key role in the immune response and are involved in the development of autoimmune diseases.",
      "MiR-155 is critical in the regulation of Th17 cell differentiation and function.",
      "Jarid2 acts as a negative regulator of miR-155 expression by interacting with the 3'UTR of its mRNA in Th17 cells.",
      "Elevated levels of miR-155 in Th17 cells can lead to increased Th17 cell differentiation and inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Jarid2 is known to play a role in the regulation of miR-155 expression, which is important in the function of various cells, including Th17 cells.\n2. TRUE: Th17 cells are indeed a crucial component of the immune system and are implicated in the pathology of various autoimmune diseases.\n3. TRUE: MiR-155 has been shown to be important in the regulation of Th17 cell differentiation and function, as it affects various genes and signaling pathways involved in these processes.\n4. FALSE [correction]: Jarid2 does not act by interacting with the 3'UTR of miR-155 mRNA. Instead, Jarid2 is typically known for its role in chromatin remodeling and gene expression regulation, rather than directly interacting with mRNAs.\n5. TRUE: Elevated levels of miR-155 have been associated with the promotion of Th17 cell differentiation and associated inflammatory responses.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 9 genes. The Hox (Homeobox) genes are a group of transcription factors that play a crucial role in the regulation of embryonic development and patterning in animals, including humans. The HoxD cluster is located on chromosome 2 and consists of the following genes:\n* HoxD1\n* HoxD2\n* HoxD3\n* HoxD8\n* HoxD9\n* HoxD10\n* HoxD13\n* HoxD13L1\n* HoxD14\nEach of these genes encodes a protein that contains a homeobox domain, a specific DNA-binding motif that is involved in the regulation of gene expression. The HoxD genes are expressed in a specific spatial and temporal pattern during embryonic development, and play a crucial role in the formation of the anterior-posterior (AP) and proximal-distal (PD) axes, as well as the development of the nervous system, limbs, and other tissues.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster consists of 9 genes.\n2. The Hox (Homeobox) genes are transcription factors that regulate embryonic development and patterning.\n3. The HoxD cluster is located on chromosome 2.\n4. Each gene in the HoxD cluster encodes a protein that contains a homeobox domain.\n5. The HoxD genes play a role in the development of the anterior-posterior and proximal-distal axes, as well as the nervous system and limbs.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster consists of 9 genes.",
      "The Hox (Homeobox) genes are transcription factors that regulate embryonic development and patterning.",
      "The HoxD cluster is located on chromosome 2.",
      "Each gene in the HoxD cluster encodes a protein that contains a homeobox domain.",
      "The HoxD genes play a role in the development of the anterior-posterior and proximal-distal axes, as well as the nervous system and limbs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster consists of 9-11 genes, more commonly referred to as containing 10 genes.\n2. TRUE\n3. FALSE [correction]: The HoxD cluster is located on chromosome 2 in mice, but in humans, it is located on chromosome 17.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein kinase 1 (CK1) is a serine/threonine kinase that plays a crucial role in various cellular processes, including signal transduction, metabolism, and DNA repair. The phosphorylation consensus motifs for CK1 are:\n1. Ser/Thr-Pro-X-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the catalytic subunit of CK1 and is commonly found in proteins that are phosphorylated by CK1.\n2. Ser/Thr-Pro-X-X-X-Ser/Thr-Gly-X-X-X (where X is any amino acid)\nThis motif is also recognized by the catalytic subunit of CK1 and is found in proteins that are phosphorylated by CK1 in response to various signals, including growth factors and hormones.\n3. Ser-X-X-X-Ser/Thr-X-X-X (where X is any amino acid)\nThis motif is recognized by the regulatory subunit of CK1 and is involved in the regulation of CK1 activity.\n4. Thr-X-X-X-Thr/Ser-X-X-X (where X is any amino acid)\nThis motif is recognized by the regulatory subunit of CK1 and is involved in the regulation of CK1 activity.\n5. Pro-X-X-X-Pro/Ser (where X is any amino acid)\nThis motif is recognized by the regulatory subunit of CK1 and is involved in the regulation of CK1 activity.\nIt's worth noting that these consensus motifs are not exclusive to CK1 and can be recognized by other kinases as well. Additionally, the specificity of kinase recognition can be influenced by the context of the surrounding amino acids and the presence of other post-translational modifications.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein kinase 1 (CK1) is a serine/threonine kinase involved in various cellular processes such as signal transduction, metabolism, and DNA repair.\n2. The phosphorylation consensus motif \"Ser/Thr-Pro-X-X-X-Ser/Thr\" is recognized by the catalytic subunit of CK1.\n3. The phosphorylation consensus motif \"Ser/Thr-Pro-X-X-X-Ser/Thr-Gly-X-X-X\" is recognized by the catalytic subunit of CK1 in response to various signals.\n4. The phosphorylation consensus motif \"Ser-X-X-X-Ser/Thr-X-X-X\" is recognized by the regulatory subunit of CK1.\n5. The phosphorylation consensus motif \"Pro-X-X-X-Pro/Ser\" is recognized by the regulatory subunit of CK1.",
    "llama-2-7b-chat-hf_fact": [
      "Casein kinase 1 (CK1) is a serine/threonine kinase involved in various cellular processes such as signal transduction, metabolism, and DNA repair.",
      "The phosphorylation consensus motif \"Ser/Thr-Pro-X-X-X-Ser/Thr\" is recognized by the catalytic subunit of CK1.",
      "The phosphorylation consensus motif \"Ser/Thr-Pro-X-X-X-Ser/Thr-Gly-X-X-X\" is recognized by the catalytic subunit of CK1 in response to various signals.",
      "The phosphorylation consensus motif \"Ser-X-X-X-Ser/Thr-X-X-X\" is recognized by the regulatory subunit of CK1.",
      "The phosphorylation consensus motif \"Pro-X-X-X-Pro/Ser\" is recognized by the regulatory subunit of CK1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The canonical phosphorylation consensus motif recognized by CK1 is \"Ser/Thr-X-X-Ser/Thr,\" where X represents any amino acid.\n3. UNKNOWN: The provided motif \"Ser/Thr-Pro-X-X-X-Ser/Thr-Gly-X-X-X\" is not a standard representation associated with CK1, and without specific context, it is unclear if this motif is relevant.\n4. FALSE [correction]: Casein kinase 1 (CK1) does not have a separate regulatory subunit; it functions as a monomeric enzyme. Therefore, it does not recognize motifs through a regulatory subunit.\n5. UNKNOWN: Given that CK1 does not have a regulatory subunit and the presented motif does not correspond to the well-established motifs recognized by CK1, the statement's validity is uncertain.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes multiple isoforms of the protein, including:\n1. Aspartate beta-hydroxylase (ASPH): The full-length form of the protein, which is the primary isoform expressed in most tissues.\n2. Tissue inhibitor of metalloproteinases 1 (TIMP1): A truncated form of ASPH that is generated through alternative splicing and functions as a tissue inhibitor of metalloproteinases.\n3. Matrix metalloproteinase 2 (MMP2): A proteolytic enzyme that is generated through alternative splicing and plays a role in extracellular matrix degradation.\n4. Matrix metalloproteinase 9 (MMP9): Another proteolytic enzyme generated through alternative splicing and involved in extracellular matrix degradation and inflammation.\n5. Prothrombin converting enzyme 1 (PCE1): A truncated form of ASPH generated through alternative splicing that is involved in blood coagulation.\nThese isoforms of ASPH have different functions and are expressed in different tissues and cell types, reflecting the diverse roles of the ASPH protein in various biological processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human ASPH gene encodes multiple isoforms of the protein.\n2. The full-length form of the protein, aspartate beta-hydroxylase (ASPH), is the primary isoform expressed in most tissues.\n3. Tissue inhibitor of metalloproteinases 1 (TIMP1) is a truncated form of ASPH that functions as a tissue inhibitor of metalloproteinases.\n4. Matrix metalloproteinase 2 (MMP2) is generated through alternative splicing of the ASPH gene and is involved in extracellular matrix degradation.\n5. Prothrombin converting enzyme 1 (PCE1) is a truncated form of ASPH involved in blood coagulation.",
    "llama-2-7b-chat-hf_fact": [
      "The human ASPH gene encodes multiple isoforms of the protein.",
      "The full-length form of the protein, aspartate beta-hydroxylase (ASPH), is the primary isoform expressed in most tissues.",
      "Tissue inhibitor of metalloproteinases 1 (TIMP1) is a truncated form of ASPH that functions as a tissue inhibitor of metalloproteinases.",
      "Matrix metalloproteinase 2 (MMP2) is generated through alternative splicing of the ASPH gene and is involved in extracellular matrix degradation.",
      "Prothrombin converting enzyme 1 (PCE1) is a truncated form of ASPH involved in blood coagulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE – The ASPH (aspartate β-hydroxylase) gene does indeed encode multiple protein isoforms through alternative splicing.\n2. UNKNOWN – While the full-length aspartate beta-hydroxylase is a known isoform of ASPH, without specific scientific literature or context, it is difficult to confirm if it is the primary isoform expressed in most tissues.\n3. FALSE [correction]: Tissue inhibitor of metalloproteinases 1 (TIMP1) is not a truncated form of ASPH. TIMP1 is a separate protein that inhibits metalloproteinases and is not generated by alternative splicing of the ASPH gene.\n4. FALSE [correction]: Matrix metalloproteinase 2 (MMP2) is not generated through alternative splicing of the ASPH gene. MMP2 is a separate gene and encodes an enzyme that is involved in the degradation of the extracellular matrix.\n5. FALSE [correction]: Prothrombin converting enzyme 1 (PCE1) is not a truncated form of ASPH. PCE1 (also known as activated factor X or factor Xa) is a separate enzyme in the blood coagulation pathway and is not derived from the ASPH gene.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was FDA approved on June 28, 2014, for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on June 28, 2014.\n2. The FDA approved empagliflozin for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on June 28, 2014.",
      "The FDA approved empagliflozin for the treatment of type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved on August 1, 2014.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis has several results:\n1. Increased sensitivity to oxidative stress: Lon1 plays a crucial role in protecting against oxidative stress by maintaining the balance of reactive oxygen species (ROS) and antioxidants. Without Lon1, Arabidopsis becomes more sensitive to oxidative stress, leading to cell death and damage.\n2. Impaired DNA repair: Lon1 is involved in the repair of DNA damage caused by ROS and other mutagenic agents. Without Lon1, DNA repair is impaired, leading to an accumulation of DNA damage and increased genome instability.\n3. Delayed cell cycle progression: Lon1 regulates the G1/S checkpoint and the progression of the cell cycle. Without Lon1, cell cycle progression is delayed, leading to a decrease in cell proliferation.\n4. Increased apoptosis: Lon1 regulates the expression of genes involved in apoptosis, and its loss leads to an increase in apoptotic cell death.\n5. Altered hormone signaling: Lon1 regulates the response to abscisic acid (ABA) and ethylene, two important plant hormones. Without Lon1, hormone signaling is altered, leading to changes in plant growth and development.\n6. Changes in gene expression: Lon1 regulates the expression of many genes involved in various cellular processes, including stress response, DNA repair, and cell cycle regulation. Without Lon1, the expression of these genes is altered, leading to changes in plant growth and development.\n7. Increased susceptibility to pathogens: Lon1 regulates the immune response and the recognition of pathogens. Without Lon1, Arabidopsis becomes more susceptible to pathogens, leading to increased disease susceptibility.\n8. Changes in root architecture: Lon1 regulates root growth and development, and its loss leads to changes in root architecture, including a decrease in root length and an increase in root branching.\n9. Altered shoot growth: Lon1 regulates shoot growth and development, and its loss leads to changes in shoot architecture, including a decrease in shoot height and an increase in",
    "llama-2-7b-chat-hf_fact_raw": "1. Without the protein Lon1, Arabidopsis becomes more sensitive to oxidative stress.\n2. Impaired DNA repair occurs in Arabidopsis when the protein Lon1 is lost.\n3. The loss of Lon1 protein leads to delayed cell cycle progression in Arabidopsis.\n4. Loss of Lon1 in Arabidopsis results in increased apoptosis.\n5. The absence of Lon1 protein leads to altered hormone signaling in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "Without the protein Lon1, Arabidopsis becomes more sensitive to oxidative stress.",
      "Impaired DNA repair occurs in Arabidopsis when the protein Lon1 is lost.",
      "The loss of Lon1 protein leads to delayed cell cycle progression in Arabidopsis.",
      "Loss of Lon1 in Arabidopsis results in increased apoptosis.",
      "The absence of Lon1 protein leads to altered hormone signaling in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Loss of Lon1 in Arabidopsis does not directly result in increased apoptosis. Instead, it could lead to defects in mitochondria-related processes, which might indirectly influence programmed cell death.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone exists in the yeast genome. In yeast, the linker histone is called H3K5ac (histone H3 lysine 5 acetylation). It is one of the five histone proteins that make up the nucleosome, along with histones H2A, H2B, H3, and H4. The linker histone is the histone that connects the nucleosomes and plays a role in the organization of chromatin into higher-order structures.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone exists in the yeast genome.\n2. The linker histone in yeast is called H3K5ac, which stands for histone H3 lysine 5 acetylation.\n3. The linker histone is one of the five histone proteins that constitute the nucleosome.\n4. The nucleosome includes histones H2A, H2B, H3, and H4, as well as the linker histone.\n5. The role of the linker histone is to connect nucleosomes and organize chromatin into higher-order structures.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone exists in the yeast genome.",
      "The linker histone in yeast is called H3K5ac, which stands for histone H3 lysine 5 acetylation.",
      "The linker histone is one of the five histone proteins that constitute the nucleosome.",
      "The nucleosome includes histones H2A, H2B, H3, and H4, as well as the linker histone.",
      "The role of the linker histone is to connect nucleosomes and organize chromatin into higher-order structures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Saccharomyces cerevisiae (a commonly studied yeast species) does not contain traditional linker histones, unlike most eukaryotic cells. Instead, it has non-histone chromosomal proteins that fulfill similar or related functions.\n2. FALSE [correction]: H3K5ac is not a linker histone; it is a post-translational modification of histone H3, specifically an acetylation at the 5th lysine residue of the histone H3 protein.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice can lower cholesterol levels. Tomato juice contains a number of compounds, including lycopene, flavonoids, and other phytochemicals, that have been shown to have a positive impact on cholesterol levels.\nSome studies have found that drinking tomato juice regularly can help to reduce total cholesterol levels, LDL (bad) cholesterol levels, and triglyceride levels. For example, a 2013 study published in the Journal of Functional Foods found that drinking 100 mL of tomato juice per day for 12 weeks resulted in significant reductions in total cholesterol and LDL cholesterol levels in healthy adults.\nOther studies have found similar results. A 2011 study published in the Journal of Nutrition found that drinking tomato juice for 12 weeks resulted in significant reductions in total cholesterol and LDL cholesterol levels in a group of adults with mild hypercholesterolemia.\nIt's thought that the lycopene and other antioxidants in tomato juice may play a role in reducing cholesterol levels by inhibiting the absorption of dietary cholesterol in the gut, as well as by reducing inflammation and oxidative stress in the body.\nIt's important to note, however, that while these findings are promising, the evidence is not yet conclusive, and more research is needed to fully understand the potential cholesterol-lowering effects of tomato juice. Additionally, it's important to remember that tomato juice is just one part of a healthy diet and lifestyle, and it's not a substitute for other cholesterol-lowering strategies, such as following a heart-healthy diet, getting regular exercise, and managing stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tomato juice contains lycopene, flavonoids, and other phytochemicals.\n2. A 2013 study in the Journal of Functional Foods reported that drinking 100 mL of tomato juice daily for 12 weeks led to significant reductions in total cholesterol and LDL cholesterol levels in healthy adults.\n3. A 2011 study in the Journal of Nutrition found significant reductions in total cholesterol and LDL cholesterol levels after drinking tomato juice for 12 weeks in adults with mild hypercholesterolemia.\n4. Lycopene and antioxidants in tomato juice may reduce cholesterol levels by inhibiting the absorption of dietary cholesterol in the gut and by reducing inflammation and oxidative stress.",
    "llama-2-7b-chat-hf_fact": [
      "Tomato juice contains lycopene, flavonoids, and other phytochemicals.",
      "A 2013 study in the Journal of Functional Foods reported that drinking 100 mL of tomato juice daily for 12 weeks led to significant reductions in total cholesterol and LDL cholesterol levels in healthy adults.",
      "A 2011 study in the Journal of Nutrition found significant reductions in total cholesterol and LDL cholesterol levels after drinking tomato juice for 12 weeks in adults with mild hypercholesterolemia.",
      "Lycopene and antioxidants in tomato juice may reduce cholesterol levels by inhibiting the absorption of dietary cholesterol in the gut and by reducing inflammation and oxidative stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The study conducted in 2013 on tomato juice's effects on cholesterol levels does not appear in my known data. A review up to my knowledge cutoff date does not confirm this specific study. Therefore, the statement could not be verified as true or false based on my data.\n3. FALSE [correction]: While certain studies have explored the effects of tomato juice on cholesterol levels, without specific details such as the name of the journal or the exact study, it cannot be reliably matched with any known studies. The provided year and the effects mentioned do not directly correspond to a specific study that I'm aware of.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are protein chaperones that play important roles in regulating mRNA stability.\nHsp70:\n* Hsp70 binds to mRNAs and protects them from degradation by the 5' exonuclease of the ribonuclease outflow complex.\n* Hsp70 can also stimulate the translation of mRNAs by interacting with ribosomes.\n* Hsp70 can also regulate mRNA stability by inhibiting the activity of the RNA exosome, a complex that degrades mRNAs.\nHsp110:\n* Hsp110 also binds to mRNAs and protects them from degradation by the 5' exonuclease of the ribonuclease outflow complex.\n* Hsp110 can also stimulate the translation of mRNAs by interacting with ribosomes.\n* Hsp110 can also regulate mRNA stability by inhibiting the activity of the RNA exosome, a complex that degrades mRNAs.\nIn summary, both Hsp70 and Hsp110 play important roles in protecting mRNAs from degradation and promoting their translation, and their dysregulation can lead to changes in mRNA stability and translation, which can have significant consequences for cellular function and disease progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 binds to mRNAs and protects them from degradation by the 5' exonuclease of the ribonuclease outflow complex.\n2. Hsp70 can stimulate the translation of mRNAs by interacting with ribosomes.\n3. Hsp70 can regulate mRNA stability by inhibiting the activity of the RNA exosome.\n4. Hsp110 also binds to mRNAs and protects them from degradation by the 5' exonuclease of the ribonuclease outflow complex.\n5. Hsp110 can stimulate the translation of mRNAs by interacting with ribosomes.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 binds to mRNAs and protects them from degradation by the 5' exonuclease of the ribonuclease outflow complex.",
      "Hsp70 can stimulate the translation of mRNAs by interacting with ribosomes.",
      "Hsp70 can regulate mRNA stability by inhibiting the activity of the RNA exosome.",
      "Hsp110 also binds to mRNAs and protects them from degradation by the 5' exonuclease of the ribonuclease outflow complex.",
      "Hsp110 can stimulate the translation of mRNAs by interacting with ribosomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hsp70 binds to mRNAs and may protect them from degradation, but typically, the exonuclease in the RNA exosome complex acts at the 3' end of mRNAs, not the 5' end.\n2. TRUE: Hsp70 can facilitate the translation of mRNAs by interacting with ribosomes and other translation initiation factors.\n3. TRUE: Hsp70 can regulate mRNA stability, potentially by interfering with RNA degradation pathways such as the RNA exosome.\n4. UNKNOWN: While Hsp110 is a molecular chaperone like Hsp70, and it might protect mRNAs from degradation, the exact mechanism and specificity for the 5' exonuclease of the ribonuclease outflow complex is not clearly established and may vary depending on the context.\n5. UNKNOWN: Similar to statement 4, while Hsp110 can interact with ribosomes and affect protein folding, the specific claim that it stimulates the translation of mRNAs by interacting directly with ribosomes is not sufficiently documented without additional context or specific references to research findings.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Deiodinases are enzymes that play a crucial role in the regulation of thyroid hormone metabolism. There are three isoforms of deiodinases present in skeletal muscle:\n1. Deiodinase type 1 (D1): D1 is the primary deiodinase isoform in skeletal muscle, and it is responsible for converting T4 to T3. T3 is the active form of thyroid hormone that plays a key role in regulating muscle metabolism and growth.\n2. Deiodinase type 2 (D2): D2 is less abundant than D1 in skeletal muscle, but it plays a role in the conversion of T4 to reverse T3 (rT3). Reverse T3 is an inactive form of thyroid hormone that can inhibit the activity of T3.\n3. Deiodinase type 3 (D3): D3 is found in low levels in skeletal muscle, and it is primarily involved in the conversion of T3 to T2 (triiodothyronine). T2 is an inactive form of thyroid hormone that is not involved in the regulation of muscle metabolism.\nOverall, the balance between the activity of these deiodinases in skeletal muscle determines the levels of active thyroid hormone available for muscle metabolism and growth.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deiodinase type 1 (D1) is present in skeletal muscle and is responsible for converting T4 to T3.\n2. Deiodinase type 2 (D2) is present in skeletal muscle and is involved in the conversion of T4 to reverse T3 (rT3).\n3. Deiodinase type 3 (D3) is present in skeletal muscle and is involved in the conversion of T3 to T2.\n4. T3 is the active form of thyroid hormone that plays a key role in regulating muscle metabolism and growth.\n5. Reverse T3 is an inactive form of thyroid hormone that can inhibit the activity of T3.",
    "llama-2-7b-chat-hf_fact": [
      "Deiodinase type 1 (D1) is present in skeletal muscle and is responsible for converting T4 to T3.",
      "Deiodinase type 2 (D2) is present in skeletal muscle and is involved in the conversion of T4 to reverse T3 (rT3).",
      "Deiodinase type 3 (D3) is present in skeletal muscle and is involved in the conversion of T3 to T2.",
      "T3 is the active form of thyroid hormone that plays a key role in regulating muscle metabolism and growth.",
      "Reverse T3 is an inactive form of thyroid hormone that can inhibit the activity of T3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deiodinase type 2 (D2) is primarily responsible for converting T4 to T3 in peripheral tissues, including skeletal muscle, not Deiodinase type 1 (D1).\n2. UNKNOWN: While Deiodinase type 2 (D2) is involved in the conversion of T4 to T3, the specific involvement of D2 in producing reverse T3 (rT3) in skeletal muscle is not clearly stated and might require more specific information.\n3. TRUE: Deiodinase type 3 (D3) is known for inactivating thyroid hormones by converting T4 to reverse T3 (rT3), and T3 to T2.\n4. TRUE: T3, or triiodothyronine, is indeed the active form of thyroid hormone and it is crucial for regulating metabolic processes across various tissues, including muscle metabolism and growth.\n5. TRUE: Reverse T3 (rT3) is an inactive form of thyroid hormone that competes with T3 for binding to thyroid hormone receptors, and in doing so, can inhibit the biological activity of T3.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Caspases are a family of enzymes that play a central role in the inflammatory response by mediating the breakdown of cellular components and contributing to the resolution of inflammation. Here are some examples of inflammatory caspase proteins:\n1. Caspase-1 (also known as interleukin-1 beta converting enzyme, or ICE): Caspase-1 is the most well-known inflammatory caspase and is activated in response to a variety of pro-inflammatory cytokines, including interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha). Caspase-1 processes these cytokines to their active forms, which then trigger an inflammatory response.\n2. Caspase-3: Caspase-3 is activated in response to apoptotic signals, such as those generated by the death receptor pathway, and plays a role in the execution of apoptosis. However, it also has been shown to be involved in the regulation of inflammation, particularly in the processing of pro-inflammatory cytokines.\n3. Caspase-8: Caspase-8 is a member of the initiator caspase family and is activated in response to death receptor ligation. It plays a role in the induction of apoptosis, but also has been shown to be involved in the regulation of inflammation, particularly in the processing of pro-inflammatory cytokines.\n4. Caspase-9: Caspase-9 is also a member of the initiator caspase family and is activated in response to death receptor ligation. It plays a role in the induction of apoptosis, but also has been shown to be involved in the regulation of inflammation, particularly in the processing of pro-inflammatory cytokines.\n5. Caspase-12: Caspase-12 is activated in response to endoplasmic reticulum (ER) stress and plays a role in the regulation of inflammation, particularly in the processing of pro-inflammatory cytokines.\nThese are some of the examples of inflammatory caspase proteins, but there are many more",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is known as interleukin-1 beta converting enzyme, or ICE, and is an inflammatory caspase.\n2. Caspase-1 is activated in response to pro-inflammatory cytokines and processes them into their active forms.\n3. Caspase-3 is involved in the regulation of inflammation and the processing of pro-inflammatory cytokines.\n4. Caspase-8 is activated in response to death receptor ligation and contributes to the regulation of inflammation.\n5. Caspase-12 is activated in response to endoplasmic reticulum stress and plays a role in the regulation of inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is known as interleukin-1 beta converting enzyme, or ICE, and is an inflammatory caspase.",
      "Caspase-1 is activated in response to pro-inflammatory cytokines and processes them into their active forms.",
      "Caspase-3 is involved in the regulation of inflammation and the processing of pro-inflammatory cytokines.",
      "Caspase-8 is activated in response to death receptor ligation and contributes to the regulation of inflammation.",
      "Caspase-12 is activated in response to endoplasmic reticulum stress and plays a role in the regulation of inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Caspase-3 is involved in the execution phase of apoptosis and is not primarily responsible for the regulation of inflammation or the processing of pro-inflammatory cytokines.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between Aurora B kinase and the polycomb protein Ring1B. Both Aurora B and Ring1B are involved in the regulation of chromatin dynamics and gene expression, particularly during mitosis.\nAurora B is a serine/threonine kinase that plays a crucial role in the proper separation of chromosomes during mitosis by regulating the congression, progression, and separation of chromosomes during the metaphase-anaphase transition. Aurora B also phosphorylates and regulates the activity of other proteins involved in the mitotic process, including the histone H3-fold protein, H3S10ph.\nRing1B, on the other hand, is a polycomb group protein that plays a critical role in the maintenance of gene silencing during mitosis. Ring1B is involved in the deposition of histone H3 tri-methylation at lysine 27 (H3K27me3), which is a repressive mark that silences gene expression. Ring1B also interacts with and regulates the activity of other polycomb group proteins, including Polycomb Repressive Complex 2 (PRC2).\nRecent studies have shown that Aurora B and Ring1B interact and cooperate in the regulation of chromatin dynamics during mitosis. Aurora B has been shown to phosphorylate and activate Ring1B, leading to the deposition of H3K27me3 and the silencing of target genes. Conversely, Ring1B has been shown to be required for the proper localization and activity of Aurora B during mitosis.\nIn summary, there is a complex interplay between Aurora B and Ring1B in the regulation of chromatin dynamics and gene expression during mitosis. Both proteins play critical roles in ensuring the proper separation of chromosomes and the maintenance of gene silencing during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and the polycomb protein Ring1B are both involved in the regulation of chromatin dynamics and gene expression during mitosis.\n2. Aurora B is a serine/threonine kinase that regulates the congression, progression, and separation of chromosomes during the metaphase-anaphase transition of mitosis.\n3. Ring1B is a polycomb group protein that contributes to the maintenance of gene silencing during mitosis by depositing the repressive histone mark H3 tri-methylation at lysine 27 (H3K27me3).\n4. Aurora B kinase phosphorylates and activates Ring1B, which leads to the deposition of the H3K27me3 mark and the silencing of target genes.\n5. Ring1B is required for the proper localization and activity of Aurora B kinase during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and the polycomb protein Ring1B are both involved in the regulation of chromatin dynamics and gene expression during mitosis.",
      "Aurora B is a serine/threonine kinase that regulates the congression, progression, and separation of chromosomes during the metaphase-anaphase transition of mitosis.",
      "Ring1B is a polycomb group protein that contributes to the maintenance of gene silencing during mitosis by depositing the repressive histone mark H3 tri-methylation at lysine 27 (H3K27me3).",
      "Aurora B kinase phosphorylates and activates Ring1B, which leads to the deposition of the H3K27me3 mark and the silencing of target genes.",
      "Ring1B is required for the proper localization and activity of Aurora B kinase during mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Aurora B kinase does not phosphorylate and activate Ring1B. Instead, Aurora B kinase and Ring1B function in separate pathways that contribute to chromatin dynamics and gene expression regulation during mitosis. Aurora B kinase is involved in chromosome alignment and segregation while Ring1B is associated with histone modification and gene silencing.\n5. FALSE [correction]: There is no direct evidence suggesting that Ring1B is required for the proper localization and activity of Aurora B kinase during mitosis. Each protein plays a distinct role during mitosis, and while they both contribute to chromatin regulation, one does not directly influence the localization and activity of the other in the manner described.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs are alterations in the splice site consensus sequences that can disrupt the normal splicing process. In vertebrates, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites are:\nDonor splice sites:\n* GU-rich sequences: GU-rich sequences are found in the donor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n* AG dinucleotides: AG dinucleotides are found in the donor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n* G-quadruplex forming sequences: G-quadruplex forming sequences are found in the donor splice site and can lead to the formation of G-quadruplexes, which can affect splicing.\n* Intron-like sequences: Intron-like sequences are found in the donor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\nAcceptor splice sites:\n* GU-rich sequences: GU-rich sequences are found in the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n* AG dinucleotides: AG dinucleotides are found in the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n* G-quadruplex forming sequences: G-quadruplex forming sequences are found in the acceptor splice site and can lead to the formation of G-quadruplexes, which can affect splicing.\n* Intron-like sequences: Intron-like sequences are found in the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\nIt's worth noting that the frequency of these non-canonical motifs can vary depending on the tissue, cell type, and developmental stage of the organism. Additionally, the effects of these non-canonical motifs on splicing can also vary and may depend on the specific context in which they are found.",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich sequences are non-canonical motifs found at both donor and acceptor splice sites in vertebrates.\n2. AG dinucleotides are non-canonical motifs found at both donor and acceptor splice sites in vertebrates.\n3. G-quadruplex forming sequences are non-canonical motifs found at both donor and acceptor splice sites in vertebrates.\n4. Intron-like sequences are non-canonical motifs found at both donor and acceptor splice sites in vertebrates.\n5. The presence of these non-canonical motifs can lead to the inclusion of cryptic exons or the skipping of exons.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich sequences are non-canonical motifs found at both donor and acceptor splice sites in vertebrates.",
      "AG dinucleotides are non-canonical motifs found at both donor and acceptor splice sites in vertebrates.",
      "G-quadruplex forming sequences are non-canonical motifs found at both donor and acceptor splice sites in vertebrates.",
      "Intron-like sequences are non-canonical motifs found at both donor and acceptor splice sites in vertebrates.",
      "The presence of these non-canonical motifs can lead to the inclusion of cryptic exons or the skipping of exons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: GU-rich sequences are indeed non-canonical motifs found at splice sites. They play a role in the regulation of alternative splicing.\n2. FALSE [correction]: AG dinucleotides are canonical motifs found at the 3' end of introns (acceptor splice site) in vertebrates.\n3. UNKNOWN: G-quadruplex forming sequences can play a role in the regulation of gene expression, but whether they are commonly found at both donor and acceptor splice sites as non-canonical motifs is not definitively established for vertebrates without specific context.\n4. TRUE: Intron-like sequences or intronic splicing enhancers/silencers can be considered non-canonical motifs that influence splicing; however, they are not splice sites themselves but rather sequences within introns that affect the splicing process.\n5. TRUE: The presence of non-canonical motifs can indeed affect the splicing process, potentially leading to the inclusion of cryptic exons or the skipping of exons, thus affecting gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "S6K1 (S6 kinase 1) is acetylated in response to activation of the PI3K (phosphatidylinositol 3-kinase) signaling pathway. Specifically, the phosphatidylinositol 3,4,5-trisphosphate (PIP3) produced by PI3K can recruit and activate S6K1, leading to its acetylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. S6K1 stands for S6 kinase 1.\n2. S6K1 is acetylated when the PI3K signaling pathway is activated.\n3. Phosphatidylinositol 3-kinase is abbreviated as PI3K.\n4. The production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) by PI3K can lead to the activation of S6K1.\n5. Activation and subsequent acetylation of S6K1 can result from the recruitment of S6K1 by PIP3.",
    "llama-2-7b-chat-hf_fact": [
      "S6K1 stands for S6 kinase 1.",
      "S6K1 is acetylated when the PI3K signaling pathway is activated.",
      "Phosphatidylinositol 3-kinase is abbreviated as PI3K.",
      "The production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) by PI3K can lead to the activation of S6K1.",
      "Activation and subsequent acetylation of S6K1 can result from the recruitment of S6K1 by PIP3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: S6K1 is phosphorylated, not acetylated when the PI3K signaling pathway is activated.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The activation of S6K1 can result from its phosphorylation due to other kinases like AKT that are recruited by PIP3; acetylation is not directly involved in S6K1 activation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. This gene encodes a subunit of the calcium channel Cav2.2, which is involved in the regulation of neuronal excitability and the formation of action potentials in the brain. Mutations in the CACNA1A gene lead to a decrease in the function of the Cav2.2 channel, resulting in an imbalance in the excitation and inhibition of neurons, leading to the characteristic episodic ataxia symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.\n2. The CACNA1A gene encodes a subunit of the calcium channel Cav2.2.\n3. Cav2.2 is involved in the regulation of neuronal excitability and formation of action potentials in the brain.\n4. Mutations in the CACNA1A gene lead to a decrease in the function of the Cav2.2 channel.\n5. A decrease in the function of the Cav2.2 channel results in an imbalance in the excitation and inhibition of neurons.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene encodes a subunit of the calcium channel Cav2.2.",
      "Cav2.2 is involved in the regulation of neuronal excitability and formation of action potentials in the brain.",
      "Mutations in the CACNA1A gene lead to a decrease in the function of the Cav2.2 channel.",
      "A decrease in the function of the Cav2.2 channel results in an imbalance in the excitation and inhibition of neurons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The CACNA1A gene encodes the α1A subunit of the voltage-dependent P/Q-type calcium channel, not Cav2.2, which is the N-type.\n3. TRUE\n4. FALSE [correction]: Mutations in the CACNA1A gene can lead to either a loss or gain of function of the P/Q-type calcium channel, depending on the type of mutation.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that modify chromatin structure by adding methyl groups to histone proteins, which can alter chromatin dynamics and impact gene expression. While the types and functions of chromomethylases in animals are not as well studied as those in plants, there is evidence that they play important roles in various cellular processes, including transcriptional regulation, DNA damage response, and cell fate determination.\nSome examples of chromomethylases found in animal genomes include:\n1. Histone methyltransferases (HMTs): These enzymes catalyze the transfer of a methyl group from S-adenosylmethionine to specific histone residues, leading to changes in chromatin structure and gene expression. HMTs are involved in various cellular processes, including transcriptional activation, repression, and maintenance of chromatin stability.\n2. Chromodomain-containing proteins: These proteins contain a chromodomain, a specific DNA-binding domain that recognizes and binds to methylated histone tails. Chromodomain-containing proteins play roles in transcriptional regulation, DNA repair, and chromatin remodeling.\n3. SETDB1 (Eset): SETDB1 is a histone methyltransferase that specifically methylates histone H3 lysine 9 (H3K9) and is involved in the regulation of gene expression, particularly in stem cells and developmental processes.\n4. KMT1E (EZH2): KMT1E is a histone methyltransferase that catalyzes the methylation of histone H3 lysine 27 (H3K27) and is involved in the regulation of gene expression, particularly in stem cells and cancer.\n5. SUV39H1 (H3K9me3): SUV39H1 is a histone methyltransferase that specifically methylates histone H3 lysine 9 (H3K9) and is involved in the regulation of gene expression, particularly in stem cells and developmental processes.\nThese are just a few examples of the chromomethylases found in animal",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases modify chromatin structure by adding methyl groups to histone proteins.\n2. Histone methyltransferases (HMTs) transfer a methyl group from S-adenosylmethionine to specific histone residues.\n3. Chromodomain-containing proteins bind to methylated histone tails and are involved in transcriptional regulation, DNA repair, and chromatin remodeling.\n4. SETDB1 (Eset) is a histone methyltransferase that specifically methylates histone H3 lysine 9 (H3K9).\n5. KMT1E (EZH2) is a histone methyltransferase that catalyzes the methylation of histone H3 lysine 27 (H3K27).",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases modify chromatin structure by adding methyl groups to histone proteins.",
      "Histone methyltransferases (HMTs) transfer a methyl group from S-adenosylmethionine to specific histone residues.",
      "Chromodomain-containing proteins bind to methylated histone tails and are involved in transcriptional regulation, DNA repair, and chromatin remodeling.",
      "SETDB1 (Eset) is a histone methyltransferase that specifically methylates histone H3 lysine 9 (H3K9).",
      "KMT1E (EZH2) is a histone methyltransferase that catalyzes the methylation of histone H3 lysine 27 (H3K27)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases typically refer to enzymes that modify DNA by adding methyl groups to cytosine bases, not to histone proteins. Histone methyltransferases are responsible for adding methyl groups to histone proteins.\n\n2. TRUE\n\n3. TRUE\n\n4. TRUE\n\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS):\n1. TFBS-tools: This package provides a collection of tools for the analysis of TFBSs, including the prediction of TFBSs, the analysis of ChIP-seq data, and the visualization of TFBSs.\n2. TRANSFAC: This package provides a comprehensive collection of TFBSs from various sources, including experimentally validated sites and predicted sites. It also includes tools for the analysis and visualization of TFBSs.\n3. ChIPseek: This package provides tools for the analysis of ChIP-seq data, including the identification of TFBSs and the analysis of histone modification profiles.\n4. HISAT2: This package provides tools for the analysis of ChIP-seq data, including the identification of TFBSs and the analysis of histone modification profiles.\n5. STAR: This package provides tools for the analysis of RNA-seq and ChIP-seq data, including the identification of TFBSs and the analysis of histone modification profiles.\n6. DeepTools: This package provides tools for the analysis of ChIP-seq data, including the identification of TFBSs and the analysis of histone modification profiles.\n7. bedtools: This package provides tools for the analysis of genomic data, including the identification of TFBSs and the analysis of histone modification profiles.\n8. UCSC Genome Browser: This package provides a web-based tool for the visualization and analysis of genomic data, including the identification of TFBSs and the analysis of histone modification profiles.\n9. Ensembl API: This package provides tools for the analysis of genomic data, including the identification of TFBSs and the analysis of histone modification profiles.\n10. GTFToBigWig: This package provides tools for the analysis of genomic data, including the identification of TFBSs and the analysis of histone modification profiles.\nThese packages can be used to analyze TFBSs in various organisms, including humans, mice, and yeast. They provide a range of tools for the analysis of TFBSs, including the prediction of TFBSs, the analysis of ChIP-seq data, and the visualization of T",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBS-tools is a package available in R/Bioconductor that includes tools for prediction, analysis of ChIP-seq data, and visualization of TFBSs.\n2. TRANSFAC is a package in R/Bioconductor that provides a comprehensive collection of TFBSs and includes tools for analysis and visualization of TFBSs.\n3. ChIPseek is an R/Bioconductor package designed for analyzing ChIP-seq data and identifying TFBSs.\n4. HISAT2 is an R/Bioconductor package that offers tools for analyzing ChIP-seq data, including identification of TFBSs.\n5. The UCSC Genome Browser package is a web-based tool available in R/Bioconductor for the visualization and analysis of genomic data, including TFBSs.",
    "llama-2-7b-chat-hf_fact": [
      "TFBS-tools is a package available in R/Bioconductor that includes tools for prediction, analysis of ChIP-seq data, and visualization of TFBSs.",
      "TRANSFAC is a package in R/Bioconductor that provides a comprehensive collection of TFBSs and includes tools for analysis and visualization of TFBSs.",
      "ChIPseek is an R/Bioconductor package designed for analyzing ChIP-seq data and identifying TFBSs.",
      "HISAT2 is an R/Bioconductor package that offers tools for analyzing ChIP-seq data, including identification of TFBSs.",
      "The UCSC Genome Browser package is a web-based tool available in R/Bioconductor for the visualization and analysis of genomic data, including TFBSs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TRANSFAC is a database that provides information on transcription factors and their corresponding DNA binding sites, but it is not a package in R/Bioconductor itself.\n3. FALSE [correction]: The correct name is ChIPseeker, not ChIPseek. ChIPseeker is an R/Bioconductor package designed for ChIP-seq data analysis and for annotating TFBSs.\n4. FALSE [correction]: HISAT2 is not an R/Bioconductor package but a fast and sensitive alignment program for mapping next-generation sequencing data, which is often used prior to ChIP-seq data analysis.\n5. FALSE [correction]: The UCSC Genome Browser itself is not a package available in R/Bioconductor. However, there is a package called \"rtracklayer\" in R/Bioconductor that allows for interfacing with the UCSC Genome Browser and other genome browsers for visualization and data retrieval.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Here are some clinical trials related to the prevention of sarcopenia:\n1. \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2019) - This study published in the Journal of the American Medical Directors Association conducted a systematic review and meta-analysis of randomized controlled trials examining the effects of exercise and nutrition interventions on sarcopenia in older adults.\n2. \"Resistance Training and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2018) - This study published in the Journal of the American Geriatrics Society randomized older adults to either a resistance training program or a nutrition intervention alone and found that both interventions were effective in preventing sarcopenia.\n3. \"Effects of a Multicomponent Exercise Program on Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2017) - This study published in the Journal of Aging and Physical Activity randomized older adults to either a multicomponent exercise program or a control group and found that the exercise program was effective in reducing sarcopenia.\n4. \"Nutritional Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2016) - This study published in the Journal of the American Geriatrics Society conducted a systematic review and meta-analysis of randomized controlled trials examining the effects of nutritional interventions on sarcopenia in older adults.\n5. \"Resistance Training and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2018) - This study published in the Journal of the American Geriatrics Society randomized older adults to either a resistance training program or a nutrition intervention alone and found that both interventions were effective in preventing sarcopenia.\n6. \"The Effects of a 12-Month Exercise Program on Sarcopenia in Older Adults:",
    "llama-2-7b-chat-hf_fact_raw": "1. The study \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was published in 2019 in the Journal of the American Medical Directors Association.\n2. The study published in the Journal of the American Geriatrics Society in 2018 found that resistance training and nutrition interventions were effective in preventing sarcopenia in older adults.\n3. The \"Effects of a Multicomponent Exercise Program on Sarcopenia in Older Adults: A Randomized Controlled Trial\" published in the Journal of Aging and Physical Activity in 2017 found that a multicomponent exercise program reduced sarcopenia in older adults.\n4. A systematic review and meta-analysis study titled \"Nutritional Interventions to Prevent Sarcopenia in Older Adults\" was published in the Journal of the American Geriatrics Society in 2016.\n5. \"Resistance Training and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" is the title of a study duplicated in the list, which was also published in the Journal of the American Geriatrics Society in 2018.",
    "llama-2-7b-chat-hf_fact": [
      "The study \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was published in 2019 in the Journal of the American Medical Directors Association.",
      "The study published in the Journal of the American Geriatrics Society in 2018 found that resistance training and nutrition interventions were effective in preventing sarcopenia in older adults.",
      "The \"Effects of a Multicomponent Exercise Program on Sarcopenia in Older Adults: A Randomized Controlled Trial\" published in the Journal of Aging and Physical Activity in 2017 found that a multicomponent exercise program reduced sarcopenia in older adults.",
      "A systematic review and meta-analysis study titled \"Nutritional Interventions to Prevent Sarcopenia in Older Adults\" was published in the Journal of the American Geriatrics Society in 2016.",
      "\"Resistance Training and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" is the title of a study duplicated in the list, which was also published in the Journal of the American Geriatrics Society in 2018."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: This statement cannot be deemed false or true definitively since there is no clear contradiction or confirmation within the provided statements. It seems to be unique and not evidently duplicated in the list, but without more information, the accuracy of the publication year or the existence of the study cannot be ascertained.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins, but some of the most well-known and widely used include:\n1. The Membrane Protein Structure Prediction (MPSP) database: This database contains a collection of membrane protein structures, along with their corresponding membrane-spanning segments and transmembrane helices.\n2. The Membrane Protein Database (MPD): This database contains information on the structure, function, and evolution of membrane proteins, including their molecular recognition features.\n3. The Protein Data Bank (PDB): This database contains a large collection of 3D structures of proteins, including membrane proteins, along with their bound ligands and other molecular recognition features.\n4. The Membrane Protein Recognition Database (MPRD): This database contains a collection of membrane protein-ligand complexes, along with information on the molecular recognition features of the protein-ligand interactions.\n5. The Membrane Protein Interaction Database (MPID): This database contains information on the interactions between membrane proteins and other molecules, including ligands, proteins, and small molecules.\n6. The Membrane Protein-Ligand Interaction Database (MPLID): This database contains information on the interactions between membrane proteins and their ligands, including the molecular recognition features of these interactions.\n7. The Membrane Protein Structure and Function Prediction (MPSFP) database: This database contains a collection of membrane protein structures and their corresponding functions, along with information on the molecular recognition features of the protein-ligand interactions.\n8. The Membrane Protein-Mutation Database (MPMD): This database contains information on the effects of mutations on the function of membrane proteins, including the molecular recognition features of the mutations.\n9. The Membrane Protein-Drug Interaction Database (MPDID): This database contains information on the interactions between membrane proteins and drugs, including the molecular recognition features of these interactions.\n10. The Membrane Protein-RNA Interaction Database (MPRID): This database contains information on the interactions between membrane proteins and RNA molecules, including the molecular recognition features of these interactions.\nThese databases are valuable resources for researchers",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Structure Prediction (MPSP) database contains a collection of membrane protein structures.\n2. The Membrane Protein Database (MPD) includes information on the structure, function, and evolution of membrane proteins.\n3. The Protein Data Bank (PDB) has a large collection of 3D structures of proteins, including membrane proteins.\n4. The Membrane Protein Recognition Database (MPRD) contains a collection of membrane protein-ligand complexes.\n5. The Membrane Protein-Ligand Interaction Database (MPLID) provides information on interactions between membrane proteins and their ligands.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Structure Prediction (MPSP) database contains a collection of membrane protein structures.",
      "The Membrane Protein Database (MPD) includes information on the structure, function, and evolution of membrane proteins.",
      "The Protein Data Bank (PDB) has a large collection of 3D structures of proteins, including membrane proteins.",
      "The Membrane Protein Recognition Database (MPRD) contains a collection of membrane protein-ligand complexes.",
      "The Membrane Protein-Ligand Interaction Database (MPLID) provides information on interactions between membrane proteins and their ligands."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe MPSP database (assuming it exists as described), the MPD, and the PDB are known resources for protein structure information. However, without specific knowledge of databases named the Membrane Protein Recognition Database (MPRD) and the Membrane Protein-Ligand Interaction Database (MPLID), it is not possible to confirm the accuracy of statements 4 and 5 without additional context or information. These databases could exist and have the functions described but cannot be verified with the information provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is metabolized by the liver and kidneys, with the liver being the primary site of metabolism. The liver metabolizes rivaroxaban to an active metabolite, which is then further metabolized by the kidneys to form the inactive metabolite. The kidneys play a minor role in the metabolism of rivaroxaban, but they are still important for its elimination from the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by the liver and the kidneys.\n2. The primary site of rivaroxaban metabolism is the liver.\n3. The liver metabolizes rivaroxaban into an active metabolite.\n4. The kidneys metabolize the active metabolite of rivaroxaban into an inactive metabolite.\n5. The kidneys play a role in the elimination of rivaroxaban from the body.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by the liver and the kidneys.",
      "The primary site of rivaroxaban metabolism is the liver.",
      "The liver metabolizes rivaroxaban into an active metabolite.",
      "The kidneys metabolize the active metabolite of rivaroxaban into an inactive metabolite.",
      "The kidneys play a role in the elimination of rivaroxaban from the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The liver metabolizes rivaroxaban primarily into inactive metabolites.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRα2 is a subtype of the thyroid hormone receptor that plays a crucial role in regulating gene expression in the heart. Studies have shown that TRα2 regulates the expression of several genes involved in cardiac function, including:\n1. α-myosin heavy chain (MHC-α): TRα2 regulates the expression of MHC-α, which is a key component of the contractile apparatus in the heart.\n2. β-myosin heavy chain (MHC-β): TRα2 also regulates the expression of MHC-β, which is another important component of the contractile apparatus in the heart.\n3. Troponin I (TnI): TRα2 regulates the expression of TnI, which is a regulatory protein that plays a crucial role in the regulation of muscle contraction in the heart.\n4. Tropomyosin (Tpm): TRα2 regulates the expression of Tpm, which is a protein that regulates the contraction of muscle fibers in the heart.\n5. GATA4: TRα2 regulates the expression of GATA4, a transcription factor that plays a crucial role in the development and maintenance of the cardiac conduction system.\n6. Nkx2.5: TRα2 regulates the expression of Nkx2.5, a transcription factor that plays a crucial role in the development and maintenance of the cardiac conduction system.\n7. Bcl-2: TRα2 regulates the expression of Bcl-2, a protein that regulates apoptosis in the heart.\n8. Bax: TRα2 regulates the expression of Bax, a protein that regulates apoptosis in the heart.\n9. Caveolin-1 (Cav-1): TRα2 regulates the expression of Cav-1, a protein that plays a crucial role in the regulation of cardiac function and metabolism.\n10. FosB (Fos-binding protein): TRα2 regulates the expression of FosB, a transcription factor that plays a crucial role in the regulation of cardiac function and metabolism.\nThese genes are just a few examples of the many genes that are regulated by TRα2 in the heart. TRα2",
    "llama-2-7b-chat-hf_fact_raw": "1. TRα2 regulates the expression of α-myosin heavy chain (MHC-α) in the heart.\n2. TRα2 regulates the expression of β-myosin heavy chain (MHC-β) in the heart.\n3. TRα2 regulates the expression of Troponin I (TnI) in the heart.\n4. TRα2 regulates the expression of Tropomyosin (Tpm) in the heart.\n5. TRα2 regulates the expression of GATA4 in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "TRα2 regulates the expression of α-myosin heavy chain (MHC-α) in the heart.",
      "TRα2 regulates the expression of β-myosin heavy chain (MHC-β) in the heart.",
      "TRα2 regulates the expression of Troponin I (TnI) in the heart.",
      "TRα2 regulates the expression of Tropomyosin (Tpm) in the heart.",
      "TRα2 regulates the expression of GATA4 in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to specific gene regulation in the heart, concerning TRα2 (a variant of thyroid hormone receptor alpha) and its influence on the expression of various cardiac proteins. Without specific scientific literature or research findings to confirm or refute these statements, it is impossible to determine the veracity of the claims about the regulatory functions of TRα2. Therefore, the truthfulness of these statements remains unknown based on the information provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Here are some available biomedical question answering systems:\n1. Biomedical Informatics Research Network (BIRN): BIRN is a question answering system that uses natural language processing and machine learning techniques to answer biomedical questions.\n2. Biomedical Question Answering System (BQAS): BQAS is a question answering system that uses a combination of natural language processing, machine learning, and domain-specific knowledge to answer biomedical questions.\n3. PubMed Central Question Answering Service (PMCQA): PMCQA is a question answering system that uses natural language processing and machine learning techniques to answer biomedical questions based on the PubMed Central database.\n4. Biomedical Natural Language Processing (BioNLP) System: BioNLP is a question answering system that uses natural language processing techniques to extract information from biomedical literature and answer questions.\n5. Biomedical Text Mining (BTM) System: BTM is a question answering system that uses natural language processing and machine learning techniques to mine biomedical text and answer questions.\n6. Biomedical Information Retrieval (BIR) System: BIR is a question answering system that uses natural language processing and machine learning techniques to retrieve biomedical information and answer questions.\n7. Biomedical Question Answering System using Deep Learning (BQA-Deep): BQA-Deep is a question answering system that uses deep learning techniques to answer biomedical questions based on biomedical text.\n8. Biomedical Question Answering System using Transfer Learning (BQA-TL): BQA-TL is a question answering system that uses transfer learning techniques to answer biomedical questions based on biomedical text.\n9. Biomedical Natural Language Processing (BioNLP) System for Clinical Decision Support (CDS): BioNLP-CDS is a question answering system that uses natural language processing techniques to extract information from clinical text and provide decision support to clinicians.\n10. Biomedical Question Answering System for Personalized Medicine (BQA-PM): BQA-PM is a question answering system that uses natural language processing and machine learning techniques to provide personalized medical information to patients based on their medical history and genetic profiles.\nThese are just a few examples of the many biomedical question answering systems that are available. Each",
    "llama-2-7b-chat-hf_fact_raw": "1. The Biomedical Informatics Research Network (BIRN) is a question answering system that aims to answer biomedical questions.\n2. The Biomedical Question Answering System (BQAS) combines natural language processing, machine learning, and domain-specific knowledge in its operation.\n3. PubMed Central Question Answering Service (PMCQA) is a question answering system based on the PubMed Central database.\n4. The Biomedical Natural Language Processing (BioNLP) System is designed to extract information from biomedical literature.\n5. The Biomedical Question Answering System using Deep Learning (BQA-Deep) employs deep learning techniques.",
    "llama-2-7b-chat-hf_fact": [
      "The Biomedical Informatics Research Network (BIRN) is a question answering system that aims to answer biomedical questions.",
      "The Biomedical Question Answering System (BQAS) combines natural language processing, machine learning, and domain-specific knowledge in its operation.",
      "PubMed Central Question Answering Service (PMCQA) is a question answering system based on the PubMed Central database.",
      "The Biomedical Natural Language Processing (BioNLP) System is designed to extract information from biomedical literature.",
      "The Biomedical Question Answering System using Deep Learning (BQA-Deep) employs deep learning techniques."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Biomedical Informatics Research Network (BIRN) is not a question answering system but a collaborative initiative designed to support the sharing and analysis of biomedical research data.\n2. UNKNOWN: Without specific information on a system named the \"Biomedical Question Answering System (BQAS),\" it is not possible to affirm or correct this statement. However, it is true that a biomedical question answering system in general could combine natural language processing, machine learning, and domain-specific knowledge.\n3. FALSE [correction]: There is no well-known service named PubMed Central Question Answering Service (PMCQA). However, PubMed Central (PMC) is a free full-text archive of biomedical and life sciences journal literature.\n4. TRUE: Biomedical Natural Language Processing (BioNLP) encompasses systems designed to extract information from biomedical literature, which may include tasks such as text mining, information extraction, and semantic understanding.\n5. UNKNOWN: The statement is plausible, as deep learning techniques are commonly used in biomedical question answering systems, but without specific details about a system named \"Biomedical Question Answering System using Deep Learning (BQA-Deep),\" it is not possible to verify the accuracy of the statement.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the betalain pathway is called bHLH (basic helix-loop-helix) transcription factors. Specifically, the bHLH transcription factor, ABH (ABSCISIC ACID INSENSITIVE 2/ABH), is a key regulator of the betalain pathway in plants. It binds to specific DNA sequences in the promoter region of betalain genes and recruits other transcription factors to activate their transcription, leading to the production of betalains.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transcription factor known as bHLH (basic helix-loop-helix) activates the betalain pathway.\n2. The ABH (ABSCISIC ACID INSENSITIVE 2/ABH) transcription factor is a key regulator of the betalain pathway in plants.\n3. ABH transcription factor binds to specific DNA sequences in the promoter region of betalain genes.\n4. The binding of ABH transcription factor is involved in recruiting other transcription factors for activation.\n5. The activation of transcription factors by ABH leads to the production of betalains.",
    "llama-2-7b-chat-hf_fact": [
      "The transcription factor known as bHLH (basic helix-loop-helix) activates the betalain pathway.",
      "The ABH (ABSCISIC ACID INSENSITIVE 2/ABH) transcription factor is a key regulator of the betalain pathway in plants.",
      "ABH transcription factor binds to specific DNA sequences in the promoter region of betalain genes.",
      "The binding of ABH transcription factor is involved in recruiting other transcription factors for activation.",
      "The activation of transcription factors by ABH leads to the production of betalains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The involvement of bHLH transcription factors in the betalain pathway is plausible as they are commonly involved in various plant development processes and secondary metabolism, but the specific role of bHLH in activating the betalain pathway would require specific scientific evidence that is not provided.\n2. FALSE [correction]: The correct name for the transcription factor is ABF2 (ABA-INSENSITIVE5/BINDING FACTOR2), not ABH. ABF2 is known to be involved in ABA signaling rather than in the regulation of betalain biosynthesis.\n3. UNKNOWN: Without specific evidence regarding the binding of the ABH transcription factor (which seems to be misnamed in the statement) to DNA sequences in the promoter region of betalain genes, the truthfulness of this statement cannot be determined.\n4. UNKNOWN: Similarly, the role of the ABH transcription factor in recruiting other transcription factors for activation cannot be determined without detailed scientific evidence.\n5. UNKNOWN: As there are inaccuracies and lack of clarity in the previous statements about the ABH transcription factor and its role in betalain production, the process by which the activation of transcription factors leads to the production of betalains remains unknown in this context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Global quantitative phosphoproteomic analyses typically involve the enrichment of phosphorylated peptides from protein samples before mass spectrometry-based analysis. The following are some of the preferred technologies for phosphorylated peptide enrichment:\n1. Immunoaffinity purification (IAP): This method uses antibodies specific to phosphorylated peptides or protein targets to enrich for phosphorylated peptides. IAP is highly specific and can be used for both protein-bound and protein-free samples.\n2. Enzymatic digestion: Enzymatic digestion with proteases such as trypsin or chymotrypsin can generate phosphorylated peptides that are more amenable to analysis.\n3. Microscale immunoaffinity purification (miIAP): This method combines the sensitivity of IAP with the throughput of miniaturized reactions. miIAP can be used for high-throughput phosphoproteomics analysis.\n4. Electrochemical phosphoproteomics (ECP): ECP is a technology that uses electrochemical reactions to enrich for phosphorylated peptides. This method can capture phosphorylated peptides in a matter of minutes and can be used for both protein-bound and protein-free samples.\n5. Fluorescence-activated cell sorting (FACS): FACS can be used to isolate phosphorylated peptides based on their fluorescence properties. This method can be used for high-throughput analysis of phosphorylated peptides.\n6. Hydrophilic interaction liquid chromatography (HILIC): HILIC can be used to separate phosphorylated peptides based on their hydrophilic properties. This method can be used for both protein-bound and protein-free samples.\n7. Reversed-phase HPLC: Reversed-phase HPLC can be used to separate phosphorylated peptides based on their hydrophobic properties. This method is commonly used for protein-bound samples.\n8. Ion exchange chromatography (IEX): IEX can be used to separate phosphorylated peptides based on",
    "llama-2-7b-chat-hf_fact_raw": "1. Immunoaffinity purification (IAP) is used to enrich for phosphorylated peptides in global quantitative phosphoproteomic analyses.\n2. Enzymatic digestion with proteases such as trypsin or chymotrypsin can be utilized to generate phosphorylated peptides for analysis.\n3. Microscale immunoaffinity purification (miIAP) combines the sensitivity of IAP with high-throughput capabilities for phosphoproteomics.\n4. Electrochemical phosphoproteomics (ECP) uses electrochemical reactions to enrich for phosphorylated peptides.\n5. Hydrophilic interaction liquid chromatography (HILIC) is a separation technique used to isolate phosphorylated peptides based on their hydrophilic properties.",
    "llama-2-7b-chat-hf_fact": [
      "Immunoaffinity purification (IAP) is used to enrich for phosphorylated peptides in global quantitative phosphoproteomic analyses.",
      "Enzymatic digestion with proteases such as trypsin or chymotrypsin can be utilized to generate phosphorylated peptides for analysis.",
      "Microscale immunoaffinity purification (miIAP) combines the sensitivity of IAP with high-throughput capabilities for phosphoproteomics.",
      "Electrochemical phosphoproteomics (ECP) uses electrochemical reactions to enrich for phosphorylated peptides.",
      "Hydrophilic interaction liquid chromatography (HILIC) is a separation technique used to isolate phosphorylated peptides based on their hydrophilic properties."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Hydrophilic interaction liquid chromatography (HILIC) is a separation technique that can be used for various applications in analytical chemistry, but it is not specifically designed to isolate phosphorylated peptides based on their hydrophilic properties; it separates molecules based on their differential polar interactions with the solvent and stationary phase.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Palmini classification is used to rate the severity of intellectual disability, specifically in individuals with Down syndrome. The Palmini classification system assigns a score based on the degree of intellectual disability, with higher scores indicating more severe impairment. The classification system is as follows:\n* Palmini I: Mild intellectual disability (IQ 50-70)\n* Palmini II: Moderate intellectual disability (IQ 30-40)\n* Palmini III: Severe intellectual disability (IQ 20-30)\n* Palmini IV: Profound intellectual disability (IQ <20)\nIt is important to note that the Palmini classification system is not a diagnostic tool, but rather a way to categorize the severity of intellectual disability in individuals with Down syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Palmini classification is used to rate the severity of intellectual disability in individuals with Down syndrome.\n2. Palmini classification assigns a score based on the degree of intellectual disability.\n3. Palmini I corresponds to mild intellectual disability with an IQ range of 50-70.\n4. Palmini II corresponds to moderate intellectual disability with an IQ range of 30-50.\n5. Palmini IV is associated with profound intellectual disability and an IQ of less than 20.",
    "llama-2-7b-chat-hf_fact": [
      "Palmini classification is used to rate the severity of intellectual disability in individuals with Down syndrome.",
      "Palmini classification assigns a score based on the degree of intellectual disability.",
      "Palmini I corresponds to mild intellectual disability with an IQ range of 50-70.",
      "Palmini II corresponds to moderate intellectual disability with an IQ range of 30-50.",
      "Palmini IV is associated with profound intellectual disability and an IQ of less than 20."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is used for categorizing different types of epilepsy surgery outcomes, not for rating the severity of intellectual disability in individuals with Down syndrome. Tools commonly used for assessing intellectual disability include the DSM-5 or the ICD classification systems.\n2. FALSE [correction]: Since the Palmini classification is related to epilepsy surgery outcomes, it does not assign a score based on the degree of intellectual disability.\n3. FALSE [correction]: Palmini I does not correspond to any classification of intellectual disability because the Palmini classification is not designed for this purpose.\n4. FALSE [correction]: Palmini II does not correspond to any classification of intellectual disability as this classification system is not meant for rating intellectual disability.\n5. FALSE [correction]: Palmini IV, within the correct context of epilepsy surgery outcomes, does not pertain to intellectual disability or an IQ at all. The statement is false in its assertion about intellectual disability classifications.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, some viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory disorder of the thyroid gland that can occur in response to various triggers, including viral infections.\nSome viruses that have been linked to the development of subacute thyroiditis include:\n1. Influenza virus: Studies have shown that influenza virus infection can trigger subacute thyroiditis in some individuals.\n2. Herpesvirus: Herpesviruses, such as herpes simplex virus and human herpesvirus 6, have been associated with subacute thyroiditis.\n3. Adenovirus: Adenovirus infection has also been linked to subacute thyroiditis in some cases.\n4. Respiratory syncytial virus (RSV): RSV infection has been implicated in the development of subacute thyroiditis in children.\n5. Human parvovirus B19: Human parvovirus B19 has been associated with subacute thyroiditis, particularly in pregnant women and children.\nIt is worth noting that the exact mechanisms by which viruses contribute to the development of subacute thyroiditis are not fully understood and may involve complex interactions between the virus, the immune system, and the thyroid gland. Further research is needed to elucidate the relationship between viral infections and subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viruses have been implicated in the etiology of human subacute thyroiditis.\n2. Influenza virus infection can trigger subacute thyroiditis in some individuals.\n3. Herpes simplex virus and human herpesvirus 6 have been associated with subacute thyroiditis.\n4. Adenovirus infection has been linked to subacute thyroiditis in some cases.\n5. Human parvovirus B19 has been associated with subacute thyroiditis, particularly in pregnant women and children.",
    "llama-2-7b-chat-hf_fact": [
      "Viruses have been implicated in the etiology of human subacute thyroiditis.",
      "Influenza virus infection can trigger subacute thyroiditis in some individuals.",
      "Herpes simplex virus and human herpesvirus 6 have been associated with subacute thyroiditis.",
      "Adenovirus infection has been linked to subacute thyroiditis in some cases.",
      "Human parvovirus B19 has been associated with subacute thyroiditis, particularly in pregnant women and children."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN \n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWhile viruses have been implicated in the etiology of human subacute thyroiditis, without specific medical literature references or reliable sources directly associating the exact viruses mentioned (Influenza virus, Herpes simplex virus, human herpesvirus 6, Adenovirus, and Human parvovirus B19) with subacute thyroiditis, it is not possible to confirm the accuracy of statements 2-5. Therefore, these statements are marked as UNKNOWN. Further research into peer-reviewed medical literature would be needed to verify these potential associations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy. EIF2AK2 (Eukaryotic Initiation Factor 2-Associated Kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor eIF2α, leading to suppression of global protein synthesis and induction of autophagy. STAT3 is a transcription factor that is involved in the regulation of many cellular processes, including inflammation, immune response, and cell survival.\nResearch has shown that STAT3 is activated downstream of EIF2AK2 and plays a role in the regulation of autophagy. EIF2AK2 activation leads to the phosphorylation and inhibition of STAT3, which in turn inhibits the transcription of genes involved in autophagy. Therefore, EIF2AK2-mediated suppression of STAT3 activity can promote autophagy by inhibiting the transcriptional repression of autophagy-related genes.\nIn summary, EIF2AK2-mediated suppression of STAT3 activity is involved in the regulation of autophagy, and this pathway may be a potential therapeutic target for the treatment of diseases characterized by impaired autophagy, such as cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 (Eukaryotic Initiation Factor 2-Associated Kinase 2) phosphorylates and inhibits the translation initiation factor eIF2α.\n3. The inhibition of eIF2α by EIF2AK2 leads to suppression of global protein synthesis and induction of autophagy.\n4. Activation of EIF2AK2 leads to the phosphorylation and inhibition of STAT3.\n5. Inhibition of STAT3 by EIF2AK2 suppresses the transcription of genes involved in autophagy.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 (Eukaryotic Initiation Factor 2-Associated Kinase 2) phosphorylates and inhibits the translation initiation factor eIF2α.",
      "The inhibition of eIF2α by EIF2AK2 leads to suppression of global protein synthesis and induction of autophagy.",
      "Activation of EIF2AK2 leads to the phosphorylation and inhibition of STAT3.",
      "Inhibition of STAT3 by EIF2AK2 suppresses the transcription of genes involved in autophagy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: STAT3 (Signal Transducer and Activator of Transcription 3) is involved in many cellular processes, including cell growth and apoptosis, and can be involved in autophagy regulation, but it is not specifically known for EIF2AK2-dependent suppression of autophagy. Instead, EIF2AK2 is more directly involved in the regulation of autophagy through eIF2α.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Activation of EIF2AK2 leads to the phosphorylation of eIF2α, not the phosphorylation and inhibition of STAT3. STAT3 is a different protein that can be activated by various cytokines and growth factors and has diverse functions in response to cellular stimuli.\n5. FALSE [correction]: Inhibition of STAT3 does suppress the transcription of genes involved in various cellular processes, including potentially autophagy, but EIF2AK2 does not inhibit STAT3. It phosphorylates eIF2α, and this leads to the suppression of global protein synthesis and may induce autophagy. The statement incorrectly combines the functions of EIF2AK2 and STAT3.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool for genomic analysis that is used to visualize and interpret the spatial organization of genomic data. It is particularly useful for analyzing data from high-throughput sequencing technologies, such as ChIP-seq (chromatin immunoprecipitation sequencing) and RNA-seq (RNA sequencing).\nHere are some of the key features and usage of Theatre:\n1. Visualization of genomic data: Theatre allows users to visualize and explore the spatial organization of genomic data, including the location of genes, transcription factor binding sites, and other regulatory elements.\n2. Interactive exploration: Users can interact with the visualization to zoom in and out, pan across the genome, and filter data to focus on specific regions or features.\n3. Integration with other tools: Theatre can be integrated with other software tools, such as BEDTools, to provide a more comprehensive view of genomic data.\n4. Analysis of chromatin structure: Theatre can be used to analyze the three-dimensional structure of chromatin, including the location of histone modifications and other epigenetic marks.\n5. Identification of regulatory elements: Theatre can be used to identify regulatory elements, such as promoters, enhancers, and silencers, based on their spatial organization and interaction with other genomic features.\n6. Study of gene expression: Theatre can be used to study the spatial organization of gene expression, including the location of mRNA and other transcripts, and the interaction between gene expression and chromatin structure.\n7. Identification of novel regulatory elements: Theatre can be used to identify novel regulatory elements, such as long-range enhancers and silencers, that may not be identified by other methods.\n8. Analysis of genomic variation: Theatre can be used to analyze the impact of genomic variation, including single nucleotide polymorphisms (SNPs) and copy number variations, on chromatin structure and gene expression.\n9. Integration with other omics data: Theatre can be used to integrate genomic data with other types of omics data, such as transcriptomics and proteomics, to provide a more comprehensive view of cellular regulation.\n10. Collaboration and sharing: Theatre allows users to share and collaborate on genomic analyses, making it easier to work with colle",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for visualizing and interpreting the spatial organization of genomic data.\n2. It is commonly used for analyzing data from high-throughput sequencing technologies such as ChIP-seq and RNA-seq.\n3. Theatre can integrate with other software tools like BEDTools for a more comprehensive analysis of genomic data.\n4. The software allows for the analysis of the three-dimensional structure of chromatin and the location of histone modifications.\n5. Theatre can be used to identify regulatory elements like promoters, enhancers, and silencers based on their spatial organization.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for visualizing and interpreting the spatial organization of genomic data.",
      "It is commonly used for analyzing data from high-throughput sequencing technologies such as ChIP-seq and RNA-seq.",
      "Theatre can integrate with other software tools like BEDTools for a more comprehensive analysis of genomic data.",
      "The software allows for the analysis of the three-dimensional structure of chromatin and the location of histone modifications.",
      "Theatre can be used to identify regulatory elements like promoters, enhancers, and silencers based on their spatial organization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without context or information on a software tool named \"Theatre\" specifically designed for visualizing genomic data, I cannot verify the truthfulness of the statement. Theatre could be a hypothetical or a less-known tool, or the statement might be referring to a different, misnamed tool used in genomics, like the UCSC Genome Browser or Integrative Genomics Viewer (IGV).\n2. UNKNOWN: As with statement 1, without proper context or confirmation that \"Theatre\" is a recognized software in the genomics community, the use case involving ChIP-seq and RNA-seq analysis cannot be verified.\n3. UNKNOWN: The statement assumes the existence and functionality of \"Theatre\" software which was not confirmed in statement 1. Therefore, whether it can integrate with BEDTools or any other software remains unknown.\n4. UNKNOWN: Again, due to the lack of confirmation on the existence or functionality of \"Theatre,\" it's unclear whether it can analyze chromatin's three-dimensional structure or histone modifications' locations.\n5. UNKNOWN: Similar to statements 1-4, without verification of the software's existence or capabilities, it cannot be confirmed that \"Theatre\" can identify regulatory elements based on spatial organization.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the size of the sequences. However, the general complexity of the algorithm is O(n^2), where n is the length of the shorter sequence.\nThe Smith-Waterman algorithm has two main steps:\n1. Computing the similarity matrix: In this step, the algorithm computes the similarity between each element of one sequence and every element of the other sequence. This step has a time complexity of O(n^2), where n is the length of the shorter sequence, since the algorithm needs to compare each element of the shorter sequence with every element of the longer sequence.\n2. Finding the maximum similarity: In this step, the algorithm finds the maximum similarity between the two sequences by scanning the similarity matrix. This step has a time complexity of O(n), since the algorithm only needs to compare the maximum similarity between each element of the shorter sequence and every element of the longer sequence.\nTherefore, the overall time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\nIt's worth noting that there are some optimizations that can be applied to the Smith-Waterman algorithm to reduce its time complexity, such as using a sliding window approach or precomputing the similarity matrix. However, these optimizations can only reduce the time complexity to O(n^2 \\* log n) or O(n^2 \\* log^2 n), respectively.",
    "llama-2-7b-chat-hf_fact_raw": "1. The general complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n2. Computing the similarity matrix in the Smith-Waterman algorithm has a time complexity of O(n^2).\n3. The step of finding the maximum similarity in the Smith-Waterman algorithm has a time complexity of O(n).\n4. The overall time complexity of the Smith-Waterman algorithm is O(n^2).\n5. Some optimizations to the Smith-Waterman algorithm can reduce its time complexity to O(n^2 * log n) or O(n^2 * log^2 n).",
    "llama-2-7b-chat-hf_fact": [
      "The general complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
      "Computing the similarity matrix in the Smith-Waterman algorithm has a time complexity of O(n^2).",
      "The step of finding the maximum similarity in the Smith-Waterman algorithm has a time complexity of O(n).",
      "The overall time complexity of the Smith-Waterman algorithm is O(n^2).",
      "Some optimizations to the Smith-Waterman algorithm can reduce its time complexity to O(n^2 * log n) or O(n^2 * log^2 n)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The step of finding the maximum similarity in the Smith-Waterman algorithm is typically included as a part of constructing the similarity matrix and does not add a separate time complexity of O(n); it is part of the O(n^2) complexity.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 is a member of the solute carrier (SLC) family of transport proteins. Specifically, it is a member of the SLC12 family, which is also known as the hydroxyl-carboxylate carrier family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the solute carrier (SLC) family of transport proteins.\n2. FLVCR1 belongs to the SLC12 family within the SLC family of transport proteins.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the solute carrier (SLC) family of transport proteins.",
      "FLVCR1 belongs to the SLC12 family within the SLC family of transport proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: FLVCR1 belongs to the SLC49 family within the SLC family of transport proteins.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in regulating gene expression in erythroid cells during erythropoiesis. The biotinylation tagging approach has been used to identify GATA-1 interacting partners. Here are some of the key interacting partners of GATA-1 that have been identified using this approach:\n1. Runx1: GATA-1 interacts with Runx1, a transcription factor that plays a critical role in regulating the expression of genes involved in erythropoiesis.\n2. ERG: GATA-1 interacts with ERG, a transcription factor that is involved in the regulation of erythroid gene expression and is often mutated in erythroleukemias.\n3. KLF1: GATA-1 interacts with KLF1, a transcription factor that regulates the expression of genes involved in erythropoiesis and is also involved in the regulation of cellular differentiation.\n4. NF-E2: GATA-1 interacts with NF-E2, a transcription factor that regulates the expression of genes involved in erythropoiesis and is also involved in the regulation of cellular differentiation.\n5. HIF1α: GATA-1 interacts with HIF1α, a transcription factor that plays a critical role in regulating the expression of genes involved in response to hypoxia.\n6. CBFA2T1: GATA-1 interacts with CBFA2T1, a transcription factor that regulates the expression of genes involved in erythropoiesis and is also involved in the regulation of cellular differentiation.\n7. TFAP2A: GATA-1 interacts with TFAP2A, a transcription factor that regulates the expression of genes involved in erythropoiesis and is also involved in the regulation of cellular differentiation.\n8. TFAP2B: GATA-1 interacts with TFAP2B, a transcription factor that regulates the expression of genes involved in erythropoiesis and is also involved in the regulation of cellular differentiation.\n9. HMX1: GATA-1 interacts with HMX",
    "llama-2-7b-chat-hf_fact_raw": "1. The biotinylation tagging approach has been used to identify GATA-1 interacting partners.\n2. GATA-1 interacts with Runx1, a transcription factor important for regulating gene expression in erythropoiesis.\n3. GATA-1 interacts with the ERG transcription factor, which is involved in erythroid gene expression regulation.\n4. KLF1 is a transcription factor that interacts with GATA-1 and is involved in the regulation of genes linked to erythropoiesis.\n5. GATA-1 interacts with the transcription factor NF-E2, which has a role in erythropoiesis gene regulation.",
    "llama-2-7b-chat-hf_fact": [
      "The biotinylation tagging approach has been used to identify GATA-1 interacting partners.",
      "GATA-1 interacts with Runx1, a transcription factor important for regulating gene expression in erythropoiesis.",
      "GATA-1 interacts with the ERG transcription factor, which is involved in erythroid gene expression regulation.",
      "KLF1 is a transcription factor that interacts with GATA-1 and is involved in the regulation of genes linked to erythropoiesis.",
      "GATA-1 interacts with the transcription factor NF-E2, which has a role in erythropoiesis gene regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBiotinylation tagging is a common method used to study protein interactions, so it is plausible that it has been used to identify GATA-1 interacting partners. The specificity of the other statements regarding interactions between GATA-1 and other transcription factors (Runx1, ERG, KLF1, and NF-E2) all of which are known to play roles in erythropoiesis, suggests that these statements are based on knowledge of erythropoiesis and transcription factor networking. Without a more specialized knowledge base or contradictory information, these statements are accepted as true.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA box-binding protein-associated factor 10) interacts with the GATA1 (GATA-binding protein 1) transcription factor to regulate the expression of genes involved in erythropoiesis (the production of red blood cells). TAF10 and GATA1 work together to activate the transcription of genes necessary for red blood cell maturation and differentiation. This interaction is important for the proper development and function of the erythroid lineage in hematopoiesis (the production of blood cells).",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interacts with GATA1 to regulate gene expression involved in erythropoiesis.\n2. Erythropoiesis is the production of red blood cells.\n3. The interaction between TAF10 and GATA1 is important for red blood cell maturation and differentiation.\n4. The proper development of the erythroid lineage in hematopoiesis depends on the interaction between TAF10 and GATA1.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interacts with GATA1 to regulate gene expression involved in erythropoiesis.",
      "Erythropoiesis is the production of red blood cells.",
      "The interaction between TAF10 and GATA1 is important for red blood cell maturation and differentiation.",
      "The proper development of the erythroid lineage in hematopoiesis depends on the interaction between TAF10 and GATA1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nNote: While the statements related to TAF10 and GATA1's role in erythropoiesis seem plausible and are typically consistent with scientific knowledge about gene regulation in blood cell development, without the specific source passage, it's not possible to verify the accuracy of these particular interactions. My responses are based on general scientific consensus regarding the roles of transcription factors like GATA1 in red blood cell development. If the passage contains specific experimental evidence or novel findings, accuracy would depend on those details.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. A DSS is a computer-based system that provides healthcare providers with clinical decision-making support and helps them make informed decisions based on patient-specific data and medical knowledge.\nSome examples of DSS for chronic pain management include:\n1. PainCare: This is a comprehensive DSS that provides healthcare providers with evidence-based recommendations for chronic pain management. It includes a pain assessment tool, treatment guidelines, and a database of medications and alternative therapies.\n2. Chronic Pain Management System (CPMS): This DSS is designed to help primary care physicians manage chronic pain in their patients. It includes a pain assessment tool, treatment recommendations, and a database of medications and alternative therapies.\n3. Pain Management and Education System (PMES): This DSS is designed to help healthcare providers manage chronic pain in their patients. It includes a pain assessment tool, treatment recommendations, and a database of medications and alternative therapies.\n4. PainPathways: This is a web-based DSS that provides healthcare providers with evidence-based recommendations for chronic pain management. It includes a pain assessment tool, treatment guidelines, and a database of medications and alternative therapies.\n5. e-Pain: This is an electronic decision support system that provides healthcare providers with evidence-based recommendations for chronic pain management. It includes a pain assessment tool, treatment guidelines, and a database of medications and alternative therapies.\n6. PAIN-Q: This is a web-based DSS that provides healthcare providers with evidence-based recommendations for chronic pain management. It includes a pain assessment tool, treatment guidelines, and a database of medications and alternative therapies.\n7. Pain-Net: This is an online DSS that provides healthcare providers with evidence-based recommendations for chronic pain management. It includes a pain assessment tool, treatment guidelines, and a database of medications and alternative therapies.\n8. Clinical Practice Guidelines for the Management of Chronic Non-Cancer Pain (CPG-CNCP): This is a web-based",
    "llama-2-7b-chat-hf_fact_raw": "1. PainCare is a decision support system that offers evidence-based recommendations for chronic pain management.\n2. The Chronic Pain Management System (CPMS) is designed to assist primary care physicians in managing chronic pain.\n3. Pain Management and Education System (PMES) includes a pain assessment tool, treatment recommendations, and a medication database.\n4. PainPathways is a web-based decision support system that provides guidelines and a database for chronic pain management.\n5. e-Pain is an electronic decision support system offering evidence-based guidelines for managing chronic pain.",
    "llama-2-7b-chat-hf_fact": [
      "PainCare is a decision support system that offers evidence-based recommendations for chronic pain management.",
      "The Chronic Pain Management System (CPMS) is designed to assist primary care physicians in managing chronic pain.",
      "Pain Management and Education System (PMES) includes a pain assessment tool, treatment recommendations, and a medication database.",
      "PainPathways is a web-based decision support system that provides guidelines and a database for chronic pain management.",
      "e-Pain is an electronic decision support system offering evidence-based guidelines for managing chronic pain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about a decision support system named \"PainCare,\" the truth of this statement cannot be verified.\n2. UNKNOWN: The statement could be true if a system named the \"Chronic Pain Management System\" (CPMS) exists as described; however, without additional context, it cannot be confirmed.\n3. UNKNOWN: Similar to the above statements, there is insufficient information to verify the existence or features of the \"Pain Management and Education System\" (PMES).\n4. UNKNOWN: The truth of this statement depends on whether there is a web-based decision support system called \"PainPathways\" with the described features. Without further context or information, it cannot be determined as true or false.\n5. UNKNOWN: This statement regarding \"e-Pain\" cannot be verified without additional information about the existence and features of the electronic decision support system mentioned.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a secreted protein that localizes to the cytoplasm and nucleus of cells. It can also be found in the extracellular space, particularly in the context of angiogenesis (the formation of new blood vessels) where it plays a role in promoting endothelial cell proliferation and migration.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a secreted protein that localizes to the cytoplasm and nucleus of cells.\n2. Angiogenin can be found in the extracellular space.\n3. Angiogenin is involved in angiogenesis, which is the formation of new blood vessels.\n4. Angiogenin promotes endothelial cell proliferation.\n5. Angiogenin promotes endothelial cell migration.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a secreted protein that localizes to the cytoplasm and nucleus of cells.",
      "Angiogenin can be found in the extracellular space.",
      "Angiogenin is involved in angiogenesis, which is the formation of new blood vessels.",
      "Angiogenin promotes endothelial cell proliferation.",
      "Angiogenin promotes endothelial cell migration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Angiogenin is indeed a secreted protein that, upon its secretion, can localize to the cytoplasm and nucleus of cells to exert its biological functions.\n2. TRUE: As a secreted protein, angiogenin can indeed be found in the extracellular space where it can interact with other cells and participate in angiogenesis.\n3. TRUE: Angiogenin is involved in angiogenesis, which is the physiological process through which new blood vessels form from pre-existing vessels.\n4. TRUE: Part of the mechanism by which angiogenin facilitates angiogenesis is by promoting the proliferation of endothelial cells, which are the cells that line the interior surface of blood vessels.\n5. TRUE: Angiogenin also promotes endothelial cell migration, another critical step in the process of angiogenesis, as these cells need to move to form new blood vessel structures.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a drug that has been shown to inhibit the activation of kinase signaling pathways in the heart, specifically the Akt/PKB signaling pathway. Ranolazine works by blocking the activity of the enzyme ATP-sensitive potassium channels (KATP channels) in cardiac cells, which are important for regulating the excitability of the heart. By inhibiting the activity of these channels, ranolazine reduces the amount of calcium that enters the cardiac cells, which in turn reduces the activation of the Akt/PKB signaling pathway.\nThe Akt/PKB signaling pathway is a key regulator of cell survival and metabolism in the heart, and it plays a critical role in protecting the heart against injury and disease. Activation of this pathway is triggered by an increase in intracellular calcium, which can occur in response to various stimuli, including physical activity and stress. Once activated, the Akt/PKB pathway phosphorylates and activates a number of downstream targets, including protein kinases and transcription factors, which regulate a variety of cellular processes, including cell survival, proliferation, and metabolism.\nBy inhibiting the activation of the Akt/PKB signaling pathway, ranolazine reduces the ability of the heart to adapt to changes in its energy demands, leading to decreased cardiac function and performance. This can be particularly problematic in conditions such as heart failure, where the heart is already under increased stress and needs to be able to adapt to changing demands in order to function properly.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine inhibits the activation of kinase signaling pathways in the heart, specifically the Akt/PKB signaling pathway.\n2. Ranolazine blocks the activity of ATP-sensitive potassium channels (KATP channels) in cardiac cells.\n3. Inhibition of KATP channels by ranolazine leads to a reduction in calcium entry into cardiac cells.\n4. The Akt/PKB signaling pathway regulates cell survival and metabolism in the heart and is protective against injury and disease.\n5. Inhibition of the Akt/PKB signaling pathway by ranolazine can lead to decreased cardiac function and performance.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine inhibits the activation of kinase signaling pathways in the heart, specifically the Akt/PKB signaling pathway.",
      "Ranolazine blocks the activity of ATP-sensitive potassium channels (KATP channels) in cardiac cells.",
      "Inhibition of KATP channels by ranolazine leads to a reduction in calcium entry into cardiac cells.",
      "The Akt/PKB signaling pathway regulates cell survival and metabolism in the heart and is protective against injury and disease.",
      "Inhibition of the Akt/PKB signaling pathway by ranolazine can lead to decreased cardiac function and performance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine is known to inhibit the late sodium current (INa) in cardiac cells, not kinase signaling pathways such as Akt/PKB.\n2. FALSE [correction]: While ranolazine inhibits the late sodium current (INa) in cardiac cells, it is not primarily known for blocking the activity of ATP-sensitive potassium channels (KATP channels) in cardiac cells.\n3. FALSE [correction]: Inhibition of KATP channels would generally lead to membrane depolarization and could potentially increase calcium entry due to the opening of voltage-dependent calcium channels. However, since ranolazine primarily affects the late sodium current, the effect on calcium entry is indirect. It reduces intracellular sodium levels, which in turn can reduce calcium overload through the sodium/calcium exchanger.\n4. TRUE\n5. FALSE [correction]: Inhibiting the Akt/PKB signaling pathway might indeed affect cardiac function, but since ranolazine does not inhibit this pathway, this statement's rationale is incorrect. Ranolazine actually improves cardiac function and performance by reducing sodium and calcium overload in ischemic cardiac cells, helping to alleviate angina.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "No, the regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria. While Vsr is induced in response to DNA damage and can be active in both growing and stationary phases of bacterial growth, there are some differences in the regulation of Vsr during these different phases.\nIn the growing phase, Vsr is primarily regulated at the transcriptional level, with the expression of the vsr gene being induced in response to DNA damage. This induction is thought to be mediated by the DNA damage response pathway, which is activated in response to DNA damage and leads to the upregulation of genes involved in DNA repair and repair-related processes, including Vsr.\nIn the stationary phase, Vsr is also regulated at the transcriptional level, but in addition to transcriptional regulation, it is also post-transcriptionally regulated. In the stationary phase, the levels of Vsr mRNA are reduced, which can be due to the downregulation of vsr transcription or the degradation of Vsr mRNA.\nIn addition, Vsr activity is also regulated by protein-protein interactions and subcellular localization. For example, Vsr is localized to the nucleoids in actively growing bacteria, but it is localized to the cytoplasm in stationary phase bacteria. This subcellular localization can affect the accessibility of Vsr to DNA and influence its activity.\nIn summary, while the regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria, there are differences in the regulation of Vsr during different phases of growth, including differences in transcriptional and post-transcriptional regulation, as well as subcellular localization.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vsr endonuclease is induced in response to DNA damage in bacteria.\n2. The vsr gene is regulated at the transcriptional level when bacteria are in the growing phase.\n3. The expression of the vsr gene is mediated by the DNA damage response pathway during the growing phase.\n4. In the stationary phase, Vsr mRNA levels are reduced due to downregulation of transcription or degradation of mRNA.\n5. Vsr endonuclease's subcellular localization varies between the nucleoids in actively growing bacteria and the cytoplasm in stationary phase bacteria.",
    "llama-2-7b-chat-hf_fact": [
      "Vsr endonuclease is induced in response to DNA damage in bacteria.",
      "The vsr gene is regulated at the transcriptional level when bacteria are in the growing phase.",
      "The expression of the vsr gene is mediated by the DNA damage response pathway during the growing phase.",
      "In the stationary phase, Vsr mRNA levels are reduced due to downregulation of transcription or degradation of mRNA.",
      "Vsr endonuclease's subcellular localization varies between the nucleoids in actively growing bacteria and the cytoplasm in stationary phase bacteria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Vsr endonuclease indeed participates in DNA repair and can be induced in response to DNA damage in bacteria.\n2. UNKNOWN - Without specific details on the regulation of the vsr gene, it's difficult to confirm or deny whether it is regulated at the transcriptional level specifically during the growing phase.\n3. UNKNOWN - Similarly, without specific information, it is uncertain whether the expression of the vsr gene is mediated by the DNA damage response pathway during the growing phase.\n4. UNKNOWN - While it is common for gene expression levels to change between growth phases, there isn't enough information to confirm specifically for Vsr mRNA levels and the mechanisms involved in its regulation during the stationary phase.\n5. UNKNOWN - Information provided does not specify the subcellular localization of the Vsr endonuclease with respect to the bacterial growth phase.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools that can be used for the prediction of beta-barrel transmembrane proteins. Some of the commonly used tools include:\n1. TMHMM: TMHMM is a widely used tool for predicting transmembrane helices in proteins. It uses a combination of sequence analysis and structural information to predict the transmembrane topology of a protein.\n2. SignalP: SignalP is a tool that predicts the presence of signal peptides in a protein sequence. Signal peptides are short sequences at the N-terminus of a protein that direct the protein to the endoplasmic reticulum for secretion. Beta-barrel transmembrane proteins often have signal peptides, so SignalP can be used to predict the presence of these sequences.\n3. PredictProtein: PredictProtein is a web server that can predict the structure and function of a protein based on its sequence. It can predict the transmembrane topology of a protein, including the presence of beta-barrels, using a combination of sequence analysis and structural information.\n4. PHD-TOPO: PHD-TOPO is a tool that predicts the transmembrane topology of a protein based on the presence of hydrophobic amino acid residues. Beta-barrel transmembrane proteins typically have a high content of hydrophobic amino acids, so PHD-TOPO can be used to predict the presence of these structures.\n5. TM-align: TM-align is a tool that aligns multiple protein structures to identify conserved transmembrane helices. It can be used to identify beta-barrel transmembrane proteins by looking for conserved helices in the aligned structures.\n6. I-TASSER: I-TASSER is a tool that predicts the structure of a protein based on its sequence. It can predict the transmembrane topology of a protein, including the presence of beta-barrels, using a combination of sequence analysis and structural information.\n7. Prodigy: Prodigy is a tool that predicts the structure and function of a protein based on its sequence. It can predict the transmembrane topology of a protein, including the presence of beta-barrels, using a combination of sequence analysis and structural information.",
    "llama-2-7b-chat-hf_fact_raw": "1. TMHMM is a tool used for predicting transmembrane helices in proteins using sequence analysis and structural information.\n2. SignalP predicts the presence of signal peptides in protein sequences.\n3. PredictProtein is a web server that can predict protein structure and function from sequence, including transmembrane topology and the presence of beta-barrels.\n4. PHD-TOPO predicts the transmembrane topology of proteins based on hydrophobic amino acid residues.\n5. I-TASSER predicts protein structure, including transmembrane topology, from sequence using sequence analysis and structural information.",
    "llama-2-7b-chat-hf_fact": [
      "TMHMM is a tool used for predicting transmembrane helices in proteins using sequence analysis and structural information.",
      "SignalP predicts the presence of signal peptides in protein sequences.",
      "PredictProtein is a web server that can predict protein structure and function from sequence, including transmembrane topology and the presence of beta-barrels.",
      "PHD-TOPO predicts the transmembrane topology of proteins based on hydrophobic amino acid residues.",
      "I-TASSER predicts protein structure, including transmembrane topology, from sequence using sequence analysis and structural information."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: PHD-TOPO predicts the transmembrane topology of proteins using neural networks based on evolutionary information from multiple sequence alignments; the prediction is not solely based on hydrophobic amino acid residues.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used to classify disorders related to the function of the protein kinase C (PKC) family. PKC is a group of enzymes that play important roles in various cellular processes, including signal transduction, cell growth, and differentiation. Galassi classification is a system used to categorize PKC-related disorders based on their molecular mechanisms and clinical features. The classification system was developed by Dr. Francesco Galassi and colleagues and includes four main categories:\n1. Class I: Disorders caused by mutations in PKC genes, such as PKC alpha-deficient disorders.\n2. Class II: Disorders caused by mutations in genes that encode regulatory factors that interact with PKC, such as G-protein-coupled receptors.\n3. Class III: Disorders caused by mutations in genes that encode downstream effectors of PKC, such as phosphatidylinositol 3-kinase (PI3K).\n4. Class IV: Disorders caused by mutations in genes that encode proteins that interact with the cytoskeleton, such as actin.\nEach class is further subdivided into subclasses based on the specific molecular mechanism or clinical feature of the disorder. Galassi classification provides a framework for understanding the complex interplay of genetic and environmental factors that contribute to PKC-related disorders and for developing new therapeutic strategies to treat these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Galassi classification is used to categorize disorders related to the function of the protein kinase C (PKC) family.\n2. The classification system was developed by Dr. Francesco Galassi and colleagues.\n3. Class I of Galassi classification includes disorders caused by mutations in PKC genes.\n4. Class II of the classification specifies disorders caused by mutations in genes that encode regulatory factors interacting with PKC.\n5. Class IV in the Galassi classification includes disorders related to mutations in genes that encode proteins interacting with the cytoskeleton.",
    "llama-2-7b-chat-hf_fact": [
      "Galassi classification is used to categorize disorders related to the function of the protein kinase C (PKC) family.",
      "The classification system was developed by Dr. Francesco Galassi and colleagues.",
      "Class I of Galassi classification includes disorders caused by mutations in PKC genes.",
      "Class II of the classification specifies disorders caused by mutations in genes that encode regulatory factors interacting with PKC.",
      "Class IV in the Galassi classification includes disorders related to mutations in genes that encode proteins interacting with the cytoskeleton."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification is used to categorize different types of arachnoid cysts, not disorders related to the function of the protein kinase C (PKC) family.\n2. UNKNOWN (without additional context, I cannot verify the accuracy of the developer's name or collaborators of the classification system)\n3. FALSE [correction]: Class I of Galassi classification includes cysts located in the middle cranial fossa without displacing the temporal lobe.\n4. FALSE [correction]: It's not about disorders caused by mutations, but rather the classification refers to the size and effect of arachnoid cysts on surrounding structures; Class II includes cysts that cause some displacement of the temporal lobe.\n5. FALSE [correction]: The Galassi classification does not include a Class IV; it only has three classes. Class III includes cysts that significantly displace the temporal lobe and also cause a shift of the midline structures.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Omenn syndrome, is a rare genetic disorder that affects the body's ability to produce red blood cells. Here are some common features of Shapiro syndrome:\n1. Anemia: People with Shapiro syndrome typically have a severe anemia, which can lead to fatigue, weakness, and shortness of breath.\n2. Bleeding tendencies: Individuals with Shapiro syndrome may experience easy bruising, petechiae (small red or purple spots on the skin), and prolonged bleeding after injury or surgery.\n3. Bone deformities: Shapiro syndrome can cause abnormal bone growth, leading to deformities such as short stature, bowed legs, and/or curved spine.\n4. Developmental delays: Children with Shapiro syndrome may experience delays in reaching developmental milestones, such as sitting, standing, and walking.\n5. Intellectual disability: Some individuals with Shapiro syndrome may have mild to moderate intellectual disability.\n6. Microcephaly: Many people with Shapiro syndrome have a smaller-than-average head size, which can be a sign of intellectual disability.\n7. Skin abnormalities: Shapiro syndrome can cause skin abnormalities such as thin skin, easy bruising, and a higher risk of skin infections.\n8. Vision problems: Some individuals with Shapiro syndrome may experience vision problems, including cataracts, glaucoma, and/or retinal detachment.\n9. Hearing loss: Shapiro syndrome can cause hearing loss, which may be conductive or sensorineural in nature.\n10. Increased risk of infections: People with Shapiro syndrome may be more susceptible to infections due to their impaired immune system function.\nIt is important to note that not all individuals with Shapiro syndrome will exhibit all of these features, and the severity of the condition can vary widely between individuals. A diagnosis of Shapiro syndrome is typically made through a combination of clinical evaluation, laboratory tests, and genetic analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome affects the body's ability to produce red blood cells.\n2. Common features of Shapiro syndrome include severe anemia, leading to fatigue, weakness, and shortness of breath.\n3. Individuals with Shapiro syndrome can experience bone deformities such as short stature, bowed legs, and/or a curved spine.\n4. Children with Shapiro syndrome may face developmental delays in sitting, standing, and walking.\n5. People with Shapiro syndrome may be more susceptible to infections due to impaired immune system function.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome affects the body's ability to produce red blood cells.",
      "Common features of Shapiro syndrome include severe anemia, leading to fatigue, weakness, and shortness of breath.",
      "Individuals with Shapiro syndrome can experience bone deformities such as short stature, bowed legs, and/or a curved spine.",
      "Children with Shapiro syndrome may face developmental delays in sitting, standing, and walking.",
      "People with Shapiro syndrome may be more susceptible to infections due to impaired immune system function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by episodic hypothermia, sweating, and corpus callosum agenesis, not by the body's inability to produce red blood cells.\n2. FALSE [correction]: Common features of Shapiro syndrome do not typically include severe anemia. Instead, they involve episodes of spontaneous hypothermia.\n3. FALSE [correction]: Shapiro syndrome is not typically associated with bone deformities such as short stature, bowed legs, and/or a curved spine.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (BRAG1-related gene 1) is linked to a rare genetic disorder called BRAG1-related syndrome, which is characterized by a range of symptoms including intellectual disability, seizures, and distinctive facial features. Mutations in the BRAG1 gene can cause this syndrome, which is also known as BRAG1-related developmental disorder.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRAG1-related syndrome is a rare genetic disorder.\n2. BRAG1-related syndrome is associated with mutations within the BRAG1 gene.\n3. Symptoms of BRAG1-related syndrome include intellectual disability, seizures, and distinctive facial features.\n4. The disorder is also referred to as BRAG1-related developmental disorder.",
    "llama-2-7b-chat-hf_fact": [
      "BRAG1-related syndrome is a rare genetic disorder.",
      "BRAG1-related syndrome is associated with mutations within the BRAG1 gene.",
      "Symptoms of BRAG1-related syndrome include intellectual disability, seizures, and distinctive facial features.",
      "The disorder is also referred to as BRAG1-related developmental disorder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct name for the syndrome is BRafGAP1-related syndrome, which is based on a genetic mutation of the gene involved, but it is often abbreviated as BRAG1. The syndrome is rare and genetic, so the statement may be considered true with clarification of the name.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is called PP1-binding protein (PP1B). PP1B is a regulatory subunit that binds to and inhibits the activity of PP1, thereby controlling the dephosphorylation of various protein substrates involved in various cellular processes, including signal transduction, cytoskeleton organization, and apoptosis.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria generate genetic diversity during stationary phase, when they are not growing or are under stress. In Bacillus subtilis, there are several mechanisms that underlie adaptive mutagenesis:\n1. DNA damage: DNA damage can occur during stationary phase due to various factors, including oxidative stress, DNA replication stress, and exposure to antibiotics. Adaptive mutagenesis can result from the repair of DNA damage through error-prone mechanisms, leading to the accumulation of mutations.\n2. Recombinational repair: Recombinational repair is a process by which DNA is repaired through the exchange of genetic material between two homologous DNA molecules. This process can also lead to the introduction of mutations, as errors can occur during the repair process.\n3. MutL-mediated mismatch repair: The MutL protein is a key player in the repair of DNA mismatches that arise during DNA replication and repair. However, MutL can also cause mutations if it misrecognizes certain DNA sequences, leading to the accumulation of mutations during stationary phase.\n4. RNA-mediated mutagenesis: RNA molecules can base-pair with DNA and cause mutations through a process called RNA-mediated mutagenesis. This mechanism can occur during stationary phase, when RNA molecules are more abundant.\n5. Horizontal gene transfer: Horizontal gene transfer, also known as lateral gene transfer, is the transfer of genetic material between different species. This can lead to the introduction of new genes or mutations into a bacterial genome during stationary phase, contributing to adaptive mutagenesis.\n6. Telomere shortening: Telomeres are repetitive DNA sequences that cap the ends of chromosomes. During stationary phase, telomeres can shorten, leading to the activation of the SOS response and the accumulation of mutations.\n7. DNA recombination: DNA recombination is the process by which DNA is exchanged between two homologous DNA molecules. This process can also lead to the introduction of mutations, as errors can occur during the recombination process.\n8. Mismatch repair-independent mutagenesis:",
    "llama-2-7b-chat-hf_fact_raw": "1. In Bacillus subtilis, adaptive mutagenesis can result from the repair of DNA damage through error-prone mechanisms.\n2. Recombinational repair can lead to the introduction of mutations in Bacillus subtilis during stationary phase.\n3. The MutL protein can cause mutations in Bacillus subtilis during stationary phase if it misrecognizes certain DNA sequences.\n4. RNA-mediated mutagenesis is a process where RNA molecules can cause mutations by base-pairing with DNA, and can occur in stationary phase.\n5. Horizontal gene transfer can introduce new genes or mutations into the Bacillus subtilis genome during stationary phase, contributing to adaptive mutagenesis.",
    "llama-2-7b-chat-hf_fact": [
      "In Bacillus subtilis, adaptive mutagenesis can result from the repair of DNA damage through error-prone mechanisms.",
      "Recombinational repair can lead to the introduction of mutations in Bacillus subtilis during stationary phase.",
      "The MutL protein can cause mutations in Bacillus subtilis during stationary phase if it misrecognizes certain DNA sequences.",
      "RNA-mediated mutagenesis is a process where RNA molecules can cause mutations by base-pairing with DNA, and can occur in stationary phase.",
      "Horizontal gene transfer can introduce new genes or mutations into the Bacillus subtilis genome during stationary phase, contributing to adaptive mutagenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: In Bacillus subtilis, adaptive mutagenesis can indeed occur through error-prone repair mechanisms that fix DNA damage.\n2. TRUE: Recombinational repair during the stationary phase in Bacillus subtilis can result in mutations, which may contribute to adaptive mutagenesis.\n3. FALSE [correction]: It is not the MisL protein that causes mutations; there seems to be a misunderstanding. MutL is involved in mismatch repair and typically works to correct DNA replication errors, but under certain conditions or in specific mutants, this system can be involved in mutagenic processes. However, it is not specifically known to cause mutations by misrecognizing DNA sequences during stationary phase unless in the context of a defect or error.\n4. UNKNOWN: RNA-mediated mutagenesis is a phenomenon that has been proposed and observed in some cases, but whether it is a significant process in Bacillus subtilis during stationary phase is not a well-established fact.\n5. TRUE: Horizontal gene transfer is a recognized mechanism by which Bacillus subtilis can acquire new genes or mutations, which can be an important factor in adaptive mutagenesis, especially during stationary phase when cells are under stress or nutrient limitation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erucic acid syndrome, is a rare but potentially life-threatening condition that can occur in individuals who consume large amounts of rutabaga (a root vegetable related to cabbage and kale) or other cruciferous vegetables.\nThe cause of erucism is the consumption of high levels of erucic acid, a toxic compound found in the Brassica genus of plants, which includes rutabaga, cabbage, and kale. Erucic acid can cause damage to the liver, kidneys, and other organs, leading to a range of symptoms including nausea, vomiting, abdominal pain, jaundice, and in severe cases, liver failure.\nOther potential causes of erucism include:\n1. Genetic predisposition: Some individuals may be more susceptible to the toxic effects of erucic acid due to genetic differences.\n2. Food contamination: Erucic acid levels in rutabaga and other cruciferous vegetables can vary depending on factors such as soil quality, irrigation, and storage conditions. Consuming contaminated or old vegetables can increase the risk of developing erucism.\n3. Cooking methods: Erucic acid is more readily absorbed through the digestive system when vegetables are cooked, especially when they are boiled or steamed. Consuming overcooked or improperly prepared rutabaga may increase the risk of erucism.\n4. Other medical conditions: Certain medical conditions, such as liver disease or kidney disease, can increase the risk of developing erucism.\nIt is essential to note that erucism is a rare condition, and most people who consume rutabaga or other cruciferous vegetables do not experience any adverse effects. However, individuals who consume large amounts of these vegetables or have pre-existing medical conditions should be aware of the potential risks and take appropriate precautions to minimize their exposure to erucic acid.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is caused by the consumption of high levels of erucic acid.\n2. Erucic acid is a toxic compound found in the Brassica genus of plants, including rutabaga, cabbage, and kale.\n3. High levels of erucic acid can cause damage to the liver, kidneys, and other organs.\n4. Genetic predisposition may make some individuals more susceptible to the toxic effects of erucic acid.\n5. Cooking methods such as boiling or steaming can increase the absorption of erucic acid through the digestive system.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is caused by the consumption of high levels of erucic acid.",
      "Erucic acid is a toxic compound found in the Brassica genus of plants, including rutabaga, cabbage, and kale.",
      "High levels of erucic acid can cause damage to the liver, kidneys, and other organs.",
      "Genetic predisposition may make some individuals more susceptible to the toxic effects of erucic acid.",
      "Cooking methods such as boiling or steaming can increase the absorption of erucic acid through the digestive system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Cooking methods such as boiling or steaming do not increase the absorption of erucic acid through the digestive system; they might actually help reduce its levels in food.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide (HCTZ) is a diuretic medication that is commonly used to treat a variety of medical conditions. Some of the most common indications for hydrochlorothiazide include:\n1. Hypertension (high blood pressure): HCTZ is often used to treat mild to moderate hypertension, as it can help to reduce blood pressure by increasing urine production and removing excess fluid from the body.\n2. Heart failure: HCTZ can help to reduce fluid buildup in the body, which can occur in people with heart failure.\n3. Edema (swelling): HCTZ can help to reduce swelling in the feet, ankles, and hands, which can occur due to various medical conditions such as liver disease, kidney disease, or cancer.\n4. Nephrotic syndrome: HCTZ can help to reduce proteinuria (excess protein in the urine) in people with nephrotic syndrome, a condition that can cause excess protein loss in the urine.\n5. Diabetic nephropathy: HCTZ can help to reduce proteinuria and albuminuria (excess protein and albumin in the urine) in people with diabetic nephropathy, a complication of diabetes that can damage the kidneys.\n6. Kidney transplantation: HCTZ can help to reduce the risk of kidney rejection in people who have undergone kidney transplantation.\n7. Cystoid macular edema: HCTZ can help to reduce the risk of cystoid macular edema, a condition that can cause vision loss in people with various medical conditions.\n8. Raynaud's phenomenon: HCTZ can help to reduce the frequency and severity of Raynaud's phenomenon, a condition that can cause discoloration and pain in the fingers and toes.\n9. Anorexigia: HCTZ can help to reduce appetite and weight loss in people with anorexigia, a condition that can cause a decrease in appetite and weight loss.\nIt is important to note that hydrochlorothiazide is not a cure for these conditions, but rather a treatment to help manage symptoms and improve quality of life. It is important to consult",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide (HCTZ) is used to treat mild to moderate hypertension by increasing urine production to reduce blood pressure.\n2. HCTZ is prescribed for reducing fluid buildup in patients with heart failure.\n3. HCTZ is indicated for the treatment of edema, specifically swelling in the feet, ankles, and hands due to various medical conditions.\n4. HCTZ is used to reduce proteinuria in people with nephrotic syndrome.\n5. HCTZ can help to reduce proteinuria and albuminuria in individuals with diabetic nephropathy.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide (HCTZ) is used to treat mild to moderate hypertension by increasing urine production to reduce blood pressure.",
      "HCTZ is prescribed for reducing fluid buildup in patients with heart failure.",
      "HCTZ is indicated for the treatment of edema, specifically swelling in the feet, ankles, and hands due to various medical conditions.",
      "HCTZ is used to reduce proteinuria in people with nephrotic syndrome.",
      "HCTZ can help to reduce proteinuria and albuminuria in individuals with diabetic nephropathy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: HCTZ is not typically used to reduce proteinuria in people with nephrotic syndrome; instead, other medications like ACE inhibitors or angiotensin receptor blockers are commonly used for this purpose.\n5. FALSE [correction]: Although HCTZ can reduce blood pressure, which can be beneficial in diabetic nephropathy, it is not primarily used to reduce proteinuria or albuminuria in individuals with diabetic nephropathy. Medications like ACE inhibitors or angiotensin receptor blockers are more commonly prescribed for reducing proteinuria in this condition.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence. Silicon-based materials have been developed and studied for their potential to improve the function of the urinary system and treat incontinence.\nOne example of this is the use of silicon-based hydrogels to create a urinary sling, which can help to support the urethra and prevent leakage. These hydrogels are made of a silicon-based material that is biocompatible and can be shaped to fit the individual patient's anatomy. They are then placed under the urethra to provide support and prevent leakage.\nSilicon has also been used in the development of other devices for the treatment of incontinence, such as slings and catheters. These devices are designed to be made of a silicon-based material that is flexible and can be easily inserted into the body. They are also designed to be biocompatible and can be left in the body for an extended period of time without causing any adverse effects.\nSilicon has also been used in the development of other devices for the treatment of incontinence, such as slings and catheters. These devices are designed to be made of a silicon-based material that is flexible and can be easily inserted into the body. They are also designed to be biocompatible and can be left in the body for an extended period of time without causing any adverse effects.\nSilicon-based materials have also been studied for their potential to improve the function of the bladder and urinary system. For example, researchers have used silicon-based materials to create a device that can be implanted in the bladder to help improve bladder function and reduce the risk of incontinence. This device is made of a silicon-based material that is designed to mimic the natural lining of the bladder and can help to improve the function of the bladder and reduce the risk of incontinence.\nIn summary, silicon has been used in the treatment of urinary incontinence through the development of silicon-based hydrogels and other devices that can help to support the urethra and improve bladder function. These devices are designed to be biocompatible and can be left in the body for an extended period of time without causing any adverse effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon-based materials have been developed and studied for the treatment of urinary incontinence.\n2. Silicon-based hydrogels have been used to create urinary slings that support the urethra and prevent leakage.\n3. The silicon-based devices like slings and catheters are designed to be flexible for insertion into the body.\n4. These silicon-based devices are biocompatible and can remain in the body for an extended time without adverse effects.\n5. Researchers have created a device from silicon-based materials that can be implanted in the bladder to improve its function and reduce the risk of incontinence.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon-based materials have been developed and studied for the treatment of urinary incontinence.",
      "Silicon-based hydrogels have been used to create urinary slings that support the urethra and prevent leakage.",
      "The silicon-based devices like slings and catheters are designed to be flexible for insertion into the body.",
      "These silicon-based devices are biocompatible and can remain in the body for an extended time without adverse effects.",
      "Researchers have created a device from silicon-based materials that can be implanted in the bladder to improve its function and reduce the risk of incontinence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Silicon-based materials, particularly medical-grade silicone, have been developed and are known to be used in various medical applications due to their flexibility and biocompatibility which is relevant to the treatment of urinary incontinence.\n2. FALSE [correction]: Silicone-based hydrogels have been used to create urinary slings that support the urethra and prevent leakage. \"Silicon\" and \"silicone\" are often confused, but in medical applications, \"silicone,\" which is a polymer, is generally used.\n3. TRUE: Silicon-based devices, which should correctly be referred to as silicone-based devices for medical applications, are indeed designed to be flexible for insertion into the body. Flexibility is a key factor for devices like slings and catheters to minimize discomfort and avoid damage to body tissues during insertion and use.\n4. TRUE: Silicone-based devices are known to be biocompatible and can remain in the body without adverse effects for various periods of time, which is why they are commonly used for medical implants and devices.\n5. UNKNOWN: Without specific information on the development of a device implantable in the bladder made from silicon-based materials, the validity of this statement cannot be confirmed. While it is plausible given the use of these materials in medical applications, no correction or affirmation can be made without more context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Intracranial aneurysms are abnormal bulges or balloon-like structures that can occur in the blood vessels of the brain. While the exact cause of intracranial aneurysms is not fully understood, there is some evidence to suggest that the moon cycle may play a role in the rupture risk of these aneurysms.\nThe association between the moon cycle and intracranial aneurysm rupture risk is based on several studies that have found a correlation between the full moon and increased rupture rates of intracranial aneurysms. For example, a study published in the journal \"Stroke\" in 2001 found that the risk of intracranial aneurysm rupture was significantly higher during the full moon than during other times of the month. Another study published in the \"Journal of Neurosurgery\" in 2010 found similar results, with a higher rupture rate during the full moon compared to other lunar phases.\nThere are several theories as to why the moon cycle may influence the rupture risk of intracranial aneurysms. One theory is that the increased gravitational forces during the full moon may cause the aneurysm wall to stretch and weaken, leading to rupture. Another theory is that the hormonal changes that occur during the menstrual cycle may play a role in the increased rupture risk.\nWhile the association between the moon cycle and intracranial aneurysm rupture risk is intriguing, it is important to note that the evidence is not yet conclusive. More research is needed to fully understand the relationship between the moon cycle and intracranial aneurysm rupture risk. Additionally, it is important to note that the majority of intracranial aneurysms do not rupture, and the risk of rupture can be reduced with proper medical treatment and management.",
    "llama-2-7b-chat-hf_fact_raw": "1. Intracranial aneurysms are abnormal bulges in the blood vessels of the brain.\n2. Some studies have found a correlation between the full moon and increased rupture rates of intracranial aneurysms.\n3. A study published in the journal \"Stroke\" in 2001 indicated that the risk of intracranial aneurysm rupture was significantly higher during the full moon than other times of the month.\n4. A study from the \"Journal of Neurosurgery\" in 2010 also found a higher rupture rate of intracranial aneurysms during the full moon compared to other lunar phases.\n5. One theory suggests that increased gravitational forces during the full moon may cause aneurysm walls to stretch and weaken, potentially leading to rupture.",
    "llama-2-7b-chat-hf_fact": [
      "Intracranial aneurysms are abnormal bulges in the blood vessels of the brain.",
      "Some studies have found a correlation between the full moon and increased rupture rates of intracranial aneurysms.",
      "A study published in the journal \"Stroke\" in 2001 indicated that the risk of intracranial aneurysm rupture was significantly higher during the full moon than other times of the month.",
      "A study from the \"Journal of Neurosurgery\" in 2010 also found a higher rupture rate of intracranial aneurysms during the full moon compared to other lunar phases.",
      "One theory suggests that increased gravitational forces during the full moon may cause aneurysm walls to stretch and weaken, potentially leading to rupture."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: No study published in the \"Stroke\" journal or any other authoritative medical journal has conclusively proven a significant correlation between the phases of the moon and the rupture rates of intracranial aneurysms. Rather, the occurrence of such medical events is generally believed to be random and not linked to lunar cycles.\n4. FALSE [correction]: There is no conclusive evidence from the \"Journal of Neurosurgery\" or other reputable sources that confirms a higher rupture rate of intracranial aneurysms during the full moon compared to other lunar phases. The alleged relationship between lunar phases and aneurysm ruptures remains scientifically unproven and is not supported by substantial medical research.\n5. FALSE [correction]: This theory lacks scientific support, as the gravitational forces exerted by the moon are too small to have such a biological effect on the human body and particularly on aneurysm walls. It is important to rely on peer-reviewed studies and established scientific consensus rather than speculative theories.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein (also known as ELAVL1) is a splicing factor that plays a critical role in the regulation of pre-mRNA splicing. HuR is a member of the ELAVL (ELAV-like RNA-binding) family of proteins, which are involved in the regulation of mRNA metabolism, including splicing, transport, and stability.\nHuR is specifically involved in the splicing of pre-mRNAs that contain introns, which are regions of non-coding RNA that are removed from the pre-mRNA during splicing to produce the mature mRNA. HuR recognizes specific sequences in the introns and binds to them, leading to the splicing of the introns and the formation of the mature mRNA.\nIn addition to its role in splicing, HuR also regulates the stability of mRNAs and can act as a translational repressor by binding to the 3' untranslated region (UTR) of target mRNAs and preventing their translation.\nOverall, HuR plays a critical role in the regulation of gene expression by controlling the splicing and stability of pre-mRNAs, and its dysregulation has been implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein (also known as ELAVL1) is involved in the regulation of pre-mRNA splicing.\n2. HuR is a member of the ELAVL family of proteins that participate in mRNA metabolism.\n3. The HuR protein regulates the splicing of pre-mRNAs by removing introns.\n4. HuR protein can regulate mRNA stability.\n5. Dysregulation of HuR protein has been implicated in diseases such as cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein (also known as ELAVL1) is involved in the regulation of pre-mRNA splicing.",
      "HuR is a member of the ELAVL family of proteins that participate in mRNA metabolism.",
      "The HuR protein regulates the splicing of pre-mRNAs by removing introns.",
      "HuR protein can regulate mRNA stability.",
      "Dysregulation of HuR protein has been implicated in diseases such as cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: While HuR protein (ELAVL1) is involved in mRNA metabolism and can influence alternative splicing events, it is not known to directly remove introns; this process is typically mediated by the spliceosome.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (Pa) is a small protein that plays a crucial role in the regulation of various cellular processes, including cell proliferation, differentiation, and survival. The c-terminal peptide of prothymosin alpha (ct-Pa) is a truncated form of the full-length Pa protein, which is generated through proteolytic processing. Here are some of the known functions of ct-Pa:\n1. Cell proliferation: Ct-Pa has been shown to stimulate cell proliferation by enhancing the activity of key cell cycle regulators, such as cyclin-dependent kinases (CDKs) and cyclins.\n2. Cell survival: Ct-Pa has been reported to promote cell survival by inhibiting the activation of pro-apoptotic proteins, such as Bax and Bak, and increasing the expression of anti-apoptotic proteins, such as Bcl-xL.\n3. Differentiation: Ct-Pa has been implicated in the regulation of cell differentiation, particularly in the context of hematopoiesis. It has been shown to promote the differentiation of hematopoietic stem cells into myeloid and lymphoid lineage cells.\n4. Inflammation: Ct-Pa has been reported to play a role in the regulation of inflammation, particularly in the context of immune response. It has been shown to inhibit the production of pro-inflammatory cytokines, such as TNF-alpha, and promote the production of anti-inflammatory cytokines, such as IL-10.\n5. Neuroprotection: Ct-Pa has been shown to have neuroprotective effects, particularly in the context of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. It has been reported to inhibit the aggregation of alpha-synuclein and prevent the death of neurons in vitro and in vivo.\nIn summary, ct-Pa is a multifunctional protein that plays a crucial role in various cellular processes, including cell proliferation, differentiation, survival, inflammation, and neuroprotection. Its dysregulation has been implicated in",
    "llama-2-7b-chat-hf_fact_raw": "1. The c-terminal peptide of prothymosin alpha (ct-Pa) stimulates cell proliferation by enhancing the activity of cell cycle regulators like CDKs and cyclins.\n2. Ct-Pa promotes cell survival by inhibiting activation of pro-apoptotic proteins such as Bax and Bak, and increases the expression of anti-apoptotic proteins like Bcl-xL.\n3. Ct-Pa is involved in the regulation of cell differentiation, particularly affecting the differentiation of hematopoietic stem cells into myeloid and lymphoid lineage cells.\n4. Ct-Pa plays a role in the regulation of inflammation by inhibiting the production of pro-inflammatory cytokines like TNF-alpha and promoting the production of anti-inflammatory cytokines such as IL-10.\n5. Ct-Pa has neuroprotective effects, which include inhibition of alpha-synuclein aggregation and protection against neuron death in the context of neurodegenerative diseases like Alzheimer's and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "The c-terminal peptide of prothymosin alpha (ct-Pa) stimulates cell proliferation by enhancing the activity of cell cycle regulators like CDKs and cyclins.",
      "Ct-Pa promotes cell survival by inhibiting activation of pro-apoptotic proteins such as Bax and Bak, and increases the expression of anti-apoptotic proteins like Bcl-xL.",
      "Ct-Pa is involved in the regulation of cell differentiation, particularly affecting the differentiation of hematopoietic stem cells into myeloid and lymphoid lineage cells.",
      "Ct-Pa plays a role in the regulation of inflammation by inhibiting the production of pro-inflammatory cytokines like TNF-alpha and promoting the production of anti-inflammatory cytokines such as IL-10.",
      "Ct-Pa has neuroprotective effects, which include inhibition of alpha-synuclein aggregation and protection against neuron death in the context of neurodegenerative diseases like Alzheimer's and Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The C-terminal peptide of prothymosin alpha (ct-Pa) is reported to stimulate cell proliferation, and it has been implicated in enhancing the activity of cell cycle regulators such as CDKs (cyclin-dependent kinases) and cyclins.\n\n2. TRUE: Ct-Pa is known to promote cell survival, and part of its mechanism involves the inhibition of pro-apoptotic proteins such as Bax and Bak, as well as an increase in the expression of anti-apoptotic proteins like Bcl-xL.\n\n3. UNKNOWN: While ct-Pa may be involved in various cellular functions, the specific regulation of cell differentiation, especially with regard to hematopoietic stem cells and their lineage differentiation, cannot be determined as true or false without specific context or source information. This requires detailed biological research for validation.\n\n4. UNKNOWN: The role of ct-Pa in regulating inflammation and its specific effects on cytokine production such as inhibiting TNF-alpha or promoting IL-10 is a specialized field of study. The accuracy of this statement would depend on current scientific research that is not specified here.\n\n5. UNKNOWN: Ct-Pa's neuroprotective effects and its specific role in inhibiting alpha-synuclein aggregation or protection against neuron death in neurodegenerative diseases like Alzheimer's and Parkinson's disease would need to be supported by specific neuroscientific studies, which are not provided in this context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Cystatin C fibrillization is mediated by a peptide fragment called the \"fibrillization-prone region\" (FPR), which is located in the N-terminal portion of the cystatin C protein. The FPR is composed of amino acids 10-24 of the full-length cystatin C protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. A peptide fragment known as the \"fibrillization-prone region\" (FPR) plays a pivotal role in human cystatin C fibrillization.\n2. The fibrillization-prone region (FPR) is located in the N-terminal portion of the cystatin C protein.\n3. The fibrillization-prone region (FPR) is composed of amino acids 10-24 of the full-length cystatin C protein.",
    "llama-2-7b-chat-hf_fact": [
      "A peptide fragment known as the \"fibrillization-prone region\" (FPR) plays a pivotal role in human cystatin C fibrillization.",
      "The fibrillization-prone region (FPR) is located in the N-terminal portion of the cystatin C protein.",
      "The fibrillization-prone region (FPR) is composed of amino acids 10-24 of the full-length cystatin C protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The fibrillization-prone region (FPR) is located in the central portion of the cystatin C protein.\n3. FALSE [correction]: The fibrillization-prone region (FPR) is actually composed of amino acids 57-64 of the full-length cystatin C protein.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α (hypoxia-inducible factor 1-alpha) increases after the administration of the cytoprotective prodrug amifostine (ethyol). Amifostine is a potent inhibitor of the enzyme phosphodiesterase (PDE) and it has been shown to increase the levels of HIF-1α in various cell types, including cancer cells.\nHIF-1α is a transcription factor that plays a crucial role in response to hypoxia, and it regulates the expression of genes involved in adaptation to hypoxia, such as angiogenesis, glucose metabolism, and cell survival. In cancer cells, HIF-1α is often overexpressed and promotes the development of a tumor-supportive microenvironment.\nThe increase in HIF-1α levels after amifostine administration is thought to be mediated by the inhibition of PDE, which leads to an increase in cGMP (cyclic guanosine monophosphate) levels. cGMP is a second messenger that regulates many cellular processes, including gene expression, and it has been shown to activate HIF-1α.\nOverall, the increase in HIF-1α levels after amifostine administration may contribute to the cytoprotective effects of this drug in various tissues, including the lung, by promoting the expression of genes involved in adaptation to hypoxia and reducing the damage caused by oxidative stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of HIF-1α increases after the administration of amifostine (ethyol).\n2. Amifostine is an inhibitor of the enzyme phosphodiesterase (PDE).\n3. HIF-1α plays a role in the cellular response to hypoxia by regulating genes involved in angiogenesis, glucose metabolism, and cell survival.\n4. In cancer cells, HIF-1α can be overexpressed and contribute to the development of a tumor-supportive microenvironment.\n5. The increase in HIF-1α levels due to amifostine is mediated by the increase in levels of cGMP (cyclic guanosine monophosphate).",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of HIF-1α increases after the administration of amifostine (ethyol).",
      "Amifostine is an inhibitor of the enzyme phosphodiesterase (PDE).",
      "HIF-1α plays a role in the cellular response to hypoxia by regulating genes involved in angiogenesis, glucose metabolism, and cell survival.",
      "In cancer cells, HIF-1α can be overexpressed and contribute to the development of a tumor-supportive microenvironment.",
      "The increase in HIF-1α levels due to amifostine is mediated by the increase in levels of cGMP (cyclic guanosine monophosphate)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The effect of amifostine on HIF-1α levels would require a specific citation from a scientific study, and as such, without the appropriate context or source, it's not possible to confirm the veracity of this statement. Amifostine is known to protect normal cells against the harmful effects of radiation and chemotherapy by scavenging free radicals and also by upregulating the production of certain cytoprotective proteins, but the direct relationship with HIF-1α increase is not general knowledge.\n   \n2. FALSE [correction]: Amifostine is not primarily known as an inhibitor of phosphodiesterase (PDE). It is a prodrug that is dephosphorylated by alkaline phosphatase into an active compound that can then act as a cytoprotective agent, mostly by scavenging free radicals and potentially through other mechanisms.\n\n3. TRUE: HIF-1α (Hypoxia-inducible factor 1-alpha) is a well-known factor that plays a significant role in the cellular response to hypoxia. It activates the transcription of various genes involved in important processes such as angiogenesis, glucose metabolism, and cell survival, which are critical for the adaptation of cells to low-oxygen conditions.\n\n4. TRUE: In cancer cells, HIF-1α can indeed be overexpressed due to the hypoxic (low oxygen) environment often found within tumors. The overexpression of HIF-1α is associated with the promotion of angiogenesis, metabolic reprogramming, and other changes within the tumor microenvironment that support tumor growth and survival.\n\n5. UNKNOWN: Like the first statement, the regulation of HIF-1α levels by amifostine and the potential mediation by cGMP levels require specific scientific evidence for confirmation. cGMP is a secondary messenger involved in various cellular processes, and while it can have numerous effects in different contexts, without a source or a specific study to reference, it's not possible to verify this claim about amifostine's mode of action regarding the increase of HIF-1α.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits histone H3 lysine 4 trimethylation (H3K4me3) marks on histone proteins. H3K4me3 is a repressive chromatin mark that is associated with gene silencing and is involved in various cellular processes, including cell fate determination, differentiation, and gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase enzyme.\n2. Set7 deposits the histone mark H3 lysine 4 trimethylation (H3K4me3).\n3. H3K4me3 is associated with gene silencing.\n4. H3K4me3 is involved in cellular processes such as cell fate determination, differentiation, and gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase enzyme.",
      "Set7 deposits the histone mark H3 lysine 4 trimethylation (H3K4me3).",
      "H3K4me3 is associated with gene silencing.",
      "H3K4me3 is involved in cellular processes such as cell fate determination, differentiation, and gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 specifically deposits the histone mark H3 lysine 4 monomethylation (H3K4me1), not trimethylation (H3K4me3).\n3. FALSE [correction]: H3K4me3 is generally associated with active gene transcription, not gene silencing.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The protein hepcidin typically contains 8 cysteine amino acid residues that form 4 disulfide bonds (or bridges), not 4 disulfide bridges.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 is a cytoplasmic protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is cytoplasmic.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is cytoplasmic."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nThe statement is highly specific and requires knowledge about the cellular localization of the protein encoded by DNAJC11. Without access to current scientific literature or a reliable scientific database providing information about the localization of the protein, it is not possible to definitively determine the veracity of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Yes, ultraconserved elements (UEs) are depleted among copy number variants (CNVs). CNVs are genomic regions that are duplicated or deleted relative to the reference genome, and they can be associated with a variety of genetic disorders.\nUltraconserved elements are regions of the genome that are highly conserved across different species and are thought to be important for the regulation of gene expression. However, these regions are often not as well-represented in CNVs as other types of genomic regions.\nStudies have shown that UEs are underrepresented in CNVs compared to the rest of the genome. For example, a study published in the journal Nature Communications in 2017 found that only 3% of CNVs in the human genome overlap with UEs, while 27% of the genome as a whole contains UEs.\nThis depletion of UEs among CNVs may be due to the fact that these regions are more likely to be functionally important and therefore more likely to be preserved in the genome. Additionally, the high conservation of UEs across different species may make them less likely to be disrupted by CNVs.\nOverall, the depletion of UEs among CNVs highlights the importance of these regions in the genome and suggests that they may play a unique role in the development and function of the human genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Copy number variants (CNVs) are genomic regions that are duplicated or deleted relative to the reference genome.\n2. Ultraconserved elements (UEs) are regions of the genome highly conserved across different species.\n3. UEs are underrepresented in CNVs compared to the rest of the genome.\n4. A study published in Nature Communications in 2017 found that only 3% of CNVs in the human genome overlap with UEs.\n5. 27% of the human genome as a whole contains UEs.",
    "llama-2-7b-chat-hf_fact": [
      "Copy number variants (CNVs) are genomic regions that are duplicated or deleted relative to the reference genome.",
      "Ultraconserved elements (UEs) are regions of the genome highly conserved across different species.",
      "UEs are underrepresented in CNVs compared to the rest of the genome.",
      "A study published in Nature Communications in 2017 found that only 3% of CNVs in the human genome overlap with UEs.",
      "27% of the human genome as a whole contains UEs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Ultraconserved elements (UEs) comprise a much smaller percentage of the human genome. While an exact percentage varies by studies, they are estimated to represent far less than 27% of the genome, typically cited as less than 1%.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Has2 (Haspin) is a protein kinase that plays a crucial role in the regulation of mitotic progression. The substrate of Has2 (Haspin) during mitosis is primarily the histone H3. Specifically, Has2 phosphorylates the threonine 3 (T3) residue of histone H3, leading to the stabilization of chromatin structures and the progression of mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Has2 (Haspin) is a protein kinase involved in the regulation of mitotic progression.\n2. The primary substrate of Has2 (Haspin) during mitosis is histone H3.\n3. Has2 phosphorylates the threonine 3 (T3) residue of histone H3 during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "Has2 (Haspin) is a protein kinase involved in the regulation of mitotic progression.",
      "The primary substrate of Has2 (Haspin) during mitosis is histone H3.",
      "Has2 phosphorylates the threonine 3 (T3) residue of histone H3 during mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The primary substrate of Haspin during mitosis is histone H3, but it specifically phosphorylates threonine 3 (T3) of histone H3, not just histone H3 in general.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a mechanism that is distinct from other RNA viruses. Here is a general overview of the mechanism of viroid replication:\n1. Infection: Viroids infect plants by moving their RNA into the cytoplasm of host cells, where they begin to replicate.\n2. RNA replication: Once inside the cytoplasm, viroid RNA is replicated through a process called \"transcriptional replication.\" This means that the viroid RNA is transcribed (copied) into a complementary RNA molecule, which is then translated into protein.\n3. Protein accumulation: The newly synthesized protein is then transported to the nucleus of the host cell, where it helps to initiate the replication of the viroid RNA.\n4. Nuclear localization: The viroid RNA is transported to the nucleus of the host cell, where it begins to replicate.\n5. Replication: The viroid RNA replicates by using the host cell's own machinery to transcribe and translate the RNA into protein. This process is repeated many times, resulting in the production of large quantities of viroid RNA.\n6. Release: The newly replicated viroid RNA is then released from the host cell through a process called \"exocytosis,\" which involves the fusion of the viroid-containing vesicles with the plasma membrane of the host cell.\n7. Infection of new cells: The released viroid RNA can then infect new host cells, starting the replication cycle again.\nOverall, the mechanism of viroid replication is a complex process that involves the movement of RNA into the cytoplasm of host cells, followed by transcriptional replication, protein accumulation, nuclear localization, replication, and release of the viroid RNA. This process is highly efficient and allows viroids to rapidly infect and replicate in a wide range of host plants.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules that infect plants.\n2. Viroid RNA is replicated in the cytoplasm of host cells through a process called \"transcriptional replication.\"\n3. The replication process of viroids involves the host cell's machinery to transcribe and translate the RNA into protein.\n4. Newly replicated viroid RNA undergoes a process called \"exocytosis\" for release from the host cell.\n5. Viroid RNA can infect new host cells, perpetuating the replication cycle.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules that infect plants.",
      "Viroid RNA is replicated in the cytoplasm of host cells through a process called \"transcriptional replication.\"",
      "The replication process of viroids involves the host cell's machinery to transcribe and translate the RNA into protein.",
      "Newly replicated viroid RNA undergoes a process called \"exocytosis\" for release from the host cell.",
      "Viroid RNA can infect new host cells, perpetuating the replication cycle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroid RNA is replicated in the nucleus or chloroplast of host cells through a process called \"rolling-circle replication.\"\n3. FALSE [correction]: The replication process of viroids does not involve translating the RNA into protein; viroids are solely composed of RNA and do not encode for proteins.\n4. FALSE [correction]: Newly replicated viroid RNA does not necessarily undergo exocytosis; instead, they are typically released when the host cell dies and breaks apart, or through mechanical means such as plant-to-plant contact.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Yes, fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD). Fibronectin is a protein that is involved in the structure and function of muscle tissue, and its levels have been found to be altered in the blood of individuals with DMD.\nStudies have shown that the levels of fibronectin in the serum of DMD patients are significantly lower than those in healthy individuals, and this reduction can be detected as early as 6 months of age. This decrease in fibronectin levels is thought to be due to the loss of muscle fibers and the degeneration of muscle tissue that occurs in DMD.\nThe use of fibronectin as a biomarker for DMD has several advantages, including its ease of measurement, its sensitivity and specificity, and its potential to detect the disease early. However, further research is needed to confirm these findings and to determine the clinical usefulness of fibronectin as a biomarker for DMD.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Fibronectin is a protein involved in the structure and function of muscle tissue.\n3. In individuals with DMD, fibronectin levels in the serum are significantly lower than those in healthy individuals.\n4. The reduction in fibronectin levels in DMD patients can be detected as early as 6 months of age.\n5. The decrease in fibronectin levels in DMD is thought to be due to the loss of muscle fibers and the degeneration of muscle tissue.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Fibronectin is a protein involved in the structure and function of muscle tissue.",
      "In individuals with DMD, fibronectin levels in the serum are significantly lower than those in healthy individuals.",
      "The reduction in fibronectin levels in DMD patients can be detected as early as 6 months of age.",
      "The decrease in fibronectin levels in DMD is thought to be due to the loss of muscle fibers and the degeneration of muscle tissue."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Fibronectin has indeed been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. TRUE: Fibronectin is a protein that is involved in cell adhesion, growth, migration, and differentiation, and plays roles in the structure and function of muscle tissue.\n3. FALSE [correction]: In individuals with DMD, fibronectin levels in the serum are generally higher, not lower, than those in healthy individuals. The increased levels are typically due to muscle damage and the inflammatory response in DMD.\n4. UNKNOWN: Without specific research data, it is difficult to confirm at exactly what age the reduction in fibronectin levels can be detected in DMD patients, or if the statement is accurate in suggesting a reduction rather than an increase of fibronectin levels.\n5. FALSE [correction]: Since the earlier statement about lower levels of fibronectin is incorrect, the reasoning provided here is also incorrect. The increase in fibronectin levels in DMD is thought to be related to the muscle fiber damage and the associated inflammatory response, not a decrease due to loss of muscle fibers and degeneration.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n1. The ENCODE (Encyclopedia of DNA Elements) Project: This project is a large-scale effort to map all of the functional elements in the human genome, including promoters, enhancers, and other regulatory elements.\n2. The Roadmap Epigenomics Project: This project is focused on generating comprehensive epigenetic maps of multiple tissues and cell types across multiple organisms, including humans, mice, and fruit flies.\n3. The Epigenome-Wide Association Study (EWAS) Project: This project is focused on identifying specific epigenetic markers associated with specific diseases or traits, such as cancer or mental health disorders.\n4. The Human Epigenome Project: This project is focused on generating a comprehensive epigenetic map of the human genome, including both promoter and gene body epigenetic marks.\n5. The Mouse Epigenome Project: This project is focused on generating a comprehensive epigenetic map of the mouse genome, including both promoter and gene body epigenetic marks.\n6. The Fruit Fly Epigenome Project: This project is focused on generating a comprehensive epigenetic map of the fruit fly genome, including both promoter and gene body epigenetic marks.\nThese projects have generated a large amount of data on the epigenetic landscape of various organisms, which are available for analysis through the DeepBlue data server.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE Project.\n2. The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.\n3. The DeepBlue epigenomic data server holds data from the Epigenome-Wide Association Study (EWAS) Project.\n4. Data from the Human Epigenome Project are available through the DeepBlue data server.\n5. The Mouse Epigenome Project data is contained in the DeepBlue epigenomic data server.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE Project.",
      "The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server holds data from the Epigenome-Wide Association Study (EWAS) Project.",
      "Data from the Human Epigenome Project are available through the DeepBlue data server.",
      "The Mouse Epigenome Project data is contained in the DeepBlue epigenomic data server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - The DeepBlue epigenomic data server contains data from the ENCODE (Encyclopedia of DNA Elements) Project.\n2. TRUE - The Roadmap Epigenomics Project data is also included in the DeepBlue epigenomic data server.\n3. UNKNOWN - Without specific information about the inclusion of data from the Epigenome-Wide Association Study (EWAS) Project in the DeepBlue data server, it's not possible to determine the veracity of this statement.\n4. UNKNOWN - Similarly, without specific information about whether data from the Human Epigenome Project is available through the DeepBlue data server, the truthfulness of this statement can't be ascertained.\n5. UNKNOWN - The inclusion of Mouse Epigenome Project data in the DeepBlue epigenomic data server cannot be confirmed or denied without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "One tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage is the \"Synonymous Codon Usage Analysis\" tool in the software package \"GeneMarkS\". This tool uses a SOM to visualize and analyze the usage of synonymous codons in a given DNA sequence. The SOM is a type of artificial neural network that can be used for dimensionality reduction and clustering of data, and it can be particularly useful for visualizing complex patterns of codon usage in large datasets.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"Synonymous Codon Usage Analysis\" tool within the software package \"GeneMarkS\" employs self-organizing maps for analyzing synonymous codon usage.\n2. The \"Synonymous Codon Usage Analysis\" tool is designed to visualize and analyze the usage of synonymous codons in DNA sequences.\n3. Self-organizing maps are a type of artificial neural network used for dimensionality reduction and clustering of data.\n4. Self-organizing maps can assist in visualizing complex patterns of codon usage within large datasets.",
    "llama-2-7b-chat-hf_fact": [
      "The \"Synonymous Codon Usage Analysis\" tool within the software package \"GeneMarkS\" employs self-organizing maps for analyzing synonymous codon usage.",
      "The \"Synonymous Codon Usage Analysis\" tool is designed to visualize and analyze the usage of synonymous codons in DNA sequences.",
      "Self-organizing maps are a type of artificial neural network used for dimensionality reduction and clustering of data.",
      "Self-organizing maps can assist in visualizing complex patterns of codon usage within large datasets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The \"Synonymous Codon Usage Analysis\" tool is not a part of the software package \"GeneMarkS.\" GeneMarkS is used for gene prediction in prokaryotic genomes and metagenomes. The synonymous codon usage analysis is generally a separate aspect of genetic research that might be performed using different specialized software or tools.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Mammary Interaction Network Domain-containing Protein 1) is a protein that is involved in the regulation of mammary gland development and lactation. It is a transcriptional coactivator that helps to activate the expression of genes involved in milk production and is essential for the formation and maintenance of the mammary gland. MINDY-1 is also known as BRCA1-interacting protein 1 (BRIP1) and is a key regulator of the BRCA1-mediated DNA repair pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 stands for Mammary Interaction Network Domain-containing Protein 1.\n2. MINDY-1 is involved in the regulation of mammary gland development and lactation.\n3. It acts as a transcriptional coactivator for genes involved in milk production.\n4. MINDY-1 is essential for the formation and maintenance of the mammary gland.\n5. MINDY-1 is also known as BRCA1-interacting protein 1 (BRIP1) and plays a role in the BRCA1-mediated DNA repair pathway.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 stands for Mammary Interaction Network Domain-containing Protein 1.",
      "MINDY-1 is involved in the regulation of mammary gland development and lactation.",
      "It acts as a transcriptional coactivator for genes involved in milk production.",
      "MINDY-1 is essential for the formation and maintenance of the mammary gland.",
      "MINDY-1 is also known as BRCA1-interacting protein 1 (BRIP1) and plays a role in the BRCA1-mediated DNA repair pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: MINDY-1 is not the same as BRCA1-interacting protein 1 (BRIP1). BRIP1 is a separate protein that interacts with BRCA1 and plays a role in the DNA repair pathway.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. PhyloBLAST: This software uses a phylogenetic approach to identify conserved genomic regions. It compares the sequences of different organisms and identifies regions that are highly conserved across different species.\n2. ConServe: This software uses a combination of sequence alignment and phylogenetic analysis to identify conserved genomic regions. It can also predict the functional importance of these regions.\n3. ConPhlAn: This software uses a phylogenetic approach to identify conserved genomic regions and predict their functional importance. It can also identify regions that are conserved across different species but not necessarily across different strains or isolates.\n4. Prokka: This software is a comprehensive tool for the analysis of conserved genomic regions in prokaryotes. It can identify conserved genes, operons, and genomic islands, as well as predict the functional importance of these regions.\n5. GERP: This software uses a hidden Markov model to identify conserved genomic regions in eukaryotes. It can also predict the functional importance of these regions and identify potential drug targets.\n6. MUSCLE: This software is a multiple sequence alignment tool that can be used to identify conserved genomic regions in multiple species. It can also predict the functional importance of these regions.\n7. HMMER: This software uses a hidden Markov model to identify conserved genomic regions in eukaryotes. It can also predict the functional importance of these regions and identify potential drug targets.\n8. Prodigal: This software is a multiple sequence alignment tool that can be used to identify conserved genomic regions in multiple species. It can also predict the functional importance of these regions.\n9. SMART: This software uses a hidden Markov model to identify conserved genomic regions in eukaryotes. It can also predict the functional importance of these regions and identify potential drug targets.\n10. Pfam: This software is a database of protein domain families that can be used to identify conserved genomic regions in prokaryotes and eukaryotes. It can also predict the functional importance of these regions.\nIt's worth noting that these software packages are not mutually exclusive, and many of them can be used in combination",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBLAST is a software that uses a phylogenetic approach to identify conserved genomic regions across different species.\n2. ConServe is a software that combines sequence alignment and phylogenetic analysis to find conserved genomic regions and predict their functional importance.\n3. Prokka is a tool for analyzing conserved genomic regions in prokaryotes, identifying conserved genes, operons, and genomic islands.\n4. GERP is a software that uses a hidden Markov model to identify conserved genomic regions in eukaryotes, and can predict functional importance and identify potential drug targets.\n5. Pfam is a database of protein domain families that helps identify conserved genomic regions in both prokaryotes and eukaryotes, and predicts their functional importance.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBLAST is a software that uses a phylogenetic approach to identify conserved genomic regions across different species.",
      "ConServe is a software that combines sequence alignment and phylogenetic analysis to find conserved genomic regions and predict their functional importance.",
      "Prokka is a tool for analyzing conserved genomic regions in prokaryotes, identifying conserved genes, operons, and genomic islands.",
      "GERP is a software that uses a hidden Markov model to identify conserved genomic regions in eukaryotes, and can predict functional importance and identify potential drug targets.",
      "Pfam is a database of protein domain families that helps identify conserved genomic regions in both prokaryotes and eukaryotes, and predicts their functional importance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: PhyloBLAST is a name that appears to suggest a phylogenetic approach to BLAST (a tool for comparing an amino acid or nucleotide sequence to a database of sequences), but its description and exact features are not clear without the specific context and there may be no conventional tool with this exact name. The description sounds plausible, but without further context, it cannot be verified.\n\n2. FALSE [correction]: There may be a misunderstanding or an incorrect association of software name and function. If ConServe is being referenced, there is a lack of information about this specific tool. However, there is a well-known software named \"Consurf\" that uses sequence alignment and phylogenetic analysis to find and predict the functional importance of conserved amino acid positions.\n\n3. TRUE: Prokka is indeed a software tool that rapidly annotates bacterial, archaeal and viral genomes, providing information about identified genes and other genomic features.\n\n4. TRUE: GERP (Genomic Evolutionary Rate Profiling) is a tool that uses statistical models, such as a hidden Markov model, to identify conserved positions or regions in multiple genome alignments and can be used to predict functional importance.\n\n5. TRUE: Pfam is a widely used database of protein families and domains; it provides annotations and functional predictions based on conserved sequences that are identified through similarities to known family members in both prokaryotes and eukaryotes.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene has been associated with several diseases, including:\n1. Hypertension: Mutations in the PIEZO2 gene have been identified as a cause of hypertension, particularly in individuals of African descent.\n2. Nephrocalcinosis: PIEZO2 mutations can lead to the development of nephrocalcinosis, a condition characterized by the accumulation of calcium oxalate kidney stones.\n3. Autism spectrum disorder: Some studies have suggested a potential association between PIEZO2 mutations and an increased risk of autism spectrum disorder. However, the relationship between the two is not fully understood and requires further research.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been identified as a cause of hypertension, particularly in individuals of African descent.\n2. PIEZO2 mutations can lead to the development of nephrocalcinosis, a condition characterized by the accumulation of calcium oxalate kidney stones.\n3. Some studies have suggested a potential association between PIEZO2 mutations and an increased risk of autism spectrum disorder.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been identified as a cause of hypertension, particularly in individuals of African descent.",
      "PIEZO2 mutations can lead to the development of nephrocalcinosis, a condition characterized by the accumulation of calcium oxalate kidney stones.",
      "Some studies have suggested a potential association between PIEZO2 mutations and an increased risk of autism spectrum disorder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the PIEZO2 gene have been associated with conditions like distal arthrogryposis and Gordon Syndrome, not hypertension. Hypertension in individuals of African descent is often associated with mutations in other genes, such as those related to the renin-angiotensin aldosterone system.\n2. FALSE [correction]: PIEZO2 mutations are linked to a variety of issues with mechanosensation and proprioception, not typically with nephrocalcinosis, which involves kidney stones often formed from calcium oxalate. Nephrocalcinosis can be related to other genetic conditions affecting the kidney's ability to handle calcium.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the processing of extracellular matrix (ECM) components, such as collagen and fibronectin, by the proteasome pathway. The ERAP1-ERAP2 dimer is involved in the degradation of these ECM components, which is important for maintaining tissue homeostasis and regulating cellular behavior.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the processing of extracellular matrix components.\n2. Collagen and fibronectin are examples of extracellular matrix components processed by ERAP1-ERAP2 dimerization.\n3. The proteasome pathway is involved in the processing of extracellular matrix components promoted by ERAP1-ERAP2 dimerization.\n4. The degradation of extracellular matrix components by the ERAP1-ERAP2 dimer is important for maintaining tissue homeostasis.\n5. The ERAP1-ERAP2 dimer plays a role in regulating cellular behavior through the degradation of extracellular matrix components.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the processing of extracellular matrix components.",
      "Collagen and fibronectin are examples of extracellular matrix components processed by ERAP1-ERAP2 dimerization.",
      "The proteasome pathway is involved in the processing of extracellular matrix components promoted by ERAP1-ERAP2 dimerization.",
      "The degradation of extracellular matrix components by the ERAP1-ERAP2 dimer is important for maintaining tissue homeostasis.",
      "The ERAP1-ERAP2 dimer plays a role in regulating cellular behavior through the degradation of extracellular matrix components."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) and ERAP2 are known to form heterodimers and are involved in the processing of peptides for MHC class I presentation. However, they are not typically associated with the degradation of extracellular matrix components. This statement, while accurately reflecting the dimerization of ERAP1 and ERAP2, makes a claim about their role that is not widely recognized in scientific literature. Since my knowledge cut-off in 2023 does not provide direct evidence against this claim, I maintain it as true for now, but it requires further clarification.\n   \n2. UNKNOWN: ERAP1 and ERAP2 are mainly known for trimming peptides for presentation by MHC class I molecules, which involves intracellular antigen processing. Without specific context or evidence to the statement that these enzymes process the extracellular matrix components such as collagen and fibronectin, the truth of this statement cannot be determined.\n\n3. FALSE [correction]: The proteasome pathway is a different protein degradation pathway and is not directly involved in the processing of extracellular matrix components by ERAP1-ERAP2 dimerization. The proteasome pathway is mainly involved in the degradation of intracellular proteins, while ERAP1 and ERAP2 are involved in the trimming of peptides for presentation on MHC class I molecules.\n\n4. UNKNOWN: While the degradation of extracellular matrix components is indeed important for maintaining tissue homeostasis, the explicit role of ERAP1-ERAP2 dimer in this process is not well-established. The ERAP enzymes are generally associated with antigen processing rather than maintaining extracellular matrix homeostasis.\n\n5. UNKNOWN: ERAP1 and ERAP2 have roles in immune surveillance by trimming peptides for MHC class I antigen presentation. While these enzymes may play a role in regulating cellular behavior, there isn't a direct and well-known pathway linking them to the degradation of extracellular matrix components that regulates cellular behavior. Therefore, the influence of the ERAP1-ERAP2 dimer in this context is unknown without further information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of embryonic development and tissue homeostasis. In non-damaged gallbladders, they have been shown to play the following functions:\nR-spondin 1:\n* Regulation of stem cell proliferation and differentiation: R-spondin 1 is a secreted protein that regulates the proliferation and differentiation of stem cells in the gallbladder, particularly during embryonic development. It promotes the proliferation of stem cells and inhibits their differentiation into mature epithelial cells.\n* Maintenance of gallbladder tissue homeostasis: R-spondin 1 also plays a role in maintaining the tissue homeostasis of the gallbladder by regulating the expression of genes involved in cell adhesion and migration.\nNoggin:\n* Regulation of BMP signaling: Noggin is a secreted protein that inhibits the activity of BMP (bone morphogenetic protein) signaling, which is involved in the regulation of cell growth, differentiation, and tissue development. In the gallbladder, Noggin regulates the expression of genes involved in the maintenance of gallbladder tissue homeostasis.\n* Maintenance of gallbladder epithelial cell proliferation: Noggin also promotes the proliferation of gallbladder epithelial cells by inhibiting the activity of BMP signaling. This is important for the maintenance of gallbladder function and the prevention of gallbladder cancer.\nIn summary, R-spondin 1 and Noggin play important roles in regulating the proliferation and differentiation of stem cells in the gallbladder, as well as maintaining the tissue homeostasis of the gallbladder by regulating BMP signaling and promoting the proliferation of epithelial cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 is a protein that regulates stem cell proliferation and differentiation in the gallbladder during embryonic development.\n2. R-spondin 1 helps maintain gallbladder tissue homeostasis by regulating genes involved in cell adhesion and migration.\n3. Noggin is a protein that inhibits bone morphogenetic protein (BMP) signaling in the gallbladder.\n4. Noggin promotes the proliferation of gallbladder epithelial cells by inhibiting BMP signaling.\n5. Both R-spondin 1 and Noggin are involved in maintaining gallbladder tissue homeostasis and function.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 is a protein that regulates stem cell proliferation and differentiation in the gallbladder during embryonic development.",
      "R-spondin 1 helps maintain gallbladder tissue homeostasis by regulating genes involved in cell adhesion and migration.",
      "Noggin is a protein that inhibits bone morphogenetic protein (BMP) signaling in the gallbladder.",
      "Noggin promotes the proliferation of gallbladder epithelial cells by inhibiting BMP signaling.",
      "Both R-spondin 1 and Noggin are involved in maintaining gallbladder tissue homeostasis and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: Noggin is a protein known to inhibit bone morphogenetic protein (BMP) signaling, but it primarily plays a role in the development of the nervous system and somite patterning; its specific actions in the gallbladder have not been characterized as extensively.\n4. UNKNOWN \n5. UNKNOWN\n\nThe regulatory roles of R-spondin 1 and Noggin are well-documented in various tissues but statements 1, 2, 4, and 5 specifically pertain to effects in the gallbladder, which are less commonly described in scientific literature. Without specific information directly linking these proteins with gallbladder development, homeostasis, or function, it is not possible to confirm these statements as true. Therefore, we can only provide a corrected statement where common knowledge about Noggin's primary role in inhibiting BMP signaling is inconsistent with the context provided in statement 3.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme that consists of four subunits: p47phox, p40phox, p67phox, and Nox5. These subunits work together to form the active enzyme complex, which is necessary for the production of ROS (reactive oxygen species) through the transfer of electrons from NADPH to oxygen.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) consists of four subunits.\n2. The subunits of NOX5 include p47phox, p40phox, p67phox, and Nox5.\n3. These subunits form an active enzyme complex.\n4. The active complex is necessary for the production of reactive oxygen species (ROS).\n5. The function of the complex involves transferring electrons from NADPH to oxygen.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) consists of four subunits.",
      "The subunits of NOX5 include p47phox, p40phox, p67phox, and Nox5.",
      "These subunits form an active enzyme complex.",
      "The active complex is necessary for the production of reactive oxygen species (ROS).",
      "The function of the complex involves transferring electrons from NADPH to oxygen."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is a single enzyme which does not consist of multiple subunits like other NOX enzymes but instead is a single polypeptide chain.\n2. FALSE [correction]: The subunits p47phox, p40phox, p67phox are associated with other NOX enzymes, not with NOX5. NOX5 does not have these subunits but may have other regulatory elements and domains within its structure.\n3. FALSE [correction]: Given that NOX5 is a single polypeptide chain and does not consist of the aforementioned subunits, it does not form an active enzyme complex in the way described. Instead, NOX5 itself is an active enzyme that can produce reactive oxygen species.\n4. TRUE: The active form of NOX5, like other NADPH oxidases, is necessary for the production of reactive oxygen species (ROS).\n5. TRUE: The function of NOX5, as with other NADPH oxidases, involves transferring electrons from NADPH to oxygen to produce reactive oxygen species (ROS).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are connected in the regulation of iron metabolism. Furin is a protease enzyme that is involved in the processing and activation of several proteins, including hepcidin, a hormone that regulates iron homeostasis in the body. Hepcidin is produced in the liver and acts as a negative regulator of iron absorption in the duodenum and iron release from macrophages. When furin is activated, it can cleave and activate hepcidin, leading to decreased iron absorption and increased iron recycling in the body. This connection between furin and hepcidin helps to regulate iron homeostasis and prevent iron overload in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme that processes and activates several proteins, including hepcidin.\n2. Hepcidin is a hormone that regulates iron homeostasis in the body.\n3. Hepcidin is produced in the liver.\n4. Hepcidin acts as a negative regulator of iron absorption in the duodenum.\n5. Hepcidin also regulates iron release from macrophages.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme that processes and activates several proteins, including hepcidin.",
      "Hepcidin is a hormone that regulates iron homeostasis in the body.",
      "Hepcidin is produced in the liver.",
      "Hepcidin acts as a negative regulator of iron absorption in the duodenum.",
      "Hepcidin also regulates iron release from macrophages."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is a protease enzyme that processes and activates several precursor proteins, but it is not involved in the activation of hepcidin.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolytic pathway, also known as the Embden-Meyerhof-Parnas (EMP) pathway. This pathway is responsible for the breakdown of glucose to produce energy in the form of ATP, NADH, and FADH2. The glycolytic pathway in yeast consists of 11 genes that are organized in a single operon, which is the largest metabolic gene cluster in the yeast genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. The glycolytic pathway is the largest metabolic gene cluster in yeast.\n2. The glycolytic pathway is also known as the Embden-Meyerhof-Parnas (EMP) pathway.\n3. This pathway breaks down glucose to produce energy in the form of ATP, NADH, and FADH2.\n4. The glycolytic pathway in yeast consists of 11 genes.\n5. These 11 genes are organized in a single operon in the yeast genome.",
    "llama-2-7b-chat-hf_fact": [
      "The glycolytic pathway is the largest metabolic gene cluster in yeast.",
      "The glycolytic pathway is also known as the Embden-Meyerhof-Parnas (EMP) pathway.",
      "This pathway breaks down glucose to produce energy in the form of ATP, NADH, and FADH2.",
      "The glycolytic pathway in yeast consists of 11 genes.",
      "These 11 genes are organized in a single operon in the yeast genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The glycolytic pathway is not necessarily the largest metabolic gene cluster in yeast; it is a major metabolic pathway, but whether it is the largest gene cluster depends on the specific metric used for \"largest\" (e.g., the number of genes, size in base pairs, etc.).\n2. TRUE\n3. FALSE [correction]: The glycolytic pathway breaks down glucose to produce energy in the form of ATP and NADH; however, FADH2 is not a product of glycolysis but is instead generated in the citric acid cycle and the oxidative phosphorylation pathway.\n4. TRUE\n5. FALSE [correction]: In yeast, the genes involved in the glycolytic pathway are not organized in a single operon like in prokaryotes. Yeast, being eukaryotes, do not typically have operon structures for metabolic pathways.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Lung-specific microRNA-targeting) is a long non-coding RNA (lncRNA) that plays a critical role in the regulation of lung development and cancer. Here are some of the key functions of LIMT lncRNA:\n1. Regulation of cell proliferation and differentiation: LIMT lncRNA has been shown to regulate the proliferation and differentiation of lung cells, particularly in the context of lung cancer. It does this by binding to and inhibiting the expression of specific microRNAs (miRNAs), which are important regulators of cell growth and differentiation.\n2. Modulation of the epithelial-to-mesenchymal transition (EMT): The EMT is a process by which epithelial cells acquire mesenchymal characteristics, such as increased motility and invasiveness. LIMT lncRNA has been shown to inhibit the EMT in lung cancer cells, which may contribute to its tumor-suppressive effects.\n3. Inhibition of angiogenesis: Angiogenesis is the formation of new blood vessels, which is a critical step in the progression of solid tumors. LIMT lncRNA has been shown to inhibit angiogenesis in lung cancer cells by regulating the expression of genes involved in this process.\n4. Regulation of immune response: LIMT lncRNA has been shown to regulate the expression of genes involved in the immune response, including those involved in the activation and proliferation of immune cells.\nOverall, the role of LIMT lncRNA is to regulate a wide range of cellular processes that are important for the development and progression of lung cancer. Its ability to regulate the expression of specific genes and proteins makes it a promising target for the development of new therapeutic strategies for the treatment of lung cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT (Lung-specific microRNA-targeting) is a long non-coding RNA that is involved in the regulation of lung development and cancer.\n2. LIMT lncRNA regulates the proliferation and differentiation of lung cells by inhibiting the expression of specific microRNAs.\n3. LIMT lncRNA has been shown to inhibit the epithelial-to-mesenchymal transition (EMT) in lung cancer cells.\n4. LIMT lncRNA inhibits angiogenesis in lung cancer cells by regulating the expression of genes involved in the formation of new blood vessels.\n5. LIMT lncRNA influences the immune response by regulating the expression of genes involved in the activation and proliferation of immune cells.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT (Lung-specific microRNA-targeting) is a long non-coding RNA that is involved in the regulation of lung development and cancer.",
      "LIMT lncRNA regulates the proliferation and differentiation of lung cells by inhibiting the expression of specific microRNAs.",
      "LIMT lncRNA has been shown to inhibit the epithelial-to-mesenchymal transition (EMT) in lung cancer cells.",
      "LIMT lncRNA inhibits angiogenesis in lung cancer cells by regulating the expression of genes involved in the formation of new blood vessels.",
      "LIMT lncRNA influences the immune response by regulating the expression of genes involved in the activation and proliferation of immune cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: LIMT (Lung-specific microRNA-targeting) is indeed a long non-coding RNA implicated in the regulation of lung development and potentially in cancer.\n2. TRUE: LIMT lncRNA can regulate the proliferation and differentiation of lung cells by targeting and inhibiting the action of specific microRNAs, which may affect gene expression.\n3. UNKNOWN: The specific effect of LIMT lncRNA on the epithelial-to-mesenchymal transition (EMT) in lung cancer cells would require a reference to research findings that confirm this statement.\n4. UNKNOWN: The role of LIMT lncRNA in inhibiting angiogenesis in lung cancer cells by regulating gene expression related to blood vessel formation would need supportive research evidence for confirmation.\n5. UNKNOWN: The influence of LIMT lncRNA on the immune response and regulation of genes involved in immune cell activation and proliferation requires specific research evidence for a true or false determination.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor packages that can be used for performing SNP (single nucleotide polymorphism) enrichment analysis. Some of the commonly used packages are:\n1. \"SNPfile\": This package provides a comprehensive set of tools for SNP analysis, including enrichment analysis. It can be used to identify overrepresented SNPs in a set of genes or regions of interest.\n2. \"SNPsnp\": This package provides a variety of tools for SNP analysis, including enrichment analysis. It can be used to identify overrepresented SNPs in a set of genes or regions of interest.\n3. \"GenomicRanges\": This package provides a set of tools for genomic range analysis, including enrichment analysis. It can be used to identify overrepresented SNPs in a set of genes or regions of interest.\n4. \"GSEA (Gene Set Enrichment Analysis)\": This package provides a comprehensive set of tools for gene set enrichment analysis, including SNP enrichment analysis. It can be used to identify overrepresented SNPs in a set of genes or regions of interest.\n5. \"MAS5 (Mixture of Aggregated Signals)\": This package provides a set of tools for gene set enrichment analysis, including SNP enrichment analysis. It can be used to identify overrepresented SNPs in a set of genes or regions of interest.\n6. \"ENSA (Enrichr)\": This package provides a comprehensive set of tools for gene set enrichment analysis, including SNP enrichment analysis. It can be used to identify overrepresented SNPs in a set of genes or regions of interest.\n7. \"GSEA-P (Gene Set Enrichment Analysis-Pathway)\": This package provides a set of tools for gene set enrichment analysis, including SNP enrichment analysis. It can be used to identify overrepresented SNPs in a set of genes or regions of interest.\n8. \"Pathway Studio\": This package provides a comprehensive set of tools for pathway analysis, including SNP enrichment analysis. It can be used to identify overrepresented SNPs in a set of genes or regions of interest.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"SNPfile\" can be used for SNP enrichment analysis.\n2. The R package \"SNPsnp\" provides tools for SNP enrichment analysis.\n3. \"GenomicRanges\" is a package used for genomic range analysis, including SNP enrichment analysis.\n4. \"GSEA\" is a package for gene set enrichment analysis that includes tools for SNP enrichment analysis.\n5. \"Pathway Studio\" is a package offering tools for pathway analysis and SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"SNPfile\" can be used for SNP enrichment analysis.",
      "The R package \"SNPsnp\" provides tools for SNP enrichment analysis.",
      "\"GenomicRanges\" is a package used for genomic range analysis, including SNP enrichment analysis.",
      "\"GSEA\" is a package for gene set enrichment analysis that includes tools for SNP enrichment analysis.",
      "\"Pathway Studio\" is a package offering tools for pathway analysis and SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: To my knowledge, there is no R package called \"SNPfile\" known for SNP enrichment analysis. The user might be referring to a different package or the name might be incorrect.\n2. UNKNOWN: There is no R package by the name \"SNPsnp\" specifically recognized for SNP enrichment analysis; however, this could be a case of a naming error, or the package might exist but is not widely known in the community.\n3. TRUE: \"GenomicRanges\" is indeed an R package used for genomic range analysis, and while it is not specifically for SNP enrichment analysis, it can be used as part of a workflow that includes SNP enrichment analysis.\n4. FALSE [correction]: \"GSEA\" stands for Gene Set Enrichment Analysis, which is specifically tailored for gene set enrichment and does not include tools for SNP enrichment analysis as its primary function.\n5. FALSE [correction]: \"Pathway Studio\" is software that provides tools for pathway analysis among other functionalities, but there is no evidence it offers specialized tools for SNP enrichment analysis. It is primarily focused on pathway analysis and visualization.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are a type of glial cell that are found in the developing brain and play a crucial role in the specification of ependymal cells. The key players involved in the specification of radial glial cells to ependymal cells include:\n1. Notch signaling pathway: Notch is a transmembrane receptor that plays a crucial role in the regulation of cell fate decisions, including the specification of radial glial cells to ependymal cells.\n2. Wnt/β-catenin signaling pathway: Wnt/β-catenin signaling is another important pathway involved in the specification of radial glial cells to ependymal cells.\n3. Shh signaling pathway: Shh is a secreted protein that regulates the specification of radial glial cells to ependymal cells through its activation of the Patched (Ptch) receptor.\n4. BMP signaling pathway: BMP (bone morphogenetic protein) signaling is also involved in the specification of radial glial cells to ependymal cells, through the activation of the Smad signaling pathway.\n5. FGF signaling pathway: FGF (fibroblast growth factor) signaling is another pathway involved in the specification of radial glial cells to ependymal cells, through the activation of the FGF receptor.\n6. Ephrin signaling pathway: Ephrin is a transmembrane protein that regulates the specification of radial glial cells to ependymal cells through its activation of the Eph receptor.\n7. Netrin signaling pathway: Netrin is a secreted protein that regulates the specification of radial glial cells to ependymal cells through its activation of the DCC (deleted in colorectal cancer) receptor.\nThese signaling pathways interact and coordinate to specify radial glial cells to ependymal cells, a process that is critical for the proper development of the brain and spinal cord.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Notch signaling pathway plays a role in the regulation of cell fate decisions, including the specification of radial glial cells to ependymal cells.\n2. Wnt/β-catenin signaling is involved in the specification of radial glial cells to ependymal cells.\n3. Shh (Sonic hedgehog) signaling, through activation of the Patched (Ptch) receptor, regulates the specification of radial glial cells to ependymal cells.\n4. BMP (bone morphogenetic protein) signaling contributes to the specification of radial glial cells to ependymal cells, through activation of the Smad signaling pathway.\n5. FGF (fibroblast growth factor) signaling, via activation of the FGF receptor, is involved in the specification of radial glial cells to ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "The Notch signaling pathway plays a role in the regulation of cell fate decisions, including the specification of radial glial cells to ependymal cells.",
      "Wnt/β-catenin signaling is involved in the specification of radial glial cells to ependymal cells.",
      "Shh (Sonic hedgehog) signaling, through activation of the Patched (Ptch) receptor, regulates the specification of radial glial cells to ependymal cells.",
      "BMP (bone morphogenetic protein) signaling contributes to the specification of radial glial cells to ependymal cells, through activation of the Smad signaling pathway.",
      "FGF (fibroblast growth factor) signaling, via activation of the FGF receptor, is involved in the specification of radial glial cells to ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Wnt/β-catenin signaling is not primarily known for the specification of radial glial cells to ependymal cells. Wnt signaling is involved in various aspects of cell differentiation and development, but this specific role is not clearly established.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe specificity of signaling pathways such as Shh, BMP, and FGF in the context of radial glial cells' specification to ependymal cells is a precise area of developmental biology that would require current, specialized knowledge or references to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of glioma, which is a type of brain cancer, that are characterized by the lack of expression of certain biomarkers, including:\n1. Tumor suppressor proteins: Triple negative gliomas typically lack the expression of tumor suppressor proteins such as p53, PTEN, and TP53.\n2. Receptors: These tumors often lack the expression of certain receptors, such as ERBB2 (HER2) and EGFR.\n3. Hormone receptors: Triple negative gliomas do not express hormone receptors, such as estrogen receptors (ERα) and progesterone receptors (PR).\n4. EGFRvIII: This is a mutated form of the EGFR protein that is commonly found in glioblastoma, a type of triple negative glioma.\n5. MGMT: O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that is often overexpressed in gliomas, including triple negative gliomas.\n6. IDH1/2: Mutations in the isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) genes are commonly found in gliomas, including triple negative gliomas, and are associated with a specific genetic mutation known as the IDH mutation.\n7. 1p/19q codeletion: Triple negative gliomas often have a loss of material on chromosomes 1p and 19q, a genetic abnormality known as 1p/19q codeletion.\n8. High proliferation rate: Triple negative gliomas tend to have a high proliferation rate, as measured by markers such as Ki67.\n9. Poor differentiation: Triple negative gliomas are typically poorly differentiated, meaning they do not have a distinctive pattern of cellular differentiation.\n10. Aggressive behavior: Triple negative gliomas are often highly aggressive and tend to grow rapidly, invade surrounding tissue, and are resistant to treatment.\nIt is important to note that the exact set of biomarkers used to diagn",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack the expression of tumor suppressor proteins such as p53, PTEN, and TP53.\n2. Triple negative gliomas often lack the expression of certain receptors, such as ERBB2 (HER2) and EGFR.\n3. Triple negative gliomas do not express hormone receptors like estrogen receptors (ERα) and progesterone receptors (PR).\n4. The EGFRvIII mutated form of the EGFR protein is commonly found in glioblastoma, a type of triple negative glioma.\n5. Triple negative gliomas often have a genetic abnormality known as 1p/19q codeletion, a loss of material on chromosomes 1p and 19q.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack the expression of tumor suppressor proteins such as p53, PTEN, and TP53.",
      "Triple negative gliomas often lack the expression of certain receptors, such as ERBB2 (HER2) and EGFR.",
      "Triple negative gliomas do not express hormone receptors like estrogen receptors (ERα) and progesterone receptors (PR).",
      "The EGFRvIII mutated form of the EGFR protein is commonly found in glioblastoma, a type of triple negative glioma.",
      "Triple negative gliomas often have a genetic abnormality known as 1p/19q codeletion, a loss of material on chromosomes 1p and 19q."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple-negative gliomas lack the expression of receptors such as estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. TP53 is a tumor suppressor gene but not a receptor, and it's not necessarily true that all triple-negative gliomas lack its expression.\n   \n2. TRUE: Triple-negative gliomas often lack the expression of certain receptors, such as ERBB2 (HER2) and EGFR, which is characteristic and helps to define the triple-negative status.\n\n3. TRUE: Triple-negative gliomas indeed do not express hormone receptors like estrogen receptors (ERα) and progesterone receptors (PR), a characteristic shared with triple-negative breast cancers from which the naming convention is borrowed.\n\n4. TRUE: The EGFRvIII mutated form of the EGFR protein is commonly found in glioblastoma, which can be a type of triple-negative glioma.\n\n5. FALSE [correction]: The genetic abnormality known as 1p/19q codeletion is characteristic of oligodendrogliomas, another type of glioma, and is generally not associated with triple-negative gliomas. Instead, triple-negative gliomas lack specific molecular markers used to classify other forms of gliomas.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (Topoisomerase II-associated protein AZ1) is a protein that is involved in the regulation of DNA topoisomerase II (Topo II) activity. Topo II is an enzyme that relaxes supercoiled DNA, which is essential for DNA replication, transcription, and repair. TOPAZ1 is a negative regulator of Topo II activity, meaning that it inhibits the activity of the enzyme. TOPAZ1 is composed of two domains: an N-terminal domain that binds to Topo II and a C-terminal domain that interacts with the DNA molecule. By inhibiting Topo II activity, TOPAZ1 helps to regulate the amount of supercoiled DNA in the cell and prevent the accumulation of DNA damage.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is involved in the regulation of DNA topoisomerase II (Topo II) activity.\n2. Topo II is an enzyme that relaxes supercoiled DNA which is vital for DNA replication, transcription, and repair.\n3. TOPAZ1 functions as a negative regulator of Topo II, inhibiting the enzyme's activity.\n4. TOPAZ1 has an N-terminal domain that binds to Topo II.\n5. TOPAZ1 has a C-terminal domain that interacts with the DNA molecule.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is involved in the regulation of DNA topoisomerase II (Topo II) activity.",
      "Topo II is an enzyme that relaxes supercoiled DNA which is vital for DNA replication, transcription, and repair.",
      "TOPAZ1 functions as a negative regulator of Topo II, inhibiting the enzyme's activity.",
      "TOPAZ1 has an N-terminal domain that binds to Topo II.",
      "TOPAZ1 has a C-terminal domain that interacts with the DNA molecule."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: The statements about TOPAZ1 and its specific functions and domains are not common knowledge, and without the specific context or source material detailing the research on TOPAZ1, the truthfulness of the statements about the regulatory role of TOPAZ1, its negative regulation of Topo II, and the specific domain interactions cannot be determined. Therefore, the responses to those statements are marked as UNKNOWN. However, the general function of Topo II as stated in statement 2 is a well-established fact in molecular biology.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The gene that controls the expression of GATA-1 isoforms is the GATA-1 gene itself. GATA-1 is a transcription factor that plays a crucial role in regulating the expression of genes involved in erythroid cell development and differentiation. The GATA-1 gene contains multiple isoforms, each with a distinct function in the regulation of erythroid gene expression. The expression of these isoforms is controlled by a complex interplay of transcriptional and post-transcriptional mechanisms, including the binding of transcription factors, splicing, and mRNA stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene controls the expression of its own isoforms.\n2. GATA-1 is a transcription factor important for gene expression in erythroid cell development and differentiation.\n3. There are multiple isoforms of the GATA-1 gene, and each has a distinct function in regulating erythroid gene expression.\n4. The expression of GATA-1 isoforms is regulated by transcriptional and post-transcriptional mechanisms.\n5. Factors influencing the expression of GATA-1 isoforms include the binding of transcription factors, splicing, and mRNA stability.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene controls the expression of its own isoforms.",
      "GATA-1 is a transcription factor important for gene expression in erythroid cell development and differentiation.",
      "There are multiple isoforms of the GATA-1 gene, and each has a distinct function in regulating erythroid gene expression.",
      "The expression of GATA-1 isoforms is regulated by transcriptional and post-transcriptional mechanisms.",
      "Factors influencing the expression of GATA-1 isoforms include the binding of transcription factors, splicing, and mRNA stability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The GATA-1 gene can indeed control the expression of its own isoforms through a process known as autoregulation.\n2. TRUE: GATA-1 is a well-known transcription factor that is essential for the proper development and differentiation of erythroid cells, which are the precursors of red blood cells.\n3. TRUE: There are multiple isoforms of the GATA-1 gene that arise due to alternative splicing, and these isoforms can have distinct functions in the regulation of erythroid gene expression.\n4. TRUE: The expression of GATA-1 isoforms is subject to regulation at multiple levels, including transcriptional and post-transcriptional mechanisms like alternative splicing and mRNA stability.\n5. TRUE: The factors that influence the expression of GATA-1 isoforms indeed include the binding of other transcription factors to regulatory regions, alternative splicing events that can generate different isoforms, and the stability of the mRNA transcripts.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a method for assessing the expression of microRNAs (miRNAs) in a given sample, such as a cell or tissue. It involves sequencing the small RNA molecules in the sample and then using computational tools to identify and quantify the different miRNAs present. The goal of MIRA-seq is to provide a comprehensive picture of the miRNA landscape in a given sample, which can be useful for understanding the regulation of gene expression and the role of miRNAs in various biological processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a method used to assess the expression of microRNAs (miRNAs) in a sample.\n2. It involves sequencing the small RNA molecules present in the sample.\n3. Computational tools are used to identify and quantify the different miRNAs in the sample.\n4. The goal of MIRA-seq is to offer a comprehensive picture of the miRNA landscape in a sample.\n5. MIRA-seq helps understand the regulation of gene expression and the role of miRNAs in biological processes.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a method used to assess the expression of microRNAs (miRNAs) in a sample.",
      "It involves sequencing the small RNA molecules present in the sample.",
      "Computational tools are used to identify and quantify the different miRNAs in the sample.",
      "The goal of MIRA-seq is to offer a comprehensive picture of the miRNA landscape in a sample.",
      "MIRA-seq helps understand the regulation of gene expression and the role of miRNAs in biological processes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq (Methylated CpG Island Recovery Assay Sequencing) is a method used to assess genome-wide DNA methylation patterns, not to assess the expression of microRNAs (miRNAs).\n2. FALSE [correction]: MIRA-seq does not involve sequencing small RNA molecules; it involves the enrichment of methylated DNA fragments and their subsequent sequencing.\n3. TRUE: Computational tools are indeed used in methods like MIRA-seq to identify and quantify different genomic features, such as methylated DNA regions in the sample, not miRNAs.\n4. TRUE: The goal of MIRA-seq is to provide a comprehensive picture of the DNA methylation landscape in a sample.\n5. FALSE [correction]: MIRA-seq helps understand the regulation of gene expression through DNA methylation and the role of such epigenetic modifications in biological processes, not specifically the role of miRNAs.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a prescription medication used to treat cryopyrin-associated periodic syndrome (CAPS) and gouty arthritis. It is also being studied for the treatment of other conditions, such as migraines and fibromyalgia.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST is a prescription medication.\n2. ARCALYST is used to treat cryopyrin-associated periodic syndrome (CAPS).\n3. ARCALYST is used to treat gouty arthritis.\n4. ARCALYST is being studied for the treatment of migraines.\n5. ARCALYST is being studied for the treatment of fibromyalgia.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST is a prescription medication.",
      "ARCALYST is used to treat cryopyrin-associated periodic syndrome (CAPS).",
      "ARCALYST is used to treat gouty arthritis.",
      "ARCALYST is being studied for the treatment of migraines.",
      "ARCALYST is being studied for the treatment of fibromyalgia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ARCALYST (rilonacept) is not specifically indicated for the treatment of gouty arthritis; however, it is approved for the treatment of recurrent pericarditis, which may have symptoms similar to those of gouty conditions. ARCALYST has also been used in the past off-label for refractory gout.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes, which are characterized by their short arm (p) and long arm (q). The following are the human acrocentric chromosomes that can be involved in Robertsonian translocations:\n1. Chromosome 13 (13q)\n2. Chromosome 14 (14q)\n3. Chromosome 15 (15q)\n4. Chromosome 16 (16q)\n5. Chromosome 21 (21q)\nIt's worth noting that Robertsonian translocations are relatively rare and typically occur spontaneously, but they can also be inherited from one's parents. These translocations can lead to a range of genetic disorders, including Down syndrome (trisomy 21), which is caused by an extra copy of chromosome 21.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrocentric chromosomes are involved in Robertsonian translocations.\n2. Human chromosome 13 can be involved in Robertsonian translocations.\n3. Human chromosome 14 can be involved in Robertsonian translocations.\n4. Human chromosome 15 can be involved in Robertsonian translocations.\n5. Human chromosome 21 can be involved in Robertsonian translocations and is associated with Down syndrome when an extra copy is present.",
    "llama-2-7b-chat-hf_fact": [
      "Acrocentric chromosomes are involved in Robertsonian translocations.",
      "Human chromosome 13 can be involved in Robertsonian translocations.",
      "Human chromosome 14 can be involved in Robertsonian translocations.",
      "Human chromosome 15 can be involved in Robertsonian translocations.",
      "Human chromosome 21 can be involved in Robertsonian translocations and is associated with Down syndrome when an extra copy is present."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific type of analysis and the data available. Here are a few options:\n1. \"brainTumor\": This package provides a set of functions for the analysis of brain tumor data, including the identification of tumor subtypes and the prediction of patient outcomes. It can be used for both pediatric and adult brain tumors.\n2. \"pediatricTumor\": This package is specifically designed for the analysis of pediatric tumors, including brain tumors. It provides a set of functions for the identification of tumor subtypes, the analysis of genomic mutations, and the prediction of patient outcomes.\n3. \"rktumor\": This package provides a set of functions for the analysis of tumor data, including the identification of tumor subtypes and the prediction of patient outcomes. It can be used for both pediatric and adult brain tumors.\n4. \"tumorSegmentation\": This package provides a set of functions for the segmentation of tumor tissue in MRI scans, which can be used to identify the location and size of brain tumors.\n5. \"brainTumorSegmentation\": This package provides a set of functions for the segmentation of brain tumors in MRI scans, including the identification of tumor subtypes and the measurement of tumor volume.\nIt's important to note that these packages are not specific to pediatric brain tumors, and may also be used for other types of tumors. Additionally, the specific package you choose will depend on the type of data you have available and the specific research question you are trying to answer.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"brainTumor\" R package provides functions for analyzing brain tumor data, including identification of tumor subtypes and prediction of patient outcomes.\n2. The \"pediatricTumor\" R package is specifically designed for the analysis of pediatric tumors, including brain tumors.\n3. The \"rktumor\" R package provides functions for analyzing tumor data, including identification of tumor subtypes and prediction of patient outcomes.\n4. The \"tumorSegmentation\" R package provides functions for the segmentation of tumor tissue in MRI scans.\n5. The \"brainTumorSegmentation\" R package provides functions for the segmentation of brain tumors in MRI scans, including identification of tumor subtypes and measurement of tumor volume.",
    "llama-2-7b-chat-hf_fact": [
      "The \"brainTumor\" R package provides functions for analyzing brain tumor data, including identification of tumor subtypes and prediction of patient outcomes.",
      "The \"pediatricTumor\" R package is specifically designed for the analysis of pediatric tumors, including brain tumors.",
      "The \"rktumor\" R package provides functions for analyzing tumor data, including identification of tumor subtypes and prediction of patient outcomes.",
      "The \"tumorSegmentation\" R package provides functions for the segmentation of tumor tissue in MRI scans.",
      "The \"brainTumorSegmentation\" R package provides functions for the segmentation of brain tumors in MRI scans, including identification of tumor subtypes and measurement of tumor volume."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information on the \"brainTumor\" R package, it is not possible to verify the accuracy of this statement.\n2. UNKNOWN: Similarly, without specific information on the \"pediatricTumor\" R package, the accuracy of this statement cannot be determined.\n3. UNKNOWN: The \"rktumor\" R package is not well-known, and without additional context or data, the truthfulness of this statement cannot be ascertained.\n4. UNKNOWN: As with the other R packages, the existence and functionality of the \"tumorSegmentation\" R package cannot be verified without additional information.\n5. UNKNOWN: The specificity of the \"brainTumorSegmentation\" R package's functions cannot be confirmed without further context or access to the package's documentation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "No, NEMO (NF-κB essential modulator) is not a zinc finger protein. NEMO is a protein that plays a crucial role in the regulation of NF-κB (nuclear factor kappa B), a transcription factor that plays a key role in the immune response. While NEMO does contain zinc finger-like domains, it is not classified as a zinc finger protein. Zinc finger proteins are a class of proteins that contain a specific sequence of amino acids that form a zinc-binding motif, which is involved in protein-protein interactions and DNA binding.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO (NF-κB essential modulator) is not classified as a zinc finger protein.\n2. NEMO plays a crucial role in the regulation of NF-κB (nuclear factor kappa B).\n3. NF-κB is a transcription factor that plays a key role in the immune response.\n4. NEMO contains zinc finger-like domains.\n5. Zinc finger proteins have a zinc-binding motif involved in protein-protein interactions and DNA binding.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO (NF-κB essential modulator) is not classified as a zinc finger protein.",
      "NEMO plays a crucial role in the regulation of NF-κB (nuclear factor kappa B).",
      "NF-κB is a transcription factor that plays a key role in the immune response.",
      "NEMO contains zinc finger-like domains.",
      "Zinc finger proteins have a zinc-binding motif involved in protein-protein interactions and DNA binding."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) can affect nucleosome positioning. TFIIS is a transcription factor that plays a crucial role in the initiation of transcription in eukaryotic cells. It has been shown to interact with nucleosomes and affect their positioning on DNA, particularly during the initiation of transcription.\nTFIIS can bind to the DNA template at the promoter region of a gene and help to recruit other transcription factors and the RNA polymerase complex to the site of transcription initiation. Once in place, TFIIS can help to disrupt or alter the existing nucleosome structure, allowing for the binding of RNA polymerase and the initiation of transcription.\nStudies have shown that TFIIS can recognize and bind to specific nucleosome structures, such as the N-tail of the histone H3, and can use this interaction to position the nucleosomes in a way that facilitates transcription initiation. Additionally, TFIIS has been shown to be involved in the regulation of nucleosome dynamics during transcription elongation, by promoting the sliding of nucleosomes along the DNA template.\nIn summary, TFIIS plays a critical role in the regulation of nucleosome positioning during transcription initiation and elongation, and its dysregulation has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS (Transcription Factor IIS) can affect nucleosome positioning on DNA.\n2. TFIIS plays a crucial role in the initiation of transcription in eukaryotic cells.\n3. TFIIS interacts with nucleosomes, particularly during transcription initiation.\n4. TFIIS can recognize and bind to specific nucleosome structures such as the N-tail of histone H3.\n5. TFIIS is involved in the regulation of nucleosome dynamics during transcription elongation.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS (Transcription Factor IIS) can affect nucleosome positioning on DNA.",
      "TFIIS plays a crucial role in the initiation of transcription in eukaryotic cells.",
      "TFIIS interacts with nucleosomes, particularly during transcription initiation.",
      "TFIIS can recognize and bind to specific nucleosome structures such as the N-tail of histone H3.",
      "TFIIS is involved in the regulation of nucleosome dynamics during transcription elongation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TFIIS does not play a crucial role in the initiation of transcription; it is involved in the process of transcription elongation by stimulating the intrinsic nuclease activity of RNA polymerase II which helps to correct RNA synthesis errors.\n3. UNKNOWN - While TFIIS interacts with RNA polymerase II during transcription elongation, it’s unclear from the statement whether TFIIS interacts directly with nucleosomes, particularly during transcription initiation.\n4. UNKNOWN - The specific binding of TFIIS to particular nucleosome structures like the N-tail of histone H3 is not commonly mentioned in connection with TFIIS function, thus this can not be determined without additional context.\n5. TRUE - TFIIS is known to be involved in transcription elongation, which includes the regulation of nucleosome dynamics.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Origins of replication in yeast (Saccharomyces cerevisiae) fire late. Specifically, they fire after the G1/S checkpoint, which is a regulatory point in the cell cycle that ensures that the cell is ready to enter the S phase of the cell cycle. This means that the origin of replication fires after the cell has completed the G1 phase of the cell cycle and is preparing to enter the S phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication in yeast (Saccharomyces cerevisiae) fire late in the cell cycle.\n2. They fire after the G1/S checkpoint in the cell cycle.\n3. The G1/S checkpoint ensures that a cell is ready to enter the S phase of the cell cycle.\n4. The origin of replication fires after the cell has completed the G1 phase of the cell cycle.\n5. The origin of replication in yeast fires as the cell is preparing to enter the S phase.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication in yeast (Saccharomyces cerevisiae) fire late in the cell cycle.",
      "They fire after the G1/S checkpoint in the cell cycle.",
      "The G1/S checkpoint ensures that a cell is ready to enter the S phase of the cell cycle.",
      "The origin of replication fires after the cell has completed the G1 phase of the cell cycle.",
      "The origin of replication in yeast fires as the cell is preparing to enter the S phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Origins of replication in yeast (Saccharomyces cerevisiae) typically fire early in the S phase of the cell cycle, not late.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as GA-rich sequences, are short sequences of nucleotides that are found in the genomes of mammals and are characterized by the presence of a high number of guanine-adenine (GA) base pairs. Here are some of the properties of mammalian GA-sequences:\n1. Distribution: GA-rich sequences are found throughout the mammalian genome, but they are more abundant in certain regions, such as gene deserts and centromeres.\n2. Length: Mammalian GA-sequences can range in length from a few hundred to several thousand base pairs.\n3. GC content: GA-rich sequences tend to have a lower GC content than the rest of the genome, with a mean GC content of around 30-40%.\n4. Dinucleotide frequency: GA-rich sequences have a higher frequency of dinucleotides (guanine-adenine) than other regions of the genome.\n5. Methylation: Mammalian GA-rich sequences are less methylated than other regions of the genome, which may contribute to their unique properties.\n6. Transcriptional activity: GA-rich sequences tend to be less active in terms of transcription compared to other regions of the genome.\n7. Chromatin structure: GA-rich sequences are associated with a more open chromatin structure, which may be related to their ability to interact with transcription factors and other regulatory proteins.\n8. Evolutionary conservation: Mammalian GA-rich sequences are highly conserved across species, indicating their functional importance.\n9. Role in regulation: GA-rich sequences have been implicated in the regulation of gene expression, particularly in the context of cellular differentiation and development.\n10. Association with disease: GA-rich sequences have been linked to various diseases, including cancer and neurological disorders, although the exact mechanisms are not yet fully understood.\nIt is important to note that the properties of mammalian GA-sequences can vary depending on the specific context and location within the genome. Further research is needed to fully understand the mechanisms by which these sequences function and their role in disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-rich sequences are found throughout the mammalian genome and are more abundant in areas such as gene deserts and centromeres.\n2. The length of mammalian GA-sequences can range from a few hundred to several thousand base pairs.\n3. GA-rich sequences have a mean GC content of around 30-40%.\n4. GA-rich sequences have a higher frequency of dinucleotides (guanine-adenine) compared to other regions of the genome.\n5. Mammalian GA-rich sequences are less methylated than other genome regions.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-rich sequences are found throughout the mammalian genome and are more abundant in areas such as gene deserts and centromeres.",
      "The length of mammalian GA-sequences can range from a few hundred to several thousand base pairs.",
      "GA-rich sequences have a mean GC content of around 30-40%.",
      "GA-rich sequences have a higher frequency of dinucleotides (guanine-adenine) compared to other regions of the genome.",
      "Mammalian GA-rich sequences are less methylated than other genome regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Mammalian GA-rich sequences are indeed found throughout the genome and can be more abundant in particular areas such as gene deserts, which are large regions of DNA with few genes, and centromeres, which are the parts of a chromosome that link sister chromatids.\n2. TRUE: The length of GA-rich sequences can vary significantly, with some being just a few hundred base pairs long while others can extend to several thousand base pairs.\n3. UNKNOWN: Without specific information on GA-rich sequences, it's not possible to determine their mean GC content. Generally, GC content can vary throughout the genome, and GA-rich sequences could fall within or outside the stated range depending on their specific composition and location.\n4. TRUE: GA-rich sequences are characterized by a higher frequency of guanine-adenine dinucleotides, which is why they are named GA-rich.\n5. UNKNOWN: The methylation status of GA-rich sequences can vary, and without specific information, it is not possible to categorically say if they are less methylated than other regions of the genome. Methylation patterns are complex and context-dependent.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "The mouse genome contains 10 Groucho-related genes (GRG), also known as Groucho-like genes (Glg). These genes are:\n1. Grm1 (Groucho-related gene 1)\n2. Grm2 (Groucho-related gene 2)\n3. Grm3 (Groucho-related gene 3)\n4. Grm4 (Groucho-related gene 4)\n5. Grm5 (Groucho-related gene 5)\n6. Grm6 (Groucho-related gene 6)\n7. Grm7 (Groucho-related gene 7)\n8. Grm8 (Groucho-related gene 8)\n9. Grm9 (Groucho-related gene 9)\n10. Grm10 (Groucho-related gene 10)\nThese genes are involved in various cellular processes, including transcriptional regulation, cell signaling, and the maintenance of tissue homeostasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse genome contains 10 Groucho-related genes (GRG).\n2. GRG are also known as Groucho-like genes (Glg).\n3. The specific genes listed are Grm1 through Grm10.\n4. GRGs are involved in transcriptional regulation.\n5. GRGs play a role in the maintenance of tissue homeostasis.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse genome contains 10 Groucho-related genes (GRG).",
      "GRG are also known as Groucho-like genes (Glg).",
      "The specific genes listed are Grm1 through Grm10.",
      "GRGs are involved in transcriptional regulation.",
      "GRGs play a role in the maintenance of tissue homeostasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The mouse genome contains Groucho-related genes, but there isn't specific evidence that the number is 10 without a proper reference.\n2. UNKNOWN: The acronym GRG could refer to Groucho-related genes, but without context, it's unclear if GRG is also known as Groucho-like genes (Glg).\n3. FALSE [correction]: The specific genes listed as Grm1 through Grm10 appear to be referring to Glutamate receptor metabotropic genes, not Groucho-related genes.\n4. TRUE: Groucho-related genes (if GRG refers to this) are indeed involved in transcriptional regulation.\n5. TRUE: Groucho-related genes are known to play roles in the maintenance of tissue homeostasis among other functions, assuming GRGs refer to Groucho-related genes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNAPII) is a complex enzyme that carries out transcription of DNA into RNA. There are two subunits of RNAPII: RPB1 (large subunit) and RPB2 (small subunit). RPB1 carries the RNA cleavage activity, also known as RNA processing or mRNA maturation. RPB1 is responsible for the final cleavage of the primary transcript to produce the mature mRNA molecule.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (RNAPII) is responsible for transcribing DNA into RNA.\n2. RNAPII has two subunits: RPB1 and RPB2.\n3. The RPB1 subunit of RNAPII carries the RNA cleavage activity.\n4. RNA cleavage activity is also known as RNA processing or mRNA maturation.\n5. RPB1 is responsible for the final cleavage of the primary transcript to produce mature mRNA.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (RNAPII) is responsible for transcribing DNA into RNA.",
      "RNAPII has two subunits: RPB1 and RPB2.",
      "The RPB1 subunit of RNAPII carries the RNA cleavage activity.",
      "RNA cleavage activity is also known as RNA processing or mRNA maturation.",
      "RPB1 is responsible for the final cleavage of the primary transcript to produce mature mRNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RNA polymerase II has multiple subunits; RPB1 and RPB2 are just two of its core subunits, but there are others as well.\n3. FALSE [correction]: The RPB1 subunit of RNAPII does not carry RNA cleavage activity; RNA cleavage is typically associated with other protein complexes, such as the cleavage and polyadenylation specificity factor (CPSF).\n4. TRUE\n5. FALSE [correction]: RPB1 is not responsible for the final cleavage of the primary transcript to produce mature mRNA; the cleavage is carried out by other proteins and complexes involved in RNA processing.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder caused by mutations in the PDE6A gene, which encodes the alpha subunit of the cGMP-gated ion channel protein (CNGA3). The PDE6A gene is located on chromosome 15q11.2 and is responsible for the production of the CNGA3 protein, which plays a critical role in the visual cycle and phototransduction in the retina.\nMutations in the PDE6A gene can lead to a range of symptoms, including:\n1. Retinal degeneration: Ohdo syndrome is characterized by progressive retinal degeneration, leading to vision loss and blindness.\n2. Cone-rod dystrophy: The disease affects both cone and rod photoreceptors, leading to a slow progression of vision loss.\n3. Macular degeneration: The macula, the central part of the retina responsible for central vision, is affected, leading to blind spots or distorted vision.\n4. Optic atrophy: The optic nerve and retina can shrink, leading to vision loss.\n5. Glaucoma: Some individuals with Ohdo syndrome may develop glaucoma, a group of eye conditions that can damage the optic nerve and lead to vision loss.\n6. Cataracts: Some individuals with Ohdo syndrome may develop cataracts, which can impair vision.\n7. Other systemic manifestations: Ohdo syndrome can also cause a range of systemic symptoms, including intellectual disability, seizures, and delayed speech and language development.\nThe genetic basis of Ohdo syndrome is caused by mutations in the PDE6A gene, which are inherited in an autosomal dominant pattern. This means that a single copy of the mutated gene is enough to cause the condition. The mutations can occur in any of the coding exons of the PDE6A gene, leading to a range of clinical manifestations.\nIn conclusion, Ohdo syndrome is a rare genetic disorder caused by mutations in the PDE6A gene, which leads to progressive retinal degeneration, cone-rod dystrophy, macular degeneration, optic atrophy, glaucoma,",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a genetic disorder caused by mutations in the PDE6A gene.\n2. The PDE6A gene is situated on chromosome 15q11.2.\n3. Mutations in the PDE6A gene can lead to progressive retinal degeneration in individuals with Ohdo syndrome.\n4. The PDE6A gene is responsible for producing the CNGA3 protein, which is involved in the visual cycle and phototransduction in the retina.\n5. The mutations causing Ohdo syndrome are inherited in an autosomal dominant pattern, meaning a single mutated gene copy can cause the condition.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a genetic disorder caused by mutations in the PDE6A gene.",
      "The PDE6A gene is situated on chromosome 15q11.2.",
      "Mutations in the PDE6A gene can lead to progressive retinal degeneration in individuals with Ohdo syndrome.",
      "The PDE6A gene is responsible for producing the CNGA3 protein, which is involved in the visual cycle and phototransduction in the retina.",
      "The mutations causing Ohdo syndrome are inherited in an autosomal dominant pattern, meaning a single mutated gene copy can cause the condition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is a genetic disorder, but it is not caused by mutations in the PDE6A gene. It is usually associated with mutations in the MED12, KAT6B, or SALL1 genes, among others.\n2. UNKNOWN: The PDE6A gene is indeed located on a chromosome, but without specifying whether statement 1 is true (which it is not), it cannot be confirmed if PDE6A is situated on chromosome 15q11.2 as associated with Ohdo syndrome. However, independently, the PDE6A gene is actually located on chromosome 5q, not 15q11.2.\n3. FALSE [correction]: Since Ohdo syndrome is not caused by mutations in the PDE6A gene, this statement is false. Mutations in the PDE6A gene can lead to progressive retinal degeneration, but this is related to a different condition known as retinitis pigmentosa.\n4. FALSE [correction]: The PDE6A gene is responsible for producing a subunit of the rod photoreceptor cGMP phosphodiesterase, which is involved in the phototransduction pathway. It's the CNGA3 gene, not PDE6A, that encodes the alpha subunit of the cone photoreceptor cyclic nucleotide-gated cation channel, which is involved in the visual cycle and phototransduction in the retina.\n5. UNKNOWN: Since the PDE6A gene is not the causative gene for Ohdo syndrome, the inheritance pattern of mutations in the PDE6A gene related to Ohdo syndrome is not relevant. However, it's worth noting that many genetic retinal degenerations, including some caused by mutations in PDE6A, can be inherited in an autosomal recessive manner. Ohdo syndrome itself has different inheritance patterns depending on the specific mutation and gene involved.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "There are several R/Bioconductor packages that have been developed for the analysis of psychiatric disease genes. Some of the popular ones include:\n1. PsychArray: This package provides tools for the analysis of genetic association studies in psychiatric disorders, including imputation, gene-based association testing, and pathway analysis.\n2. PsychGen: This package offers a set of tools for the analysis of genetic data in psychiatric disorders, including gene-based association testing, pathway analysis, and genomic regression.\n3. PsychGWAS: This package provides tools for genome-wide association study (GWAS) analysis in psychiatric disorders, including imputation, association testing, and visualization of results.\n4. PsychSeq: This package offers tools for the analysis of genomic sequence data in psychiatric disorders, including variant discovery, gene expression analysis, and functional annotation.\n5. RiskPredict: This package provides tools for predicting the risk of psychiatric disorders based on genetic and clinical data, including machine learning algorithms and statistical models.\n6. GWASTools: This package offers a collection of tools for GWAS analysis in psychiatric disorders, including imputation, association testing, and visualization of results.\n7. PsychBioma: This package provides tools for the analysis of genomic data in psychiatric disorders, including gene expression analysis, pathway analysis, and functional annotation.\n8. PsychGenetics: This package offers a set of tools for the analysis of genetic data in psychiatric disorders, including gene-based association testing, pathway analysis, and genomic regression.\n9. PsychRisk: This package provides tools for predicting the risk of psychiatric disorders based on genetic and clinical data, including machine learning algorithms and statistical models.\n10. PsychGenome: This package offers tools for the analysis of genomic data in psychiatric disorders, including gene expression analysis, pathway analysis, and functional annotation.\nIt's worth noting that these packages are constantly evolving, and new packages may be developed in the future.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PsychArray R/Bioconductor package provides tools for the analysis of genetic association studies in psychiatric disorders.\n2. The PsychGen R/Bioconductor package offers a set of tools for the analysis of genetic data in psychiatric disorders.\n3. PsychGWAS is an R/Bioconductor package providing tools for genome-wide association study analysis in psychiatric disorders.\n4. PsychSeq is an R/Bioconductor package developed for the analysis of genomic sequence data in psychiatric disorders.\n5. The GWASTools R/Bioconductor package offers a collection of tools for genome-wide association study analysis in psychiatric disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The PsychArray R/Bioconductor package provides tools for the analysis of genetic association studies in psychiatric disorders.",
      "The PsychGen R/Bioconductor package offers a set of tools for the analysis of genetic data in psychiatric disorders.",
      "PsychGWAS is an R/Bioconductor package providing tools for genome-wide association study analysis in psychiatric disorders.",
      "PsychSeq is an R/Bioconductor package developed for the analysis of genomic sequence data in psychiatric disorders.",
      "The GWASTools R/Bioconductor package offers a collection of tools for genome-wide association study analysis in psychiatric disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The name \"PsychArray\" does not correspond to any widely recognized R/Bioconductor package. However, without more specific context or information, I cannot definitively say if such a package exists or not.\n2. FALSE [correction]: The correct name of the package is \"psych\" on CRAN (not \"PsychGen\"), which provides tools for personality, psychometric, and psychological research. It is not specifically tailored to genetic data in psychiatric disorders.\n3. FALSE [correction]: There is no widely recognized R/Bioconductor package called \"PsychGWAS\". However, the \"GWASTools\" is an R/Bioconductor package that offers tools for genome-wide association study analysis, which can be used in various fields, including psychiatric disorders.\n4. UNKNOWN: Like \"PsychArray,\" the name \"PsychSeq\" does not correspond to any widely recognized R/Bioconductor package. Without additional context, it cannot be determined if such a package exists.\n5. TRUE: The \"GWASTools\" R/Bioconductor package does indeed offer a collection of tools for genome-wide association study (GWAS) analysis, which can be applied to psychiatric disorders among other fields of study.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "The \"swirl sign\" is a clinical sign used in the diagnosis of intracerebral hemorrhage (ICH). It is characterized by a swirling or spiral pattern of bleeding in the brain, which can be seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\nThe swirl sign is caused by the blood that has escaped from the ruptured blood vessel and has flowed through the brain tissue, creating a spiral or swirling pattern as it mixes with the surrounding brain tissue. The sign is often seen in the setting of spontaneous ICH, which occurs when a blood vessel in the brain ruptures due to various factors such as high blood pressure, aneurysms, or arteriovenous malformations.\nThe swirl sign can be observed in various locations in the brain, including the cerebral cortex, basal ganglia, thalamus, and cerebellum. It is often seen in the peripheral region of the hemorrhage, away from the center of the bleed.\nThe swirl sign is important in the diagnosis of ICH because it can help identify the location and extent of the bleeding. It can also provide clues about the underlying cause of the hemorrhage, such as the presence of an aneurysm or arteriovenous malformation.\nHowever, it is important to note that the swirl sign is not specific to ICH and can also be seen in other conditions such as cerebral edema or tumors. Therefore, it should be interpreted in conjunction with other clinical and imaging findings to make a definitive diagnosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"swirl sign\" is used in the diagnosis of intracerebral hemorrhage (ICH).\n2. It manifests as a swirling or spiral pattern seen on CT or MRI scans.\n3. Swirl sign is associated with the presence of blood that has mixed with surrounding brain tissue following a rupture in a blood vessel.\n4. It can occur in various parts of the brain including the cerebral cortex, basal ganglia, thalamus, and cerebellum.\n5. The swirl sign can help identify the location and extent of bleeding in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "The \"swirl sign\" is used in the diagnosis of intracerebral hemorrhage (ICH).",
      "It manifests as a swirling or spiral pattern seen on CT or MRI scans.",
      "Swirl sign is associated with the presence of blood that has mixed with surrounding brain tissue following a rupture in a blood vessel.",
      "It can occur in various parts of the brain including the cerebral cortex, basal ganglia, thalamus, and cerebellum.",
      "The swirl sign can help identify the location and extent of bleeding in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA polymerase II-associated factor 1) expression is induced by a variety of factors, including:\n1. Abiotic stressors: ROF1 expression is increased in response to abiotic stressors such as drought, salt, and high temperature.\n2. Hormones: ROF1 expression is regulated by plant hormones, including ethylene, auxin, and cytokinin.\n3. Developmental cues: ROF1 expression is developmentally regulated, with higher levels of expression in young tissues and during specific developmental stages.\n4. Light: ROF1 expression is regulated by light, with higher levels of expression in light-exposed tissues.\n5. Genetic mutations: Mutations in genes involved in RNA polymerase II transcriptional elongation, such as RNA polymerase II subunit B (RPB1), can lead to increased ROF1 expression.\n6. Transcription factors: ROF1 expression is regulated by a variety of transcription factors, including the MYB-type transcription factor, MYB11.\n7. miRNAs: ROF1 expression is also regulated by miRNAs, with certain miRNAs inhibiting ROF1 expression by binding to its 3'UTR (untranslated region).\n8. Epigenetic modifications: ROF1 expression can also be regulated by epigenetic modifications, such as DNA methylation and histone modifications, which can affect the stability of ROF1 mRNA or the recruitment of RNA-binding proteins to the promoter region.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is increased in response to abiotic stressors like drought, salt, and high temperature.\n2. Plant hormones such as ethylene, auxin, and cytokinin regulate Arabidopsis ROF1 expression.\n3. Arabidopsis ROF1 expression is developmentally regulated, with higher levels in young tissues and during certain developmental stages.\n4. Light exposure results in higher levels of Arabidopsis ROF1 expression.\n5. Mutations in genes involved in RNA polymerase II transcriptional elongation can lead to increased Arabidopsis ROF1 expression.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is increased in response to abiotic stressors like drought, salt, and high temperature.",
      "Plant hormones such as ethylene, auxin, and cytokinin regulate Arabidopsis ROF1 expression.",
      "Arabidopsis ROF1 expression is developmentally regulated, with higher levels in young tissues and during certain developmental stages.",
      "Light exposure results in higher levels of Arabidopsis ROF1 expression.",
      "Mutations in genes involved in RNA polymerase II transcriptional elongation can lead to increased Arabidopsis ROF1 expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Arabidopsis ROF1 (AtFKBP62) has been shown to be upregulated in response to various abiotic stresses including drought, salinity, and high temperature.\n2. UNKNOWN: While plant hormones do regulate many aspects of plant development and response to stress, the direct effect of ethylene, auxin, and cytokinin on Arabidopsis ROF1 expression is not clearly stated here and requires specific evidence to confirm.\n3. TRUE: Developmentally regulated expression is common in plants, and it is plausible that Arabidopsis ROF1 shows differential expression patterns during various stages of growth and in different tissues.\n4. UNKNOWN: The specific response of Arabidopsis ROF1 expression to light exposure would depend on experimental evidence, which is not provided here.\n5. UNKNOWN: The impact of mutations in genes responsible for RNA polymerase II transcriptional elongation on Arabidopsis ROF1 expression would require empirical evidence to verify, and such a specific relationship is not common knowledge in plant biology without specific research supporting it.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein alpha-2-macroglobulin (A2M). Mutations in the A2M gene can lead to the accumulation of abnormal A2M proteins in the kidneys, which can cause progressive kidney damage and eventual renal failure.",
    "llama-2-7b-chat-hf_fact_raw": "1. Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.\n2. Mutations in the A2M gene can cause hereditary renal amyloidosis.\n3. Abnormal A2M proteins can accumulate in the kidneys due to A2M gene mutations.\n4. Accumulation of abnormal A2M proteins in the kidneys can cause progressive kidney damage.\n5. Progressive kidney damage due to abnormal A2M proteins can lead to renal failure.",
    "llama-2-7b-chat-hf_fact": [
      "Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.",
      "Mutations in the A2M gene can cause hereditary renal amyloidosis.",
      "Abnormal A2M proteins can accumulate in the kidneys due to A2M gene mutations.",
      "Accumulation of abnormal A2M proteins in the kidneys can cause progressive kidney damage.",
      "Progressive kidney damage due to abnormal A2M proteins can lead to renal failure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Alpha-2-macroglobulin (A2M) is not the most common cause of hereditary renal amyloidosis. Mutations in the genes encoding transthyretin (TTR), fibrinogen A alpha chain (AFIB), apolipoprotein A1 (APOA1), and lysozyme are more commonly associated with hereditary renal amyloidosis.\n2. FALSE [correction]: Mutations in the A2M gene are not typically associated with hereditary renal amyloidosis. Hereditary renal amyloidosis is more commonly caused by mutations in other genes, such as TTR, AFIB, APOA1, and lysozyme.\n3. UNKNOWN: Without specific information on mutations in the A2M gene and their effects, it's not possible to confirm whether abnormal A2M proteins can accumulate in the kidneys due to gene mutations. This is not typical for hereditary renal amyloidosis.\n4. UNKNOWN: Since A2M gene mutations are not typical causes of hereditary renal amyloidosis, it's difficult to determine without additional context if accumulation of abnormal A2M proteins in the kidneys can cause progressive kidney damage in this scenario.\n5. UNKNOWN: Similarly, without confirming that abnormal A2M proteins cause kidney damage due to A2M gene mutations, it's impossible to confirm that this could lead to renal failure in the context of hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed. The hippocampus is a complex brain structure involved in various cognitive and memory functions, and its proteome has been studied in detail to understand its molecular mechanisms and functions.\nSeveral studies have used mass spectrometry-based proteomics techniques to analyze the proteins present in the hippocampus of mice. These studies have identified thousands of proteins, including structural proteins, enzymes, receptors, and regulatory proteins.\nSome of the key findings from these studies include:\n1. The hippocampus contains a large number of proteins involved in synaptic transmission and plasticity, such as N-methyl-D-aspartate (NMDA) receptors, AMPA receptors, and synaptotagmin.\n2. The hippocampus also contains proteins involved in the regulation of gene expression, such as transcription factors, histone-modifying enzymes, and RNA-binding proteins.\n3. The hippocampus is rich in proteins involved in the regulation of oxidative stress and antioxidant defenses, such as glutathione peroxidase and superoxide dismutase.\n4. The hippocampus contains proteins involved in the regulation of inflammation, such as cytokines and chemokines, and proteins involved in the clearance of extracellular debris, such as the ubiquitin-proteasome system.\n5. The hippocampus is also rich in proteins involved in the regulation of cellular stress responses, such as heat shock proteins and chaperones.\nThese studies have provided a comprehensive overview of the proteins present in the hippocampus of mice and have identified many potential targets for the development of new drugs and therapies for neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been studied using mass spectrometry-based proteomics techniques.\n2. Studies have identified thousands of proteins in the mouse hippocampus, including structural proteins, enzymes, receptors, and regulatory proteins.\n3. Proteins involved in synaptic transmission and plasticity, like N-methyl-D-aspartate (NMDA) receptors and AMPA receptors, are found in the hippocampus.\n4. The mouse hippocampus contains proteins that regulate gene expression, including transcription factors and RNA-binding proteins.\n5. Proteins involved in oxidative stress responses, such as glutathione peroxidase and superoxide dismutase, are present in the hippocampus of mice.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been studied using mass spectrometry-based proteomics techniques.",
      "Studies have identified thousands of proteins in the mouse hippocampus, including structural proteins, enzymes, receptors, and regulatory proteins.",
      "Proteins involved in synaptic transmission and plasticity, like N-methyl-D-aspartate (NMDA) receptors and AMPA receptors, are found in the hippocampus.",
      "The mouse hippocampus contains proteins that regulate gene expression, including transcription factors and RNA-binding proteins.",
      "Proteins involved in oxidative stress responses, such as glutathione peroxidase and superoxide dismutase, are present in the hippocampus of mice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nEach statement provided aligns with common scientific knowledge about the complexity of the proteome of the mouse hippocampus and the types of proteins that would be expected to be found within it, including those involved in synaptic transmission, gene expression regulation, and oxidative stress response.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "No, mouse chromosomes are not acrocentric. Acrocentric chromosomes are a type of chromosome that has a long arm (q arm) that is much longer than the short arm (p arm). In contrast, mouse chromosomes are euchromatic, meaning that the length of the short and long arms is roughly equal. So, while mouse chromosomes do not have the characteristic acrocentric structure of some other organisms, they are still eukaryotic chromosomes with a similar overall structure.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Acrocentric chromosomes have a long arm that is much longer than the short arm.\n3. Mouse chromosomes are euchromatic, indicating that their short and long arms are roughly equal in length.\n4. Mouse chromosomes have a similar overall structure to other eukaryotic chromosomes.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Acrocentric chromosomes have a long arm that is much longer than the short arm.",
      "Mouse chromosomes are euchromatic, indicating that their short and long arms are roughly equal in length.",
      "Mouse chromosomes have a similar overall structure to other eukaryotic chromosomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are acrocentric.\n2. TRUE\n3. FALSE [correction]: Mouse chromosomes being acrocentric means that they have a long arm that is much longer than the short arm, not that their arms are roughly equal in length. Euchromatin refers to a state of chromatin that is less condensed and transcriptionally active, not to arm length equality.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs in clinical trials for the treatment of pancreatic cancer. Some examples include:\n1. Vitrakvi (larotrectinib): This is a first-in-class, oral TRK inhibitor that is being developed by Bayer and Loxo Oncology. Vitrakvi is currently in Phase 3 clinical trials for the treatment of adult patients with metastatic pancreatic ductal adenocarcinoma (PDAC) with a neuroendocrine histology, and has also been granted Fast Track and Orphan Drug Designation by the FDA for this indication.\n2. RX-0201: This is a small molecule inhibitor of the mTOR pathway being developed by Rexahn Pharmaceuticals. RX-0201 is currently in Phase 2 clinical trials for the treatment of pancreatic cancer, and has also been granted Fast Track status by the FDA for this indication.\n3. BLU-667: This is an oral inhibitor of the PI3K/AKT/mTOR signaling pathway being developed by Blueprint Medicines. BLU-667 is currently in Phase 1 clinical trials for the treatment of various solid tumors, including pancreatic cancer.\n4. AL-3317: This is a small molecule inhibitor of the PI3K/AKT/mTOR signaling pathway being developed by Aldeyra Therapeutics. AL-3317 is currently in Phase 1 clinical trials for the treatment of various solid tumors, including pancreatic cancer.\nIt's important to note that these are just a few examples of siRNA-based drugs in clinical trials for the treatment of pancreatic cancer, and there are likely many other drugs in various stages of development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vitrakvi (larotrectinib) is in Phase 3 clinical trials for the treatment of adult patients with metastatic pancreatic ductal adenocarcinoma (PDAC) with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion.\n2. RX-0201 is in Phase 2 clinical trials for the treatment of pancreatic cancer.\n3. BLU-667 is in Phase 1 clinical trials for the treatment of various solid tumors, including pancreatic cancer.\n4. AL-3317 is in Phase 1 clinical trials for the treatment of various solid tumors, including pancreatic cancer.\n5. Vitrakvi (larotrectinib) has been granted Fast Track and Orphan Drug Designation by the FDA for the treatment of pancreatic cancer.\n\nNote: The response includes incorrect details stating Vitrakvi (larotrectinib) as an siRNA-based drug when it is actually a small molecule TRK inhibitor, and similarly, RX-0201, BLU-667, and AL-3317 are also not siRNA-based drugs. However, for the purpose of this task, I have extracted factual statements based on the details given in the answer, but please note that they contain inaccuracies regarding the classification of the drugs as siRNA-based treatments.",
    "llama-2-7b-chat-hf_fact": [
      "Vitrakvi (larotrectinib) is in Phase 3 clinical trials for the treatment of adult patients with metastatic pancreatic ductal adenocarcinoma (PDAC) with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion.",
      "RX-0201 is in Phase 2 clinical trials for the treatment of pancreatic cancer.",
      "BLU-667 is in Phase 1 clinical trials for the treatment of various solid tumors, including pancreatic cancer.",
      "AL-3317 is in Phase 1 clinical trials for the treatment of various solid tumors, including pancreatic cancer.",
      "Vitrakvi (larotrectinib) has been granted Fast Track and Orphan Drug Designation by the FDA for the treatment of pancreatic cancer.",
      "te: The response includes incorrect details stating Vitrakvi (larotrectinib) as an siRNA-based drug when it is actually a small molecule TRK inhibitor, and similarly, RX-0201, BLU-667, and AL-3317 are also not siRNA-based drugs. However, for the purpose of this task, I have extracted factual statements based on the details given in the answer, but please note that they contain inaccuracies regarding the classification of the drugs as siRNA-based treatments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n6. UNKNOWN\n\nNote: The response indicates prior incorrect details and cautions regarding the classification of the drugs, but without the full and accurate context or a current update on clinical trials and FDA designations, the true/false verification of statements 1, 4, 5, and 6 is not possible with certainty.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG (Heterochromatin Protein G) pore is a protein complex that regulates the movement of DNA and proteins between the nucleus and the cytoplasm in eukaryotic cells. The HPG pore is composed of several proteins, including HPG1 and HPG2, which form a central pore through which DNA and proteins can pass. The pore is located in the nuclear envelope, the double membrane that surrounds the nucleus, and it plays a crucial role in regulating the transport of molecules between the nucleus and the cytoplasm.\nThe HPG pore is involved in several cellular processes, including:\n1. DNA repair: The HPG pore allows the transport of repair proteins and DNA fragments to the site of DNA damage, where they can be repaired.\n2. Nuclear protein import: The HPG pore allows the import of proteins from the cytoplasm into the nucleus, where they can perform their functions.\n3. Nuclear protein export: The HPG pore also allows the export of proteins from the nucleus to the cytoplasm, where they can be degraded or modified.\n4. mRNA export: The HPG pore plays a role in the export of mRNA molecules from the nucleus to the cytoplasm, where they can be translated into proteins.\n5. Cell cycle regulation: The HPG pore has been implicated in the regulation of the cell cycle, with changes in the pore's activity affecting the progression of cells through the cell cycle.\nDysregulation of the HPG pore has been implicated in several diseases, including cancer and neurodegenerative disorders. For example, studies have shown that the HPG pore is overactive in some types of cancer, leading to the uncontrolled proliferation of cancer cells. Conversely, the HPG pore has been shown to be underactive in certain neurodegenerative disorders, such as Alzheimer's disease, leading to the accumulation of toxic proteins in the brain.\nOverall, the HPG pore is a crucial component of the nuclear envelope that plays a central role in regulating the transport of molecules between the nucleus and the cytoplasm",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore regulates the movement of DNA and proteins between the nucleus and the cytoplasm in eukaryotic cells.\n2. The HPG pore is composed of several proteins, including HPG1 and HPG2.\n3. The HPG pore is located in the nuclear envelope, which surrounds the nucleus.\n4. Dysregulation of the HPG pore has been implicated in several diseases, including cancer and neurodegenerative disorders.\n5. The HPG pore's activity is linked with the cell cycle and can affect the progression of cells through it.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore regulates the movement of DNA and proteins between the nucleus and the cytoplasm in eukaryotic cells.",
      "The HPG pore is composed of several proteins, including HPG1 and HPG2.",
      "The HPG pore is located in the nuclear envelope, which surrounds the nucleus.",
      "Dysregulation of the HPG pore has been implicated in several diseases, including cancer and neurodegenerative disorders.",
      "The HPG pore's activity is linked with the cell cycle and can affect the progression of cells through it."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Nuclear Pore Complex (NPC) regulates the movement of molecules across the nuclear envelope, not the \"HPG pore\".\n2. UNKNOWN: Since \"HPG pore\" is an inappropriate term and likely a mistake for the Nuclear Pore Complex, it is not possible to verify the components named HPG1 and HPG2 without the correct context.\n3. FALSE [correction]: If \"HPG pore\" is meant to represent the Nuclear Pore Complex, then the statement should read that the Nuclear Pore Complex is located in the nuclear envelope, which surrounds the nucleus.\n4. TRUE: While \"HPG pore\" is incorrect and presumably refers to the Nuclear Pore Complex, dysregulation of the Nuclear Pore Complex has indeed been implicated in several diseases, including cancer and neurodegenerative disorders.\n5. TRUE: The activity of the Nuclear Pore Complex is linked with the cell cycle and can affect the progression of cells through it. Assuming \"HPG pore\" is a misspelling or incorrect reference to the Nuclear Pore Complex, this statement is accurate.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes (Nemateome) initiative is a large-scale effort to sequence the genomes of all known species of nematode worms, which are a group of microscopic worms that include parasitic and free-living species. The initiative was launched in 2011 and is funded by the National Institutes of Health (NIH) in the United States.\nNematodes are a diverse group of organisms that include many species that are important as model organisms in scientific research, as well as several species that are important parasites of humans, plants, and other organisms. Despite their small size, nematodes have complex genomes that are rich in genetic variation, and they have evolved a wide range of strategies to survive and reproduce in different environments.\nThe goal of the Nemateome initiative is to generate high-quality genome sequences for all known species of nematodes, as well as to develop new computational and bioinformatic tools for analyzing and interpreting nematode genome data. The initiative is focused on generating draft-quality genome sequences for at least 959 species of nematodes, including both free-living and parasitic species.\nThe Nemateome initiative is expected to provide new insights into the evolution, development, and behavior of nematodes, as well as their interactions with other organisms. It will also provide new opportunities for the development of novel drugs and other therapies for the control of nematode parasites, which are important causes of disease in humans and animals.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the genomes of all known species of nematode worms.\n2. The initiative was launched in 2011.\n3. The National Institutes of Health (NIH) in the United States fund the 959 Nematode Genomes initiative.\n4. The initiative's goal is to produce high-quality genome sequences for all known species of nematodes.\n5. The Nemateome initiative intends to create new computational and bioinformatic tools for analyzing nematode genome data.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the genomes of all known species of nematode worms.",
      "The initiative was launched in 2011.",
      "The National Institutes of Health (NIH) in the United States fund the 959 Nematode Genomes initiative.",
      "The initiative's goal is to produce high-quality genome sequences for all known species of nematodes.",
      "The Nemateome initiative intends to create new computational and bioinformatic tools for analyzing nematode genome data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 959 Nematode Genomes initiative does not aim to sequence the genomes of all known species of nematode worms. Instead, it aims to sequence a representative 959 nematode species, reflecting the known diversity within the phylum Nematoda.\n2. TRUE\n3. UNKNOWN: Without specific information on the funding source, it is not possible to confirm or refute the statement about the National Institutes of Health (NIH) funding the 959 Nematode Genomes initiative.\n4. TRUE: The initiative's goal is indeed to produce high-quality genome sequences, although it is for 959 representative species rather than all known species of nematodes.\n5. UNKNOWN: The statement about the Nemateome initiative creating computational and bioinformatic tools is not confirmed within the context of the given statements. Further information would be needed to verify this claim.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the popular ones include:\n1. NIPT: This package provides a comprehensive set of tools for analyzing NIPT data, including quality control, sample classification, and genetic variant detection.\n2. Prenat: This package is specifically designed for the analysis of NIPT data and provides functions for data preprocessing, sample classification, and genetic variant detection.\n3. PrenatalGenetics: This package provides a set of tools for the analysis of NIPT data, including data preprocessing, sample classification, and genetic variant detection.\n4. PrenatalTesting: This package provides functions for the analysis of NIPT data, including quality control, sample classification, and genetic variant detection.\n5. NIPTworkflow: This package provides a workflow for the analysis of NIPT data, including data preprocessing, sample classification, and genetic variant detection.\nIt is important to note that the choice of the R package will depend on the specific requirements of the analysis and the type of data being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package named \"NIPT\" provides tools for analyzing NIPT data, including quality control, sample classification, and genetic variant detection.\n2. The R package named \"Prenat\" is designed for the analysis of NIPT data and includes functions for data preprocessing, sample classification, and genetic variant detection.\n3. The R package \"PrenatalGenetics\" offers a set of tools for the analysis of NIPT data.\n4. The R package \"PrenatalTesting\" provides functions for analyzing NIPT data, including quality control and sample classification.\n5. The R package \"NIPTworkflow\" delivers a workflow for the analysis of NIPT data.",
    "llama-2-7b-chat-hf_fact": [
      "The R package named \"NIPT\" provides tools for analyzing NIPT data, including quality control, sample classification, and genetic variant detection.",
      "The R package named \"Prenat\" is designed for the analysis of NIPT data and includes functions for data preprocessing, sample classification, and genetic variant detection.",
      "The R package \"PrenatalGenetics\" offers a set of tools for the analysis of NIPT data.",
      "The R package \"PrenatalTesting\" provides functions for analyzing NIPT data, including quality control and sample classification.",
      "The R package \"NIPTworkflow\" delivers a workflow for the analysis of NIPT data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: There is no R package specifically named \"Prenat\". It is possible that this refers to the \"PrenatalCNV\" package which does perform analyses on NIPT data.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nR packages are often developed and named by their authors, and without a specific and updated database of current R packages (which is beyond my last update), it is difficult to confirm the existence and functionality of these packages unless they are well-known in the field. Therefore, without additional context or access to a current repository list, such as CRAN or Bioconductor, the verification of the statements regarding lesser-known or potentially hypothetical R packages is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare genetic disorder that affects the development of the brain and nervous system. It is characterized by a range of symptoms that can vary in severity and impact the individual's cognitive, motor, and behavioral abilities.\nThe main features of Achenbach's syndrome include:\n1. Delayed or absent speech and language development: Individuals with Achenbach's syndrome may have difficulty learning to speak and may have a limited vocabulary.\n2. Intellectual disability: Achenbach's syndrome can result in mild to severe intellectual disability, which can affect an individual's ability to learn and adapt to new situations.\n3. Autism-like behaviors: Many individuals with Achenbach's syndrome display behaviors that are similar to those seen in autism spectrum disorder (ASD), such as difficulty with social interactions and repetitive behaviors.\n4. Distinctive facial features: Achenbach's syndrome is often associated with distinctive facial features, including a flat nose, widely spaced eyes, and a small jaw.\n5. Growth delays: Children with Achenbach's syndrome may experience delays in their growth and development, including delayed reach milestones and shorter stature.\n6. Seizures: Some individuals with Achenbach's syndrome may experience seizures, which can be a result of the disorder or a separate condition.\n7. Vision problems: Achenbach's syndrome can cause vision problems, including strabismus (crossed eyes) and nystagmus (involuntary eye movements).\n8. Hearing loss: Some individuals with Achenbach's syndrome may experience hearing loss or impairment.\n9. Sleep disturbances: Achenbach's syndrome can disrupt sleep patterns, leading to insomnia or other sleep disturbances.\n10. Other health problems: Individuals with Achenbach's syndrome may experience a range of other health problems, including gastrointestinal issues, feeding difficulties, and muscle weakness.\nAchenbach's syndrome is caused by mutations in the PTK2B gene, which is involved in the formation and maintenance of the cytoske",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome affects the development of the brain and nervous system.\n2. The syndrome can result in mild to severe intellectual disability.\n3. Individuals with Achenbach's syndrome may display behaviors similar to autism spectrum disorder.\n4. Achenbach's syndrome is associated with distinctive facial features, such as a flat nose, widely spaced eyes, and a small jaw.\n5. Achenbach's syndrome is caused by mutations in the PTK2B gene.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome affects the development of the brain and nervous system.",
      "The syndrome can result in mild to severe intellectual disability.",
      "Individuals with Achenbach's syndrome may display behaviors similar to autism spectrum disorder.",
      "Achenbach's syndrome is associated with distinctive facial features, such as a flat nose, widely spaced eyes, and a small jaw.",
      "Achenbach's syndrome is caused by mutations in the PTK2B gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is a condition that primarily affects the hands, causing spontaneous bruising or bleeding.\n2. FALSE [correction]: Achenbach's syndrome does not typically result in intellectual disability as it is primarily related to the hands.\n3. FALSE [correction]: Achenbach's syndrome is not known to be associated with behaviors similar to autism spectrum disorder.\n4. FALSE [correction]: Achenbach's syndrome does not cause distinctive facial features; it is associated with hand symptoms.\n5. FALSE [correction]: Achenbach's syndrome is not known to be caused by mutations in the PTK2B gene or any other gene; the cause is not well understood, but it is thought to be related to local vascular issues in the hands.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "There are several algorithms used for the detection of long repeat expansions in genomic DNA, including:\n1. RepeatMasker: This is a widely used algorithm that uses a combination of sequence similarity and k-mer analysis to identify repetitive elements in a genome.\n2. GCG: The Genomic Context of Genes (GCG) algorithm uses a combination of sequence context and k-mer analysis to identify repetitive elements in a genome.\n3. LIFEX: The Long INterval Fragments eXtraction (LIFEX) algorithm is a more recent method that uses a combination of k-mer analysis and hidden Markov models to detect long repeat expansions.\n4. REPEAT-IT: The REpeat Primed Extension (REPEAT-IT) algorithm is a probabilistic method that uses a combination of k-mer analysis and hidden Markov models to detect long repeat expansions.\n5. REPuter: The REPuter algorithm is a more recent method that uses a combination of k-mer analysis and machine learning to detect long repeat expansions.\n6. DeepRepeats: The DeepRepeats algorithm is a deep learning-based method that uses a combination of convolutional neural networks (CNNs) and long short-term memory (LSTM) networks to detect long repeat expansions.\n7. Prognosticate: The Prognosticate algorithm is a machine learning-based method that uses a combination of feature engineering and machine learning to predict the presence of long repeat expansions in a genome.\n8. RepeatHunter: The RepeatHunter algorithm is a more recent method that uses a combination of k-mer analysis and machine learning to detect long repeat expansions.\nIt's worth noting that the choice of algorithm will depend on the specific requirements of the analysis and the characteristics of the data being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm that uses sequence similarity and k-mer analysis to identify repetitive elements in a genome.\n2. The Genomic Context of Genes (GCG) algorithm combines sequence context and k-mer analysis to identify repetitive elements in a genome.\n3. The Long INterval Fragments eXtraction (LIFEX) algorithm employs k-mer analysis and hidden Markov models to detect long repeat expansions.\n4. The REPuter algorithm utilizes k-mer analysis and machine learning for the detection of long repeat expansions.\n5. DeepRepeats is a deep learning-based algorithm that uses convolutional neural networks and long short-term memory networks to detect long repeat expansions.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm that uses sequence similarity and k-mer analysis to identify repetitive elements in a genome.",
      "The Genomic Context of Genes (GCG) algorithm combines sequence context and k-mer analysis to identify repetitive elements in a genome.",
      "The Long INterval Fragments eXtraction (LIFEX) algorithm employs k-mer analysis and hidden Markov models to detect long repeat expansions.",
      "The REPuter algorithm utilizes k-mer analysis and machine learning for the detection of long repeat expansions.",
      "DeepRepeats is a deep learning-based algorithm that uses convolutional neural networks and long short-term memory networks to detect long repeat expansions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Genomic Context of Genes (GCG) does not refer to a known standard algorithm for identifying repetitive elements in a genome based on sequence context and k-mer analysis. The GCG might refer to software for analysis and management of genomic data, but it is not specifically about identifying repetitive elements using the mentioned methods.\n3. UNKNOWN: While the Long INterval Fragments eXtraction (LIFEX) algorithm could be a tool used in genomics, without specific context or a reference to an established algorithm with this name, its functions and methods cannot be confirmed.\n4. FALSE [correction]: The REPuter algorithm identifies and visualizes repetitive elements in genomic sequences, but it primarily uses suffix tree methods, not k-mer analysis and machine learning, for the detection of repeats.\n5. UNKNOWN: While DeepRepeats may suggest a deep learning-based algorithm that could potentially use convolutional neural networks (CNNs) and long short-term memory (LSTM) networks, without specific confirmation of an existing algorithm by this name and description, its authenticity and method cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been shown to promote the growth and progression of certain types of brain tumors, including:\n1. Medulloblastoma: Neuroligin-3 is overexpressed in a subset of medulloblastomas, a type of pediatric brain cancer that arises in the cerebellum.\n2. Glioblastoma: Neuroligin-3 is also overexpressed in glioblastoma, the most common and aggressive type of primary brain cancer.\n3. Meningioma: Neuroligin-3 has been shown to be overexpressed in some meningiomas, which are benign tumors that arise from the meninges, the protective coverings of the brain and spinal cord.\nOverall, the overexpression of neuroligin-3 has been linked to the development and progression of various types of brain tumors, and it is being explored as a potential therapeutic target for the treatment of these diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is overexpressed in a subset of medulloblastomas.\n2. Medulloblastomas are a type of pediatric brain cancer that arises in the cerebellum.\n3. Neuroligin-3 is overexpressed in glioblastoma, the most common and aggressive type of primary brain cancer.\n4. Neuroligin-3 has been shown to be overexpressed in some meningiomas.\n5. Meningiomas are benign tumors that arise from the meninges, the protective coverings of the brain and spinal cord.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is overexpressed in a subset of medulloblastomas.",
      "Medulloblastomas are a type of pediatric brain cancer that arises in the cerebellum.",
      "Neuroligin-3 is overexpressed in glioblastoma, the most common and aggressive type of primary brain cancer.",
      "Neuroligin-3 has been shown to be overexpressed in some meningiomas.",
      "Meningiomas are benign tumors that arise from the meninges, the protective coverings of the brain and spinal cord."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Neuroligin-3 has been found to be overexpressed in a subset of medulloblastomas, which could have implications for how the disease develops or responds to treatment.\n2. TRUE: Medulloblastomas are indeed a type of pediatric brain tumor that originates in the cerebellum, which is located at the back of the brain.\n3. UNKNOWN: Without specific research data or references provided, it is difficult to confirm whether Neuroligin-3 is overexpressed in glioblastoma. This statement could be true if validated by scientific research, but the information provided does not allow for a definitive answer.\n4. UNKNOWN: As with the previous statement about glioblastoma, confirming overexpression of Neuroligin-3 in meningiomas would require specific scientific evidence, which is not provided.\n5. TRUE but Incomplete [correction]: Meningiomas generally arise from the meninges, and while many are benign, not all meningiomas are. Some can be atypical or malignant, meaning they could be more aggressive and possibly recur after treatment.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles are typically in the range of 10-100 nanometers (nm) in diameter, although they can vary in size depending on the specific organism and the type of gas they are storing. For example, gas vesicles in the bacterium Shewanella oneidensis are typically around 20-30 nm in diameter, while those in the bacterium Rhodobacter sphaeroides are around 50-100 nm in diameter.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles generally range from 10-100 nanometers in diameter.\n2. The size of gas vesicles can vary based on the organism and the type of gas stored.\n3. Gas vesicles in the bacterium Shewanella oneidensis are usually around 20-30 nanometers in diameter.\n4. Gas vesicles in the bacterium Rhodobacter sphaeroides are typically around 50-100 nanometers in diameter.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles generally range from 10-100 nanometers in diameter.",
      "The size of gas vesicles can vary based on the organism and the type of gas stored.",
      "Gas vesicles in the bacterium Shewanella oneidensis are usually around 20-30 nanometers in diameter.",
      "Gas vesicles in the bacterium Rhodobacter sphaeroides are typically around 50-100 nanometers in diameter."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles typically range from 50-500 nanometers in diameter.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modifying chromatin structure. Here are some of the BET proteins that have been identified:\n1. BET1 (Bromodomain-Containing Protein 1): Also known as BRD1, this protein is a key regulator of gene expression and is involved in various cellular processes, including cell proliferation, differentiation, and survival.\n2. BET2 (Bromodomain-Containing Protein 2): Similar to BRD1, BET2 is also involved in regulating gene expression and is implicated in various cellular processes, including cell proliferation and differentiation.\n3. BET3 (Bromodomain-Containing Protein 3): This protein is similar to BRD1 and BRD2 and is involved in regulating gene expression and chromatin structure.\n4. BET4 (Bromodomain-Containing Protein 4): Also known as BRDT, this protein is a member of the BET family and is involved in regulating gene expression and chromatin structure.\n5. BRD4 (Bromodomain-Containing Protein 4): Similar to BRD3, BRD4 is also involved in regulating gene expression and chromatin structure.\n6. BRD5 (Bromodomain-Containing Protein 5): This protein is the most recently identified member of the BET family and is involved in regulating gene expression and chromatin structure.\nIt is worth noting that there are other BET proteins as well, such as BET6 and BET7, which are less well-studied but may also play a role in regulating gene expression and chromatin structure.",
    "llama-2-7b-chat-hf_fact_raw": "1. BET1, also known as BRD1, is a protein that regulates gene expression and is involved in cell proliferation, differentiation, and survival.\n2. BET2, similar to BRD1, is involved in the regulation of gene expression and is implicated in cell proliferation and differentiation.\n3. BET3 is involved in regulating gene expression and chromatin structure.\n4. BET4, also known as BRDT, is a member of the BET protein family and is involved in regulating gene expression and chromatin structure.\n5. BRD5 is the most recently identified member of the BET protein family and is involved in gene expression regulation and chromatin structure.",
    "llama-2-7b-chat-hf_fact": [
      "BET1, also known as BRD1, is a protein that regulates gene expression and is involved in cell proliferation, differentiation, and survival.",
      "BET2, similar to BRD1, is involved in the regulation of gene expression and is implicated in cell proliferation and differentiation.",
      "BET3 is involved in regulating gene expression and chromatin structure.",
      "BET4, also known as BRDT, is a member of the BET protein family and is involved in regulating gene expression and chromatin structure.",
      "BRD5 is the most recently identified member of the BET protein family and is involved in gene expression regulation and chromatin structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BET1 is not also known as BRD1. BRD2, BRD3, BRD4, and BRDT are members of the BET (Bromodomain and ExtraTerminal domain) family of proteins that regulate gene expression. BRD1 is usually not classified within this family.\n2. FALSE [correction]: There is no BET protein family member known as BET2. BET proteins typically refer to BRD2, BRD3, BRD4, and BRDT.\n3. TRUE: BET proteins are involved in regulating gene expression and chromatin structure, and while BET3 is not a standard designation for these proteins, members of the broader protein family do perform these functions.\n4. TRUE: BRDT (Bromodomain, Testis-specific) is indeed a BET protein family member and is involved in regulating gene expression and chromatin structure, particularly in the testis.\n5. FALSE [correction]: As of my last update, the BET protein family traditionally includes BRD2, BRD3, BRD4, and BRDT. There is no officially recognized BET protein family member known as BRD5. Additionally, BRD5 is not a known designation within the BET protein family or other common nomenclature for bromodomain-containing proteins.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "One algorithm that has been developed for predicting protein subcellular localization using deep learning is the \"DeepLoc\" algorithm. DeepLoc is a deep learning-based method that uses a convolutional neural network (CNN) to predict the subcellular localization of a given protein sequence. It was developed by the lab of Dr. David Baker at the University of Washington and was first published in a 2018 paper titled \"DeepLoc: A Deep Learning Method for Predicting Protein Subcellular Localization\".\nDeepLoc uses a CNN to learn features from a protein sequence that are predictive of its subcellular localization. The CNN is trained on a large dataset of protein sequences and their corresponding subcellular localization annotations. During training, the CNN learns to extract features from the protein sequence that are important for predicting localization, such as sequence conservation, structural features, and sequence similarity to known localization signals.\nDeepLoc has been shown to be highly accurate in predicting protein subcellular localization, outperforming other machine learning-based methods in some studies. It has also been used to predict the localization of proteins in a variety of organisms, including bacteria, yeast, and humans.\nOverall, DeepLoc is an example of a deep learning-based algorithm that has been developed for predicting protein subcellular localization using machine learning. It has the potential to be a useful tool for understanding the subcellular localization of proteins and for identifying new localization signals.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"DeepLoc\" algorithm is a deep learning-based method for predicting protein subcellular localization.\n2. DeepLoc uses a convolutional neural network (CNN) to learn features from protein sequences.\n3. The DeepLoc algorithm was developed by Dr. David Baker's lab at the University of Washington.\n4. The algorithm DeepLoc was first published in a 2018 paper.\n5. DeepLoc has been used to predict the localization of proteins in organisms including bacteria, yeast, and humans.",
    "llama-2-7b-chat-hf_fact": [
      "The \"DeepLoc\" algorithm is a deep learning-based method for predicting protein subcellular localization.",
      "DeepLoc uses a convolutional neural network (CNN) to learn features from protein sequences.",
      "The DeepLoc algorithm was developed by Dr. David Baker's lab at the University of Washington.",
      "The algorithm DeepLoc was first published in a 2018 paper.",
      "DeepLoc has been used to predict the localization of proteins in organisms including bacteria, yeast, and humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The DeepLoc algorithm was developed by researchers at the Technical University of Denmark, not by Dr. David Baker's lab at the University of Washington.\n4. FALSE [correction]: The algorithm DeepLoc was first published in a 2017 paper.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "MULTOVL is a gene that encodes for a protein called Multi-Valued Light-Activated Opsin (MVAO). MVAO is a light-sensitive protein that is involved in regulating various cellular processes, including cell signaling, gene expression, and circadian rhythm. MULTOVL is a splice variant of the MVAO gene, which is expressed in specific tissues and cells, such as the retina and pineal gland.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is a gene that encodes for a protein called Multi-Valued Light-Activated Opsin (MVAO).\n2. Multi-Valued Light-Activated Opsin (MVAO) is involved in regulating cell signaling, gene expression, and circadian rhythm.\n3. MULTOVL is a splice variant of the MVAO gene.\n4. The MVAO gene is expressed in specific tissues and cells, including the retina and pineal gland.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is a gene that encodes for a protein called Multi-Valued Light-Activated Opsin (MVAO).",
      "Multi-Valued Light-Activated Opsin (MVAO) is involved in regulating cell signaling, gene expression, and circadian rhythm.",
      "MULTOVL is a splice variant of the MVAO gene.",
      "The MVAO gene is expressed in specific tissues and cells, including the retina and pineal gland."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: If MULTOVL is a gene, it cannot be a splice variant of the MVAO gene; a splice variant would be a different version of the mRNA derived from the MVAO gene.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment. Studies have shown that GDF15 levels are altered in response to metformin treatment in various tissues, including the liver, muscle, and adipose tissue.\nMetformin has been shown to decrease GDF15 levels in the liver and muscle, while increasing GDF15 levels in adipose tissue. These changes in GDF15 levels may reflect the anti-inflammatory and anti-oxidant effects of metformin, as well as its ability to improve insulin sensitivity.\nGDF15 has been shown to have a role in the regulation of glucose and lipid metabolism, and its levels are altered in various metabolic disorders, including type 2 diabetes and obesity. Therefore, measuring GDF15 levels may provide valuable information on the effectiveness of metformin treatment and its potential side effects.\nHowever, it is important to note that GDF15 is not a specific biomarker for metformin treatment, and its levels can be affected by other factors, such as inflammation and oxidative stress. Therefore, multiple biomarkers may be needed to accurately assess the effectiveness of metformin treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.\n2. GDF15 levels are altered in response to metformin treatment in tissues including the liver, muscle, and adipose tissue.\n3. Metformin decreases GDF15 levels in the liver and muscle.\n4. Metformin increases GDF15 levels in adipose tissue.\n5. GDF15 has a role in the regulation of glucose and lipid metabolism.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.",
      "GDF15 levels are altered in response to metformin treatment in tissues including the liver, muscle, and adipose tissue.",
      "Metformin decreases GDF15 levels in the liver and muscle.",
      "Metformin increases GDF15 levels in adipose tissue.",
      "GDF15 has a role in the regulation of glucose and lipid metabolism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Metformin increases GDF15 levels in the liver and muscle, not decreases.\n4. UNKNOWN (The statement may be consistent with current hypotheses or findings, but without specific studies or evidence presented, the effect of metformin on GDF15 levels in adipose tissue cannot be confidently confirmed.)\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing, also known as multiple intron retention, is a type of splicing event in which a intron is retained in the final mRNA transcript more than once. This type of splicing is more common in short introns, which are typically 100-200 nucleotides in length.\nRecursive splicing can occur through different mechanisms, including:\n1. Intron-intron interactions: Short introns are more likely to interact with each other, leading to the retention of one or more introns in the final mRNA transcript.\n2. 3' splice site recognition: In some cases, the 3' splice site of one intron can be recognized by the spliceosome as a 5' splice site of a neighboring intron, leading to the retention of both introns in the final mRNA transcript.\n3. Incomplete splicing: In some cases, the spliceosome may not complete the splicing reaction, leading to the retention of some introns in the final mRNA transcript.\nRecursive splicing can have important regulatory functions, such as the control of gene expression, and it can also lead to the formation of cryptic mRNAs, which can be subject to different translation or degradation pathways.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Short introns that undergo recursive splicing are typically 100-200 nucleotides in length.\n3. Intron-intron interactions can lead to recursive splicing by retaining one or more introns in the final mRNA transcript.\n4. Recursive splicing can result from recognition of an intron's 3' splice site as a 5' splice site of a neighboring intron, causing both introns to be retained in the final mRNA transcript.\n5. Recursive splicing serves regulatory functions, such as control of gene expression, and can result in the formation of cryptic mRNAs.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Short introns that undergo recursive splicing are typically 100-200 nucleotides in length.",
      "Intron-intron interactions can lead to recursive splicing by retaining one or more introns in the final mRNA transcript.",
      "Recursive splicing can result from recognition of an intron's 3' splice site as a 5' splice site of a neighboring intron, causing both introns to be retained in the final mRNA transcript.",
      "Recursive splicing serves regulatory functions, such as control of gene expression, and can result in the formation of cryptic mRNAs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The frequency of recursive splicing in short versus long introns is not provided, and this is a highly specific topic which requires expert knowledge or a specific literature source to confirm.\n2. UNKNOWN: This is a specific detail that would require expert knowledge or a specific literature source to verify. The typical length of introns undergoing recursive splicing can vary depending on the organism and the genes involved.\n3. FALSE [correction]: Intron-intron interactions do not lead to the retention of introns in the final mRNA transcript during recursive splicing. Instead, recursive splicing is a process that resolves long introns by breaking them down into smaller pieces through a series of splicing events, ultimately removing introns from the mature mRNA.\n4. FALSE [correction]: Recursive splicing does not involve the recognition of an intron's 3' splice site as a 5' splice site of a neighboring intron; rather, it involves the recognition of a splice site within an intron that acts as a 3' splice site, followed by a later stage where it acts as a 5' splice site to join separate parts of an exon.\n5. TRUE: Recursive splicing can serve regulatory functions, such as the control of gene expression levels, and can result in alternative mRNA transcripts, some of which may be noncanonical or 'cryptic'.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used for identifying the functional regions of a gene, specifically the enhancer regions, by using the TALE (Transcription Activator-Like Evolution) nuclease to create a genomic map of enhancer-promoter interactions. The TALE-iD method is used to identify the cis-acting elements that regulate gene expression, such as enhancers, silencers, and other regulatory elements, and to understand the spatial organization of these elements in the genome.\nThe TALE-iD method works by using a TALE nuclease to introduce specific double-stranded breaks in the genome at specific locations, which are then repaired by the cell's own repair machinery. The repair process results in the introduction of small insertions or deletions (indels) at the break sites, which can be used to map the location of cis-acting elements in the genome. By analyzing the indels introduced by the TALE nuclease, researchers can identify the functional regions of the genome, such as enhancers, and determine how they interact with the promoter region of a gene to regulate its expression.\nThe TALE-iD method has several advantages over other methods for identifying cis-acting elements, including its high resolution and specificity, as well as its ability to identify functional elements in both coding and non-coding regions of the genome. It has been used to study the regulation of gene expression in a variety of organisms, including humans, and has applications in fields such as developmental biology, cancer research, and drug discovery.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is a method used for identifying the functional regions of a gene, including enhancer regions.\n2. The TALE-iD method utilizes TALE (Transcription Activator-Like Effector) nuclease to create a genomic map of enhancer-promoter interactions.\n3. The TALE-iD technique identifies cis-acting elements that regulate gene expression like enhancers, silencers, and other regulatory elements.\n4. The method operates by introducing specific double-stranded breaks in the genome at predetermined locations, which are repaired introducing insertions or deletions (indels) that help map cis-acting elements.\n5. TALE-iD is noted for its high resolution and specificity in identifying functional elements in both coding and non-coding regions of the genome.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is a method used for identifying the functional regions of a gene, including enhancer regions.",
      "The TALE-iD method utilizes TALE (Transcription Activator-Like Effector) nuclease to create a genomic map of enhancer-promoter interactions.",
      "The TALE-iD technique identifies cis-acting elements that regulate gene expression like enhancers, silencers, and other regulatory elements.",
      "The method operates by introducing specific double-stranded breaks in the genome at predetermined locations, which are repaired introducing insertions or deletions (indels) that help map cis-acting elements.",
      "TALE-iD is noted for its high resolution and specificity in identifying functional elements in both coding and non-coding regions of the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While TALEs (Transcription Activator-Like Effectors) can be used for genome editing, TALE-iD likely refers to a method that utilizes TALEs for identifying functional regions rather than actively inducing double-strand breaks as nucleases do.\n3. TRUE\n4. FALSE [correction]: The method likely involves the use of TALE proteins to bind specific DNA sequences to identify functional regions, not necessarily to introduce double-stranded breaks which is more characteristic of TALE nucleases used in genome editing.\n5. TRUE, assuming TALE-iD does indeed offer high resolution and specificity for mapping functional elements, which is a characteristic of methods that utilize TALEs for genomic research. Without more context, however, it's impossible to confirm the resolution and specificity of this method, so this is based on the possible capabilities of TALE-related technologies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Image: CL-Image is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It also includes a number of pre-built image processing tools, such as edge detection and color correction.\n2. ImageTk: ImageTk is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It also includes a number of pre-built image processing tools, such as edge detection and color correction.\n3. Lisp-Image: Lisp-Image is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It also includes a number of pre-built image processing tools, such as edge detection and color correction.\n4. OpenLisp-Image: OpenLisp-Image is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It also includes a number of pre-built image processing tools, such as edge detection and color correction.\n5. Lisp-Image-Pro: Lisp-Image-Pro is a Lisp image processing framework that provides a set of advanced image processing functions, including filtering, resizing, and thresholding. It also includes a number of pre-built image processing tools, such as edge detection and color correction.\nThese are some of the popular Lisp frameworks for image processing, and there are many other Lisp libraries and frameworks available for image processing as well.",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp framework developed for image processing.\n2. ImageTk is a Lisp framework developed for image processing.\n3. Lisp-Image is a Lisp framework developed for image processing.\n4. OpenLisp-Image is a Lisp framework developed for image processing.\n5. Lisp-Image-Pro is a Lisp framework developed for image processing that provides a set of advanced functions.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp framework developed for image processing.",
      "ImageTk is a Lisp framework developed for image processing.",
      "Lisp-Image is a Lisp framework developed for image processing.",
      "OpenLisp-Image is a Lisp framework developed for image processing.",
      "Lisp-Image-Pro is a Lisp framework developed for image processing that provides a set of advanced functions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: ImageTk is not a Lisp framework; it is a Python module that allows for the creation of images with the Tkinter library.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote that due to the specificity of software frameworks, and lack of widespread information about Lisp frameworks for image processing, the veracity of the claims about \"CL-Image,\" \"Lisp-Image,\" \"OpenLisp-Image,\" and \"Lisp-Image-Pro\" could not be verified with the information at hand as of my knowledge cutoff date. This kind of software might exist in niche circles or may have been developed after the knowledge cutoff date and without widely available documentation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "The yeast species Saccharomyces cerevisiae (baker's yeast) underwent a whole genome duplication (WGD) event about 1,000 million years ago, resulting in the duplication of approximately 80% of its genes. This means that about 600-700 genes in S. cerevisiae are the result of this ancient WGD event.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae (baker's yeast) underwent a whole genome duplication (WGD) event approximately 1,000 million years ago.\n2. The WGD event resulted in the duplication of about 80% of the genes in Saccharomyces cerevisiae.\n3. There are about 600-700 genes in Saccharomyces cerevisiae that are the result of the ancient WGD event.",
    "llama-2-7b-chat-hf_fact": [
      "Saccharomyces cerevisiae (baker's yeast) underwent a whole genome duplication (WGD) event approximately 1,000 million years ago.",
      "The WGD event resulted in the duplication of about 80% of the genes in Saccharomyces cerevisiae.",
      "There are about 600-700 genes in Saccharomyces cerevisiae that are the result of the ancient WGD event."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Saccharomyces cerevisiae (baker's yeast) underwent a whole genome duplication (WGD) event approximately 100 million years ago, not 1,000 million years ago.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that binds to the complex formed by the estrogen response element (ERE) and the histone-modifying enzyme, histone acetyltransferase (HAT).",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is a nuclear receptor.\n2. Esrrb binds to the complex formed by the estrogen response element (ERE).\n3. The complex that Esrrb binds to includes the histone-modifying enzyme, histone acetyltransferase (HAT).",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is a nuclear receptor.",
      "Esrrb binds to the complex formed by the estrogen response element (ERE).",
      "The complex that Esrrb binds to includes the histone-modifying enzyme, histone acetyltransferase (HAT)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Estrogen-related receptor β (Esrrb) does not bind to estrogen response elements (ERE); it binds to estrogen-related response elements (ERRE).\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 (Zinc finger CCHC-type zinc finger protein 17) is a transcriptional repressor that plays a crucial role in regulating gene expression, particularly during embryonic development and cell differentiation. It is a member of the CCHC-type zinc finger protein family, which are characterized by the presence of a conserved CCHC (cysteine- histidine-cysteine) zinc finger domain.\nZCCHC17 has been shown to regulate the expression of a variety of genes involved in different biological processes, including cell adhesion, migration, and survival. It is known to bind to specific DNA sequences and recruit chromatin-modifying complexes to repress gene transcription. ZCCHC17 has also been implicated in the regulation of stem cell self-renewal and differentiation, as well as in the development and progression of certain cancers.\nOverall, the role of ZCCHC17 is to fine-tune the expression of specific genes during development and cell differentiation, and its dysregulation has been implicated in a variety of diseases, including cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a transcriptional repressor involved in regulating gene expression.\n2. The protein plays a crucial role during embryonic development and cell differentiation.\n3. ZCCHC17 is a member of the CCHC-type zinc finger protein family.\n4. It binds to specific DNA sequences to repress gene transcription.\n5. Dysregulation of ZCCHC17 has been implicated in the development and progression of certain cancers.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a transcriptional repressor involved in regulating gene expression.",
      "The protein plays a crucial role during embryonic development and cell differentiation.",
      "ZCCHC17 is a member of the CCHC-type zinc finger protein family.",
      "It binds to specific DNA sequences to repress gene transcription.",
      "Dysregulation of ZCCHC17 has been implicated in the development and progression of certain cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ZCCHC17, also known as zinc finger CCHC domain-containing protein 17, is not known to be a transcriptional repressor; it is typically described as a nucleic acid binding protein, often involved in mRNA processing.\n2. UNKNOWN: While many zinc finger proteins are involved in development and differentiation, without specific literature references, the role of ZCCHC17 in these processes is not clear.\n3. TRUE: ZCCHC17 is indeed a member of the CCHC-type zinc finger protein family.\n4. UNKNOWN: The specific mechanism of how ZCCHC17 functions, including whether it binds to DNA sequences to repress gene transcription, is not well-defined without further context.\n5. UNKNOWN: Specific studies would need to be cited to confirm the involvement of ZCCHC17 dysregulation in cancer development and progression. Without such references, the statement's accuracy is unclear.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is composed of several proteins in human cells. The main proteins that form the NPC are:\n1. Nucleoporin 1 (Nup1): A major component of the NPC, Nup1 is responsible for the central channel of the pore.\n2. Nucleoporin 2 (Nup2): Nup2 is another critical component of the NPC and helps regulate the transport of molecules across the nuclear envelope.\n3. Nucleoporin 3 (Nup3): Nup3 is involved in the formation of the nuclear pore basket and helps regulate the transport of molecules between the nucleus and cytoplasm.\n4. Nucleoporin 4 (Nup4): Nup4 is a minor component of the NPC, but it plays a crucial role in the regulation of nucleocytoplasmic transport.\n5. Nucleoporin 5 (Nup5): Nup5 is a small protein that is involved in the formation of the nuclear pore basket and helps regulate the transport of molecules between the nucleus and cytoplasm.\n6. Nucleoporin 6 (Nup6): Nup6 is a minor component of the NPC, but it plays a crucial role in the regulation of nucleocytoplasmic transport.\n7. Nucleoporin 7 (Nup7): Nup7 is a small protein that is involved in the formation of the nuclear pore basket and helps regulate the transport of molecules between the nucleus and cytoplasm.\n8. Nucleoporin 8 (Nup8): Nup8 is a minor component of the NPC, but it plays a crucial role in the regulation of nucleocytoplasmic transport.\n9. Nucleoporin 9 (Nup9): Nup9 is a small protein that is involved in the formation of the nuclear pore basket and helps regulate the transport of molecules between the nucleus and cytoplasm.\n10. Nucleoporin 10 (Nup10): Nup10 is a minor component of the NPC, but it plays a crucial role in the",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) in human cells is composed of several proteins.\n2. Nucleoporin 1 (Nup1) is a major component of the NPC, responsible for the central channel of the pore.\n3. Nucleoporin 2 (Nup2) is a critical component of the NPC that helps regulate the transport of molecules across the nuclear envelope.\n4. Nucleoporin 3 (Nup3) is involved in the formation of the nuclear pore basket and helps regulate molecule transport between the nucleus and cytoplasm.\n5. Nucleoporin 4 (Nup4) plays a crucial role in the regulation of nucleocytoplasmic transport despite being a minor component of the NPC.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex (NPC) in human cells is composed of several proteins.",
      "Nucleoporin 1 (Nup1) is a major component of the NPC, responsible for the central channel of the pore.",
      "Nucleoporin 2 (Nup2) is a critical component of the NPC that helps regulate the transport of molecules across the nuclear envelope.",
      "Nucleoporin 3 (Nup3) is involved in the formation of the nuclear pore basket and helps regulate molecule transport between the nucleus and cytoplasm.",
      "Nucleoporin 4 (Nup4) plays a crucial role in the regulation of nucleocytoplasmic transport despite being a minor component of the NPC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Nucleoporin 1 (Nup1) is not universally recognized as a major component of the NPC in human cells. In human cells, NPC components are typically referred to as Nups followed by their apparent molecular weight (in kDa) rather than sequential numbering. For example, Nup62 refers to a nucleoporin of around 62 kDa.\n3. FALSE [correction]: Similar to the issue with Nup1, Nup2 is not a standard designation for a nucleoporin in human cells. Nucleoporins are named based on their molecular weight, and specific functions of Nup2 would be unclear without further context.\n4. UNKNOWN: Without more context, it's unclear whether Nup3 exists as it's not a standard nomenclature for nucleoporins. Standard nucleoporin naming conventions do not generally include sequential numbering like Nup3, and their functions would need to be specified.\n5. UNKNOWN: As with Nup3, the naming convention of Nup4 is not standard. The role mentioned might be accurate for a nucleoporin, but without proper identification according to the standard molecular weight-based naming convention, the exact identity, and function of Nup4 remains unclear.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II inhibitor, specifically a topoisomerase II alpha (Topo IIα) inhibitor. Topo IIα is a key enzyme involved in DNA replication and repair, and is overexpressed in many cancer cells. Gepotidacin works by binding to the active site of Topo IIα and inhibiting its activity, leading to the accumulation of double-stranded breaks in DNA and ultimately causing cell death in cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. Gepotidacin specifically inhibits topoisomerase II alpha (Topo IIα).\n3. Topo IIα is involved in DNA replication and repair.\n4. Topo IIα is overexpressed in many cancer cells.\n5. Gepotidacin causes accumulation of double-stranded breaks in DNA, which can lead to cancer cell death.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "Gepotidacin specifically inhibits topoisomerase II alpha (Topo IIα).",
      "Topo IIα is involved in DNA replication and repair.",
      "Topo IIα is overexpressed in many cancer cells.",
      "Gepotidacin causes accumulation of double-stranded breaks in DNA, which can lead to cancer cell death."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is a topoisomerase inhibitor, but it specifically inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, not mammalian topoisomerase II.\n2. FALSE [correction]: Gepotidacin does not specifically inhibit topoisomerase II alpha (Topo IIα) in humans; it targets bacterial topoisomerases.\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWhile statements 3 and 4 are generally true about Topo IIα, the fifth statement is unclear in this context since Gepotidacin is not typically described in relation to human cancer cell treatment or causing double-stranded breaks in cancer cells. Gepotidacin is an antibacterial agent, and its mechanism of action and effects are relevant to bacterial cells. The information provided does not specify the effects of Gepotidacin on human cancer cells or its potential to cause accumulation of double-stranded breaks in human DNA.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Spatially-aware Processing Workflow) is a software framework designed to enable the efficient and scalable processing of large-scale spatial data, such as those generated by satellite imagery, LiDAR (Light Detection and Ranging), and other remote sensing technologies. It is an open-source software framework developed by the University of California, Berkeley and is widely used in the field of geospatial analysis and machine learning.\nCanvas SPW provides a set of tools and libraries for processing and analyzing spatial data, including:\n1. Data ingestion: Canvas SPW can handle large volumes of spatial data and can ingest data from various sources, including satellite imagery, LiDAR data, and other remote sensing technologies.\n2. Data preprocessing: Canvas SPW provides tools for preprocessing spatial data, including data cleaning, filtering, and transformation.\n3. Data visualization: Canvas SPW includes tools for visualizing spatial data, including 2D and 3D visualization, and support for multiple visualization libraries.\n4. Machine learning: Canvas SPW provides tools for training and deploying machine learning models on spatial data, including support for popular deep learning frameworks like TensorFlow and PyTorch.\n5. Spatial analysis: Canvas SPW includes a range of spatial analysis tools, including spatial join, buffer, and aggregation.\n6. Database integration: Canvas SPW can integrate with various databases, including PostGIS, MySQL, and MongoDB, to enable the storage and querying of spatial data.\nSome of the key features of Canvas SPW include:\n1. Scalability: Canvas SPW is designed to handle large-scale spatial data and can scale to meet the needs of large organizations.\n2. Flexibility: Canvas SPW supports a wide range of spatial data formats and can be used with a variety of machine learning frameworks.\n3. Ease of use: Canvas SPW provides a user-friendly interface and is easy to use, even for users without extensive programming experience.\n4. Integration with other tools: Canvas SPW can integrate with other tools and frameworks, such as QGIS, GDAL, and Shapely, to provide a comprehensive geospatial analysis workflow.\nOverall, Canvas SPW is a powerful and flexible framework for processing and",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a software framework developed by the University of California, Berkeley for processing large-scale spatial data.\n2. It handles data from sources like satellite imagery, LiDAR, and other remote sensing technologies.\n3. Canvas SPW enables the training and deployment of machine learning models on spatial data with support for TensorFlow and PyTorch.\n4. The framework is designed to integrate with various databases such as PostGIS, MySQL, and MongoDB.\n5. Canvas SPW can scale to meet the demands of large organizations.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a software framework developed by the University of California, Berkeley for processing large-scale spatial data.",
      "It handles data from sources like satellite imagery, LiDAR, and other remote sensing technologies.",
      "Canvas SPW enables the training and deployment of machine learning models on spatial data with support for TensorFlow and PyTorch.",
      "The framework is designed to integrate with various databases such as PostGIS, MySQL, and MongoDB.",
      "Canvas SPW can scale to meet the demands of large organizations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on \"Canvas SPW,\" it is impossible to verify the accuracy of these statements. Additionally, as of my last update in April 2023, \"Canvas SPW\" does not appear to be a widely recognized software framework, and no information is readily available to confirm or refute these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (STimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response to viral infections. STING agonists are substances that activate STING and trigger an interferon response. Here are some examples of STING agonists:\n1. Poly(I:C): Poly(I:C) is a synthetic analog of viral double-stranded RNA and is a well-known STING agonist.\n2. DNA-based STING agonists: Certain DNA structures, such as nanoparticles or aptamers, can also activate STING and trigger an interferon response.\n3. Cyclic dinucleotides (CDNs): CDNs are synthetic molecules that mimic the structure of bacterial DNA and can activate STING.\n4. Small molecule agonists: Some small molecules, such as glycolytic inhibitors, have been identified as STING agonists.\n5. Toll-like receptor (TLR) agonists: TLRs are pattern recognition receptors that recognize pathogen-associated molecular patterns (PAMPs) and can activate STING.\n6. RNA-based STING agonists: Some RNA molecules, such as small interfering RNAs (siRNAs) or microRNAs (miRNAs), can activate STING.\n7. Antibody-based STING agonists: Antibodies that bind to STING can activate it and trigger an interferon response.\n8. Protein-based STING agonists: Some proteins, such as the protein TRAF6, can activate STING.\nIt's worth noting that the above list is not exhaustive and new STING agonists are being identified and developed as research continues.",
    "llama-2-7b-chat-hf_fact_raw": "1. Poly(I:C) is a synthetic analog of viral double-stranded RNA and is known as a STING agonist.\n2. DNA-based structures, such as nanoparticles or aptamers, can activate the STING protein.\n3. Cyclic dinucleotides (CDNs) are synthetic molecules that can activate STING.\n4. Small molecule agonists like glycolytic inhibitors have been identified as STING agonists.\n5. Toll-like receptor (TLR) agonists can activate the STING protein.",
    "llama-2-7b-chat-hf_fact": [
      "Poly(I:C) is a synthetic analog of viral double-stranded RNA and is known as a STING agonist.",
      "DNA-based structures, such as nanoparticles or aptamers, can activate the STING protein.",
      "Cyclic dinucleotides (CDNs) are synthetic molecules that can activate STING.",
      "Small molecule agonists like glycolytic inhibitors have been identified as STING agonists.",
      "Toll-like receptor (TLR) agonists can activate the STING protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Poly(I:C) is a synthetic analog of viral double-stranded RNA, but it is known as a TLR3 agonist, not a STING agonist.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Small molecule agonists have been identified as STING agonists, but glycolytic inhibitors are not typically classified as STING agonists; they target the glycolysis metabolic pathway.\n5. FALSE [correction]: Toll-like receptor (TLR) agonists can activate TLR pathways. Some of these pathways can lead to STING activation indirectly through production of type I interferons, but TLR agonists themselves are not direct activators of the STING protein.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Slicing-based Chromatin Accessibility and Genomics Exploration) is a computational method used to analyze the three-dimensional structure of chromosomes and understand how it relates to gene expression. It is a combination of two techniques:\n1. Slicing: This involves cutting the chromatin into smaller pieces, called \"slices,\" along the length of the chromosome. These slices are then used to generate a three-dimensional map of the chromatin structure.\n2. CAGE (Chromatin Accessibility Genomics): This technique is used to measure the accessibility of different regions of the chromatin to the RNA polymerase enzyme, which is involved in transcribing DNA into RNA. By comparing the accessibility of different regions of the chromatin, researchers can identify areas that are more or less accessible to RNA polymerase, which can indicate which regions are more or less active in gene expression.\nBy combining these two techniques, SLIC-CAGE provides a comprehensive view of the three-dimensional structure of chromosomes and how it relates to gene expression. This can help researchers understand how different regions of the chromatin interact with each other and how this affects gene expression, which can have important implications for our understanding of development, disease, and the aging process.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a computational method used to analyze the three-dimensional structure of chromosomes and their relation to gene expression.\n2. SLIC-CAGE is a combination of the Slicing technique and CAGE (Chromatin Accessibility Genomics).\n3. The Slicing technique cuts the chromatin into smaller pieces to generate a three-dimensional map of chromatin structure.\n4. CAGE measures the accessibility of different chromatin regions to RNA polymerase, which transcribes DNA into RNA.\n5. SLIC-CAGE aims to provide a comprehensive view of chromosome structure and its effects on gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a computational method used to analyze the three-dimensional structure of chromosomes and their relation to gene expression.",
      "SLIC-CAGE is a combination of the Slicing technique and CAGE (Chromatin Accessibility Genomics).",
      "The Slicing technique cuts the chromatin into smaller pieces to generate a three-dimensional map of chromatin structure.",
      "CAGE measures the accessibility of different chromatin regions to RNA polymerase, which transcribes DNA into RNA.",
      "SLIC-CAGE aims to provide a comprehensive view of chromosome structure and its effects on gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SLIC-CAGE is not known as a computational method for analyzing the three-dimensional structure of chromosomes. SLIC (Serial Liquid Crystal) is related to display technology and CAGE stands for Cap Analysis Gene Expression, which is a method used to identify the transcription start sites of genes.\n2. FALSE [correction]: Given that SLIC-CAGE is not a recognized method in genetics or genomics, it cannot be a combination of Slicing technique and CAGE (Chromatin Accessibility Genomics). Furthermore, CAGE usually stands for Cap Analysis of Gene Expression, a technique related to studying gene expression, not Chromatin Accessibility Genomics.\n3. UNKNOWN: As SLIC-CAGE is not identified as a recognized method, the description of the Slicing technique in this context is not verifiable.\n4. FALSE [correction]: CAGE actually stands for Cap Analysis of Gene Expression, a technique used to analyze gene expression by identifying the locations of transcription start sites.\n5. FALSE [correction]: Since SLIC-CAGE as described does not exist, it cannot aim to provide a comprehensive view of chromosome structure and its effects on gene expression. CAGE can however contribute to the understanding of gene expression by identifying transcription start sites.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (LEM domain-containing protein 3) is a protein that plays several important roles in the regulation of gene expression, cell signaling, and cellular processes. Here are some of the known roles of LEM-3:\n1. Transcriptional regulation: LEM-3 is a transcriptional coactivator that plays a role in the regulation of gene expression by interacting with transcription factors and modulating their activity.\n2. Cell signaling: LEM-3 is involved in the regulation of various cell signaling pathways, including the Wnt/β-catenin pathway, the Notch pathway, and the PI3K/Akt pathway.\n3. Cell adhesion and migration: LEM-3 regulates cell adhesion and migration by interacting with cadherins and catenins, and by modulating the activity of proteins involved in these processes.\n4. Cancer: LEM-3 has been implicated in the development and progression of various types of cancer, including breast, lung, and colon cancer. It is thought to play a role in the regulation of tumor cell migration and invasion, as well as in the development of resistance to chemotherapy.\n5. Neurodegeneration: LEM-3 has been linked to the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. It is thought to play a role in the regulation of protein degradation and the clearance of toxic proteins in the brain.\nOverall, LEM-3 is a multifunctional protein that plays a complex and diverse set of roles in the regulation of cellular processes, and its dysregulation has been implicated in a variety of diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 (LEM domain-containing protein 3) is involved in the transcriptional regulation as a coactivator that modulates transcription factors' activity.\n2. LEM-3 is part of the regulation of various cell signaling pathways, including Wnt/β-catenin, Notch, and PI3K/Akt pathways.\n3. LEM-3 regulates cell adhesion and migration by interacting with cadherins and catenins.\n4. LEM-3 has been implicated in the development and progression of various types of cancer, such as breast, lung, and colon cancer.\n5. LEM-3 has been linked to neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, through its role in regulating protein degradation and clearance of toxic proteins.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 (LEM domain-containing protein 3) is involved in the transcriptional regulation as a coactivator that modulates transcription factors' activity.",
      "LEM-3 is part of the regulation of various cell signaling pathways, including Wnt/β-catenin, Notch, and PI3K/Akt pathways.",
      "LEM-3 regulates cell adhesion and migration by interacting with cadherins and catenins.",
      "LEM-3 has been implicated in the development and progression of various types of cancer, such as breast, lung, and colon cancer.",
      "LEM-3 has been linked to neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, through its role in regulating protein degradation and clearance of toxic proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe information provided does not offer enough context to assess the accuracy of the statements about LEM-3 (LEM domain-containing protein 3). The role of LEM-3 in cellular processes and disease progression often requires specific scientific knowledge and references to research studies. Without such context, the veracity of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "As a biomedical scientist, I am not familiar with a software tool called \"tmVar\". Could you please provide more context or clarify which \"tmVar\" you are referring to? There are many different tools and software programs available in the field of bioinformatics and computational biology, and without more information, it is difficult to provide a comprehensive list of releases for a specific tool.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases of somatic mutations in normal cells, but one of the most well-known and widely used is the Cancer Genome Atlas (TCGA) database. TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. The database contains RNA sequencing data and clinical information from thousands of samples of normal tissue and various types of cancer, including breast, lung, colon, and many others. The data in TCGA is used to identify somatic mutations in normal cells and to understand the genetic changes that occur in cancer development and progression. Other databases that contain information on somatic mutations in normal cells include the ExAC (Exome Aggregation Consortium) database and the COSMIC (Catalogue of Somatic Mutations in Cancer) database.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) database is a well-known and widely used database of somatic mutations in normal cells.\n2. TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n3. The TCGA database aims to catalogue genomic changes in various types of cancer.\n4. The TCGA database includes RNA sequencing data and clinical information from thousands of samples of normal tissue and various types of cancer.\n5. Other databases that include information on somatic mutations in normal cells are the ExAC database and the COSMIC database.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) database is a well-known and widely used database of somatic mutations in normal cells.",
      "TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The TCGA database aims to catalogue genomic changes in various types of cancer.",
      "The TCGA database includes RNA sequencing data and clinical information from thousands of samples of normal tissue and various types of cancer.",
      "Other databases that include information on somatic mutations in normal cells are the ExAC database and the COSMIC database."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cancer Genome Atlas (TCGA) database is a well-known and widely used database of somatic mutations in cancer cells, not normal cells.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The ExAC database (now part of the gnomAD database) primarily contains information on genetic variation in the general population, not specifically somatic mutations in normal cells. The COSMIC database, however, does include information on somatic mutations in cancers.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that are implemented in Java. Here are some of them:\n1. GraphKite: GraphKite is a lightweight graph kernel library written in Java. It provides a simple and efficient implementation of graph kernel algorithms and is designed to be used in large-scale graph processing applications.\n2. JGraphT: JGraphT is a Java library for graph theory that provides a simple and efficient implementation of graph kernel algorithms. It is designed to be used in large-scale graph processing applications and provides a wide range of graph algorithms and data structures.\n3. GraphCrunch: GraphCrunch is a Java library for graph processing that provides a simple and efficient implementation of graph kernel algorithms. It is designed to be used in large-scale graph processing applications and provides a wide range of graph algorithms and data structures.\n4. GraphSim: GraphSim is a Java library for graph simulation that provides a simple and efficient implementation of graph kernel algorithms. It is designed to be used in large-scale graph processing applications and provides a wide range of graph algorithms and data structures.\n5. GraphSphere: GraphSphere is a Java library for graph processing that provides a simple and efficient implementation of graph kernel algorithms. It is designed to be used in large-scale graph processing applications and provides a wide range of graph algorithms and data structures.\n6. GraphX: GraphX is a Java library for graph processing that provides a simple and efficient implementation of graph kernel algorithms. It is designed to be used in large-scale graph processing applications and provides a wide range of graph algorithms and data structures.\n7. JGraph: JGraph is a Java library for graph theory that provides a simple and efficient implementation of graph kernel algorithms. It is designed to be used in large-scale graph processing applications and provides a wide range of graph algorithms and data structures.\n8. Neo4j: Neo4j is a graph database that provides a simple and efficient implementation of graph kernel algorithms. It is designed to be used in large-scale graph processing applications and provides a wide range of graph algorithms and data structures.\n9. OrientDB: OrientDB is a graph database that provides a simple and efficient implementation of graph kernel algorithms. It is designed to be used in large-scale graph processing applications and provides a wide range of graph algorithms and data structures.\n10. Titan: Titan is a graph database that provides a simple and efficient implementation of graph kernel algorithms",
    "llama-2-7b-chat-hf_fact_raw": "1. GraphKite is a graph kernel library that is implemented in Java.\n2. JGraphT is a Java library that provides graph kernel algorithms and is intended for large-scale graph processing applications.\n3. GraphCrunch is a Java library for graph processing with an emphasis on graph kernel algorithms.\n4. GraphSim is a Java-based library for graph simulation that includes graph kernel algorithms.\n5. Neo4j is a graph database that offers an implementation of graph kernel algorithms in Java.",
    "llama-2-7b-chat-hf_fact": [
      "GraphKite is a graph kernel library that is implemented in Java.",
      "JGraphT is a Java library that provides graph kernel algorithms and is intended for large-scale graph processing applications.",
      "GraphCrunch is a Java library for graph processing with an emphasis on graph kernel algorithms.",
      "GraphSim is a Java-based library for graph simulation that includes graph kernel algorithms.",
      "Neo4j is a graph database that offers an implementation of graph kernel algorithms in Java."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: JGraphT is a Java library that provides a mathematical graph-theory objects and algorithms. It is not specifically focused on graph kernel algorithms or intended solely for large-scale graph processing applications.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Neo4j is a graph database management system but it doesn't specifically offer an implementation of graph kernel algorithms in Java.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "The SHERLOCKv2 platform is an advancement over the original SHERLOCK platform and includes four key advances:\n1. Improved specificity: SHERLOCKv2 uses a novel mechanism to improve the specificity of the assay, reducing false positives and increasing the accuracy of the results.\n2. Increased sensitivity: SHERLOCKv2 has been optimized to detect lower levels of target DNA, allowing for more sensitive detection of genetic material.\n3. Reduced assay time: The SHERLOCKv2 platform has been streamlined to reduce the assay time from hours to minutes, making it more efficient and practical for use in a clinical setting.\n4. Multiplexing capabilities: SHERLOCKv2 allows for the detection of multiple targets in a single assay, enabling the detection of multiple genetic mutations in a single test. This is achieved through the use of different probes that target specific regions of the genome, allowing for the simultaneous detection of multiple targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 platform is designed to improve the specificity of the assay.\n2. The sensitivity of the SHERLOCKv2 platform has been optimized for detecting lower levels of target DNA.\n3. The assay time for the SHERLOCKv2 platform has been reduced from hours to minutes.\n4. SHERLOCKv2 features multiplexing capabilities, allowing detection of multiple targets in a single assay.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 platform is designed to improve the specificity of the assay.",
      "The sensitivity of the SHERLOCKv2 platform has been optimized for detecting lower levels of target DNA.",
      "The assay time for the SHERLOCKv2 platform has been reduced from hours to minutes.",
      "SHERLOCKv2 features multiplexing capabilities, allowing detection of multiple targets in a single assay."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nWithout additional context or specific results to counter these statements, they align with what would be expected from an improved version of a diagnostic platform like SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing), which uses CRISPR technology for the detection of sequences. The \"v2\" suggests an updated or advanced version, which would imply improvements such as increased specificity, better sensitivity, quicker assay times, and potentially multiplexing capabilities.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a heuristic algorithm used to solve the Traveling Salesman Problem (TSP), which is a classic problem in computer science and operations research. The algorithm was first proposed by David B. Shmoys and Richard L. Gupta in 1975.\nThe basic idea of the Bartender algorithm is to break down the TSP into smaller subproblems and solve them recursively. The algorithm works as follows:\n1. Divide the set of cities into clusters: The algorithm starts by dividing the set of cities into clusters of roughly equal size. The number of clusters is determined by the problem instance.\n2. Solve the subproblems: For each cluster, the algorithm solves a smaller TSP instance by recursively applying the Bartender algorithm to the subset of cities within the cluster.\n3. Combine the solutions: After solving the subproblems, the algorithm combines the solutions to obtain a solution for the original TSP instance.\n4. Prune the solution: Finally, the algorithm prunes the solution to obtain a shorter tour that visits each city exactly once and returns to the starting city.\nThe Bartender algorithm has a time complexity of O(n^3), where n is the number of cities, and a space complexity of O(n^2), where n is the number of cities. While the algorithm is not as efficient as some other algorithms for solving TSP instances with a small number of cities, it is simple to implement and has been used in a variety of applications, including scheduling and logistics.\nThe Bartender algorithm is also known as the \"divide-and-conquer\" algorithm, as it divides the TSP instance into smaller subproblems and solves them recursively. The algorithm is named after the bartender who divides a large order of drinks into smaller glasses and serves them to the customers.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm was proposed by David B. Shmoys and Richard L. Gupta in 1975.\n2. It is used to solve the Traveling Salesman Problem (TSP).\n3. The algorithm divides the set of cities into clusters to solve the problem.\n4. The Bartender algorithm has a time complexity of O(n^3).\n5. The algorithm has a space complexity of O(n^2).",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm was proposed by David B. Shmoys and Richard L. Gupta in 1975.",
      "It is used to solve the Traveling Salesman Problem (TSP).",
      "The algorithm divides the set of cities into clusters to solve the problem.",
      "The Bartender algorithm has a time complexity of O(n^3).",
      "The algorithm has a space complexity of O(n^2)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There appears to be no information available about an algorithm named \"Bartender\" being proposed by David B. Shmoys and Richard L. Gupta in 1975. Moreover, David B. Shmoys has contributed to the field of algorithms and optimization, but there is no record of the specific \"Bartender algorithm\" associated with these authors.\n2. UNKNOWN: Since the existence of the Bartender algorithm is not established, its application to solve the Traveling Salesman Problem (TSP) cannot be confirmed.\n3. UNKNOWN: Similarly, without verification of the algorithm's existence or methodology, the statement that it divides the set of cities into clusters to solve the problem cannot be assessed.\n4. UNKNOWN: Without information pertaining to the Bartender algorithm and its processes, no assessment can be made regarding its time complexity.\n5. UNKNOWN: There is no available information on the Bartender algorithm to verify the claim of its space complexity being O(n^2).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree Online: This is a popular web-based platform that allows users to create and edit family trees, connect with other researchers, and access a large database of genealogical records.\n2. MyHeritage: MyHeritage is another well-known web-based platform that provides tools for creating and sharing family trees, as well as access to historical records and DNA testing.\n3. FamilySearch: FamilySearch is a free genealogy website provided by The Church of Jesus Christ of Latter-day Saints. It offers a range of tools for creating and sharing family trees, as well as access to historical records and other resources.\n4. GenoPro: GenoPro is a web-based genealogy software that allows users to create and edit family trees, as well as add photos, documents, and other media.\n5. Legacy Family Tree: Legacy Family Tree is a web-based genealogy software that provides tools for creating and editing family trees, as well as access to historical records and other resources.\n6. FamilyTreeWebinars: FamilyTreeWebinars is a web-based platform that offers live and recorded genealogy webinars, as well as access to a range of genealogy resources and tools.\n7. GenealogyBank: GenealogyBank is a web-based platform that provides access to historical newspapers, obituaries, and other genealogy resources.\n8. Findmypast: Findmypast is a web-based platform that provides access to historical records and genealogy resources, including birth, marriage, and death records, census records, and more.\n9. Ancestry.com: Ancestry.com is a popular web-based platform that provides access to a vast library of genealogy records, including birth, marriage, and death records, census records, and more.\n10. BillionGraves: BillionGraves is a web-based platform that provides access to a database of over 100 million burial records, as well as tools for creating and sharing family trees.\nThese are just a few examples of the many web-based pedigree editors available. Each platform has its own unique features and offerings, so it's worth exploring several to find the one that best",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Online is a web-based platform for creating and editing family trees.\n2. MyHeritage provides tools for creating and sharing family trees and offers access to historical records and DNA testing.\n3. FamilySearch is a free genealogy website provided by The Church of Jesus Christ of Latter-day Saints and includes tools for creating family trees.\n4. GenoPro is a web-based genealogy software that allows adding photos, documents, and other media to family trees.\n5. Ancestry.com offers a library of genealogy records, including birth, marriage, and death records, and census records.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Online is a web-based platform for creating and editing family trees.",
      "MyHeritage provides tools for creating and sharing family trees and offers access to historical records and DNA testing.",
      "FamilySearch is a free genealogy website provided by The Church of Jesus Christ of Latter-day Saints and includes tools for creating family trees.",
      "GenoPro is a web-based genealogy software that allows adding photos, documents, and other media to family trees.",
      "Ancestry.com offers a library of genealogy records, including birth, marriage, and death records, and census records."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Pedigree Online is not the name of a known web-based platform for creating and editing family trees. However, there are other popular platforms, such as Geni.com or Ancestry.com that offer these services.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GenoPro is not primarily web-based; it is desktop genealogy software that requires installation on a computer to use for creating family trees and attaching photos, documents, and other media.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, including:\n1. The Venom Database: This database contains information on venomous animals, including spiders, snakes, and scorpions, and includes data on the composition, structure, and function of their venoms.\n2. The Spider Venom Toxin Database (SVTD): This database is dedicated specifically to spider venom toxins and includes information on their chemical structure, gene sequence, and biological activity.\n3. The Toxinology Database: This database contains information on various types of toxins, including spider venom toxins, and includes data on their chemical structure, biological activity, and potential applications.\n4. The Natural Products Dictionary (NPD): This database contains information on natural products, including spider venom toxins, and includes data on their chemical structure, biological activity, and biosynthesis.\n5. The ToxinTech Database: This database contains information on various types of toxins, including spider venom toxins, and includes data on their chemical structure, biological activity, and potential applications.\n6. The VenomToxin Database (VTD): This database contains information on venomous animals, including spiders, and includes data on the composition, structure, and function of their venoms, as well as their potential applications.\n7. The Spider Venom Database (SVD): This database is dedicated specifically to spider venom and includes information on its composition, structure, and function, as well as its potential applications.\n8. The ToxinToxinome Database (TTD): This database contains information on various types of toxins, including spider venom toxins, and includes data on their chemical structure, biological activity, and potential applications.\n9. The Venomous Animals Database (VAD): This database contains information on various types of venomous animals, including spiders, snakes, and scorpions, and includes data on their venom composition, structure, and function.\n10. The Toxinology Research Database (TRD): This database contains information on various types of toxins, including spider venom toxins, and includes data on their chemical structure, biological activity, and potential applications.\nThese databases are valuable resources for researchers",
    "llama-2-7b-chat-hf_fact_raw": "1. The Venom Database includes information on venomous animals such as spiders and covers composition, structure, and function of their venoms.\n2. The Spider Venom Toxin Database focuses specifically on spider venom toxins, including chemical structure and biological activity.\n3. The Toxinology Database contains information on various types of toxins, including spider venom toxins.\n4. The Natural Products Dictionary covers natural products, with spider venom toxins included, providing data on their chemical structure and biological activity.\n5. The VenomToxin Database contains data on venomous animals, including spiders, with emphasis on venom composition and potential applications.",
    "llama-2-7b-chat-hf_fact": [
      "The Venom Database includes information on venomous animals such as spiders and covers composition, structure, and function of their venoms.",
      "The Spider Venom Toxin Database focuses specifically on spider venom toxins, including chemical structure and biological activity.",
      "The Toxinology Database contains information on various types of toxins, including spider venom toxins.",
      "The Natural Products Dictionary covers natural products, with spider venom toxins included, providing data on their chemical structure and biological activity.",
      "The VenomToxin Database contains data on venomous animals, including spiders, with emphasis on venom composition and potential applications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Axitinib is a tyrosine kinase inhibitor that has been investigated in clinical trials for the treatment of various types of cancer, including pancreatic cancer. While the results of these trials have been mixed, there is some evidence to suggest that axitinib may have a potential role in prolonging survival in patients with pancreatic cancer.\nOne phase 2 clinical trial published in 2018 found that axitinib treatment was associated with improved overall survival in patients with advanced pancreatic cancer. In this trial, 23% of patients treated with axitinib had a complete or partial response to treatment, and the median overall survival was 11.6 months, which was longer than the median survival of 6.7 months in the control group.\nAnother phase 3 clinical trial published in 2020 found that axitinib did not meet the primary endpoint of improved overall survival in patients with advanced pancreatic cancer compared to the control group. However, the study did find that axitinib was associated with improved progression-free survival (PFS) and overall survival in patients with specific biomarkers.\nIt is important to note that these studies were small and had limited sample sizes, so further research is needed to confirm these findings and establish the safety and efficacy of axitinib for the treatment of pancreatic cancer. Additionally, axitinib has been associated with significant side effects, including fatigue, nausea, and diarrhea, which can impact quality of life.\nIn summary, while there is some evidence to suggest that axitinib may have a potential role in prolonging survival in patients with pancreatic cancer, further research is needed to confirm these findings and establish the safety and efficacy of this treatment approach.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor used in clinical trials for treating various types of cancer, including pancreatic cancer.\n2. A phase 2 clinical trial published in 2018 indicated an improved overall survival with axitinib treatment for advanced pancreatic cancer patients, with a median survival of 11.6 months compared to 6.7 months in the control group.\n3. In the same trial, 23% of patients treated with axitinib had a complete or partial response.\n4. A phase 3 clinical trial published in 2020 found that axitinib did not meet the primary endpoint of improved overall survival for patients with advanced pancreatic cancer when compared to the control group.\n5. The same phase 3 clinical trial found that axitinib was associated with improved progression-free survival (PFS) and overall survival in patients with specific biomarkers.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor used in clinical trials for treating various types of cancer, including pancreatic cancer.",
      "A phase 2 clinical trial published in 2018 indicated an improved overall survival with axitinib treatment for advanced pancreatic cancer patients, with a median survival of 11.6 months compared to 6.7 months in the control group.",
      "In the same trial, 23% of patients treated with axitinib had a complete or partial response.",
      "A phase 3 clinical trial published in 2020 found that axitinib did not meet the primary endpoint of improved overall survival for patients with advanced pancreatic cancer when compared to the control group.",
      "The same phase 3 clinical trial found that axitinib was associated with improved progression-free survival (PFS) and overall survival in patients with specific biomarkers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWhile the first statement regarding axitinib being a tyrosine kinase inhibitor used in clinical trials for treating various types of cancer is true, the remaining statements about specific clinical trials, their outcomes, patient responses, and related findings cannot be confirmed or denied without access to the specific clinical trial results or medical literature cited. Clinical trial outcomes for drugs can vary and require specific data to assess the veracity of any given claim. Therefore, these details remain unknown without further context or references.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein L) regulates F-actin dynamics through its interaction with actin-binding proteins, such as cofilin and G-actin. MLP binds to these proteins and inhibits their activity, thereby regulating the dynamics of F-actin filaments.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Microtubule-associated protein L) interacts with actin-binding proteins.\n2. Cofilin and G-actin are actin-binding proteins that interact with MLP.\n3. MLP binding to cofilin and G-actin inhibits their activity.\n4. Inhibition of cofilin and G-actin activity by MLP regulates F-actin filament dynamics.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Microtubule-associated protein L) interacts with actin-binding proteins.",
      "Cofilin and G-actin are actin-binding proteins that interact with MLP.",
      "MLP binding to cofilin and G-actin inhibits their activity.",
      "Inhibition of cofilin and G-actin activity by MLP regulates F-actin filament dynamics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MLP (Muscle LIM Protein), also known as CSRP3, is associated with muscle development and is not known for directly interacting with actin-binding proteins. It is more known for its involvement in the structural organization of sarcomeres in muscle cells.\n2. FALSE [correction]: While cofilin and G-actin are indeed actin-binding proteins, there is no established interaction between them and MLP (Muscle LIM Protein). Cofilin binds to actin filaments (F-actin) rather than G-actin, promoting filament depolymerization.\n3. FALSE [correction]: Since there is no interaction established between MLP and cofilin or G-actin, MLP cannot inhibit their activity. Furthermore, the activity of cofilin and G-actin refers to actin dynamics, not directly to inhibition by MLP.\n4. FALSE [correction]: Because MLP does not directly interact with cofilin and G-actin, it is incorrect to state that MLP inhibits their activity and thereby regulates F-actin filament dynamics. It's more accurate to say that cofilin regulates F-actin filament dynamics on its own by promoting the depolymerization of F-actin.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "The number of pseudokinases in the human kinome is not a fixed number and can vary depending on the source of the data and the criteria used to define a pseudokinase. However, according to some recent studies, there are approximately 30-40 pseudokinases in the human kinome. These pseudokinases are proteins that have some characteristics of kinases, such as a catalytic domain, but do not have the ability to transfer phosphate groups to other proteins. They are thought to play non-canonical roles in cellular signaling pathways.",
    "llama-2-7b-chat-hf_fact_raw": "1. The number of pseudokinases in the human kinome is estimated to be approximately 30-40 according to some recent studies.\n2. Pseudokinases are proteins with some characteristics of kinases.\n3. Pseudokinases possess a catalytic domain.\n4. Pseudokinases do not have the ability to transfer phosphate groups to other proteins.\n5. Pseudokinases are thought to play non-canonical roles in cellular signaling pathways.",
    "llama-2-7b-chat-hf_fact": [
      "The number of pseudokinases in the human kinome is estimated to be approximately 30-40 according to some recent studies.",
      "Pseudokinases are proteins with some characteristics of kinases.",
      "Pseudokinases possess a catalytic domain.",
      "Pseudokinases do not have the ability to transfer phosphate groups to other proteins.",
      "Pseudokinases are thought to play non-canonical roles in cellular signaling pathways."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While traditionally pseudokinases were thought to lack kinase activity, many have been shown to have the ability to transfer phosphate groups to other proteins, albeit often at lower levels of activity or through atypical mechanisms.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE (apolipoprotein E) mimetics are compounds that mimic the structure and function of the apolipoprotein E protein, which plays a crucial role in lipid metabolism and inflammation. Here are three examples of apoE mimetics:\n1. AZD-10040: This is a synthetic apoE mimetic that has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of non-alcoholic fatty liver disease (NAFLD).\n2. CRT0066101: This is a small molecule apoE mimetic that has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of NAFLD.\n3. GS-99730: This is a synthetic apoE mimetic that has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of NAFLD. It has also been shown to reduce the progression of atherosclerosis in animal models.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD-10040 is a synthetic apoE mimetic.\n2. CRT0066101 is a small molecule apoE mimetic.\n3. GS-99730 is a synthetic apoE mimetic that has been shown to reduce the progression of atherosclerosis in animal models.",
    "llama-2-7b-chat-hf_fact": [
      "AZD-10040 is a synthetic apoE mimetic.",
      "CRT0066101 is a small molecule apoE mimetic.",
      "GS-99730 is a synthetic apoE mimetic that has been shown to reduce the progression of atherosclerosis in animal models."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nThere is not enough context provided about these specific compounds, their classifications, or research findings to accurately determine the truthfulness of these statements. Without specific information on AZD-10040, CRT0066101, and GS-99730 or access to current scientific databases to verify these claims, it's impossible to ascertain their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (SAM and HD-like protein 1) is an enzyme that plays a crucial role in regulating the innate immune response to viral infections. There are sex differences in SAMHD1 activity, with studies suggesting that females have higher levels of SAMHD1 activity compared to males.\nOne study found that female mice have higher levels of SAMHD1 protein expression in their livers compared to males, and that this difference is maintained even after adjusting for body size. Another study found that female human peripheral blood mononuclear cells have higher levels of SAMHD1 activity compared to males.\nThe mechanisms underlying these sex differences in SAMHD1 activity are not fully understood, but may be related to differences in hormone levels and gene expression between males and females. Estrogen, for example, has been shown to increase SAMHD1 expression in some cell types, while androgens have the opposite effect.\nSex differences in SAMHD1 activity may have important implications for the immune response to viral infections. For example, one study found that female mice are more resistant to certain viral infections, such as HIV, than males, and that this resistance is mediated in part by differences in SAMHD1 activity. Another study found that males are more susceptible to certain viral infections, such as hepatitis B, than females, and that this susceptibility is associated with lower levels of SAMHD1 activity.\nOverall, these findings suggest that sex differences in SAMHD1 activity may play a role in the immune response to viral infections, and that further research is needed to fully understand the mechanisms underlying these differences.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 (SAM and HD-like protein 1) is an enzyme involved in the regulation of the innate immune response to viral infections.\n2. Studies have shown that females have higher levels of SAMHD1 activity compared to males.\n3. A study indicated that female mice have higher levels of SAMHD1 protein expression in their livers than male mice.\n4. Research found that female human peripheral blood mononuclear cells exhibit higher levels of SAMHD1 activity compared to those of males.\n5. Estrogen has been shown to increase SAMHD1 expression in some cell types.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 (SAM and HD-like protein 1) is an enzyme involved in the regulation of the innate immune response to viral infections.",
      "Studies have shown that females have higher levels of SAMHD1 activity compared to males.",
      "A study indicated that female mice have higher levels of SAMHD1 protein expression in their livers than male mice.",
      "Research found that female human peripheral blood mononuclear cells exhibit higher levels of SAMHD1 activity compared to those of males.",
      "Estrogen has been shown to increase SAMHD1 expression in some cell types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 (RUNX2 transcription factor 1) has been shown to inhibit astrocyte differentiation. RUNX2 is a transcription factor that plays a critical role in the regulation of cell fate decisions, including the differentiation of neural progenitor cells into astrocytes. Studies have shown that RUNX2 can repress the expression of genes involved in astrocyte differentiation and inhibit the process of astrocyte maturation. This suggests that RUNX2 may play a role in regulating the balance between neural progenitor cell proliferation and differentiation, and may be involved in the development of certain neurological disorders, such as brain cancer and neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 (RUNX2 transcription factor 1) inhibits astrocyte differentiation.\n2. RUNX2 is involved in the regulation of cell fate decisions.\n3. Studies have indicated that RUNX2 represses gene expression involved in astrocyte differentiation.\n4. RUNX2 can inhibit the maturation of astrocytes.\n5. RUNX2 may play a role in the development of certain neurological disorders.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 (RUNX2 transcription factor 1) inhibits astrocyte differentiation.",
      "RUNX2 is involved in the regulation of cell fate decisions.",
      "Studies have indicated that RUNX2 represses gene expression involved in astrocyte differentiation.",
      "RUNX2 can inhibit the maturation of astrocytes.",
      "RUNX2 may play a role in the development of certain neurological disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RUNX2 (Runt-related transcription factor 2) is actually known for promoting osteoblast differentiation and being involved in bone formation.\n2. TRUE: RUNX2 is involved in the regulation of cell fate decisions, especially in osteoblast differentiation during bone development.\n3. UNKNOWN: Without specific studies to reference, it is unclear if RUNX2 represses gene expression involved in astrocyte differentiation. It is primarily associated with bone development; whether it has a repressive role in astrocyte differentiation would require specific evidence.\n4. UNKNOWN: There is no standard information available with the current context about RUNX2’s role in inhibiting the maturation of astrocytes. Its known functions relate to bone development and osteoblast maturation.\n5. UNKNOWN: The statement is too vague without specific studies or disorders mentioned, so it's difficult to determine the validity of RUNX2’s role in the development of certain neurological disorders. It is mainly implicated in bone and skeletal development.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stansby excision arthroplasty is a surgical procedure that is typically performed in the knee joint. It is a type of arthroplasty, or joint replacement, that involves removing a portion of the bone in the knee joint and replacing it with an artificial implant. The procedure is typically performed to treat severe knee osteoarthritis that has not responded to other treatments, such as physical therapy, medication, or injections. The goal of the procedure is to relieve pain, improve knee function, and restore quality of life.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stansby excision arthroplasty is performed in the knee joint.\n2. The procedure involves removing a portion of the bone in the knee joint.\n3. An artificial implant is used to replace the removed portion of the knee bone in the Cobb-Stansby excision arthroplasty.\n4. Cobb-Stansby excision arthroplasty is typically used to treat severe knee osteoarthritis.\n5. The goal of the Cobb-Stansby excision arthroplasty is to relieve pain and improve knee function.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stansby excision arthroplasty is performed in the knee joint.",
      "The procedure involves removing a portion of the bone in the knee joint.",
      "An artificial implant is used to replace the removed portion of the knee bone in the Cobb-Stansby excision arthroplasty.",
      "Cobb-Stansby excision arthroplasty is typically used to treat severe knee osteoarthritis.",
      "The goal of the Cobb-Stansby excision arthroplasty is to relieve pain and improve knee function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stansby excision arthroplasty is performed in the thumb base joint, not the knee joint.\n2. TRUE\n3. FALSE [correction]: In the Cobb-Stansby excision arthroplasty, a portion of the trapezium bone in the wrist is removed and typically not replaced with an artificial implant; instead, other techniques like tendon interposition or ligament reconstruction may be used.\n4. FALSE [correction]: Cobb-Stansby excision arthroplasty is typically used to treat severe osteoarthritis of the trapeziometacarpal joint at the base of the thumb, not the knee.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 has been shown to promote epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells. EMT is a process by which epithelial cells lose their cell-cell adhesion and gain mesenchymal characteristics, such as increased migration and invasiveness. GRHL2 is a transcription factor that regulates the expression of genes involved in EMT, including the repression of epithelial genes and the activation of mesenchymal genes. Over-expression of GRHL2 has been shown to promote EMT in various types of cancer, including breast, lung, and colon cancer, and is associated with cancer progression and metastasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types.\n2. EMT is a process where epithelial cells lose cell-cell adhesion and gain mesenchymal characteristics like increased migration and invasiveness.\n3. GRHL2 is a transcription factor that regulates gene expression involved in the EMT process.\n4. Over-expression of GRHL2 has been observed in various types of cancer, including breast, lung, and colon cancer.\n5. GRHL2 over-expression is associated with cancer progression and metastasis.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types.",
      "EMT is a process where epithelial cells lose cell-cell adhesion and gain mesenchymal characteristics like increased migration and invasiveness.",
      "GRHL2 is a transcription factor that regulates gene expression involved in the EMT process.",
      "Over-expression of GRHL2 has been observed in various types of cancer, including breast, lung, and colon cancer.",
      "GRHL2 over-expression is associated with cancer progression and metastasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 is typically associated with the inhibition of epithelial-to-mesenchymal transition (EMT) in various cell types, not the promotion of EMT.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Given that GRHL2 inhibits EMT, over-expression of GRHL2 is often associated with a reduction in cancer progression and metastasis, not an increase.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-bet (T-box transcription factor Eomesodermin) and Eomesodermin (Eomes) are two T-cell-specific transcription factors that have been implicated in lung cancer.\nT-bet is a transcription factor that plays a critical role in the differentiation of T cells and the immune response. In lung cancer, T-bet has been shown to be downregulated in tumor-infiltrating T cells, leading to a decrease in anti-tumor immunity. Overexpression of T-bet has been associated with improved prognosis in lung cancer patients.\nEomes, on the other hand, is a transcription factor that regulates the expression of genes involved in cell proliferation, differentiation, and survival. In lung cancer, Eomes has been shown to be overexpressed in tumor cells, leading to the infiltration of immune suppressive cells and the evasion of immune surveillance. Overexpression of Eomes has been associated with poor prognosis in lung cancer patients.\nBoth T-bet and Eomes have been implicated in the development and progression of lung cancer, and their dysregulation may contribute to the immune evasion and tumor progression in this disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet (T-box transcription factor Eomesodermin) has been implicated in lung cancer.\n2. Eomesodermin (Eomes) is a T-cell-specific transcription factor that has been implicated in lung cancer.\n3. T-bet has been found to be downregulated in tumor-infiltrating T cells in lung cancer patients.\n4. Overexpression of T-bet in lung cancer patients has been associated with an improved prognosis.\n5. Overexpression of Eomes in lung cancer has been linked to poor prognosis in patients.",
    "llama-2-7b-chat-hf_fact": [
      "T-bet (T-box transcription factor Eomesodermin) has been implicated in lung cancer.",
      "Eomesodermin (Eomes) is a T-cell-specific transcription factor that has been implicated in lung cancer.",
      "T-bet has been found to be downregulated in tumor-infiltrating T cells in lung cancer patients.",
      "Overexpression of T-bet in lung cancer patients has been associated with an improved prognosis.",
      "Overexpression of Eomes in lung cancer has been linked to poor prognosis in patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: T-bet (T-box transcription factor TBX21) has been implicated in lung cancer, not Eomesodermin (Eomes).\n2. FALSE [correction]: Eomesodermin (Eomes) is not a T-cell-specific transcription factor; however, it does play a role in T cell function and has been implicated in cancer, including lung cancer.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 (G protein-coupled receptor 151) is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. However, GPR151 has been found to be involved in various biological processes, including:\n1. Inflammation: GPR151 has been shown to be involved in the regulation of inflammation, with studies suggesting that it may play a role in the resolution of inflammation.\n2. Immune response: GPR151 has been implicated in the regulation of immune responses, including the activation of T cells and the production of cytokines.\n3. Metabolism: GPR151 has been linked to the regulation of glucose and lipid metabolism, with studies suggesting that it may play a role in the regulation of insulin sensitivity and glucose uptake.\n4. Neuroprotection: GPR151 has been shown to be involved in the regulation of neuroprotection, with studies suggesting that it may play a role in the protection of neurons against oxidative stress and excitotoxicity.\n5. Cardiovascular health: GPR151 has been linked to the regulation of cardiovascular health, with studies suggesting that it may play a role in the regulation of blood pressure and the prevention of cardiovascular disease.\nOverall, GPR151 is a complex receptor that is involved in a variety of physiological processes, and further research is needed to fully understand its role in health and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is defined as an orphan receptor, which means it lacks a well-defined endogenous ligand and a clear physiological function.\n2. GPR151 is involved in the regulation of inflammation according to some studies.\n3. Studies have implicated GPR151 in the regulation of immune responses, including T cell activation and cytokine production.\n4. GPR151 has been linked to the regulation of glucose and lipid metabolism and may influence insulin sensitivity and glucose uptake.\n5. Research suggests that GPR151 plays a role in neuroprotection, including protecting neurons against oxidative stress and excitotoxicity.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is defined as an orphan receptor, which means it lacks a well-defined endogenous ligand and a clear physiological function.",
      "GPR151 is involved in the regulation of inflammation according to some studies.",
      "Studies have implicated GPR151 in the regulation of immune responses, including T cell activation and cytokine production.",
      "GPR151 has been linked to the regulation of glucose and lipid metabolism and may influence insulin sensitivity and glucose uptake.",
      "Research suggests that GPR151 plays a role in neuroprotection, including protecting neurons against oxidative stress and excitotoxicity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWhile I can confirm that GPR151 is considered an orphan receptor, based on the information provided, whether the subsequent statements about GPR151's involvement in inflammation, immune responses, metabolism regulation, or neuroprotection are accurate would require access to specific scientific studies or literature supporting those claims. The information provided does not give sufficient details to confirm or deny statements 2-5, hence they are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone intradermal quadrivalent vaccine contains the following attenuated live viruses:\n1. FluA/H1N1: A strain of the A/California/7/2009 (H1N1) subtype\n2. FluA/H3N2: A strain of the A/Victoria/361/2019 (H3N2) subtype\n3. FluB/Victoria: A strain of the B/Victoria lineage\n4. FluB/Yamagata: A strain of the B/Yamagata lineage.\nIt's important to note that the specific strains of the viruses contained in the vaccine may vary depending on the year and the manufacturer of the vaccine.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains a strain of the A/California/7/2009 (H1N1) subtype.\n2. The vaccine includes a strain of the A/Victoria/361/2019 (H3N2) subtype.\n3. A strain of the B/Victoria lineage is part of the vaccine.\n4. It also contains a strain of the B/Yamagata lineage.\n5. The specific strains of the viruses in the vaccine may vary depending on the year and the manufacturer.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains a strain of the A/California/7/2009 (H1N1) subtype.",
      "The vaccine includes a strain of the A/Victoria/361/2019 (H3N2) subtype.",
      "A strain of the B/Victoria lineage is part of the vaccine.",
      "It also contains a strain of the B/Yamagata lineage.",
      "The specific strains of the viruses in the vaccine may vary depending on the year and the manufacturer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe first four statements require specific information about the composition of the Fluzone intradermal quadrivalent vaccine for a particular year, which can change annually based on the World Health Organization's recommendations for the most common circulating strains. Without the specific year or more context, it's impossible to confirm the accuracy of these statements. The fifth statement is true because the specific strains included in influenza vaccines do vary annually to match the strains predicted to be most prevalent during the upcoming flu season.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene, also known as the tumor necrosis factor receptor superfamily member 2 (TNFSF2) gene, has been genetically associated with Systemic Lupus Erythematosus (SLE). Specifically, mutations in the TNFR2 gene's promoter region and intron 1 have been identified as risk factors for SLE. These mutations may lead to increased TNFR2 expression and contribute to the development of SLE by disrupting the regulation of immune responses.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).\n2. Mutations in the TNFR2 gene's promoter region have been identified as risk factors for SLE.\n3. Mutations in intron 1 of the TNFR2 gene are associated with an increased risk for SLE.\n4. Increased TNFR2 expression may contribute to the development of SLE.\n5. These mutations potentially disrupt the regulation of immune responses, contributing to SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).",
      "Mutations in the TNFR2 gene's promoter region have been identified as risk factors for SLE.",
      "Mutations in intron 1 of the TNFR2 gene are associated with an increased risk for SLE.",
      "Increased TNFR2 expression may contribute to the development of SLE.",
      "These mutations potentially disrupt the regulation of immune responses, contributing to SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The TNFR2 gene has been implicated in genetic studies to be associated with autoimmune diseases, including Systemic Lupus Erythematosus (SLE).\n2. TRUE: Mutations in the promoter region of certain genes, such as TNFR2, can influence the gene's expression levels and have been associated with diseases like SLE.\n3. UNKNOWN: Without specific evidence provided in this context, the association of mutations in intron 1 of the TNFR2 gene with an increased risk for SLE cannot be confirmed as true or false.\n4. TRUE: Increased expression of TNFR2 has been proposed to potentially contribute to autoimmune processes, including those involved in SLE. TNFR2 is involved in immune responses and its dysregulation may play a role in the development of SLE.\n5. TRUE: Mutations in regulatory regions of genes involved in the immune response, such as the TNFR2, can disrupt the normal regulation and contribute to the pathogenesis of autoimmune diseases like SLE.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "There is currently no licensed vaccine available for the prevention of peanut allergy. Peanut allergy is a complex and severe immune-mediated disorder that is caused by an abnormal response of the immune system to peanut proteins. While there have been some promising results from clinical trials of experimental vaccines, more research is needed to determine their safety and effectiveness in humans.\nOne of the most promising approaches to developing a peanut allergy vaccine is based on the use of a specific peanut protein, called Ara h 1, which is known to be a major allergen responsible for the immune response to peanuts. This protein is used as the active ingredient in the vaccine, which is administered orally or by injection. The vaccine works by introducing small amounts of the allergen to the immune system, gradually desensitizing the immune system to the allergen and reducing the severity of the allergic response.\nHowever, it is important to note that the development of a peanut allergy vaccine is still in its early stages, and there are many challenges to overcome before it can become a widely available treatment. These challenges include:\n1. Safety: The safety of the vaccine must be carefully evaluated in clinical trials to ensure that it does not cause adverse reactions or interact with other medications.\n2. Efficacy: The vaccine must be shown to be effective in reducing the severity of peanut allergy reactions in clinical trials.\n3. Durability: The vaccine must be shown to provide long-term protection against peanut allergy, and the duration of protection must be determined.\n4. Cost-effectiveness: The cost of the vaccine must be evaluated to determine its affordability and value compared to other treatments for peanut allergy.\n5. Regulatory approval: The vaccine must be approved by regulatory agencies, such as the Food and Drug Administration (FDA) in the United States, before it can be made available to patients.\nWhile a peanut allergy vaccine shows promise, it is still in the experimental stage, and more research is needed to determine its safety and effectiveness. In the meantime, the best treatment",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no licensed vaccine available for the prevention of peanut allergy.\n2. The vaccine development for peanut allergy is based on the use of a specific peanut protein called Ara h 1.\n3. Clinical trials must evaluate the safety of the peanut allergy vaccine to ensure it does not cause adverse reactions.\n4. The efficacy of the peanut allergy vaccine must be shown in clinical trials.\n5. The vaccine must receive regulatory approval, such as from the FDA, before it can be made available to patients.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no licensed vaccine available for the prevention of peanut allergy.",
      "The vaccine development for peanut allergy is based on the use of a specific peanut protein called Ara h 1.",
      "Clinical trials must evaluate the safety of the peanut allergy vaccine to ensure it does not cause adverse reactions.",
      "The efficacy of the peanut allergy vaccine must be shown in clinical trials.",
      "The vaccine must receive regulatory approval, such as from the FDA, before it can be made available to patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE (as of my last update in early 2023, there was no licensed vaccine for the prevention of peanut allergies)\n2. UNKNOWN (specific details about the protein used in the development of hypothetical peanut allergy vaccines are not provided; while Ara h 1 is a peanut protein and could be used in vaccine research, without specific context, it is impossible to confirm the accuracy of this statement)\n3. TRUE (clinical trials must evaluate the safety of any vaccine, including a peanut allergy vaccine, to ensure it does not cause adverse reactions)\n4. TRUE (clinical trials are designed to measure the efficacy of vaccines, hence the efficacy of the peanut allergy vaccine must be proven in clinical trials)\n5. TRUE (vaccines must receive regulatory approval from agencies such as the FDA before they can be administered to patients)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome at position Xp11.2.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. The specific chromosomal position of the mouse Fxy gene is Xp11.2.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "The specific chromosomal position of the mouse Fxy gene is Xp11.2."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The specific chromosomal position of the mouse Fxy gene is not designated as Xp11.2 as that notation is typically used for human chromosomes. Mouse chromosomal locations are usually depicted differently. Without the exact location for the mouse Fxy gene, this statement is incorrect as stated and needs the appropriate chromosomal designation for mice.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "Methidiumpropyl-EDTA (MPE) sequencing, also known as MPE-seq, is a method for sequencing DNA that is based on the covalent binding of a reactive dye, methidiumpropyl-EDTA (MPE), to the 5'-phosphate group of DNA. Here is a brief overview of the basis of the MPE-seq method:\n1. Chemical modification: MPE is a reactive dye that reacts with the 5'-phosphate group of DNA to form a stable, covalent bond. This modification results in the formation of a fluorescently labeled DNA molecule.\n2. Separation: The labeled DNA molecules are then separated from the unmodified DNA molecules using a variety of techniques, such as gel electrophoresis or capillary electrophoresis.\n3. Detection: The separated labeled DNA molecules are then detected using a fluorescence-based detection system, such as a fluorescence microscope or a high-throughput sequencing platform.\n4. Data analysis: The resulting data is then analyzed using specialized software to determine the sequence of the DNA molecule.\nMPE-seq has several advantages over other DNA sequencing methods, including its high sensitivity, specificity, and resolution. It is also relatively simple to perform and does not require complex or expensive equipment. However, it is important to note that MPE-seq is not as widely used as other sequencing methods, such as next-generation sequencing (NGS), and may not be as well-suited for certain types of DNA sequencing applications.",
    "llama-2-7b-chat-hf_fact_raw": "1. Methidiumpropyl-EDTA sequencing is based on the covalent binding of a reactive dye, methidiumpropyl-EDTA (MPE), to the 5'-phosphate group of DNA.\n2. The chemical modification with MPE results in the formation of a fluorescently labeled DNA molecule.\n3. Labeled DNA molecules are separated from unmodified DNA molecules using techniques like gel electrophoresis or capillary electrophoresis.\n4. Detection of the separated labeled DNA molecules is performed using fluorescence-based systems.\n5. MPE-seq is touted to have high sensitivity, specificity, and resolution compared to some other DNA sequencing methods.",
    "llama-2-7b-chat-hf_fact": [
      "Methidiumpropyl-EDTA sequencing is based on the covalent binding of a reactive dye, methidiumpropyl-EDTA (MPE), to the 5'-phosphate group of DNA.",
      "The chemical modification with MPE results in the formation of a fluorescently labeled DNA molecule.",
      "Labeled DNA molecules are separated from unmodified DNA molecules using techniques like gel electrophoresis or capillary electrophoresis.",
      "Detection of the separated labeled DNA molecules is performed using fluorescence-based systems.",
      "MPE-seq is touted to have high sensitivity, specificity, and resolution compared to some other DNA sequencing methods."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The chemical modification with MPE results in the formation of a cleavable complex at the site of DNA where the enzyme cuts, not a fluorescently labeled DNA molecule.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genome-Wide Association Study) is typically implemented using a variety of programming languages depending on the specific requirements and the research question being addressed. However, some popular programming languages used for GWAS analysis include:\n1. R: R is a popular language for statistical computing and graphics, and is widely used in the genetics and genomics field. Many GWAS studies use R to perform the analysis and visualize the results.\n2. Python: Python is a versatile language that is widely used in bioinformatics and genomics. Many GWAS studies use Python for data analysis, particularly for whole-genome sequencing data.\n3. MATLAB: MATLAB is a high-level programming language that is commonly used in bioinformatics and genomics for data analysis and visualization. It is particularly useful for large-scale genomic analysis and for performing complex statistical analyses.\n4. SAS: SAS (Statistical Analysis System) is a software suite that is widely used in the statistics and genomics field. It provides a comprehensive set of tools for data management, analysis, and visualization, and is particularly useful for large-scale genomic analysis.\n5. Julia: Julia is a new language that is gaining popularity in the bioinformatics and genomics field. It is designed to be fast and efficient, and provides a number of advantages over traditional programming languages for GWAS analysis.\nIt's worth noting that the choice of programming language will depend on the specific requirements of the study, the research question being addressed, and the level of complexity of the analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. R is a language widely used in genetics and genomics for statistical computing and graphics.\n2. Python is commonly utilized in bioinformatics and genomics for data analysis, especially for whole-genome sequencing data.\n3. MATLAB is used in bioinformatics and genomics for large-scale data analysis and complex statistical analyses.\n4. SAS is a software suite used in the statistics and genomics field for data management, analysis, and visualization.\n5. Julia is a programming language that is becoming popular in the bioinformatics and genomics field due to its design for speed and efficiency.",
    "llama-2-7b-chat-hf_fact": [
      "R is a language widely used in genetics and genomics for statistical computing and graphics.",
      "Python is commonly utilized in bioinformatics and genomics for data analysis, especially for whole-genome sequencing data.",
      "MATLAB is used in bioinformatics and genomics for large-scale data analysis and complex statistical analyses.",
      "SAS is a software suite used in the statistics and genomics field for data management, analysis, and visualization.",
      "Julia is a programming language that is becoming popular in the bioinformatics and genomics field due to its design for speed and efficiency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: MATLAB is used in bioinformatics and genomics, but it is more known for its applications in engineering, physics, and high-performance computing, among other areas. While it can be used for complex statistical analyses, it’s not specifically recognized for large-scale data analysis within bioinformatics and genomics in comparison to languages like R and Python.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as verubecestat) is an oral small molecule inhibitor of the enzyme BET (bromodomain and extraterminal) that has been investigated for the treatment of amyotrophic lateral sclerosis (ALS). While there is ongoing research in this area, there is currently no strong evidence to suggest that xaliproden improves the prognosis of ALS.\nSome early-stage clinical trials have suggested that xaliproden may have some potential as a treatment for ALS, including slowing the progression of muscle weakness and atrophy, improving functional abilities, and reducing the number of hospitalizations. However, these findings are based on relatively small studies and more research is needed to confirm these results and establish the long-term safety and efficacy of xaliproden for ALS treatment.\nIn summary, while there is some promise in the preclinical and early-stage clinical trials of xaliproden as a potential treatment for ALS, more research is needed to fully understand its effects on the prognosis of this devastating disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is an oral small molecule inhibitor of the enzyme BET (bromodomain and extraterminal).\n2. Xaliproden has been investigated for the treatment of amyotrophic lateral sclerosis (ALS).\n3. No strong evidence currently exists to suggest that xaliproden improves the prognosis of ALS.\n4. Early-stage clinical trials have indicated that xaliproden may slow the progression of muscle weakness and atrophy in ALS.\n5. Further research is required to confirm the potential benefits and establish the long-term safety and efficacy of xaliproden for ALS treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is an oral small molecule inhibitor of the enzyme BET (bromodomain and extraterminal).",
      "Xaliproden has been investigated for the treatment of amyotrophic lateral sclerosis (ALS).",
      "No strong evidence currently exists to suggest that xaliproden improves the prognosis of ALS.",
      "Early-stage clinical trials have indicated that xaliproden may slow the progression of muscle weakness and atrophy in ALS.",
      "Further research is required to confirm the potential benefits and establish the long-term safety and efficacy of xaliproden for ALS treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Xaliproden is not an inhibitor of the enzyme BET; it is a neurotrophic compound studied for neurodegenerative diseases.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a transgenic line of mice that expresses a transgene in chromosome 17.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line is a transgenic line of mice.\n2. In the LiPS-A3S line, a transgene is inserted into chromosome 17.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line is a transgenic line of mice.",
      "In the LiPS-A3S line, a transgene is inserted into chromosome 17."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout access to the specific scientific literature or the explicit information from the original passage that discusses the LiPS-A3S line of mice, it is not possible to verify these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that can be used for predicting drug synergy. Some of the popular ones include:\n1. DeepDrug: DeepDrug is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of cancer genes. It uses a convolutional neural network (CNN) architecture to identify the most important protein-protein interactions and predict drug synergy.\n2. Drug2gene: Drug2gene is a deep learning model that predicts drug synergy by analyzing the gene expression profiles of cancer cells treated with different drugs. It uses a recurrent neural network (RNN) architecture to identify the genes that are differentially expressed between drug-treated and untreated cells and predict drug synergy.\n3. Synergypredict: Synergypredict is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of cancer genes. It uses a graph convolutional neural network (GCNN) architecture to identify the most important protein-protein interactions and predict drug synergy.\n4. DrugSynergizer: DrugSynergizer is a deep learning model that predicts drug synergy by analyzing the gene expression profiles of cancer cells treated with different drugs. It uses a combination of CNN and RNN architectures to identify the genes that are differentially expressed between drug-treated and untreated cells and predict drug synergy.\n5. ChEA-Net: ChEA-Net is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of cancer genes. It uses a combination of CNN and RNN architectures to identify the most important protein-protein interactions and predict drug synergy.\n6. Drug-Drug-Interaction Predictor (DDIP): DDIP is a deep learning model that predicts drug synergy by analyzing the gene expression profiles of cancer cells treated with different drugs. It uses a combination of CNN and RNN architectures to identify the genes that are differentially expressed between drug-treated and untreated cells and predict drug synergy.\n7. Drug-Target Interaction Predictor (DTIP): DTIP is a deep learning model that predicts drug syn",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepDrug is a deep learning model that uses a convolutional neural network architecture to predict drug synergy by analyzing protein-protein interaction networks of cancer genes.\n2. Drug2gene uses a recurrent neural network architecture to predict drug synergy by analyzing gene expression profiles of cancer cells treated with different drugs.\n3. Synergypredict is a deep learning model that utilizes a graph convolutional neural network to predict drug synergy from protein-protein interaction networks.\n4. DrugSynergizer combines convolutional and recurrent neural network architectures to predict drug synergy by analyzing gene expression profiles of cancer cells.\n5. ChEA-Net is a deep learning model that employs both CNN and RNN architectures to predict drug synergy through an analysis of protein-protein interaction networks.",
    "llama-2-7b-chat-hf_fact": [
      "DeepDrug is a deep learning model that uses a convolutional neural network architecture to predict drug synergy by analyzing protein-protein interaction networks of cancer genes.",
      "Drug2gene uses a recurrent neural network architecture to predict drug synergy by analyzing gene expression profiles of cancer cells treated with different drugs.",
      "Synergypredict is a deep learning model that utilizes a graph convolutional neural network to predict drug synergy from protein-protein interaction networks.",
      "DrugSynergizer combines convolutional and recurrent neural network architectures to predict drug synergy by analyzing gene expression profiles of cancer cells.",
      "ChEA-Net is a deep learning model that employs both CNN and RNN architectures to predict drug synergy through an analysis of protein-protein interaction networks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about the deep learning model \"DeepDrug,\" it is not possible to verify the accuracy of the statement regarding its architecture and application. \n2. UNKNOWN: The statement about \"Drug2gene\" using a recurrent neural network cannot be verified without additional information about the model and its architecture.\n3. UNKNOWN: The statement about \"Synergypredict\" using graph convolutional neural networks for drug synergy prediction is specific, but without reference to a source or further context, it is not possible to assess the truthfulness of this claim.\n4. UNKNOWN: The details provided about \"DrugSynergizer\" combining convolutional and recurrent neural network architectures sounds plausible, but its truth cannot be determined without more context or reference to the model's specifics.\n5. UNKNOWN: The statement about \"ChEA-Net\" employing both CNN and RNN architectures is very specific; however, without further context or a known reference, the truthfulness of the statement about this model cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "A cloud-based platform for comparing Genome-Wide Association Studies (GWAS) called \"GWASome\" has been developed. GWASome is a web-based platform that enables researchers to compare and integrate data from multiple GWAS, identify shared genetic signals, and perform meta-analyses. It allows users to upload and analyze their own GWAS data, as well as access and analyze publicly available GWAS data from databases such as the National Center for Biotechnology Information's (NCBI) dbGaP and the Psychiatric Genomics Consortium (PGC). GWASome provides a user-friendly interface for researchers to perform complex statistical analyses and visualize results, making it easier to identify genetic associations with complex diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. GWASome is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).\n2. GWASome enables researchers to integrate data from multiple GWAS and perform meta-analyses.\n3. Users can upload and analyze their own GWAS data on GWASome.\n4. GWASome grants access to publicly available GWAS data from sources like the National Center for Biotechnology Information's (NCBI) dbGaP and the Psychiatric Genomics Consortium (PGC).\n5. GWASome provides a user-friendly interface for the visualization of results and performance of complex statistical analyses.",
    "llama-2-7b-chat-hf_fact": [
      "GWASome is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).",
      "GWASome enables researchers to integrate data from multiple GWAS and perform meta-analyses.",
      "Users can upload and analyze their own GWAS data on GWASome.",
      "GWASome grants access to publicly available GWAS data from sources like the National Center for Biotechnology Information's (NCBI) dbGaP and the Psychiatric Genomics Consortium (PGC).",
      "GWASome provides a user-friendly interface for the visualization of results and performance of complex statistical analyses."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe context does not provide sufficient information to verify the specific functionalities and features of a cloud-based platform named \"GWASome.\" Since GWASome is not a widely recognized platform at the time of my training data, and without specific details about this platform and its capabilities, we cannot determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a monoclonal antibody that targets the Wilms' tumor 1 (WT1) protein, which is overexpressed in many types of cancer, including sarcomas. Studies have shown that CMB305 can bind to WT1-positive sarcoma cells and induce cell death through mechanisms that involve the activation of immune cells and the inhibition of cell proliferation.\nCMB305 has been investigated as a potential therapeutic agent for the treatment of sarcomas, including osteosarcoma and soft tissue sarcoma. In clinical trials, CMB305 has been shown to be well-tolerated and to have antitumor activity in patients with advanced sarcomas. However, further research is needed to fully understand the efficacy and safety of CMB305 in this context.\nIn summary, CMB305 can be used against sarcomas by targeting the WT1 protein, which is overexpressed in many sarcoma subtypes. While further research is needed to fully evaluate its potential as a therapeutic agent, CMB305 has shown promise as a potential treatment option for sarcoma patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a monoclonal antibody that targets the Wilms' tumor 1 (WT1) protein.\n2. The WT1 protein is overexpressed in many types of cancer, including sarcomas.\n3. CMB305 can bind to WT1-positive sarcoma cells and induce cell death.\n4. Clinical trials have been conducted to investigate CMB305 as a potential therapeutic agent for the treatment of sarcomas.\n5. CMB305 has shown to be well-tolerated and to have antitumor activity in patients with advanced sarcomas.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a monoclonal antibody that targets the Wilms' tumor 1 (WT1) protein.",
      "The WT1 protein is overexpressed in many types of cancer, including sarcomas.",
      "CMB305 can bind to WT1-positive sarcoma cells and induce cell death.",
      "Clinical trials have been conducted to investigate CMB305 as a potential therapeutic agent for the treatment of sarcomas.",
      "CMB305 has shown to be well-tolerated and to have antitumor activity in patients with advanced sarcomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE \n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nPlease note that while I stated that it is TRUE that clinical trials have been conducted for CMB305, the outcomes of such trials, such as tolerance and antitumor activity, can change with new data and results from ongoing research. As such, without the most current data, statements about the efficacy and tolerability are deemed UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Behçet's triad, is a clinical syndrome that is commonly associated with Behçet's disease, a chronic inflammatory disorder that affects the blood vessels and can cause a variety of symptoms, including:\n1. Uveitis (inflammation of the eye): This is the most common manifestation of the Saint's Triad, and it can cause symptoms such as eye pain, redness, sensitivity to light, and blurred vision.\n2. Mucous membrane ulceration: Behçet's disease can cause ulcers to develop on the mucous membranes, including the mouth, nose, and genitals. These ulcers can be painful and can make it difficult to eat, breathe, or perform other daily activities.\n3. Arthritis: Behçet's disease can cause joint pain, swelling, and stiffness, similar to rheumatoid arthritis. The joints most commonly affected are those in the hands and feet.\nTogether, these three symptoms make up the Saint's Triad, which is often used to diagnose Behçet's disease. However, not everyone with Behçet's disease will develop all three symptoms, and some people may have additional symptoms not included in the triad.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad is associated with Behçet's disease.\n2. Uveitis is the most common manifestation of the Saint's Triad, potentially causing eye pain, redness, sensitivity to light, and blurred vision.\n3. Mucous membrane ulceration in areas such as the mouth, nose, and genitals is a manifestation of the Saint's Triad.\n4. Arthritis affecting the joints in the hands and feet can be a manifestation of the Saint's Triad in Behçet's disease.\n5. The Saint's Triad is used to diagnose Behçet's disease, although not everyone with the disease develops all three symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad is associated with Behçet's disease.",
      "Uveitis is the most common manifestation of the Saint's Triad, potentially causing eye pain, redness, sensitivity to light, and blurred vision.",
      "Mucous membrane ulceration in areas such as the mouth, nose, and genitals is a manifestation of the Saint's Triad.",
      "Arthritis affecting the joints in the hands and feet can be a manifestation of the Saint's Triad in Behçet's disease.",
      "The Saint's Triad is used to diagnose Behçet's disease, although not everyone with the disease develops all three symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct term is the \"MAGIC syndrome\" or \"Behçet's triad,\" which consists of recurrent oral aphthous ulcers, genital ulcers, and uveitis.\n2. TRUE\n3. TRUE\n4. UNKNOWN: While arthritis can be a symptom of Behçet's disease, it is not traditionally part of the classic triad mentioned in statement 1. The classic triad includes oral aphthous ulcers, genital ulcers, and uveitis. Arthritis may still occur but is not part of the \"Saint's Triad\" as the question seems to mistake.\n5. FALSE [correction]: The term \"Saint's Triad\" appears to be incorrect or a misunderstanding. Behçet's disease can be diagnosed with a combination of clinical criteria, including recurrent oral ulcers, genital ulcers, and eye inflammation (uveitis), along with other potential systemic involvements. The symptoms mentioned can be part of the diagnostic criteria, but not under the label \"Saint's Triad.\" Also, the International Criteria for Behçet's Disease (ICBD) includes a points system for various symptoms to aid in diagnosis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients. Studies have shown that high levels of LY6K expression are associated with improved overall survival, disease-free survival, and response to chemotherapy in NSCLC patients. This is thought to be due to the anti-inflammatory and anti-tumorigenic effects of LY6K, which can help to suppress the growth and proliferation of cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. High levels of LY6K expression are associated with improved overall survival in NSCLC patients.\n3. High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.\n4. High levels of LY6K expression are associated with improved response to chemotherapy in NSCLC patients.\n5. LY6K is thought to have anti-inflammatory and anti-tumorigenic effects which help suppress the growth and proliferation of cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "High levels of LY6K expression are associated with improved overall survival in NSCLC patients.",
      "High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.",
      "High levels of LY6K expression are associated with improved response to chemotherapy in NSCLC patients.",
      "LY6K is thought to have anti-inflammatory and anti-tumorigenic effects which help suppress the growth and proliferation of cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K has been associated with poor prognosis for non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: High levels of LY6K expression are generally associated with poor overall survival in NSCLC patients.\n3. FALSE [correction]: High levels of LY6K expression are generally associated with poor disease-free survival in NSCLC patients.\n4. UNKNOWN\n5. FALSE [correction]: LY6K is often viewed as having pro-tumorigenic effects which promote the growth and proliferation of cancer cells.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "During cytokinesis, the CDK (cyclin-dependent kinase) inhibitor p21 is dephosphorylated, leading to the activation of CDKs and the progression of cytokinesis. Here are some other CDK targets that are dephosphorylated during cytokinesis:\n1. Cyclin-dependent kinase 1 (CDK1): CDK1 is a key regulator of the G2/M checkpoint and is inhibited by p21 during cytokinesis.\n2. Cyclin-dependent kinase 2 (CDK2): CDK2 is involved in the regulation of the G1/S checkpoint and is also inhibited by p21 during cytokinesis.\n3. Cyclin-dependent kinase 5 (CDK5): CDK5 is involved in the regulation of microtubule dynamics and is inhibited by p21 during cytokinesis.\n4. Polo-like kinase 1 (PLK1): PLK1 is involved in the regulation of microtubule dynamics and is inhibited by p21 during cytokinesis.\n5. Aurora kinase A (AURKA): AURKA is involved in the regulation of microtubule dynamics and is inhibited by p21 during cytokinesis.\nBy dephosphorylating these CDKs, p21 allows for the proper progression of cytokinesis by inhibiting the activity of these enzymes and promoting the proper separation of the daughter cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. The CDK inhibitor p21 is dephosphorylated during cytokinesis.\n2. CDK1 is dephosphorylated and inhibited by p21 during cytokinesis.\n3. CDK2 is involved in the G1/S checkpoint regulation and inhibited by p21 during cytokinesis.\n4. CDK5 is associated with microtubule dynamics regulation and inhibited by p21 during cytokinesis.\n5. Polo-like kinase 1 (PLK1) and Aurora kinase A (AURKA) are both involved in microtubule dynamics regulation and inhibited by p21 during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "The CDK inhibitor p21 is dephosphorylated during cytokinesis.",
      "CDK1 is dephosphorylated and inhibited by p21 during cytokinesis.",
      "CDK2 is involved in the G1/S checkpoint regulation and inhibited by p21 during cytokinesis.",
      "CDK5 is associated with microtubule dynamics regulation and inhibited by p21 during cytokinesis.",
      "Polo-like kinase 1 (PLK1) and Aurora kinase A (AURKA) are both involved in microtubule dynamics regulation and inhibited by p21 during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The CDK inhibitor p21 is not directly involved in the process of dephosphorylation during cytokinesis. It acts mainly by inhibiting cyclin-dependent kinase (CDK) activities.\n2. FALSE [correction]: CDK1 is not dephosphorylated by p21; instead, CDK1 activity is inhibited when it is bound by p21. Phosphatases, not p21, dephosphorylate CDK1.\n3. TRUE: CDK2 is involved in the G1/S checkpoint regulation, and it can be inhibited by p21. However, the part of the statement mentioning inhibition by p21 during cytokinesis is more complex since p21 inhibits CDK2 not specifically during cytokinesis but as part of cell cycle control mechanisms generally.\n4. FALSE [correction]: CDK5 is indeed associated with microtubule dynamics and neuronal functions, but its regulation by p21 is not typically emphasized in the context of cytokinesis. CDK5's primary roles are in the nervous system.\n5. FALSE [correction]: While Polo-like kinase 1 (PLK1) and Aurora kinase A (AURKA) are both involved in microtubule dynamics, their inhibition by p21 during cytokinesis is not well-established. They are primarily regulated by other mechanisms and proteins.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a drug that acts as a potent and selective inhibitor of the enzyme glycogen synthase kinase-3 (GSK-3). GSK-3 is a key regulator of various cellular processes, including cell signaling, metabolism, and gene expression. Xanamem has been shown to have potential therapeutic applications in the treatment of various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a drug that inhibits the enzyme glycogen synthase kinase-3 (GSK-3).\n2. Glycogen synthase kinase-3 (GSK-3) is involved in regulating cellular processes such as signaling, metabolism, and gene expression.\n3. Xanamem has potential therapeutic applications in treating diseases like cancer, neurodegenerative disorders, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a drug that inhibits the enzyme glycogen synthase kinase-3 (GSK-3).",
      "Glycogen synthase kinase-3 (GSK-3) is involved in regulating cellular processes such as signaling, metabolism, and gene expression.",
      "Xanamem has potential therapeutic applications in treating diseases like cancer, neurodegenerative disorders, and metabolic disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n\nWithout specific knowledge of the drug Xanamem, including whether it exists or is theoretical and information regarding its particular applications and efficacy, it is not possible to verify the first and third statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "In yeast, the interaction between Hof1 and Cyk3 plays a crucial role in regulating the cellular response to oxidative stress. Hof1 (Hydrogen Peroxide-inducible Factor 1) is a transcription factor that is activated in response to hydrogen peroxide (H2O2) and other oxidants, while Cyk3 (Cyclic AMP-dependent Protein Kinase Kinase 3) is a protein kinase that is involved in the regulation of various cellular processes, including cell signaling and stress responses.\nThe interaction between Hof1 and Cyk3 is important for the regulation of the cellular response to oxidative stress in yeast. When Hof1 is activated in response to oxidative stress, it translocates to the nucleus and binds to specific DNA sequences, leading to the activation of target genes involved in the response to oxidative stress. Cyk3 is required for the proper activation of these target genes, as it phosphorylates and activates the transcriptional coactivator CBP (CREB-binding protein), which is necessary for the recruitment of RNA polymerase to the promoter regions of the target genes.\nIn addition to its role in the response to oxidative stress, the Hof1-Cyk3 interaction also plays a role in the regulation of cell growth and proliferation. Cyk3 has been shown to phosphorylate and activate the protein kinase A (PKA) pathway, which is involved in the regulation of cell growth and proliferation. The interaction between Hof1 and Cyk3 may also play a role in the regulation of the PKA pathway, as Hof1 has been shown to inhibit the activity of PKA in some contexts.\nOverall, the interaction between Hof1 and Cyk3 is an important aspect of the cellular response to oxidative stress in yeast, and dysregulation of this interaction has been implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hof1 (Hydrogen Peroxide-inducible Factor 1) is a transcription factor in yeast that is activated in response to hydrogen peroxide (H2O2) and other oxidants.\n2. Cyk3 (Cyclic AMP-dependent Protein Kinase Kinase 3) is a protein kinase involved in regulating cellular processes such as cell signaling and stress responses in yeast.\n3. Hof1 translocates to the nucleus and binds to specific DNA sequences, activating target genes involved in oxidative stress response when activated.\n4. Cyk3 phosphorylates and activates the transcriptional coactivator CBP (CREB-binding protein) necessary for RNA polymerase recruitment to the promoter regions of oxidative stress response genes.\n5. Cyk3 also phosphorylates and activates the protein kinase A (PKA) pathway, which is involved in regulating cell growth and proliferation in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "Hof1 (Hydrogen Peroxide-inducible Factor 1) is a transcription factor in yeast that is activated in response to hydrogen peroxide (H2O2) and other oxidants.",
      "Cyk3 (Cyclic AMP-dependent Protein Kinase Kinase 3) is a protein kinase involved in regulating cellular processes such as cell signaling and stress responses in yeast.",
      "Hof1 translocates to the nucleus and binds to specific DNA sequences, activating target genes involved in oxidative stress response when activated.",
      "Cyk3 phosphorylates and activates the transcriptional coactivator CBP (CREB-binding protein) necessary for RNA polymerase recruitment to the promoter regions of oxidative stress response genes.",
      "Cyk3 also phosphorylates and activates the protein kinase A (PKA) pathway, which is involved in regulating cell growth and proliferation in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Cyk3 (Cytokinesis Protein 3) is involved in the regulation of cytokinesis in yeast, not predominantly in cell signaling and stress responses. The name might suggest involvement in cyclic AMP-dependent protein kinase pathways, but Cyk3's actual function is in the regulation of cell division.\n3. TRUE\n4. FALSE [correction]: Cyk3 does not phosphorylate and activate CBP (CREB-binding protein), which is a transcriptional coactivator in higher eukaryotes, not in yeast. Yeast do not have CBP but have other transcriptional regulators. Also, the primary functions of Cyk3 are not related to this process.\n5. FALSE [correction]: Cyk3's primary role is not related to the phosphorylation and activation of the protein kinase A (PKA) pathway. Although the PKA pathway is indeed involved in regulating cell growth and proliferation in yeast, Cyk3's known functions are associated with cytokinesis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including gastric cancer. Some T-UCRs that have been studied in gastric cancer include:\n1. TARDBP-AS1: This T-UCR has been shown to be upregulated in gastric cancer and promotes cancer cell proliferation and migration.\n2. HOTAIR: This T-UCR has been implicated in the development and progression of gastric cancer, and its overexpression is associated with poor prognosis.\n3. MALAT1: This T-UCR has been shown to be upregulated in gastric cancer and promotes cancer cell migration and invasion.\n4. MKLF1-AS1: This T-UCR has been implicated in the development and progression of gastric cancer, and its overexpression is associated with poor prognosis.\n5. XBP1-AS1: This T-UCR has been shown to be upregulated in gastric cancer and promotes cancer cell proliferation and migration.\nIt's worth noting that the specific T-UCRs that are implicated in gastric cancer may vary depending on the stage and subtype of the cancer, as well as the individual patient. Further research is needed to fully understand the role of T-UCRs in gastric cancer and to identify potential therapeutic targets for this disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. TARDBP-AS1 is a T-UCR that has been shown to be upregulated in gastric cancer and promotes cancer cell proliferation and migration.\n2. The T-UCR HOTAIR has been implicated in the development and progression of gastric cancer and is associated with a poor prognosis when overexpressed.\n3. MALAT1 is a T-UCR that has been shown to be upregulated in gastric cancer and promotes cancer cell migration and invasion.\n4. MKLF1-AS1 is a T-UCR implicated in the development and progression of gastric cancer, and its overexpression is associated with poor prognosis.\n5. XBP1-AS1 is a T-UCR that has been shown to be upregulated in gastric cancer and promotes cancer cell proliferation and migration.",
    "llama-2-7b-chat-hf_fact": [
      "TARDBP-AS1 is a T-UCR that has been shown to be upregulated in gastric cancer and promotes cancer cell proliferation and migration.",
      "The T-UCR HOTAIR has been implicated in the development and progression of gastric cancer and is associated with a poor prognosis when overexpressed.",
      "MALAT1 is a T-UCR that has been shown to be upregulated in gastric cancer and promotes cancer cell migration and invasion.",
      "MKLF1-AS1 is a T-UCR implicated in the development and progression of gastric cancer, and its overexpression is associated with poor prognosis.",
      "XBP1-AS1 is a T-UCR that has been shown to be upregulated in gastric cancer and promotes cancer cell proliferation and migration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nThe statements primarily refer to different T-UCRs (Transcribed Ultraconserved Regions), which are a specific class of noncoding RNA molecules. These statements are very specific and would require access to the latest scientific research to verify each one fully. Without the current research data or publications, the validity of the statement about MKLF1-AS1 cannot be confirmed. However, the statements regarding TARDBP-AS1, HOTAIR, and MALAT1 being associated with upregulation in gastric cancer, and their roles in promoting proliferation, migration, and invasion, are in line with findings from various studies in the field of cancer biology. The statement about XBP1-AS1 is also consistent with research findings in diseases such as cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects multiple organ systems. The LSI was developed to provide a standardized way of evaluating the severity of SLE and to help clinicians and researchers compare the results of different studies.\nThe LSI includes the following components:\n1. Physical examination findings, including the presence of malar rash, photosensitivity, and other organ-specific manifestations.\n2. Laboratory test results, including the levels of autoantibodies (antibodies produced by the immune system that attack the body's own tissues), inflammatory markers (such as erythrocyte sedimentation rate and C-reactive protein), and kidney and liver function tests.\n3. Disease activity scores, such as the SLE Responder Index (SRI) or the British Isles Lupus Activity Group (BILD) score, which assess the severity of SLE based on the patient's symptoms, laboratory test results, and organ involvement.\n4. Patient-reported outcomes, such as the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) or the Quality of Life in SLE (QoL-SLE) questionnaire, which assess the patient's subjective experience of SLE symptoms and their impact on daily life.\nThe LSI is calculated by assigning points for each of these components based on a predetermined scoring system, with higher scores indicating greater disease severity. The LSI has been shown to be a useful tool for evaluating the severity of SLE and for monitoring the effectiveness of treatment interventions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed to standardize the evaluation of SLE severity and to aid in the comparison of research study results.\n3. Components of the LSI include physical examination findings like the presence of malar rash and photosensitivity.\n4. The LSI incorporates laboratory test results, including levels of autoantibodies and inflammatory markers.\n5. Disease activity scores such as the SLE Responder Index (SRI) or the British Isles Lupus Activity Group (BILD) score are part of the LSI.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed to standardize the evaluation of SLE severity and to aid in the comparison of research study results.",
      "Components of the LSI include physical examination findings like the presence of malar rash and photosensitivity.",
      "The LSI incorporates laboratory test results, including levels of autoantibodies and inflammatory markers.",
      "Disease activity scores such as the SLE Responder Index (SRI) or the British Isles Lupus Activity Group (BILD) score are part of the LSI."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The existence of a specific \"Lupus Severity Index\" (LSI) needs verification, as there are various scales and tools to assess the severity and activity of SLE, such as the SLE Disease Activity Index (SLEDAI), the Systemic Lupus Activity Measure (SLAM), etc.\n2. UNKNOWN: Given the uncertainty about the specific existence of the LSI, the intention behind its development cannot be accurately assessed without further information.\n3. UNKNOWN: If an LSI exists as described, it might include such physical examination findings, but the statement cannot be verified without specific knowledge of this index.\n4. UNKNOWN: Similarly, this statement about the inclusion of laboratory results in the LSI could be reasonable for a disease severity index, but cannot be verified without concrete information about the LSI.\n5. FALSE [correction]: The SLE Responder Index (SRI) and the British Isles Lupus Activity Group (BILAG) score are separate indices used to measure SLE activity and are not components of any single severity scale such as a putative LSI.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several human disorders caused by de novo mutations, including:\n1. Nephrogenic diabetes insipidus (NDI): ZSWIM6 mutations are a common cause of NDI, a rare genetic disorder characterized by the inability to regulate fluid levels in the body.\n2. Bartter syndrome type 3: ZSWIM6 mutations have been identified in individuals with Bartter syndrome type 3, a rare kidney disorder that affects the balance of electrolytes in the body.\n3. Hypokalemic periodic paralysis (HypoPP): ZSWIM6 mutations have been found to cause HypoPP, a rare genetic disorder characterized by muscle weakness and paralysis triggered by low potassium levels.\n4. Familial atypical teratozoospermia (FATZ): ZSWIM6 mutations have been identified in some cases of FATZ, a rare genetic disorder characterized by abnormal sperm morphology.\nThese disorders are typically caused by de novo mutations in the ZSWIM6 gene, which are not present in both parents and are inherited as a single mutation in the affected individual.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nephrogenic diabetes insipidus is a rare genetic disorder associated with mutations in the ZSWIM6 gene.\n2. Bartter syndrome type 3 has been identified in individuals with mutations in the ZSWIM6 gene.\n3. Hypokalemic periodic paralysis is a genetic disorder caused by mutations in the ZSWIM6 gene.\n4. Familial atypical teratozoospermia has been linked to mutations in the ZSWIM6 gene.\n5. De novo mutations in the ZSWIM6 gene are not present in both parents of the affected individual.",
    "llama-2-7b-chat-hf_fact": [
      "Nephrogenic diabetes insipidus is a rare genetic disorder associated with mutations in the ZSWIM6 gene.",
      "Bartter syndrome type 3 has been identified in individuals with mutations in the ZSWIM6 gene.",
      "Hypokalemic periodic paralysis is a genetic disorder caused by mutations in the ZSWIM6 gene.",
      "Familial atypical teratozoospermia has been linked to mutations in the ZSWIM6 gene.",
      "De novo mutations in the ZSWIM6 gene are not present in both parents of the affected individual."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Nephrogenic diabetes insipidus can be associated with mutations in several genes, including the ZSWIM6 gene, albeit it is not the most common genetic cause.\n2. FALSE [correction]: Bartter syndrome type 3 is associated with mutations in the CLCNKB gene, not the ZSWIM6 gene.\n3. FALSE [correction]: Hypokalemic periodic paralysis is typically caused by mutations in the CACNA1S or SCN4A genes, not the ZSWIM6 gene.\n4. UNKNOWN: There is limited information available regarding the link between familial atypical teratozoospermia and mutations in the ZSWIM6 gene. Further research would be required to confirm such an association.\n5. TRUE: De novo mutations are changes that occur in an individual's genome for the first time and are not inherited from either parent. This implies that neither parent of the affected individual carries the mutation in their own genetic material.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is used to classify diseases related to the nervous system, particularly those that affect the brain and spinal cord. The classification system was developed by Dr. Paul Koos and is commonly used in neurology to diagnose and manage neurological disorders.\nSome examples of diseases that can be classified using the Koos Classification include:\n1. Stroke and cerebrovascular diseases (Koos I)\n2. Dementia and other cognitive disorders (Koos II)\n3. Parkinson's disease and other movement disorders (Koos III)\n4. Seizure disorders (Koos IV)\n5. Multiple sclerosis and other demyelinating diseases (Koos V)\n6. Brain and spinal cord injuries (Koos VI)\n7. Neurodegenerative diseases (Koos VII)\n8. Infections of the nervous system (Koos VIII)\n9. Tumors of the nervous system (Koos IX)\n10. Autoimmune and inflammatory diseases of the nervous system (Koos X)\nEach of these categories represents a distinct group of disorders that share common features and characteristics, and the Koos Classification provides a useful framework for organizing and understanding these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify diseases related to the nervous system.\n2. Dr. Paul Koos developed the Koos Classification system.\n3. Stroke and cerebrovascular diseases are classified under Koos I in the Koos Classification.\n4. Dementia and other cognitive disorders are classified under Koos II in the Koos Classification.\n5. Parkinson's disease and other movement disorders are classified under Koos III in the Koos Classification.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify diseases related to the nervous system.",
      "Dr. Paul Koos developed the Koos Classification system.",
      "Stroke and cerebrovascular diseases are classified under Koos I in the Koos Classification.",
      "Dementia and other cognitive disorders are classified under Koos II in the Koos Classification.",
      "Parkinson's disease and other movement disorders are classified under Koos III in the Koos Classification."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is used to classify vestibular schwannomas (also known as acoustic neuromas) based on their size and relationship to the brainstem and cerebellum, not diseases related to the nervous system in general.\n2. UNKNOWN\n3. FALSE [correction]: Stroke and cerebrovascular diseases are not classified under Koos I in the Koos Classification since the Koos Classification specifically pertains to vestibular schwannomas.\n4. FALSE [correction]: Dementia and other cognitive disorders are not classified under Koos II as the Koos Classification does not concern these conditions.\n5. FALSE [correction]: Parkinson's disease and other movement disorders are not classified under Koos III in the Koos Classification as it is not relevant to movement disorders but rather to the classification of vestibular schwannomas.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a potent and selective inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase). In vivo, AZD8601 has been shown to have a range of effects, including:\n1. Inhibition of tumor growth: AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, both in vitro and in vivo.\n2. Induction of apoptosis: AZD8601 has been shown to induce apoptosis (programmed cell death) in tumor cells, which can lead to a decrease in tumor volume.\n3. Inhibition of angiogenesis: AZD8601 has been shown to inhibit the formation of new blood vessels, which are essential for tumor growth and survival.\n4. Enhancement of chemotherapy: AZD8601 has been shown to enhance the effectiveness of certain chemotherapeutic agents, such as paclitaxel, in inhibiting tumor growth.\n5. Immune modulation: AZD8601 has been shown to modulate the immune response, including the activation of immune cells and the production of cytokines, which can help to combat cancer.\n6. Anti-inflammatory effects: AZD8601 has been shown to have anti-inflammatory effects, which can help to reduce inflammation in various tissues and organs.\n7. Neuroprotection: AZD8601 has been shown to have neuroprotective effects, which can help to protect against neurodegenerative diseases such as Alzheimer's and Parkinson's.\nIt is important to note that the effects of AZD8601 can vary depending on the specific context in which it is used, and more research is needed to fully understand its mechanisms of action in different tissues and organs.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is an inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase).\n2. AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer.\n3. AZD8601 has been reported to induce apoptosis in tumor cells.\n4. AZD8601 has been found to inhibit angiogenesis, the formation of new blood vessels.\n5. AZD8601 has demonstrated the ability to enhance the effectiveness of chemotherapeutic agents like paclitaxel in inhibiting tumor growth.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is an inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase).",
      "AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer.",
      "AZD8601 has been reported to induce apoptosis in tumor cells.",
      "AZD8601 has been found to inhibit angiogenesis, the formation of new blood vessels.",
      "AZD8601 has demonstrated the ability to enhance the effectiveness of chemotherapeutic agents like paclitaxel in inhibiting tumor growth."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not an inhibitor of PI3K; it is an mRNA therapy designed to encode for vascular endothelial growth factor A (VEGF-A).\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: While AZD8601 is involved in the process related to blood vessels, it is not an inhibitor of angiogenesis. Instead, as an mRNA therapy for VEGF-A, it aims to promote angiogenesis, which could be beneficial in conditions such as heart disease by promoting the generation of new blood vessels.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (Spatially-Organized High-Frequency Structures) are created through a process called \"self-organization\" in which the DNA molecule is able to fold into specific patterns and structures without the need for any external influence or guidance. This process is driven by the interactions between the DNA molecule and its surrounding environment, including other proteins and molecules.\nThere are several factors that can contribute to the formation of SAHFs, including:\n1. Chromatin structure: The way in which the DNA molecule is packaged into chromatin can influence the formation of SAHFs. For example, the presence of compact chromatin structures can create a more stable environment that is more likely to form SAHFs.\n2. DNA sequence: The sequence of the DNA molecule can also play a role in the formation of SAHFs. Certain sequences can create a more stable or more flexible structure that is more likely to form SAHFs.\n3. Protein binding: The presence of certain proteins can influence the formation of SAHFs by altering the interactions between the DNA molecule and its surrounding environment. For example, proteins that bind to specific sequences of the DNA molecule can create a more stable or more flexible structure that is more likely to form SAHFs.\n4. Enzymatic activity: Enzymes that modify the DNA molecule, such as methyltransferases or histone-modifying enzymes, can also influence the formation of SAHFs. For example, the presence of certain methyl groups on the DNA molecule can create a more stable or more flexible structure that is more likely to form SAHFs.\n5. Environmental factors: Environmental factors, such as temperature, pH, or the presence of certain ions, can also influence the formation of SAHFs. For example, certain temperatures or ion concentrations can alter the stability of the DNA molecule, making it more or less likely to form SAHFs.\nOverall, the formation of SAHFs is a complex process that is influenced by a variety of factors, including the structure of the DNA molecule, the presence of certain proteins and molecules, and environmental factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs are created through a process called \"self-organization.\"\n2. The chromatin structure can influence the formation of SAHFs, with compact chromatin structures likely to create a more stable environment for SAHF formation.\n3. The DNA sequence can affect the likelihood of forming SAHFs, where certain sequences may lead to more stable or flexible structures.\n4. Protein binding to specific sequences of the DNA molecule can affect the formation of SAHFs, potentially creating more stable or flexible structures.\n5. Environmental factors such as temperature, pH, or ion concentrations can influence the stability of the DNA molecule and the formation of SAHFs.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs are created through a process called \"self-organization.\"",
      "The chromatin structure can influence the formation of SAHFs, with compact chromatin structures likely to create a more stable environment for SAHF formation.",
      "The DNA sequence can affect the likelihood of forming SAHFs, where certain sequences may lead to more stable or flexible structures.",
      "Protein binding to specific sequences of the DNA molecule can affect the formation of SAHFs, potentially creating more stable or flexible structures.",
      "Environmental factors such as temperature, pH, or ion concentrations can influence the stability of the DNA molecule and the formation of SAHFs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - SAHFs (Senescence-Associated Heterochromatin Foci) are indeed formed through a process of self-organization during cellular senescence.\n2. TRUE - Chromatin structure can influence the formation of SAHFs. Compact chromatin is typically associated with heterochromatic regions that are more likely to contribute to SAHF formation, which are characteristic of senescent cells.\n3. TRUE - The DNA sequence can affect the likelihood of forming SAHFs since different sequences may have varying propensities for forming the structures associated with heterochromatin.\n4. TRUE - Protein binding to specific DNA sequences does have an impact on chromatin structure and thus can influence the formation of SAHFs. Various proteins, including chromatin remodelers and modifiers, can alter the chromatin landscape and possibly the stability of SAHFs.\n5. TRUE - Environmental factors such as temperature, pH, or ion concentrations can influence the stability of the DNA molecule and thus have the potential to affect chromatin structure and SAHF formation, although the specifics will depend on the particular conditions and the cellular context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95, Drosophila homologue of the mammalian DlgA gene) domain is a protein-binding domain found in the SATB1 (SALL4-associated transcription factor 1) protein. SATB1 is a transcription factor that plays a crucial role in the regulation of gene expression during embryonic development and adult tissue homeostasis. The PDZ domain of SATB1 is involved in the following functions:\n1. Protein-protein interactions: The PDZ domain of SATB1 binds to other proteins, including the cytoskeleton protein PDZK1 (also known as PDZ-RhoGAP), which helps regulate the localization and activity of SATB1.\n2. Subcellular localization: The PDZ domain of SATB1 directs the protein to specific subcellular regions, such as the nuclear envelope and the cytoskeleton, where it can interact with other proteins and regulate their activity.\n3. Protein degradation: The PDZ domain of SATB1 can also mediate the ubiquitination and degradation of target proteins, contributing to the regulation of gene expression and cellular signaling.\nIn summary, the PDZ domain of SATB1 plays a multifaceted role in regulating protein-protein interactions, subcellular localization, and protein degradation, all of which contribute to the overall function of SATB1 in regulating gene expression and cellular behavior.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain of SATB1 binds to other proteins, including the cytoskeleton protein PDZK1.\n2. The PDZ domain of SATB1 directs the protein to specific subcellular regions, such as the nuclear envelope and the cytoskeleton.\n3. The PDZ domain of SATB1 can mediate the ubiquitination and degradation of target proteins.\n4. SATB1 is a transcription factor that plays a crucial role in the regulation of gene expression during embryonic development and adult tissue homeostasis.\n5. The PDZ domain stands for PSD-95, Drosophila homologue of the mammalian DlgA gene.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain of SATB1 binds to other proteins, including the cytoskeleton protein PDZK1.",
      "The PDZ domain of SATB1 directs the protein to specific subcellular regions, such as the nuclear envelope and the cytoskeleton.",
      "The PDZ domain of SATB1 can mediate the ubiquitination and degradation of target proteins.",
      "SATB1 is a transcription factor that plays a crucial role in the regulation of gene expression during embryonic development and adult tissue homeostasis.",
      "The PDZ domain stands for PSD-95, Drosophila homologue of the mammalian DlgA gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: The PDZ domain stands for \"PSD-95, Dlg (Discs large), ZO-1 (Zonula occludens-1).\". It is named after the first few proteins in which such a domain was found: the post-synaptic density protein 95 (PSD-95) in mammals, the Drosophila disc large tumor suppressor (Dlg1), and the tight junction protein ZO-1 in mammals.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS (Block-and-Replace Incremental Scene Synthesis) technique is a computer graphics technique used to generate photorealistic images of scenes that have been partially destroyed or damaged. The basis of the BLISS technique is to block out the original scene, and then replace the blocked-out regions with new, detailed elements, such as buildings, trees, or other objects, in a way that is visually coherent and realistic. The technique is often used in computer-generated imagery (CGI) for movies, video games, and other applications where realistic destruction and damage are important.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is used in computer graphics to generate photorealistic images of partially destroyed or damaged scenes.\n2. The basis of the BLISS technique involves blocking out the original scene.\n3. The BLISS technique involves replacing blocked-out regions with new, detailed elements.\n4. Elements added using the BLISS technique may include buildings, trees, or other objects.\n5. The BLISS technique is used in CGI for movies, video games, and other applications requiring realistic representation of destruction and damage.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is used in computer graphics to generate photorealistic images of partially destroyed or damaged scenes.",
      "The basis of the BLISS technique involves blocking out the original scene.",
      "The BLISS technique involves replacing blocked-out regions with new, detailed elements.",
      "Elements added using the BLISS technique may include buildings, trees, or other objects.",
      "The BLISS technique is used in CGI for movies, video games, and other applications requiring realistic representation of destruction and damage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The BLISS technique is not a known standard technique in computer graphics for generating photorealistic images of partially destroyed or damaged scenes. The term does not correspond to a widely recognized method in that context.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven that the initial statement about the BLISS technique being used in computer graphics is false, the subsequent statements about the specifics of the technique cannot be verified and are therefore marked as UNKNOWN. The term BLISS might be hypothetical, not well-known, or simply incorrect in this context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Sure! Here are three NK3R (Neuromedin K receptor) antagonists:\n1. A-841715: A potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including migraine, nausea, and vomiting.\n2. MK-0357: A potent and selective NK3R antagonist that has been shown to have potential in the treatment of migraine and other disorders.\n3. LY-392998: A potent and selective NK3R antagonist that has been shown to have potential in the treatment of migraine, nausea, and vomiting.",
    "llama-2-7b-chat-hf_fact_raw": "1. A-841715 is a potent and selective NK3R antagonist.\n2. MK-0357 is a potent and selective NK3R antagonist with potential in treating migraine and other disorders.\n3. LY-392998 is a potent and selective NK3R antagonist with potential in treating migraine, nausea, and vomiting.",
    "llama-2-7b-chat-hf_fact": [
      "A-841715 is a potent and selective NK3R antagonist.",
      "MK-0357 is a potent and selective NK3R antagonist with potential in treating migraine and other disorders.",
      "LY-392998 is a potent and selective NK3R antagonist with potential in treating migraine, nausea, and vomiting."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information or context to validate the statement about A-841715, I cannot determine if it is true or false.\n2. UNKNOWN: Similarly, without additional details or context regarding MK-0357, its properties, and potential clinical uses, the truth value of this statement cannot be ascertained.\n3. UNKNOWN: The statement about LY-392998 cannot be verified without appropriate references or scientific data about the substance and its efficacy in treating specified conditions.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-911865.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-911865 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-911865 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, also known as Shanchol, is a cholera vaccine that has been shown to provide protection against moderate to severe cholera in clinical trials.\nThe protective efficacy of Vaxchora against moderate to severe cholera was evaluated in a phase 3 clinical trial conducted in Bangladesh, where cholera is a major public health concern. The trial enrolled 32,000 adults aged 18-60 years, with 16,000 participants receiving the vaccine and 16,000 receiving a placebo. The participants were followed for 12 months after vaccination to assess the incidence of cholera.\nThe results of the trial showed that Vaxchora was highly effective in preventing moderate to severe cholera, with a vaccine efficacy of 80.5% (95% CI: 71.2-87.9) against culture-confirmed cholera. This means that among participants who received the vaccine, 80.5% were protected against developing moderate to severe cholera, compared to 71.2-87.9% in the placebo group.\nAdditionally, Vaxchora was found to be 64.3% (95% CI: 54.5-73.5) effective in preventing culture-confirmed cholera in children aged 2-17 years, and 67.7% (95% CI: 58.4-76.7) effective in preventing cholera in pregnant women.\nOverall, the protective efficacy of Vaxchora against moderate to severe cholera is high, and it has the potential to be an important tool in controlling cholera outbreaks and reducing the burden of this disease in endemic regions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is also known as Shanchol and is a vaccine for cholera.\n2. A phase 3 clinical trial for Vaxchora's efficacy was conducted in Bangladesh with 32,000 adult participants aged 18-60.\n3. The trial showed a vaccine efficacy of 80.5% against culture-confirmed moderate to severe cholera in adults who received Vaxchora.\n4. Vaxchora was found to be 64.3% effective against culture-confirmed cholera in children aged 2-17 years.\n5. The vaccine also showed a 67.7% effectiveness in preventing cholera in pregnant women.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is also known as Shanchol and is a vaccine for cholera.",
      "A phase 3 clinical trial for Vaxchora's efficacy was conducted in Bangladesh with 32,000 adult participants aged 18-60.",
      "The trial showed a vaccine efficacy of 80.5% against culture-confirmed moderate to severe cholera in adults who received Vaxchora.",
      "Vaxchora was found to be 64.3% effective against culture-confirmed cholera in children aged 2-17 years.",
      "The vaccine also showed a 67.7% effectiveness in preventing cholera in pregnant women."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Vaxchora and Shanchol are different vaccines for cholera.\n2. FALSE [correction]: Without details of a specific phase 3 clinical trial's design and results, the statement cannot be verified.\n3. UNKNOWN: The statement provides specific data, but without source verification, the true efficacy of Vaxchora in such a trial cannot be confirmed.\n4. UNKNOWN: As with the previous statement, specific efficacy data is provided, but the accuracy of this data cannot be confirmed without source information.\n5. UNKNOWN: The effectiveness of the vaccine in pregnant women cannot be verified without proper citation or detailed study results.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine, also known as the \"Shanchol\" vaccine, which was approved by the US Food and Drug Administration (FDA) in 2007. This vaccine is made by Sanofi Pasteur and is recommended for adults aged 18 through 64 years who are traveling to areas where cholera is common.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was an oral vaccine known as \"Shanchol.\"\n2. The \"Shanchol\" cholera vaccine was approved by the US Food and Drug Administration (FDA) in 2007.\n3. The manufacturer of the \"Shanchol\" vaccine is Sanofi Pasteur.\n4. The \"Shanchol\" cholera vaccine is recommended for adults aged 18 through 64 years.\n5. The vaccine is suggested for individuals traveling to areas where cholera is common.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was an oral vaccine known as \"Shanchol.\"",
      "The \"Shanchol\" cholera vaccine was approved by the US Food and Drug Administration (FDA) in 2007.",
      "The manufacturer of the \"Shanchol\" vaccine is Sanofi Pasteur.",
      "The \"Shanchol\" cholera vaccine is recommended for adults aged 18 through 64 years.",
      "The vaccine is suggested for individuals traveling to areas where cholera is common."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was not \"Shanchol\", but \"Vaxchora\".\n2. FALSE [correction]: \"Shanchol\" has not been approved by the US FDA. \"Vaxchora\" was approved by the FDA in 2016.\n3. FALSE [correction]: The manufacturer of \"Shanchol\" is Shantha Biotechnics, a subsidiary of Sanofi, but the US-approved cholera vaccine \"Vaxchora\" is manufactured by PaxVax Berna GmbH (part of Emergent BioSolutions).\n4. UNKNOWN: Without context, it's unclear whether this statement was intended to refer to \"Shanchol\" or \"Vaxchora\". For \"Vaxchora\", the vaccine is recommended for adults 18 to 64. The statement may be true for \"Vaxchora\" but would require confirmation for \"Shanchol\".\n5. TRUE: Cholera vaccines, including \"Vaxchora\" approved in the US, are recommended for travelers to areas with active cholera transmission.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the X-linked gene encoding the protein CD40 ligand (CD40L). CD40L is a co-stimulatory molecule that helps activate B cells and activate the immune response. Mutations in the CD40L gene can lead to a defect in the activation and function of B cells, resulting in CVID. It is estimated that approximately 50% of CVID cases in Europeans are caused by mutations in the CD40L gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency in Europeans is mutations in the CD40L gene.\n2. CD40L is a co-stimulatory molecule that helps activate B cells and the immune response.\n3. Mutations in the CD40L gene can lead to a defect in B cell activation and function.\n4. Approximately 50% of common variable immunodeficiency cases in Europeans are caused by mutations in the CD40L gene.",
    "llama-2-7b-chat-hf_fact": [
      "The most common monogenic cause of common variable immunodeficiency in Europeans is mutations in the CD40L gene.",
      "CD40L is a co-stimulatory molecule that helps activate B cells and the immune response.",
      "Mutations in the CD40L gene can lead to a defect in B cell activation and function.",
      "Approximately 50% of common variable immunodeficiency cases in Europeans are caused by mutations in the CD40L gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common monogenic cause of common variable immunodeficiency in Europeans is mutations in the TNFRSF13B gene, encoding the TACI protein, not CD40L.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Mutations in the CD40L gene do not account for 50% of common variable immunodeficiency cases in Europeans; rather, they are a cause of a different primary immunodeficiency, typically X-linked Hyper IgM syndrome. The percentage of CVID cases caused by mutations in a specific gene like TNFRSF13B is usually much smaller and varies among different populations.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been found to be mutated or downregulated in various types of autoimmune diseases, including Systemic Lupus Erythematosus (SLE). SLE is a complex and heterogeneous autoimmune disease that affects multiple organ systems, including the skin, joints, kidneys, and nervous system.\nStudies have shown that IFIT1 plays a critical role in regulating the immune response and preventing autoimmune diseases, including SLE. The IFIT1 gene encodes for a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), which is a member of the interferon-induced protein 1 (IFI1) family. IFIT1 is a key regulator of the antiviral response and plays a role in the recognition and clearance of viral infections.\nMutations or downregulation of the IFIT1 gene have been associated with an increased susceptibility to SLE. Studies have shown that IFIT1 deficiency leads to an impaired antiviral response and an increased susceptibility to infections, which can contribute to the development of SLE. Additionally, IFIT1 has been shown to play a role in regulating the immune response and preventing autoimmune diseases by suppressing the activation and proliferation of autoreactive T cells and B cells.\nOverall, the role of the IFIT1 gene in SLE is complex and multifaceted, and further research is needed to fully understand its mechanisms of action and its potential as a therapeutic target for the treatment of this disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene has been found to be mutated or downregulated in Systemic Lupus Erythematosus (SLE) and other autoimmune diseases.\n2. IFIT1 encodes for a protein that is a member of the interferon-induced protein 1 (IFI1) family.\n3. IFIT1 plays a critical role in regulating the immune response and preventing autoimmune diseases.\n4. Mutations or downregulation of the IFIT1 gene have been associated with an increased susceptibility to Systemic Lupus Erythematosus.\n5. IFIT1 is involved in the antiviral response and helps in the recognition and clearance of viral infections.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene has been found to be mutated or downregulated in Systemic Lupus Erythematosus (SLE) and other autoimmune diseases.",
      "IFIT1 encodes for a protein that is a member of the interferon-induced protein 1 (IFI1) family.",
      "IFIT1 plays a critical role in regulating the immune response and preventing autoimmune diseases.",
      "Mutations or downregulation of the IFIT1 gene have been associated with an increased susceptibility to Systemic Lupus Erythematosus.",
      "IFIT1 is involved in the antiviral response and helps in the recognition and clearance of viral infections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: It is known that the IFIT1 gene can be involved in immune system regulation and has been associated with autoimmune diseases, such as Systemic Lupus Erythematosus (SLE).\n2. FALSE [correction]: IFIT1 encodes for a protein that is a member of the interferon-induced proteins with tetratricopeptide repeats (IFITs) family, not the interferon-induced protein 1 (IFI1) family.\n3. TRUE: The IFIT1 protein plays an important role in immune response regulation, which does include preventing autoimmune diseases.\n4. TRUE: Genetic variations including mutations or altered expressions (downregulation) of the IFIT1 gene have been linked to an increased susceptibility to autoimmune diseases like Systemic Lupus Erythematosus (SLE).\n5. TRUE: IFIT1 is known to be involved in the antiviral response, playing a role in the recognition and response to viral infections.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a patient-reported outcome measure (PROM) used to assess the severity of elbow pain and disability in patients with various conditions affecting the elbow joint, such as tennis elbow (lateral epicondylitis), golfer's elbow (medial epicondylitis), and post-traumatic elbow pain. The score assesses the patient's experience of pain, stiffness, and function in the affected elbow, and can be used to evaluate the effectiveness of treatment interventions.\nThe LES consists of 12 items that are rated on a 5-point Likert scale, with higher scores indicating greater severity of symptoms. The items include:\n1. Pain on extension\n2. Pain on flexion\n3. Pain on pronation\n4. Pain on supination\n5. Stiffness on extension\n6. Stiffness on flexion\n7. Stiffness on pronation\n8. Stiffness on supination\n9. Functional disability\n10. Sports or activities limitations\n11. Work or daily activities limitations\n12. Global assessment of elbow symptoms\nThe scores from each item are summed to give a total LES score, which can range from 0 to 60. A higher score indicates greater severity of elbow symptoms and disability. The LES has been shown to have good reliability and validity in various studies, and is widely used in clinical practice and research to assess the effectiveness of treatments for elbow conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the severity of elbow pain and disability in patients.\n2. It is a patient-reported outcome measure (PROM) used for various conditions affecting the elbow joint, such as tennis elbow, golfer's elbow, and post-traumatic elbow pain.\n3. The LES consists of 12 items, and each item is rated on a 5-point Likert scale.\n4. The total LES score can range from 0 to 60, with higher scores indicating greater severity of symptoms.\n5. The LES has been shown to have good reliability and validity in various studies.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the severity of elbow pain and disability in patients.",
      "It is a patient-reported outcome measure (PROM) used for various conditions affecting the elbow joint, such as tennis elbow, golfer's elbow, and post-traumatic elbow pain.",
      "The LES consists of 12 items, and each item is rated on a 5-point Likert scale.",
      "The total LES score can range from 0 to 60, with higher scores indicating greater severity of symptoms.",
      "The LES has been shown to have good reliability and validity in various studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Liverpool Elbow Score (LES) consists of 10 items, and each item is rated on a 5-point Likert scale.\n4. FALSE [correction]: Since the LES consists of 10 items with a 5-point scale, the total score can range from 10 to 50, with higher scores indicating greater severity of symptoms.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project is a large-scale genomics initiative launched in 2015 in the UK with the goal of analyzing the genetic data of 100,000 patients with rare and common diseases, including cancer. As part of this project, there have been several efforts to analyze the genomes of sarcoma patients in order to better understand the genetic changes that drive the disease and to identify potential therapeutic targets.\n1. The Sarcoma Project: The Sarcoma Project is a sub-project of the 100,000 Genomes Project that focuses specifically on the analysis of sarcoma genomes. The project aims to analyze the whole genome sequence of 500 sarcoma patients, as well as their clinical and demographic data, in order to identify genetic mutations and other genomic changes that are associated with the disease.\n2. Identification of novel driver mutations: The Sarcoma Project has identified several novel driver mutations in sarcoma genomes, including mutations in genes such as KRAS, PIK3CA, and ATRX. These findings have implications for the development of new therapeutic strategies for sarcoma treatment.\n3. Development of a sarcoma genomics resource: The Sarcoma Project has developed a comprehensive genomics resource for sarcoma, which includes a database of sarcoma genomes, transcriptomes, and methylomes. This resource will be made available to researchers worldwide, and will provide a valuable tool for the study of sarcoma biology and the development of new therapies.\n4. Investigation of the genetic heterogeneity of sarcoma: The Sarcoma Project has shown that sarcoma is a genetically heterogeneous disease, with different subtypes of the disease associated with different genetic mutations. This finding has implications for the development of targeted therapies for sarcoma.\n5. Identification of potential therapeutic targets: The Sarcoma Project has identified several potential therapeutic targets for sarcoma, including the PI3K/AKT signaling pathway, which is commonly mutated in sarcoma. These findings have implications for the development of",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2015 in the UK to analyze genetic data of patients with rare and common diseases, including cancer.\n2. The Sarcoma Project within the 100,000 Genomes initiative aims to analyze the whole genome sequences of 500 sarcoma patients.\n3. The Sarcoma Project has identified novel driver mutations in sarcoma genomes, citing mutations in genes such as KRAS, PIK3CA, and ATRX.\n4. A comprehensive genomics resource for sarcoma has been developed by the Sarcoma Project, including a database of genomes, transcriptomes, and methylomes.\n5. The Sarcoma Project has evidenced that sarcoma is a genetically heterogeneous disease, with different subtypes associated with distinct genetic mutations.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2015 in the UK to analyze genetic data of patients with rare and common diseases, including cancer.",
      "The Sarcoma Project within the 100,000 Genomes initiative aims to analyze the whole genome sequences of 500 sarcoma patients.",
      "The Sarcoma Project has identified novel driver mutations in sarcoma genomes, citing mutations in genes such as KRAS, PIK3CA, and ATRX.",
      "A comprehensive genomics resource for sarcoma has been developed by the Sarcoma Project, including a database of genomes, transcriptomes, and methylomes.",
      "The Sarcoma Project has evidenced that sarcoma is a genetically heterogeneous disease, with different subtypes associated with distinct genetic mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Yes, the protein ALEX1 (Armadillo-like protein 1) contains armadillo repeats. ALEX1 is a transcriptional repressor that is involved in regulating gene expression and is characterized by the presence of multiple armadillo (ARM) repeats in its structure. These repeats are composed of a conserved 40-amino acid sequence that is found throughout the protein and are thought to be responsible for its DNA-binding and transcriptional repression activities.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. ALEX1 is a transcriptional repressor.\n3. ALEX1 is involved in regulating gene expression.\n4. Armadillo (ARM) repeats in ALEX1 are composed of a conserved 40-amino acid sequence.\n5. The armadillo repeats in ALEX1 are thought to be responsible for its DNA-binding and transcriptional repression activities.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "ALEX1 is a transcriptional repressor.",
      "ALEX1 is involved in regulating gene expression.",
      "Armadillo (ARM) repeats in ALEX1 are composed of a conserved 40-amino acid sequence.",
      "The armadillo repeats in ALEX1 are thought to be responsible for its DNA-binding and transcriptional repression activities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Armadillo (ARM) repeats are typically composed of approximately 42 amino acid residues, not a conserved 40-amino acid sequence.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Enzymes that remove histone modifications include:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone demethylases include KDM4B, KDM5, and JMJD2.\n2. Histone acetyltransferases (HATs): These enzymes add acetyl groups to histone proteins, leading to changes in chromatin structure and gene expression. Examples of HATs include p300 and CBP (CREB-binding protein).\n3. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of HDACs include HDAC1, HDAC2, and HDAC6.\n4. Lysine-specific demethylase 1 (LSD1): This enzyme removes methyl groups from histone H3 lysine 4, leading to changes in chromatin structure and gene expression.\n5. Arginine methyltransferases: These enzymes add methyl groups to histone proteins, leading to changes in chromatin structure and gene expression. Examples of arginine methyltransferases include PRMT5 and PRMT6.\n6. Histone ubiquitin ligases: These enzymes ubiquitinate histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone ubiquitin ligases include RING1B and RING1A.\n7. Ubiquitin-protein ligases (E3s): These enzymes ubiquitinate histone proteins, leading to changes in chromatin structure and gene expression. Examples of E3s include UBE2C and UBE2D.\n8. Ubiquitin-protein ligases (E2s): These enzymes conjugate ubiquitin to histone proteins, leading to changes in chromatin structure and gene expression. Examples of E2s include UBE1 and UBE2A.\n9. SUMO-protein ligases (PML-domain-containing E3s): These enzymes ubiquit",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases are enzymes that remove methyl groups from histone proteins.\n2. Histone acetyltransferases (HATs) add acetyl groups to histone proteins.\n3. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n4. Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4.\n5. Histone ubiquitin ligases ubiquitinate histone proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases are enzymes that remove methyl groups from histone proteins.",
      "Histone acetyltransferases (HATs) add acetyl groups to histone proteins.",
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4.",
      "Histone ubiquitin ligases ubiquitinate histone proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Head CT scans are a common imaging tool used to diagnose and monitor various conditions, including brain tumors. While head CT scans themselves do not directly increase the risk of developing a brain tumor, there are some potential risks and considerations to be aware of:\n1. Radiation exposure: CT scans involve exposure to ionizing radiation, which can increase the risk of cancer, including brain tumors, over time. However, the risk is generally considered to be low, and the benefits of a CT scan often outweigh the risks.\n2. False positives: There is a small chance of false positive results on a CT scan, which can lead to unnecessary further testing and treatment. This can be stressful and may result in complications if not properly managed.\n3. Misdiagnosis: While CT scans are highly accurate, there is still a small chance of misdiagnosis, particularly if the scan is read by a less experienced radiologist. This can lead to delays in proper diagnosis and treatment.\n4. Neurotoxicity: Some studies have suggested that repeated exposure to CT scans may be associated with neurotoxicity, including cognitive decline, memory loss, and seizures. However, the evidence is not yet conclusive, and more research is needed to fully understand the potential risks.\nIn summary, while head CT scans do not directly increase the risk of developing a brain tumor, there are potential risks and considerations to be aware of, including radiation exposure, false positives, misdiagnosis, and neurotoxicity. It is important to discuss the potential benefits and risks with your healthcare provider before undergoing a CT scan.",
    "llama-2-7b-chat-hf_fact_raw": "1. CT scans involve exposure to ionizing radiation, which can increase the risk of cancer, including brain tumors, over time.\n2. There is a small chance of false positive results on a CT scan, which can lead to unnecessary further testing and treatment.\n3. There is a possibility of misdiagnosis with CT scans, particularly if the scan is interpreted by a less experienced radiologist.\n4. Some studies have suggested that repeated exposure to CT scans may be associated with neurotoxicity, including cognitive decline, memory loss, and seizures.\n5. The benefits of a CT scan often outweigh the risks, particularly when used to diagnose and monitor conditions like brain tumors.",
    "llama-2-7b-chat-hf_fact": [
      "CT scans involve exposure to ionizing radiation, which can increase the risk of cancer, including brain tumors, over time.",
      "There is a small chance of false positive results on a CT scan, which can lead to unnecessary further testing and treatment.",
      "There is a possibility of misdiagnosis with CT scans, particularly if the scan is interpreted by a less experienced radiologist.",
      "Some studies have suggested that repeated exposure to CT scans may be associated with neurotoxicity, including cognitive decline, memory loss, and seizures.",
      "The benefits of a CT scan often outweigh the risks, particularly when used to diagnose and monitor conditions like brain tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is associated with neural development and differentiation, but not directly with neural pluripotency. Sox2 would be a more accurate example of a gene associated with pluripotency.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region has several DNase I hypersensitive sites (DHS), which are regions of the genome that are more susceptible to cleavage by the enzyme DNase I. The exact number of DHS sites in the beta globin locus region can vary depending on the specific strain of mouse and the method used to identify them, but in general, there are several well-defined DHS sites in this region.\nSome of the most well-studied DHS sites in the beta globin locus region include:\n1. DHS1: This site is located upstream of the beta globin gene cluster and is characterized by a high level of DNase I hypersensitivity.\n2. DHS2: This site is located downstream of the beta globin gene cluster and is also known as the \"major\" DHS site.\n3. DHS3: This site is located near the 3' end of the beta globin gene cluster and is characterized by a lower level of DNase I hypersensitivity compared to DHS1 and DHS2.\n4. DHS4: This site is located near the 5' end of the beta globin gene cluster and is characterized by a high level of DNase I hypersensitivity.\n5. DHS5: This site is located in the intron of the beta globin gene and is characterized by a low level of DNase I hypersensitivity.\nThe number of DHS sites in the beta globin locus region can vary depending on the specific strain of mouse, but in general, there are around 5-7 well-defined DHS sites in this region. These DHS sites play important roles in regulating the expression of the beta globin gene and are involved in various cellular processes, including gene expression, DNA repair, and chromatin remodeling.",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta globin locus region contains several DNase I hypersensitive sites (DHS).\n2. The number of DHS sites in the beta globin locus region can vary depending on the specific strain of mouse and the identification method used.\n3. DHS1 is located upstream of the beta globin gene cluster and is highly susceptible to cleavage by DNase I.\n4. DHS2 is located downstream of the beta globin gene cluster, also known as the \"major\" DHS site.\n5. The general range for the number of well-defined DHS sites in the murine beta globin locus region is around 5-7.",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta globin locus region contains several DNase I hypersensitive sites (DHS).",
      "The number of DHS sites in the beta globin locus region can vary depending on the specific strain of mouse and the identification method used.",
      "DHS1 is located upstream of the beta globin gene cluster and is highly susceptible to cleavage by DNase I.",
      "DHS2 is located downstream of the beta globin gene cluster, also known as the \"major\" DHS site.",
      "The general range for the number of well-defined DHS sites in the murine beta globin locus region is around 5-7."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: DHS2 is typically located upstream of the beta globin gene cluster and is one of the major regulatory elements, not necessarily located downstream.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "There are several European influenza vaccines available, including:\n1. Fluad: This is a quadrivalent vaccine (protecting against four strains) and is approved for use in individuals aged 65 years and older.\n2. Flucelvax: This is a quadrivalent vaccine and is approved for use in individuals aged 18 years and older.\n3. Fluarix: This is a trivalent vaccine (protecting against three strains) and is approved for use in individuals aged 6 months and older.\n4. Fluvirin: This is a trivalent vaccine and is approved for use in individuals aged 6 months and older.\n5. Aggrezza: This is a quadrivalent vaccine and is approved for use in individuals aged 18 years and older.\n6. Fluad: This is a quadrivalent vaccine and is approved for use in individuals aged 65 years and older.\n7. Grippol: This is a quadrivalent vaccine and is approved for use in individuals aged 18 years and older.\n8. Vaxigrip: This is a trivalent vaccine and is approved for use in individuals aged 6 months and older.\n9. Vaxcel: This is a trivalent vaccine and is approved for use in individuals aged 6 months and older.\n10. Flu-Tetra: This is a quadrivalent vaccine and is approved for use in individuals aged 18 years and older.\nPlease note that this is not an exhaustive list, and there may be other European influenza vaccines available. Additionally, the approval status and recommendations for use may vary depending on the country and region.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluad is a quadrivalent vaccine approved for use in individuals aged 65 years and older.\n2. Flucelvax is a quadrivalent vaccine approved for use in individuals aged 18 years and older.\n3. Fluarix is a trivalent vaccine approved for use in individuals aged 6 months and older.\n4. Fluvirin is a trivalent vaccine approved for use in individuals aged 6 months and older.\n5. Aggrezza is a quadrivalent vaccine approved for use in individuals aged 18 years and older.",
    "llama-2-7b-chat-hf_fact": [
      "Fluad is a quadrivalent vaccine approved for use in individuals aged 65 years and older.",
      "Flucelvax is a quadrivalent vaccine approved for use in individuals aged 18 years and older.",
      "Fluarix is a trivalent vaccine approved for use in individuals aged 6 months and older.",
      "Fluvirin is a trivalent vaccine approved for use in individuals aged 6 months and older.",
      "Aggrezza is a quadrivalent vaccine approved for use in individuals aged 18 years and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Fluarix is a quadrivalent vaccine approved for use in individuals aged 6 months and older.\n4. FALSE [correction]: Fluvirin is a quadrivalent vaccine approved for use in individuals aged 4 years and older.\n5. FALSE [correction]: Aggrezza is not a vaccine; it is a medication used to treat adults with tardive dyskinesia.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the geneome of Paramyxovirus is segmented, negative-sense RNA. Paramyxoviruses are a family of viruses that include the viruses that cause measles, mumps, and parainfluenza. Their genome is composed of several segments of negative-sense RNA, each of which encodes a different protein. The segments are connected by non-coding regions called introns, and the resulting RNA molecule is coated with a cap at the 5' end and a poly(A) tail at the 3' end. The negative-sense RNA genome is transcribed by the viral RNA-dependent RNA polymerase in the cytoplasm of infected cells, and the resulting RNA is then translated into proteins that are involved in the replication and transcription of the virus.",
    "llama-2-7b-chat-hf_fact_raw": "1. The genome of Paramyxoviruses consists of negative-sense RNA.\n2. Paramyxoviruses include viruses that cause measles, mumps, and parainfluenza.\n3. The genome of Paramyxoviruses is not segmented; it is a single strand of RNA.\n4. Paramyxovirus RNA genome has a cap at the 5' end and a poly(A) tail at the 3' end.\n5. The negative-sense RNA genome of Paramyxoviruses is transcribed by viral RNA-dependent RNA polymerase in the cytoplasm of infected cells.",
    "llama-2-7b-chat-hf_fact": [
      "The genome of Paramyxoviruses consists of negative-sense RNA.",
      "Paramyxoviruses include viruses that cause measles, mumps, and parainfluenza.",
      "The genome of Paramyxoviruses is not segmented; it is a single strand of RNA.",
      "Paramyxovirus RNA genome has a cap at the 5' end and a poly(A) tail at the 3' end.",
      "The negative-sense RNA genome of Paramyxoviruses is transcribed by viral RNA-dependent RNA polymerase in the cytoplasm of infected cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for the treatment of plaque psoriasis. It is a topical cream that works by inhibiting the activity of cytokines, which are pro-inflammatory molecules that play a role in the development of psoriasis. By reducing the activity of these cytokines, roflumilast cream can help to reduce the inflammation and skin cell proliferation that are characteristic of psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for the treatment of plaque psoriasis.\n2. Roflumilast cream works by inhibiting the activity of cytokines.\n3. Cytokines are pro-inflammatory molecules involved in the development of psoriasis.\n4. The cream helps to reduce inflammation in psoriasis patients.\n5. Roflumilast cream also helps to reduce skin cell proliferation in psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for the treatment of plaque psoriasis.",
      "Roflumilast cream works by inhibiting the activity of cytokines.",
      "Cytokines are pro-inflammatory molecules involved in the development of psoriasis.",
      "The cream helps to reduce inflammation in psoriasis patients.",
      "Roflumilast cream also helps to reduce skin cell proliferation in psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIt is worth noting that I assumed the accuracy of the statements based on the current medical knowledge as of my last update. Roflumilast is known to be a phosphodiesterase 4 (PDE4) inhibitor, and such inhibitors can reduce inflammation and have been used in the treatment of conditions like plaque psoriasis. They work by inhibiting the activity of this particular enzyme and thus can lead to reduced production of pro-inflammatory cytokines. By doing this, they can also reduce symptoms such as inflammation and the proliferation of skin cells associated with psoriasis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Several tools have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the commonly used tools:\n1. RNAhybrid: RNAhybrid is a tool that uses a combination of sequence and structural features to predict the secondary and tertiary structure of RNA molecules, including ncRNA promoters.\n2. Prodigy: Prodigy is a tool that uses a combination of machine learning algorithms and structural bioinformatics to predict the secondary and tertiary structure of RNA molecules, including ncRNA promoters.\n3. RNAfold: RNAfold is a tool that uses a dynamic programming algorithm to predict the secondary structure of RNA molecules, including ncRNA promoters.\n4. Infernal: Infernal is a tool that uses a combination of machine learning algorithms and structural bioinformatics to predict the secondary and tertiary structure of RNA molecules, including ncRNA promoters.\n5. RNA-Prospector: RNA-Prospector is a tool that uses a combination of sequence and structural features to predict the secondary and tertiary structure of RNA molecules, including ncRNA promoters.\n6. Pfold: Pfold is a tool that uses a dynamic programming algorithm to predict the secondary structure of RNA molecules, including ncRNA promoters.\n7. RNA-Prodigy: RNA-Prodigy is a tool that uses a combination of machine learning algorithms and structural bioinformatics to predict the secondary and tertiary structure of RNA molecules, including ncRNA promoters.\n8. RNA-Structure-Predictor: RNA-Structure-Predictor is a tool that uses a combination of sequence and structural features to predict the secondary and tertiary structure of RNA molecules, including ncRNA promoters.\n9. RNA-3D-Predictor: RNA-3D-Predictor is a tool that uses a combination of sequence and structural features to predict the three-dimensional structure of RNA molecules, including ncRNA promoters.\n10. PIcker: PIcker is a tool",
    "llama-2-7b-chat-hf_fact_raw": "1. RNAhybrid is a tool used to predict the structure of RNA molecules, including ncRNA promoters.\n2. Prodigy is a tool employing machine learning and structural bioinformatics for predicting RNA structures, including ncRNA promoters.\n3. RNAfold uses a dynamic programming algorithm to predict the secondary structure of RNA molecules, including ncRNA promoters.\n4. Infernal is a tool that predicts the structure of RNA molecules, including ncRNA promoters, through machine learning and structural bioinformatics.\n5. Pfold employs a dynamic programming algorithm for predicting the secondary structure of RNA molecules, including ncRNA promoters.",
    "llama-2-7b-chat-hf_fact": [
      "RNAhybrid is a tool used to predict the structure of RNA molecules, including ncRNA promoters.",
      "Prodigy is a tool employing machine learning and structural bioinformatics for predicting RNA structures, including ncRNA promoters.",
      "RNAfold uses a dynamic programming algorithm to predict the secondary structure of RNA molecules, including ncRNA promoters.",
      "Infernal is a tool that predicts the structure of RNA molecules, including ncRNA promoters, through machine learning and structural bioinformatics.",
      "Pfold employs a dynamic programming algorithm for predicting the secondary structure of RNA molecules, including ncRNA promoters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RNAhybrid is a tool used to find potential binding sites of microRNAs in an RNA sequence, not specifically to predict the structure of RNA molecules or ncRNA promoters.\n2. FALSE [correction]: Prodigy is a web-server and tool for predicting the binding affinity of protein-protein complexes, not for predicting RNA structures.\n3. TRUE: RNAfold is a tool that uses a dynamic programming algorithm to predict the secondary structure of single-stranded RNA molecules, which could include ncRNA promoters.\n4. FALSE [correction]: Infernal is a tool that uses covariance models to predict RNA structure and alignment, but it does not employ machine learning and structural bioinformatics.\n5. TRUE: Pfold uses a probabilistic model based on a dynamic programming algorithm to predict RNA secondary structures, which can include ncRNA promoters.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM (Systematic Workbench for Integrative Modeling) is a tool that uses a systems biology approach to identify genes that are differentially expressed between two or more conditions, such as healthy and diseased tissues. Based on the information provided in the paper you mentioned, here are some examples of genes that SWIM has identified as down-regulated in glioblastoma:\n1. CDKN2A: The gene encoding the protein p16, which is a tumor suppressor that regulates the cell cycle and is frequently mutated in glioblastoma.\n2. TP53: The gene encoding the tumor suppressor protein TP53, which is a crucial regulator of cell cycle arrest, apoptosis, and DNA repair. Mutations in TP53 are common in glioblastoma.\n3. PTEN: The gene encoding the protein phosphatase and tensin homolog (PTEN), which is a negative regulator of the PI3K/Akt signaling pathway and is frequently mutated or lost in glioblastoma.\n4. PDCD4: The gene encoding the protein programmed cell death 4 (PDCD4), which is a pro-apoptotic protein that is down-regulated in many types of cancer, including glioblastoma.\n5. BAX: The gene encoding the pro-apoptotic protein Bcl-2-associated X protein (BAX), which is involved in the regulation of programmed cell death.\n6. BNIP3: The gene encoding the pro-apoptotic protein Bcl-2-interacting protein 3 (BNIP3), which is involved in the regulation of programmed cell death.\n7. CYP2C9: The gene encoding the cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9), which is involved in the metabolism of drugs and other xenobiotics.\n8. CYP3A4: The gene encoding the cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4), which is involved in the metabolism of drugs and other xenobiotics.\n9. UBE2",
    "llama-2-7b-chat-hf_fact_raw": "1. CDKN2A is identified by SWIM as down-regulated in glioblastoma and encodes the tumor suppressor protein p16.\n2. TP53 is a gene identified by SWIM as down-regulated in glioblastoma, encoding the tumor suppressor protein TP53.\n3. PTEN, which encodes the phosphatase and tensin homolog protein, is found to be frequently mutated or lost in glioblastoma and identified by SWIM as down-regulated.\n4. PDCD4, a gene that encodes the programmed cell death 4 protein, is down-regulated in glioblastoma according to SWIM.\n5. BAX, a gene encoding Bcl-2-associated X protein, is involved in programmed cell death and identified as down-regulated in glioblastoma by SWIM.",
    "llama-2-7b-chat-hf_fact": [
      "CDKN2A is identified by SWIM as down-regulated in glioblastoma and encodes the tumor suppressor protein p16.",
      "TP53 is a gene identified by SWIM as down-regulated in glioblastoma, encoding the tumor suppressor protein TP53.",
      "PTEN, which encodes the phosphatase and tensin homolog protein, is found to be frequently mutated or lost in glioblastoma and identified by SWIM as down-regulated.",
      "PDCD4, a gene that encodes the programmed cell death 4 protein, is down-regulated in glioblastoma according to SWIM.",
      "BAX, a gene encoding Bcl-2-associated X protein, is involved in programmed cell death and identified as down-regulated in glioblastoma by SWIM."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nPlease note that while I confirmed the roles of CDKN2A, TP53, and PTEN in glioblastomas as stated, there isn't enough public information about SWIM's findings on PDCD4 and BAX specifically in relation to glioblastoma, hence the response \"UNKNOWN\" for those statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for studying Topologically Associating Domains (TADs), including:\n1. TADbit: This package provides functions for the analysis of TADs in chromatin structure and gene regulation. It can be used to identify TADs, analyze their boundaries, and investigate their functional implications.\n2. Tissue: This package provides a comprehensive framework for the analysis of chromatin structure and gene expression in various tissues. It includes tools for identifying TADs, as well as for analyzing their interactions with other chromatin features and gene expression.\n3. ChromHMM: This package provides a Bayesian framework for the analysis of chromatin structure and gene regulation. It includes tools for identifying TADs, as well as for modeling their interactions with other chromatin features and gene expression.\n4. Chromatin3D: This package provides a comprehensive framework for the analysis of chromatin structure and gene regulation in 3D. It includes tools for identifying TADs, as well as for analyzing their interactions with other chromatin features and gene expression.\n5. R/TAD: This package provides a collection of functions for the analysis of TADs in R. It includes tools for identifying TADs, as well as for analyzing their boundaries and functional implications.\n6. TADtrack: This package provides a set of tools for the analysis of TADs in RNA-seq data. It includes functions for identifying TADs, as well as for analyzing their expression profiles and functional implications.\n7. TAD-seq: This package provides a comprehensive framework for the analysis of TADs in single-cell RNA-seq data. It includes tools for identifying TADs, as well as for analyzing their expression profiles and functional implications.\n8. TAD-diff: This package provides a set of tools for the analysis of TADs in single-cell RNA-seq data. It includes functions for identifying TADs, as well as for analyzing their expression profiles and functional implications.\n9. TAD-profile: This package provides a set of functions for the analysis of TADs in RNA-seq data. It includes tools for identifying TADs, as well as for analyzing their expression profiles and functional implications.\n10. TAD",
    "llama-2-7b-chat-hf_fact_raw": "1. TADbit is an R package developed for the analysis of Topologically Associating Domains (TADs) in chromatin structure and gene regulation.\n2. The Tissue R package includes tools for identifying TADs and analyzing their interactions with other chromatin features and gene expression in various tissues.\n3. ChromHMM is an R package that provides a Bayesian framework for the analysis of chromatin structure and gene regulation, including tools for identifying TADs.\n4. Chromatin3D is an R package for analyzing chromatin structure and gene regulation in 3D, which includes tools for identifying TADs.\n5. R/TAD is a collection of functions for the analysis of TADs in R, which includes tools for identifying their boundaries and analyzing their functional implications.",
    "llama-2-7b-chat-hf_fact": [
      "TADbit is an R package developed for the analysis of Topologically Associating Domains (TADs) in chromatin structure and gene regulation.",
      "The Tissue R package includes tools for identifying TADs and analyzing their interactions with other chromatin features and gene expression in various tissues.",
      "ChromHMM is an R package that provides a Bayesian framework for the analysis of chromatin structure and gene regulation, including tools for identifying TADs.",
      "Chromatin3D is an R package for analyzing chromatin structure and gene regulation in 3D, which includes tools for identifying TADs.",
      "R/TAD is a collection of functions for the analysis of TADs in R, which includes tools for identifying their boundaries and analyzing their functional implications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: ChromHMM is not an R package but rather a computational tool designed to learn the chromatin states of a cell using a hidden Markov model. It is not specifically focused on TADs nor is it implemented in R.\n4. TRUE\n5. FALSE [correction]: There is no widely recognized R package specifically named \"R/TAD\". The term might refer to various R functions related to TAD analysis, but it's not a formal package name. Common R packages used in TAD analysis include 'TADbit' and 'HiCseg', among others.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "There are several bioconductor tools that have been developed for accessing bacterial regulatory networks. Some of the popular tools include:\n1. CRISPR-CasE (CRISPR-CasE: A Bioconductor Package for Genome-Wide CRISPR-CasE Regulatory Network Analysis): This tool provides a comprehensive framework for analyzing the regulatory networks of bacteria using CRISPR-CasE systems.\n2. Bacteriophage (Bacteriophage: A Bioconductor Package for Bacteriophage Regulatory Network Analysis): This tool is designed for analyzing the regulatory networks of bacteriophages, which are viruses that infect bacteria.\n3. RegulonDB (RegulonDB: A Bioconductor Package for Bacterial Regulatory Network Analysis): This tool provides a comprehensive database of bacterial regulatory networks, including information on transcriptional regulators, their target genes, and the regulatory interactions between them.\n4. RNAscope (RNAscope: A Bioconductor Package for RNA Sequence Analysis): This tool is designed for analyzing RNA sequences in bacteria, including the analysis of regulatory RNAs such as small RNAs and RNA polymerase sigma factors.\n5. Bacterial Gene Regulation (Bacterial Gene Regulation: A Bioconductor Package for Bacterial Gene Regulation Analysis): This tool provides a comprehensive framework for analyzing the regulation of bacterial genes, including the analysis of transcriptional regulators, operons, and gene clusters.\n6. GeneNet (GeneNet: A Bioconductor Package for Bacterial Gene Regulatory Network Analysis): This tool is designed for analyzing the regulatory networks of bacterial genes, including the analysis of transcriptional regulators, their target genes, and the regulatory interactions between them.\n7. Bacterial Regulatory Network (Bacterial Regulatory Network: A Bioconductor Package for Bacterial Regulatory Network Analysis): This tool provides a comprehensive framework for analyzing the regulatory networks of bacteria, including the analysis of transcriptional regulators, their target genes, and the regulatory interactions between them.\n8.",
    "llama-2-7b-chat-hf_fact_raw": "1. CRISPR-CasE is a Bioconductor package developed for genome-wide CRISPR-CasE regulatory network analysis in bacteria.\n2. Bacteriophage is a Bioconductor package designed for bacteriophage regulatory network analysis.\n3. RegulonDB is a Bioconductor package that provides a database for bacterial regulatory networks, including transcriptional regulators and their target genes.\n4. RNAscope is a Bioconductor package for RNA sequence analysis in bacteria, including regulatory RNAs.\n5. GeneNet is a Bioconductor package used for analyzing bacterial gene regulatory networks, focusing on transcriptional regulators and their interactions.",
    "llama-2-7b-chat-hf_fact": [
      "CRISPR-CasE is a Bioconductor package developed for genome-wide CRISPR-CasE regulatory network analysis in bacteria.",
      "Bacteriophage is a Bioconductor package designed for bacteriophage regulatory network analysis.",
      "RegulonDB is a Bioconductor package that provides a database for bacterial regulatory networks, including transcriptional regulators and their target genes.",
      "RNAscope is a Bioconductor package for RNA sequence analysis in bacteria, including regulatory RNAs.",
      "GeneNet is a Bioconductor package used for analyzing bacterial gene regulatory networks, focusing on transcriptional regulators and their interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: RegulonDB is not a Bioconductor package; it is a database that contains information on transcriptional regulation and gene regulatory networks of Escherichia coli, but it is not contained within Bioconductor.\n4. UNKNOWN\n5. FALSE [correction]: GeneNet is not exclusively a Bioconductor package nor is it solely used for analyzing bacterial gene regulatory networks. GeneNet is a more general package that can be used for the inference of gene regulatory networks, but its application is not limited to bacteria.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are aromatic amino acids, which include:\n1. Tyrosine\n2. Tryptophan\n3. Phenylalanine\n4. Tyrosine\n5. Dopamine\n6. Serotonin\n7. Melatonin\nThese amino acids are important building blocks for various physiological processes in the body, including neurotransmission, hormone synthesis, and immune function. The shikimate pathway is a metabolic pathway that occurs in the cytosol of cells and is involved in the biosynthesis of these aromatic amino acids from simpler precursors.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway results in the production of aromatic amino acids.\n2. Tyrosine is an end product of the shikimate pathway.\n3. Tryptophan is an end product of the shikimate pathway.\n4. Phenylalanine is an end product of the shikimate pathway.\n5. The shikimate pathway occurs in the cytosol of cells.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway results in the production of aromatic amino acids.",
      "Tyrosine is an end product of the shikimate pathway.",
      "Tryptophan is an end product of the shikimate pathway.",
      "Phenylalanine is an end product of the shikimate pathway.",
      "The shikimate pathway occurs in the cytosol of cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The shikimate pathway occurs in the chloroplasts of plant cells and in the plastids of algae, while in bacteria, it takes place in the cytoplasm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is used to treat Nelson's syndrome, which is a rare condition that occurs after surgical removal of a pituitary tumor. Cabergoline is a dopamine receptor agonist that can help to reduce the growth of the remaining pituitary tissue and alleviate the symptoms of Nelson's syndrome, such as rapid growth of the pituitary gland, visual disturbances, and hormonal imbalances.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that can occur after the surgical removal of a pituitary tumor.\n3. Cabergoline is a dopamine receptor agonist.\n4. Treatment with cabergoline can help reduce the growth of remaining pituitary tissue in patients with Nelson's syndrome.\n5. Symptoms of Nelson's syndrome may include rapid growth of the pituitary gland, visual disturbances, and hormonal imbalances.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that can occur after the surgical removal of a pituitary tumor.",
      "Cabergoline is a dopamine receptor agonist.",
      "Treatment with cabergoline can help reduce the growth of remaining pituitary tissue in patients with Nelson's syndrome.",
      "Symptoms of Nelson's syndrome may include rapid growth of the pituitary gland, visual disturbances, and hormonal imbalances."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome; it is used to treat other conditions like prolactinomas and Parkinson's disease. Nelson's syndrome often requires other treatments such as radiotherapy or repeat surgery.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Cabergoline is generally not used to treat Nelson's syndrome or reduce the growth of remaining pituitary tissue in these patients. The standard treatment might involve surgical interventions or radiotherapy.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder that affects the nervous system and is characterized by a combination of symptoms including:\n1. Severe intellectual disability: Individuals with Liebenberg syndrome typically have significant cognitive impairments, including intellectual disability and delayed development.\n2. Spasticity: Muscle stiffness and spasticity are common in individuals with Liebenberg syndrome, which can affect movement and coordination.\n3. Scoliosis: Many individuals with Liebenberg syndrome have a curvature of the spine (scoliosis), which can lead to back pain and other musculoskeletal problems.\n4. Seizures: Seizures are a common feature of Liebenberg syndrome, and can vary in severity and frequency.\n5. Vision problems: Individuals with Liebenberg syndrome may experience vision problems, including cataracts, glaucoma, and/or optic atrophy.\n6. Hearing loss: Hearing loss is another common feature of Liebenberg syndrome, and can range from mild to severe.\n7. Sleep disturbances: Individuals with Liebenberg syndrome may experience sleep disturbances, including insomnia and/or sleep apnea.\n8. Autism spectrum disorder: Some individuals with Liebenberg syndrome may also have a diagnosis of autism spectrum disorder (ASD), which can affect social interaction, communication, and behavior.\nThese symptoms can vary in severity and may change over time, and in some cases, additional symptoms may also be present. The main manifestation of Liebenberg syndrome is the combination of intellectual disability and spasticity, which can significantly impact an individual's quality of life.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder that affects the nervous system.\n2. Individuals with Liebenberg syndrome typically have intellectual disability and delayed development.\n3. Muscle stiffness and spasticity are common in individuals with Liebenberg syndrome.\n4. Many individuals with Liebenberg syndrome experience curvature of the spine known as scoliosis.\n5. Seizures are a common feature of Liebenberg syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder that affects the nervous system.",
      "Individuals with Liebenberg syndrome typically have intellectual disability and delayed development.",
      "Muscle stiffness and spasticity are common in individuals with Liebenberg syndrome.",
      "Many individuals with Liebenberg syndrome experience curvature of the spine known as scoliosis.",
      "Seizures are a common feature of Liebenberg syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: Without additional context or specific information on a condition named \"Liebenberg syndrome,\" it is impossible to verify the accuracy of these statements. This syndrome does not appear in common medical literature or databases, which suggests that it might be an uncommon or a fictitious condition. Conclusions cannot be drawn without credible sources.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "MPS1 (Microtubule-associated protein 1) kinase is an enzyme that plays a crucial role in regulating the stability of microtubules, which are essential for cell division and intracellular transport. Here are some orally bioavailable MPS1 kinase inhibitors that have been identified or developed:\n1. LY294002: LY294002 is a widely used MPS1 kinase inhibitor that was first identified in the early 1990s. It has been shown to inhibit MPS1 kinase activity in various cell types, including cancer cells, and has been used as a tool compound to study the function of MPS1 in cellular processes such as cell division and intracellular transport.\n2. PP2: PP2 (4-phenylbutyric acid) is a phosphatidylinositol 3-kinase (PI3K) inhibitor that has been shown to inhibit MPS1 kinase activity in some studies. However, the potency of PP2 as an MPS1 inhibitor is lower than that of LY294002.\n3. GSK2334470: GSK2334470 is a small molecule inhibitor of MPS1 kinase that was identified using a high-throughput screening assay. It has been shown to inhibit MPS1 kinase activity in various cell types, including cancer cells, and has been shown to have antitumor activity in mouse xenograft models.\n4. BAY-1000394: BAY-1000394 is a small molecule inhibitor of MPS1 kinase that was identified using a structure-based screening approach. It has been shown to inhibit MPS1 kinase activity in various cell types, including cancer cells, and has been shown to have antitumor activity in mouse xenograft models.\n5. RX-0201: RX-0201 is a small molecule inhibitor of MPS1 kinase that was developed using a structure-based design approach. It has been shown to inhibit MPS",
    "llama-2-7b-chat-hf_fact_raw": "1. LY294002 is a widely used MPS1 kinase inhibitor identified in the early 1990s.\n2. PP2, also known as 4-phenylbutyric acid, is a phosphatidylinositol 3-kinase inhibitor that can inhibit MPS1 kinase activity.\n3. GSK2334470 is a small molecule inhibitor of MPS1 kinase identified through high-throughput screening.\n4. BAY-1000394 is a small molecule inhibitor of MPS1 kinase identified through a structure-based screening approach and has demonstrated antitumor activity in mouse xenograft models.\n5. RX-0201 is an inhibitor of MPS1 kinase developed using a structure-based design approach.",
    "llama-2-7b-chat-hf_fact": [
      "LY294002 is a widely used MPS1 kinase inhibitor identified in the early 1990s.",
      "PP2, also known as 4-phenylbutyric acid, is a phosphatidylinositol 3-kinase inhibitor that can inhibit MPS1 kinase activity.",
      "GSK2334470 is a small molecule inhibitor of MPS1 kinase identified through high-throughput screening.",
      "BAY-1000394 is a small molecule inhibitor of MPS1 kinase identified through a structure-based screening approach and has demonstrated antitumor activity in mouse xenograft models.",
      "RX-0201 is an inhibitor of MPS1 kinase developed using a structure-based design approach."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: LY294002 is a widely used phosphatidylinositol 3-kinase (PI3K) inhibitor, not an MPS1 kinase inhibitor, identified in the early 1990s.\n2. FALSE [correction]: PP2 is a src-family kinase inhibitor, not a phosphatidylinositol 3-kinase inhibitor, and it is not known as 4-phenylbutyric acid. 4-Phenylbutyric acid is a different compound used for different purposes.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: RX-0201 (Archexin) is an antisense oligonucleotide inhibitor of Akt1, not an inhibitor of MPS1 kinase.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Golimumab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, has been tested for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. However, it has not been specifically tested for the treatment of diabetes.\nGolimumab works by blocking the activity of TNF-alpha, a protein that is involved in the inflammation and immune response. By inhibiting the activity of TNF-alpha, golimumab can help to reduce inflammation and improve symptoms in patients with autoimmune diseases. However, it is not approved by the US Food and Drug Administration (FDA) for the treatment of diabetes, and its efficacy and safety in this condition have not been established through clinical trials.\nThere are other medications that have been approved by the FDA for the treatment of diabetes, including metformin, sulfonylureas, thiazolidinediones, and glucagon-like peptide-1 (GLP-1) receptor agonists. These medications work by different mechanisms to improve insulin sensitivity, increase insulin production, or reduce glucose production in the liver. If you have diabetes and are interested in learning more about the available treatment options, you should consult with your healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.\n2. Golimumab has been tested for the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.\n3. Golimumab has not been specifically tested for the treatment of diabetes.\n4. The US Food and Drug Administration (FDA) has not approved golimumab for the treatment of diabetes.\n5. Medications approved by the FDA for the treatment of diabetes include metformin, sulfonylureas, thiazolidinediones, and glucagon-like peptide-1 (GLP-1) receptor agonists.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.",
      "Golimumab has been tested for the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.",
      "Golimumab has not been specifically tested for the treatment of diabetes.",
      "The US Food and Drug Administration (FDA) has not approved golimumab for the treatment of diabetes.",
      "Medications approved by the FDA for the treatment of diabetes include metformin, sulfonylureas, thiazolidinediones, and glucagon-like peptide-1 (GLP-1) receptor agonists."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by an autosomal recessive mutation in the LMNA gene. This gene encodes for the protein lamin A, which is involved in the structure and maintenance of chromatin. The mutation leads to a deficiency of functional lamin A, resulting in the rapid aging and degeneration of cells, which is characteristic of progeria.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria, also known as Hutchinson-Gilford progeria syndrome, is caused by a mutation in the LMNA gene.\n2. The LMNA gene encodes for the protein lamin A.\n3. Lamin A is involved in the structure and maintenance of chromatin.\n4. The mutation in the LMNA gene leads to a deficiency of functional lamin A.\n5. The deficiency of functional lamin A results in the rapid aging and degeneration of cells characteristic of progeria.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria, also known as Hutchinson-Gilford progeria syndrome, is caused by a mutation in the LMNA gene.",
      "The LMNA gene encodes for the protein lamin A.",
      "Lamin A is involved in the structure and maintenance of chromatin.",
      "The mutation in the LMNA gene leads to a deficiency of functional lamin A.",
      "The deficiency of functional lamin A results in the rapid aging and degeneration of cells characteristic of progeria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The mutation in the LMNA gene leads to the production of an abnormal form of lamin A, known as progerin, which is not fully processed and remains farnesylated, causing disruption to the nuclear envelope and cellular function.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Variants at 12q14 and 12q24 have been associated with various diseases and conditions, including:\n12q14:\n* Bipolar disorder: Variants in this region have been associated with an increased risk of bipolar disorder.\n* Schizophrenia: Some studies have found an increased risk of schizophrenia in individuals with variants in this region.\n* Major depressive disorder: Some studies have found an increased risk of major depressive disorder in individuals with variants in this region.\n* Autoimmune diseases: Variants in this region have been associated with an increased risk of autoimmune diseases, such as rheumatoid arthritis and lupus.\n12q24:\n* Prostate cancer: Variants in this region have been associated with an increased risk of prostate cancer.\n* Breast cancer: Some studies have found an increased risk of breast cancer in individuals with variants in this region.\n* Ovarian cancer: Some studies have found an increased risk of ovarian cancer in individuals with variants in this region.\n* Cardiovascular disease: Variants in this region have been associated with an increased risk of cardiovascular disease, including heart attack and stroke.\nIt is important to note that the associations between these variants and disease risk are complex and not fully understood, and more research is needed to determine the exact mechanisms by which these variants contribute to disease risk.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants at 12q14 have been associated with an increased risk of bipolar disorder.\n2. An increased risk of schizophrenia has been found in individuals with variants at 12q14.\n3. Studies suggest a link between variants at 12q14 and a higher risk of major depressive disorder.\n4. Variants in the 12q14 region have been linked to an increased risk of autoimmune diseases, including rheumatoid arthritis and lupus.\n5. Variants at 12q24 have been associated with an increased risk of prostate cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Variants at 12q14 have been associated with an increased risk of bipolar disorder.",
      "An increased risk of schizophrenia has been found in individuals with variants at 12q14.",
      "Studies suggest a link between variants at 12q14 and a higher risk of major depressive disorder.",
      "Variants in the 12q14 region have been linked to an increased risk of autoimmune diseases, including rheumatoid arthritis and lupus.",
      "Variants at 12q24 have been associated with an increased risk of prostate cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided relate to complex genetic associations that can only be verified through scientific research and genetic studies. Without specific references to peer-reviewed research or a consensus within the scientific community, it is not possible to determine the accuracy of these associations.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Roundabout (Robo) receptors are activated by a variety of ligands, including:\n1. Robo1: The primary ligand for Robo1 is the epidermal growth factor repeats (EGFR) family member, EGFRvIII.\n2. Robo2: Robo2 is activated by the ligand N-myc downstream-regulated gene 1 (NDRG1).\n3. Robo3: Robo3 is activated by the ligand G protein-coupled receptor 119 (GPR119).\n4. Robo4: Robo4 is activated by the ligand fibroblast growth factor receptor 1 (FGFR1).\nThese ligands bind to the extracellular domain of Robo receptors, leading to the activation of downstream signaling pathways that regulate cell migration, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. The primary ligand for Robo1 is the epidermal growth factor repeats (EGFR) family member, EGFRvIII.\n2. Robo2 is activated by the ligand N-myc downstream-regulated gene 1 (NDRG1).\n3. Robo3 is activated by the ligand G protein-coupled receptor 119 (GPR119).\n4. Robo4 is activated by the ligand fibroblast growth factor receptor 1 (FGFR1).\n5. Ligands of Robo receptors bind to their extracellular domain.",
    "llama-2-7b-chat-hf_fact": [
      "The primary ligand for Robo1 is the epidermal growth factor repeats (EGFR) family member, EGFRvIII.",
      "Robo2 is activated by the ligand N-myc downstream-regulated gene 1 (NDRG1).",
      "Robo3 is activated by the ligand G protein-coupled receptor 119 (GPR119).",
      "Robo4 is activated by the ligand fibroblast growth factor receptor 1 (FGFR1).",
      "Ligands of Robo receptors bind to their extracellular domain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The primary ligand for Robo1 is Slit, not the epidermal growth factor repeats (EGFR) family member, EGFRvIII.\n2. UNKNOWN\n3. FALSE [correction]: Robo3 is activated by the ligand NELL2, not G protein-coupled receptor 119 (GPR119).\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Yes, TFII-I (Transcription Factor IIA, Subunit I) plays a role in megakaryopoiesis, which is the process of developing megakaryocytes, the precursors of platelets, in the bone marrow. TFII-I is a transcription factor that is essential for the regulation of genes involved in platelet production and function.\nStudies have shown that TFII-I is required for the proper differentiation of megakaryocytes and the maintenance of platelet function. TFII-I regulates the expression of genes involved in platelet-specific proteins, such as glycoproteins IIb/IIIa and von Willebrand factor, which are important for platelet adhesion, aggregation, and signaling.\nMice lacking TFII-I have impaired platelet function and an increased risk of bleeding due to defects in platelet production and function. Conversely, overexpression of TFII-I has been shown to enhance platelet function and reduce the risk of bleeding in certain disease models.\nIn summary, TFII-I plays a critical role in regulating the transcription of genes involved in megakaryopoiesis and platelet function, and its dysregulation can lead to impaired platelet function and an increased risk of bleeding.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I (Transcription Factor IIA, Subunit I) is involved in the process of megakaryopoiesis, the development of megakaryocytes in the bone marrow.\n2. Megakaryocytes are the precursors of platelets.\n3. TFII-I is essential for the proper differentiation of megakaryocytes and the maintenance of platelet function.\n4. Mice lacking TFII-I have shown impaired platelet function and an increased risk of bleeding.\n5. Overexpression of TFII-I has been shown to enhance platelet function and reduce the risk of bleeding in certain disease models.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I (Transcription Factor IIA, Subunit I) is involved in the process of megakaryopoiesis, the development of megakaryocytes in the bone marrow.",
      "Megakaryocytes are the precursors of platelets.",
      "TFII-I is essential for the proper differentiation of megakaryocytes and the maintenance of platelet function.",
      "Mice lacking TFII-I have shown impaired platelet function and an increased risk of bleeding.",
      "Overexpression of TFII-I has been shown to enhance platelet function and reduce the risk of bleeding in certain disease models."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFII-I (Transcription Factor II-I) is known to be involved in the initiation of transcription by RNA polymerase II; however, GATA-1 and other factors are mainly involved in the process of megakaryopoiesis.\n2. TRUE\n3. UNKNOWN: While transcription factors play a critical role in differentiating various cell types, including megakaryocytes, the specific role of TFII-I in megakaryocyte differentiation and maintenance of platelet function is not well-established and may depend on additional context from the passage.\n4. UNKNOWN: The effects of a lack of TFII-I on mice and their platelet function are not commonly documented, and without further context from the passage, the impact on platelet function and bleeding risk cannot be determined.\n5. UNKNOWN: There is insufficient information to determine the truth of this statement; the effects of overexpression of TFII-I on platelet function and bleeding risk would require specific experimental results and context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. CYP2D6 is responsible for the metabolism of approximately 20-30% of clinically used drugs, including atenolol, and plays a major role in the elimination of the drug from the body. Individual variations in CYP2D6 expression and activity can affect the metabolism and efficacy of atenolol, and may lead to altered drug responses in some patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. CYP2D6 is involved in the metabolism of approximately 20-30% of clinically used drugs.\n3. CYP2D6 plays a major role in the elimination of atenolol from the body.\n4. Individual variations in CYP2D6 expression and activity can affect the metabolism and efficacy of atenolol.\n5. Altered CYP2D6 expression and activity may lead to altered drug responses in some patients.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "CYP2D6 is involved in the metabolism of approximately 20-30% of clinically used drugs.",
      "CYP2D6 plays a major role in the elimination of atenolol from the body.",
      "Individual variations in CYP2D6 expression and activity can affect the metabolism and efficacy of atenolol.",
      "Altered CYP2D6 expression and activity may lead to altered drug responses in some patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the cytochrome P450 system, including CYP2D6. It is excreted primarily unchanged in the urine.\n2. TRUE\n3. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, it does not play a major role in the elimination of atenolol from the body.\n4. FALSE [correction]: Because atenolol is not significantly metabolized by CYP2D6, individual variations in CYP2D6 expression and activity are not likely to affect the metabolism and efficacy of atenolol to a clinically significant extent.\n5. TRUE (This statement is generally true for drugs that are metabolized by CYP2D6; however, since it's vague and doesn't specify atenolol, it could lead to misunderstanding in this context. For atenolol specifically, this is not relevant, but without more context or specification, the general statement is true.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Expansion Hunter is a software tool used for the detection of genomic expansion events in DNA sequences. Here are some versions of Expansion Hunter:\n1. Expansion Hunter 1.0: This was the first version of the software, released in 2006. It could detect simple repeat expansions and provided basic visualization tools.\n2. Expansion Hunter 2.0: Released in 2010, this version included several improvements, such as the ability to detect complex repeat expansions and to visualize the results in a more detailed manner.\n3. Expansion Hunter 3.0: This version was released in 2013 and included several new features, such as the ability to detect expansions in non-coding regions of the genome and to analyze the results in the context of the entire genome.\n4. Expansion Hunter 4.0: Released in 2017, this version included several significant updates, including the ability to detect expansions in RNA and to analyze the results in the context of gene expression data.\n5. Expansion Hunter 5.0: The latest version of the software, released in 2020, includes several new features, such as the ability to detect expansions in non-coding RNA and to analyze the results in the context of epigenetic marks.\n6. Expansion Hunter Lite: This is a simplified version of the software, designed for researchers who only need to analyze small datasets. It includes a limited set of features compared to the full version of the software.\n7. Expansion Hunter Cloud: This is a cloud-based version of the software, allowing researchers to analyze large datasets without the need for local installation.\n8. Expansion Hunter API: This is an application programming interface (API) that allows researchers to integrate Expansion Hunter into their own software or pipelines.\n9. Expansion Hunter Server: This is a server-based version of the software, designed for high-throughput analysis of large datasets.\n10. Expansion Hunter Workbench: This is a graphical user interface (GUI) for Expansion Hunter, allowing researchers to perform analysis and visualization of genomic expansion events without the need for programming.",
    "llama-2-7b-chat-hf_fact_raw": "1. Expansion Hunter is a software tool used for the detection of genomic expansion events in DNA sequences.\n2. Expansion Hunter 1.0 was the first version of the software, released in 2006.\n3. Expansion Hunter 2.0 was released in 2010.\n4. Expansion Hunter 3.0 was released in 2013.\n5. Expansion Hunter 4.0 was released in 2017.",
    "llama-2-7b-chat-hf_fact": [
      "Expansion Hunter is a software tool used for the detection of genomic expansion events in DNA sequences.",
      "Expansion Hunter 1.0 was the first version of the software, released in 2006.",
      "Expansion Hunter 2.0 was released in 2010.",
      "Expansion Hunter 3.0 was released in 2013.",
      "Expansion Hunter 4.0 was released in 2017."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Expansion Hunter 1.0 was released in 2017, not 2006.\n3. FALSE [correction]: Expansion Hunter 2.0's release date is unknown, but given the first version was released in 2017, it could not have been released in 2010.\n4. FALSE [correction]: It is unlikely that Expansion Hunter 3.0 was released in 2013 as the first version was released in 2017; however, I don't have the exact release date for version 3.0.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (a disintegrin and metalloproteinase domain-containing protein 18) is a member of the ADAMTS (a disintegrin and metalloproteinase domain-containing protein) family of proteins, which are involved in the regulation of various cellular processes, including cell signaling, adhesion, and extracellular matrix (ECM) remodeling.\nAdamts18 has been shown to play a role in hormone receptor signaling, particularly in the regulation of estrogen receptor (ER) signaling. Adamts18 is capable of cleaving and activating the ER, leading to enhanced ER activity and downstream signaling. This process is thought to be involved in the regulation of various physiological processes, including cell growth, differentiation, and survival.\nIn addition, Adamts18 has been shown to interact with other signaling molecules, including the epidermal growth factor receptor (EGFR) and the protease activated receptor 2 (PAR2), and may play a role in the regulation of multiple signaling pathways.\nOverall, the role of Adamts18 in hormone receptor signaling is complex and multifaceted, and further research is needed to fully understand its mechanisms of action and its potential as a therapeutic target for various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a member of the ADAMTS family of proteins.\n2. These proteins are involved in regulation of cellular processes such as cell signaling, adhesion, and ECM remodeling.\n3. Adamts18 plays a role in the regulation of estrogen receptor signaling.\n4. It has the capability to cleave and activate the estrogen receptor, leading to enhanced activity and downstream signaling.\n5. Adamts18 is known to interact with signaling molecules including the epidermal growth factor receptor (EGFR) and protease activated receptor 2 (PAR2).",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a member of the ADAMTS family of proteins.",
      "These proteins are involved in regulation of cellular processes such as cell signaling, adhesion, and ECM remodeling.",
      "Adamts18 plays a role in the regulation of estrogen receptor signaling.",
      "It has the capability to cleave and activate the estrogen receptor, leading to enhanced activity and downstream signaling.",
      "Adamts18 is known to interact with signaling molecules including the epidermal growth factor receptor (EGFR) and protease activated receptor 2 (PAR2)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin motifs) family is indeed involved in a variety of cellular processes, including cell signaling, adhesion, and extracellular matrix (ECM) remodeling. However, specific functions of individual ADAMTS family members can vary significantly, and without specific references regarding ADAMTS18's role in estrogen receptor signaling or interactions with EGFR and PAR2, it is impossible to confirm statements 3, 4, and 5 as true or false. They remain unknown without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the histone methyltransferase (HMT) enzyme, SETDB1 (also known as Eset or KMT1E). SETDB1 is a lysine-specific methyltransferase that catalyzes the mono-methylation of histone H3 lysine 9 (H3K9), leading to the repressive chromatin mark H3K9me3. Thiazovivin binds to the active site of SETDB1 and prevents it from methylating histone H3, thereby inhibiting the enzyme's activity. This leads to a decrease in the levels of H3K9me3 and an increase in the expression of genes that are normally repressed by this mark. Thiazovivin has been shown to have potential as a therapeutic agent for the treatment of various cancers, including leukemia and solid tumors, by inhibiting the proliferation of cancer cells and inducing apoptosis (programmed cell death).",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a small molecule inhibitor of the histone methyltransferase enzyme, SETDB1.\n2. SETDB1 catalyzes the mono-methylation of histone H3 lysine 9, leading to the creation of the repressive chromatin mark H3K9me3.\n3. Thiazovivin binds to the active site of SETDB1, preventing it from methylating histone H3.\n4. As a result of Thiazovivin's action, there is a decrease in the levels of H3K9me3.\n5. Thiazovivin has been shown to have potential as a therapeutic agent for the treatment of various cancers by inhibiting cancer cell proliferation and inducing apoptosis.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a small molecule inhibitor of the histone methyltransferase enzyme, SETDB1.",
      "SETDB1 catalyzes the mono-methylation of histone H3 lysine 9, leading to the creation of the repressive chromatin mark H3K9me3.",
      "Thiazovivin binds to the active site of SETDB1, preventing it from methylating histone H3.",
      "As a result of Thiazovivin's action, there is a decrease in the levels of H3K9me3.",
      "Thiazovivin has been shown to have potential as a therapeutic agent for the treatment of various cancers by inhibiting cancer cell proliferation and inducing apoptosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of the histone methyltransferase enzyme, SETDB1; it is a small molecule inhibitor that has been found to enhance the survival of human embryonic stem cells.\n2. TRUE\n3. FALSE [correction]: Thiazovivin does not bind to the active site of SETDB1 because it is not an inhibitor of this enzyme. The statement is incorrect regarding the action of Thiazovivin.\n4. FALSE [correction]: As Thiazovivin is not an inhibitor of SETDB1, it does not directly lead to a decrease in the levels of H3K9me3 through the mechanism described.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  }
]